
<html lang="en"     class="pb-page"  data-request-id="6973787b-ca9f-4b43-bebe-35ef58d5c55d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b00963;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors" /></meta><meta name="dc.Creator" content="Xuezhen  Zhu" /></meta><meta name="dc.Creator" content="Iris L. K.  Wong" /></meta><meta name="dc.Creator" content="Kin-Fai  Chan" /></meta><meta name="dc.Creator" content="Jiahua  Cui" /></meta><meta name="dc.Creator" content="Man Chun  Law" /></meta><meta name="dc.Creator" content="Tsz Cheung  Chong" /></meta><meta name="dc.Creator" content="Xuesen  Hu" /></meta><meta name="dc.Creator" content="Larry M. C.  Chow" /></meta><meta name="dc.Creator" content="Tak Hang  Chan" /></meta><meta name="dc.Description" content="The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors. A homodimer, Ac22(Az8)2, with m-methoxyc..." /></meta><meta name="Description" content="The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors. A homodimer, Ac22(Az8)2, with m-methoxyc..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 29, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00963" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00963" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00963" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00963" /></link>
        
    
    

<title>Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00963" /></meta><meta property="og:title" content="Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0023.jpeg" /></meta><meta property="og:description" content="The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors. A homodimer, Ac22(Az8)2, with m-methoxycarbonylbenzyloxy substitution at C-3 of the flavone moieties and a bis-triazole-containing linker (21 atoms between the two flavones) showed low toxicity (IC50 toward L929, 3T3, and HFF-1 &gt; 100 μM), potent BCRP-inhibitory activity (EC50 = 1–2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp &gt; 455–909). Ac22(Az8)2 inhibits BCRP-ATPase activity, blocks the drug efflux activity of BCRP, elevates the intracellular drug accumulation, and finally restores the drug sensitivity of BCRP-overexpressing cells. It does not down-regulate the surface BCRP protein expression to enhance the drug retention. Therefore, Ac22(Az8)2 and similar flavonoid dimers appear to be promising candidates for further development into combination therapy to overcome MDR cancers with BCRP overexpression." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00963"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00963">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00963&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00963&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00963&amp;href=/doi/10.1021/acs.jmedchem.9b00963" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8578-8608</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00946" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00972" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xuezhen Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuezhen Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuezhen++Zhu">Xuezhen Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Iris L. K. Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Iris L. K. Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Iris+L.+K.++Wong">Iris L. K. Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kin-Fai Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kin-Fai Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kin-Fai++Chan">Kin-Fai Chan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1475-288X" title="Orcid link">http://orcid.org/0000-0003-1475-288X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiahua Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiahua Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Environmental Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiahua++Cui">Jiahua Cui</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7164-6851" title="Orcid link">http://orcid.org/0000-0001-7164-6851</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Man Chun Law</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Man Chun Law</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Man+Chun++Law">Man Chun Law</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsz Cheung Chong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsz Cheung Chong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsz+Cheung++Chong">Tsz Cheung Chong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuesen Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuesen Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuesen++Hu">Xuesen Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Larry M. C. Chow</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Larry M. C. Chow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div></div><span class="conrtib-corresp"><strong>*</strong>For L.M.C.C., Phone: (852)-34008662: Fax: (852)-23649932; E-mail: <a href="/cdn-cgi/l/email-protection#f5999487878cdb969d9a82b5859a998c80db909180db9d9e"><span class="__cf_email__" data-cfemail="6804091a1a11460b00071f28180704111d460d0c1d460003">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Larry+M.+C.++Chow">Larry M. C. Chow</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9222-8322" title="Orcid link">http://orcid.org/0000-0002-9222-8322</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Tak Hang Chan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tak Hang Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Applied Biology and Chemical Technology and State Key Laboratory of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</div><div class="loa-info-affiliations-info">Department of Chemistry, McGill University, Montreal, Quebec H3A 2K6, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>For T.H.C., Phone: (852)-34008670; Fax: (852)-23649932; E-mail: <a href="/cdn-cgi/l/email-protection#720613195f1a131c155c111a131c32021d1e0b075c1716075c1a19"><span class="__cf_email__" data-cfemail="7b0f1a1056131a151c5518131a153b0b1417020e551e1f0e551310">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tak+Hang++Chan">Tak Hang Chan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8702-4499" title="Orcid link">http://orcid.org/0000-0002-8702-4499</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00963&amp;href=/doi/10.1021%2Facs.jmedchem.9b00963" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8578–8608</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 29, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 June 2019</li><li><span class="item_label"><b>Published</b> online</span>29 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 September 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00963" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00963</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8578%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXuezhen%2BZhu%252C%2BIris%2BL.%2BK.%2BWong%252C%2BKin-Fai%2BChan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D18%26contentID%3Dacs.jmedchem.9b00963%26title%3DTriazole%2BBridged%2BFlavonoid%2BDimers%2Bas%2BPotent%252C%2BNontoxic%252C%2Band%2BHighly%2BSelective%2BBreast%2BCancer%2BResistance%2BProtein%2B%2528BCRP%252FABCG2%2529%2BInhibitors%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8608%26publicationDate%3DSeptember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00963"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1401</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00963" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xuezhen&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Iris&quot;,&quot;last_name&quot;:&quot;L. K. Wong&quot;},{&quot;first_name&quot;:&quot;Kin-Fai&quot;,&quot;last_name&quot;:&quot;Chan&quot;},{&quot;first_name&quot;:&quot;Jiahua&quot;,&quot;last_name&quot;:&quot;Cui&quot;},{&quot;first_name&quot;:&quot;Man&quot;,&quot;last_name&quot;:&quot;Chun Law&quot;},{&quot;first_name&quot;:&quot;Tsz&quot;,&quot;last_name&quot;:&quot;Cheung Chong&quot;},{&quot;first_name&quot;:&quot;Xuesen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Larry&quot;,&quot;last_name&quot;:&quot;M. C. Chow&quot;},{&quot;first_name&quot;:&quot;Tak&quot;,&quot;last_name&quot;:&quot;Hang Chan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8578-8608&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00963&quot;},&quot;abstract&quot;:&quot;The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors. A homodimer, Ac22(Az8)2, with m-methoxycarbonylbenzyloxy substitution at C-3 of the flavone moieties and a bis-triazole-containing linker (21 atoms between the two flavones) showed low toxicity (IC50 toward L929, 3T3, and HFF-1 &gt; 100 μM), potent BCRP-inhibitory activity (EC50 = 1–2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp &gt; 455–909). Ac22(Az8)2 inhibits BCRP-ATPase activity, blocks the drug efflux activity of BCRP, elevates the intracellular drug accumulation, and finally restores the drug sensitivity of BCRP-overexpressing cells. It does not down-regulate the surface BCRP protein expression to enhance the drug retention. Therefore, Ac22(Az8)2 and similar flavonoid dimers appear to be promising candidates for further development into combination therapy to overcome MDR cancers with BCRP overexpression.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00963&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00963" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00963&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00963" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00963&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00963" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00963&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00963&amp;href=/doi/10.1021/acs.jmedchem.9b00963" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00963" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00963" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00963%26sid%3Dliteratum%253Aachs%26pmid%3D31465686%26genre%3Darticle%26aulast%3DZhu%26date%3D2019%26atitle%3DTriazole%2BBridged%2BFlavonoid%2BDimers%2Bas%2BPotent%252C%2BNontoxic%252C%2Band%2BHighly%2BSelective%2BBreast%2BCancer%2BResistance%2BProtein%2B%2528BCRP%252FABCG2%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D18%26spage%3D8578%26epage%3D8608%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a>,</li><li><a href="/action/doSearch?ConceptID=291829" title="Flavonoids">Flavonoids</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/jmcmar.2019.62.issue-18/20190926/jmcmar.2019.62.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors. A homodimer, <b>Ac22(Az8)</b><sub><b>2</b></sub>, with <i>m</i>-methoxycarbonylbenzyloxy substitution at C-3 of the flavone moieties and a <i>bis-</i>triazole-containing linker (21 atoms between the two flavones) showed low toxicity (IC<sub>50</sub> toward L929, 3T3, and HFF-1 > 100 μM), potent BCRP-inhibitory activity (EC<sub>50</sub> = 1–2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp > 455–909). <b>Ac22(Az8)</b><sub><b>2</b></sub> inhibits BCRP-ATPase activity, blocks the drug efflux activity of BCRP, elevates the intracellular drug accumulation, and finally restores the drug sensitivity of BCRP-overexpressing cells. It does not down-regulate the surface BCRP protein expression to enhance the drug retention. Therefore, <b>Ac22(Az8)</b><sub><b>2</b></sub> and similar flavonoid dimers appear to be promising candidates for further development into combination therapy to overcome MDR cancers with BCRP overexpression.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer causes a significant number of human deaths in the world.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> For cancer patients, chemotherapy remains one of the critical treatments. However, multidrug resistance (MDR) often emerges to become a major impediment to successful chemotherapy. Overexpression of an active ATP-binding cassette (ABC) transporter protein on the plasma membrane of cancer cells is a common mechanism for causing drug resistance.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Three major ABC transporter proteins including P-glycoprotein (P-gp; ABCB1), multidrug resistance-associated protein 1 (MRP1; ABCC1), and breast cancer resistance protein (BCRP; ABCG2) have been associated with MDR in cancer.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> They can pump many structurally and mechanistically diverse anticancer drugs out of the cancer cells and render these drugs ineffective at a therapeutic dosage. Using the mutliplatform approach analysis (<a href="https://www.carislifesciences.com/wp-content/uploads/2015/05/Drug-Efflux-Pump-Expression-in-50000-Molecularly-Profiled-Cancer-Patients_ASCO-2015.pdf" class="extLink">https://www.carislifesciences.com/wp-content/uploads/2015/05/Drug-Efflux-Pump-Expression-in-50000-Molecularly-Profiled-Cancer-Patients_ASCO-2015.pdf</a>), across all tumors profiled (n = 51,939), MRP1 positivity was highest at 81%, BCRP was at 66%, and P-gp was the lowest at 23%. About 29% of the patients tested exhibit coexpression of all three drug transporters. The ABC transporter proteins are also expressed in many normal tissues and are believed to perform a protective role. For ABC transporters expressed in the brain, testis, and placenta, they protect these “sanctuaries” from cytotoxins; and for those expressed in the liver, gastrointestinal tract, and kidney they are used to excrete toxins, protecting the entire organism.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">BCRP, unlike P-gp and MRP1, is a 72 kDa half transporter and has a distinct structure which consists of only one cytosolic nucleotide-binding domain (NBD) and one transmembrane domain (TMD).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Several investigations have indicated that it would form a dimeric or tetrameric structure when it functions as a transporter.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13">(9−13)</a> BCRP was found to be overexpressed in a number of human cancers and associated with clinical drug resistance and lower survival rate.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21">(14−21)</a> Moreover, it is highly overexpressed in normal and putative cancer stem cells.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> Since its identification in 1998,<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> numerous anticancer drugs including methotrexate,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> mitoxantrone,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> topotecan,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> irinotecan,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and its active metabolite SN-38,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> as well as some tyrosine kinase inhibitors (TKIs),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> have been identified as substrates of BCRP. Coadministration of a potent inhibitor of ABC transporter such as P-gp with an anticancer drug has been evaluated in several clinical trials to overcome MDR but led to a disappointing outcome.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> One factor which may account for the lack of success is likely the effect of the inhibitor on the pharmacokinetics of the anticancer drug.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is suggested that further improvement of inhibitors of ABC transporters should focus on potency and specificity to minimize unexpected pharmacokinetic effects.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In the case of BCRP, the first identified inhibitor was fumitremorgin C (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) with EC<sub>50</sub> around 1–5 μM.<a onclick="showRef(event, 'ref31 ref36'); return false;" href="javascript:void(0);" class="ref ref31 ref36">(31,35)</a> It was found to be neurotoxic and unsuitable for clinical development.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(35)</a> In subsequent studies, one of the analogues of fumitremorgin C, Ko143 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> was identified as a potent and selective inhibitor of BCRP with EC<sub>50</sub> around 10 nM.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(37)</a> It is not stable in mouse plasma, even though when administered p.o. to inhibit intestinal BCRP. Ko143 markedly increased the oral bioavailability of topotecan in mice.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> Tariquidar (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(38)</a> a third-generation P-gp inhibitor, has also been reported to inhibit BCRP with EC<sub>50</sub> around 100 nM.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(39)</a> Recently, Wiese and his group reported that 2,4,6-substituted quinazolines (with EC<sub>50</sub> = 20–71 nM),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(40)</a> 2,4-disubstituted pyridopyrimidines (with EC<sub>50</sub> = 37 nM),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(41)</a> and 4-anilino-2-pyridylquinazolines and -pyrimidines (with EC<sub>50</sub> = 21 nM) are highly potent and nontoxic inhibitors of BCRP.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(42)</a> Recently, the crystal structure of human BCRP has been reported and provides insight about the binding of BCRP with its substrates and inhibitors.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(43,44)</a> These binding results may provide the essential structural basis for discovery of novel BCRP modulators.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of fumitremorgin C, Ko143, tariquidar, and general structures I and II.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Flavonoids are abundantly present in fruits and vegetables and commonly regarded as safe substances for human consumption. Many natural flavonoids are found to exhibit moderate activity in modulating ABC transporters.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(45)</a> Because of the pseudodimeric structure of ABC transporters, we reasoned that a bivalent approach by coupling two flavonoid moieties together may provide potent and nontoxic inhibitors of ABC transporters. Previously, we synthesized a series of flavonoid dimers of general structure I (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) with polyethylene glycol (PEG) linkers, and some of them showed promising P-gp- and MRP1-modulating activities with nanomolar EC<sub>50</sub> values (70–170 nM).<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52 ref53">(46−51)</a> The inhibitory selectivity of I toward P-gp or MRP-1 depends critically on the linker length, with four PEG groups in I (<i>n</i> = 4) selective for P-gp<a onclick="showRef(event, 'ref48 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51">(46−49)</a> and with five to six PEG groups (I, <i>n</i> = 5–6) selective for MRP1.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a> Recently, we have successfully employed the copper(I) catalyzed Huisgen 1,3-dipolar cycloaddition reaction between azide and alkyne to efficiently synthesize triazole-linked flavonoid dimers of general structure II (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as potent MRP1 inhibitors.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> Interestingly, out of the 300-member synthetic library, the 21 most active compounds (EC<sub>50</sub> = 53–298 nM for reversing DOX resistance in 2008/MRP1) discovered in these triazole-linked flavonoid dimers all have linkers with 13–17 atoms between the two flavonoid moieties, similar in linker length to I with <i>n</i> = 5–6.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a> In the process, we also found that some of the compounds showed inhibitory activities against BCRP.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> In this study, we further construct more triazole-linked flavonoid dimers to discover potent and nontoxic inhibitors of BCRP, to explore the structure activity relationship and, on that basis, discover a specific inhibitor of BCRP over P-gp and MRP1.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Design and Synthesis of Triazole and <i>Bis</i>-triazole Bridged Flavonoid Dimers</h3><div class="NLM_p">The copper(I) catalyzed Huisgen 1,3-dipolar cycloaddition reaction between azides and alkynes (commonly known as CuAAC reaction)<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(53)</a> was used to prepare the triazole and <i>bis</i>-triazole bridged flavonoid dimers. The alkynes <b>Ac1–3, Ac5, Ac12, Ac13</b>, and <b>Ac16</b> and the azides <b>Az1–3</b>, <b>Az11–13</b>, and <b>Az17</b> were conveniently prepared according to the procedure described in the previous study.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> To further expand structural diversity, we synthesized additional flavonoid bearing azides <b>Az8</b>, <b>Az9, Az14</b>, and <b>Az15</b>. The azides <b>Az8–9</b> were prepared starting from compounds <b>1a</b>–<b>b</b> which was followed by debenzylation and alkylation with methyl 3-(bromomethyl)benzoate to furnish compounds <b>1c</b>–<b>d</b>. Azides <b>Az8–9</b> were realized after the conversion of the hydroxyl group in <b>1c</b>–<b>d</b> to an azido group (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). For <b>Az14–15</b>, the hydroxylated flavones <b>2b</b>–<b>c</b> were coupled with 2,2′-(benzylazanediyl)diethanol under Mitsunobu conditions and the hydroxyl group of the coupling product was converted to an azido group to furnish the desired azides (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). With one flavonoid bearing an acetylene group <b>AcN</b> and another flavonoid bearing an azido group <b>AzM</b>, a triazole bridged flavonoid dimer <b>AcNAzM</b> could be easily obtained by employing the CuAAC reaction (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Treatment of the diacetylenes <b>Ac15</b> with two mole equivalents of azides (<b>Az1–3, Az8, Az9, Az11–13, Az16</b>, and <b>Az17</b>) in the presence of a catalytic amount of Cu(PPh<sub>3</sub>)<sub>3</sub>Br under THF refluxing temperature afforded the <i>bis</i>-triazole bridged flavonoid dimers <b>Ac15(AzM)</b><sub><b>2</b></sub> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Their dimeric nature was confirmed by their high-resolution mass and NMR spectra. Altogether, a library of 74-members of pure triazole and <i>bis</i>-triazole bridged homo- and hetero-flavonoid dimers was constructed and tested with biological assays for inhibitory activity against BCRP, MRP1, and P-gp.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Azides <b>Az8</b> and <b>Az9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) H<sub>2</sub>, Pd/C, MeOH, rt; (b) K<sub>2</sub>CO<sub>3</sub>, methyl 3-(bromomethyl)benzoate, acetone, reflux; (ii) (a) methanesulfonyl chloride, NEt<sub>3</sub>, DCM, 0 °C; (b) NaN<sub>3</sub>, ACN.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Azides <b>Az14</b> and <b>Az15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PPh<sub>3</sub>, DIAD, THF; (ii) (a) methanesulfonyl chloride, NEt<sub>3</sub>, DCM, 0 °C; (b) NaN<sub>3</sub>, ACN.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazole and <i>Bis</i>-triazole Bridged Flavonoid Dimers<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) cat. Cu(PPh<sub>3</sub>)<sub>3</sub>Br, THF, reflux, 12 h.</p></p></figure><div class="NLM_p">After biological assays of these flavonoid dimers, <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub> exhibited not only high BCRP-modulating activity but also good selectivity for BCRP. These promising results encouraged us to carry out further structural optimization of these compounds with various diacetylenes including <b>Ac22–31</b>. The diacetylenes <b>Ac22–25</b> are commercially available. The diacetylenes <b>Ac26, Ac29</b>, and <b>Ac31</b> were prepared according to the previous procedure.<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(52−54)</a> Treatment of amine <b>3a</b>–<b>b</b> with propargyl bromide furnished the diacetylenes <b>Ac28</b> and <b>Ac30</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The desired <i>bis</i>-triazole bridged flavonoid dimers were furnished by treatment of azides <b>Az8</b> and <b>Az9</b> with various diacetylenes in the presence of a catalytic amount of Cu(PPh<sub>3</sub>)<sub>3</sub>Br in reasonably good yields (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The chemical structures of all alkynes, azides, and clicked dimers are summarized in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, respectively.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of Alkynes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of Azides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diacetylenes <b>Ac28 and Ac30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) propargyl bromide, acetone, rt.</p></p></figure><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Analogues of <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) cat. Cu(PPh<sub>3</sub>)<sub>3</sub>Br, THF, reflux, 12 h.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. BCRP-, MRP1-, and P-gp-Modulating Activity of Flavonoid Dimers<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0014.gif" alt="" id="gr9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0015.gif" alt="" id="GRAPHIC-d7e851-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0016.gif" alt="" id="GRAPHIC-d7e852-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0017.gif" alt="" id="GRAPHIC-d7e853-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">A total of 74 compounds were synthesized and their BCRP-, MRP1-, and P-gp-modulating activities were determined. The EC<sub>50</sub> value was used to differentiate the MDR reversal potency of these flavonoid dimers. The EC<sub>50</sub> value was presented as mean ± standard deviation. <i>N</i> = 2–7 independent experiments. L929 is a normal mouse fibroblast cell line. The cytotoxicity of these compounds toward L929 was tested. Ko143, <b>FD-4e</b>, and cyclosporine A are BCRP, MRP1, and P-gp inhibitors, respectively. They were included in the assay as positive controls. *The chemical structure, cytotoxicity, and EC<sub>50</sub> values for reversing MRP1-mediated drug resistance have been previously reported.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> Here, we included them in order to make a comparison. ND = not determined. The chemical structures of these compounds are shown in the <a class="ref internalNav" href="#notes2" aria-label="Supporting Information">Supporting Information</a>. / = not applicable.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.2.  Biological Assay Results</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.2.1.  BCRP-Modulating Activity of Triazole and <i>Bis</i>-triazole Bridged Flavonoid Dimers</h4><div class="NLM_p">For the biological assays, four different cell lines were employed in this study including (i) BCRP-transfected human embryonic kidney cell line HEK293/R2; (ii) mitoxantrone-selected breast cancer cell line MCF7-MX100 in which the BCRP transporter protein was found to be overexpressed; (iii) MRP1-transfected ovarian cancer cell line 2008/MRP1; and (iv) P-gp-transfected human breast cancer cell line LCC6MDR (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The effective concentration (EC<sub>50</sub>), at which the modulator can reduce the IC<sub>50</sub> of an anticancer drug toward a cell line by half, was used to differentiate the inhibitory potency of the flavonoid dimers. A lower EC<sub>50</sub> value implies that the flavonoid dimer displays higher potency to reverse BCRP-, MRP1-, and P-gp-mediated drug resistance. For positive controls in the biological assays, Ko143 (EC<sub>50</sub> = 9 nM in HEK293/R2 and MCF7-MX100), a BCRP-specific modulator, cyclosporine A (EC<sub>50</sub> = 32 nM in LCC6MDR), a known P-gp inhibitor, and the flavonoid dimer, <b>FD-4e</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, EC<sub>50</sub> = 111 nM in 2008/MRP1), previously reported to possess promising MRP1-modulating activity were used.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a> The triazole bridged flavonoid dimers would be considered as potent MDR chemosensitizers if they exhibit EC<sub>50</sub> values lower than that of positive controls. In addition, the cytotoxicity (IC<sub>50</sub>) of these compounds toward L929 cells, a normal mouse fibroblast cell line, was also determined as an indication of their potential toxicity. The results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_p last">Some of these flavonoid dimers exhibited potent MDR inhibitory activity against BCRP for the two cell lines HEK293/R2 and MCF7-MX100 in restoring topotecan cytotoxicity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, among the 74 compounds tested, 11 compounds, <b>Ac2Az9</b>, <b>Ac3Az4</b>, <b>Ac3Az9</b>, <b>Ac3Az11</b>, <b>Ac5Az8</b>, <b>Ac5Az9</b>, <b>Ac12Az8</b>, <b>Ac12Az9</b>, <b>Ac13Az9</b>, <b>Ac15(Az8)</b><sub><b>2</b></sub>, and <b>Ac15(Az9)</b><sub><b>2</b></sub>, display a more potent activity than Ko143 in both cell lines with EC<sub>50</sub> in the range of 0.9–7.9 nM. Equally important is the fact that these potent compounds are essentially nontoxic toward L929 with IC<sub>50</sub> > 100 μM. In contrast, Ko143 has an IC<sub>50</sub> = 31 μM. These triazole bridged flavonoid dimers are therefore potent and nontoxic inhibitors of BCRP.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">2.2.2.  Structure Activity Relationship (SAR) of Flavonoid Dimers and BCRP-Inhibitory Activity</h4><div class="NLM_p">In order to understand the SAR for inhibiting BCRP activity, we have (1) introduced various substituents at C-6 or C-7 on the A-ring or at C-3 on the C-ring of the flavonoid moiety; (2) synthesized different linker lengths between the two flavonoids; (3) located the linker at different positions of the flavonoid; and (4) designed the linker with a N-atom bearing benzyl substituent. For easier analysis of the results, we reformatted the EC<sub>50</sub> data of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> into <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>B. Each cell in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> represents the EC<sub>50</sub> of <b>AcNAzM</b> in reversing topotecan resistance in HEK293/R2 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A) or MCF7-MX100 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>B) with different color coding for different potencies. First, the potency is attributed to the presence of the two flavonoid moieties. Compound <b>Ac15(Az16)</b><sub><b>2</b></sub> contains no flavonoid and is essentially nonactive (EC<sub>50</sub> > 1000 nM) whereas all other compounds in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> with two flavonoid moieties are active (EC<sub>50</sub> 1–543 nM). Second, it is clear from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> that flavonoid dimers derived from <b>Az8</b> or <b>Az9</b> are highly potent irrespective of the Ac component to which they are coupled with EC<sub>50</sub> ranged from 1 to 24 nM. For dimers not containing <b>Az8</b> or <b>Az9</b>, the most potent compound is <b>Ac3Az4</b> with EC<sub>50</sub> = 3.1–4.0 nM, suggesting that a fluorine substitution in ring A of the azide component can enhance potency. Comparing <b>Az2</b> with <b>Az12</b> where the difference is the location of the linker, suggests that placing the linker at C-7 of the A ring in the azide component may be preferred. On the other hand, replacing an oxygen atom in the linker by a benzylamine group did not lead to lower EC<sub>50</sub> as we compare <b>Ac5Az14</b> with <b>Ac5Az1</b> or <b>Ac5Az15</b> with <b>Ac5Az11</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of EC<sub>50</sub> of Triazole Bridged Flavonoid Dimers for Reversing BCRP-, MRP1-, and P-gp-Mediated Drug Resistance<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0018.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The mean EC<sub>50</sub> (nM) value of each flavonoid dimer for reversing BCRP-, MRP1-, and P-gp mediated drug resistance is listed. A red color gradient was used to quantitatively discriminate from high-to-low MDR reversal potency. The EC<sub>50</sub> values lower than or equal to 10 nM are in red scale, bolded, and underlined. <i>N</i> = 2–7 independent experiments. (A) BCRP-modulating activity of the HEK293/R2 cell line, (B) BCRP-modulating activity of the MCF7-MX100 cell line, (C) MRP1-modulating activity of the 2008/MRP1 cell line, and (D) P-gp-modulating activity of the LCC6MDR cell line. The box in gray indicates that the flavonoid dimers have not been synthesized.</p></div></div><div></div></div><div class="NLM_p">Among the different acetylene-derived dimers, <b>Ac3AzM</b> dimers displayed the most promising BCRP inhibitory potency if we exclude the dominant effect of <b>Az8</b> and <b>Az9</b> on activity mentioned above (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>B), suggesting that 7-fluoro substitution on the A-ring in acetylene-containing flavone may play an important role in enhancing the BCRP inhibitory activity. In contrast, a 6-methyl substitution (<b>Ac5AzM</b>) on the A-ring did not increase the potency as the EC<sub>50</sub> ranged from 15 nM to 543 nM, excluding <b>Ac5Az8</b> and <b>Ac5Az9</b>. Comparing <b>Ac1Az1</b> with <b>Ac2Az1</b>, their EC<sub>50</sub> values are similar, suggesting that the location of the linker for the Ac component, either at the A or B ring, does not make a substantial difference on the activity.</div><div class="NLM_p last"><b>Ac15</b> is different from all other <b>AcN</b> considered thus far. It is a diacetylene with no flavonoid by itself. It generated flavonoid homodimers when it was coupled with 2 mol equivalents of azido monomers, <b>AzM</b>, to form <b>Ac15(AzM)</b><sub><b>2</b></sub>. Their BCRP-modulating activity appeared to be similar to other flavonoid dimers <b>AcNAzM</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, structurally, <b>Ac15(AzM)</b><sub><b>2</b></sub> contains two triazole groups in the linker whereas the other <b>AcNAzM</b> dimers have only one triazole group in the linker. The effect of such structural difference on MRP1- and P-gp-modulating activity would be further explored.</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">2.2.3.  MRP1 and P-gp Inhibitory Activity of Flavonoid Dimers</h4><div class="NLM_p last">The inhibitory activities against MRP1 and P-gp of these 74 compounds were also tested (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>C and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a><b>D</b>). Compounds <b>Ac2Az4</b>, <b>Ac3Az11</b>, <b>Ac5Az1</b>, <b>Ac12Az1</b>, <b>Ac16Az1</b>, and <b>Ac16Az2</b> displayed the highest MRP1-inhibitory potency with EC<sub>50</sub> less than 100 nM, more potent than the positive control <b>FD-4e</b> with EC<sub>50</sub> = 110.7 nM (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>C), as previously reported.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(50)</a> In contrast, all 74 compounds are less potent than the positive control, cyclosporine A (EC<sub>50</sub> = 32.0 nM), in their P-gp inhibitory activity. Compounds <b>Ac3Az11</b> and <b>Ac3Az12</b> showed the highest P-gp inhibitory potency with EC<sub>50</sub> at 68.7 and 88.5 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>D). The linker length effect of flavonoid dimers to modulate P-gp and MRP1 transporters has been previously reported for compounds of general structure I.<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52 ref53">(46−51)</a> A good inhibitor of P-gp or MRP1 should have 4 PEG linker or 5–6 PEG linker, respectively, to make the two flavone moieties bind to transporters selectively.<a onclick="showRef(event, 'ref49 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref52">(47,50)</a> Shorter or longer linkers would lead to less inhibition toward these two transporters. For the triazole-bridged flavonoid dimers in the present study, all the potent MRP1 inhibitors have linkers with 13–17 atoms between the two flavonoid moieties, similar in linker length to I with <i>n</i> = 5–6.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> For the most active P-gp inhibitors in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>D, <b>Ac3Az11</b> and <b>Ac3Az12</b> contain 13–16 atoms between the two flavonoids, slightly longer than the optimal length of I with <i>n</i> = 4 (12 atoms in between the two flavonoids). In this context, the 11 compounds, <b>Ac2Az9, Ac3Az4, Ac3Az9, Ac3Az11, Ac5Az8, Ac5Az9, Ac12Az8, Ac12Az9, Ac13Az9, Ac15(Az8)</b><sub><b>2</b></sub>, and <b>Ac15(Az9)</b><sub><b>2</b></sub><b>,</b> with the most potent activity against BCRP (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>B) contain 13–27 atoms between the two flavonoids. The linker length requirement for inhibitory activity against BCRP thus appears to be less stringent. This offers an opportunity to design inhibitors which are more selective for BCRP. Specifically, of the 11 most active compounds, the two <i>bis</i>-triazole bridged dimers, <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub>, have the longest linker length with 21 and 27 atoms, respectively. Indeed, both compounds showed only modest activity toward MRP1 (EC<sub>50</sub> = 442–458 nM) and essentially no activity toward P-gp (EC<sub>50</sub> > 1000 nM) as expected from their longer than optimal linker length for MRP1 and P-gp inhibition. They are potent (EC<sub>50</sub> = 3–5 nM), nontoxic (IC<sub>50</sub> > 100 μM toward L929 cells), and selective inhibitors of BCRP.</div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">2.2.4.  Analogues of <b>Ac15(Az8)<sub>2</sub></b> and <b>Ac15(Az9)<sub>2</sub></b> and BCRP Selectivity Relationship</h4><div class="NLM_p">We define the selectivity index of an inhibitor for transporter A over transporter B as the inverse ratio of EC<sub>50</sub> of the inhibitor for transporter A over the EC<sub>50</sub> of the same inhibitor for transporter B (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The selectivity index of <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub> is about 86–139 for BCRP over MRP1 and >189–303 for BCRP over P-gp depending on the cell lines used (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In order to further improve the BCRP selectivity, several analogues of <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub> have been synthesized by varying the structure of the diacetylene <b>Ac15</b> as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Their biological data are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. We examine first the effect of replacing the <i>N</i>-benzyl group in <b>Ac15</b> with <i>N</i>-phenyl (<b>Ac26</b>) or <i>N</i>-4-pyridinylmethyl (<b>Ac28</b>). <b>Ac26(Az8)</b><sub><b>2</b></sub> and <b>Ac26(Az9)</b><sub><b>2</b></sub> are about as potent as the <b>Ac15</b> counterparts, so both <i>N</i>-benzyl and <i>N</i>-phenyl have a significant effect on BCRP-modulation. On the other hand, replacing <i>N</i>-benzyl with <i>N</i>-4-pyridinylmethyl leads to diminished activity because <b>Ac28(Az8)</b><sub><b>2</b></sub> is much less potent than <b>Ac15(Az8)</b><sub><b>2</b></sub>. In fact, the <i>N</i>-group does not appear to be essential at all for BCRP inhibitory activity. <b>Ac24(Az8)</b><sub><b>2</b></sub> and <b>Ac25(Az8)</b><sub><b>2</b></sub> are as potent as <b>Ac15(Az8)</b><sub><b>2</b></sub> with CH<sub>2</sub> or O replacing N-benzyl, respectively. The difference between <b>Ac24</b> and <b>Ac22</b> is that the conformationally flexible three carbon CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub> chain in <b>Ac24</b> is replaced by an aromatic ring with a conformationally rigid three carbon chain (<i>m</i>-substitution) in <b>Ac22</b>. Interestingly, <b>Ac22(Az8)</b><sub><b>2</b></sub> is slightly more active than <b>Ac24(Az8)</b><sub><b>2</b></sub>. The reason may not be due to the aromatic ring because <b>Ac23(Az8)</b><sub><b>2</b></sub> is less potent than either <b>Ac22(Az8)</b><sub><b>2</b></sub> or <b>Ac24(Az8)</b><sub><b>2</b></sub>. The compounds <b>Ac29(Az8)</b><sub><b>2</b></sub><b>, Ac30(Az8)</b><sub><b>2</b></sub>, and <b>Ac31(Az8)</b><sub><b>2</b></sub> are all less potent, suggesting that the presence of two nitrogen amines in the linker did not enhance BCRP inhibition. Of the compounds in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, five dimers, <b>Ac22(Az8)</b><sub><b>2</b></sub>, <b>Ac24(Az8)</b><sub><b>2</b></sub>, <b>Ac25(Az8)</b><sub><b>2</b></sub>, <b>Ac26(Az8)</b><sub><b>2</b></sub>, and <b>Ac26(Az9)</b><sub><b>2</b></sub>, display a more potent activity than Ko143 in inhibiting BCRP in both cell lines. All five compounds are essentially nontoxic toward L929, 3T3, and HFF-1 cells (IC<sub>50</sub> > 100 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Importantly, all five compounds are essentially devoid of inhibitory activity against MRP1 and P-gp (EC<sub>50</sub> > 1000 nM) and thus are highly selective inhibitors of BCRP (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). For the moment, <b>Ac22(Az8)</b><sub><b>2</b></sub> (EC<sub>50</sub> = 1.1–2.2 nM), being the most potent BCRP inhibitor among the five, has been chosen for further biological characterization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. EC<sub>50</sub> (nM) of Ac15(Az8)<sub>2</sub> and Ac15(Az9)<sub>2</sub> Analogues for Reversing MDR and Their BCRP-Selectivity<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0019.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Thirteen <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub> analogues were synthesized and their BCRP-, MRP1-, and P-gp-modulating activities determined. The EC<sub>50</sub> value was used to differentiate the MDR reversal potency of analogues. The EC<sub>50</sub> value was presented as mean ± standard deviation. <i>N</i> = 2–4 independent experiments. L929 and 3T3 are normal mouse fibroblast cell lines. HFF-1 is a normal human skin fibroblast. The cytotoxicity of these compounds toward normal fibroblasts was tested. A specific BCRP inhibitor Ko143 was included as a positive control. A red color gradient was used to quantitatively discriminate from high-to-low BCRP selectivity over MRP1 and P-gp. The selectivity index for BCRP over MRP1 = EC<sub>50</sub> for reversing MRP1-mediated DOX resistance in 2008/MRP1 cells/EC<sub>50</sub> for reversing BCRP-mediated topotecan resistance in HEK293/R2 cells or MCF7-MX100 cells. The selectivity index for BCRP over P-gp = EC<sub>50</sub> for reversing P-gp mediated paclitaxel resistance in LCC6MDR cells/EC<sub>50</sub> for reversing BCRP-mediated topotecan resistance in HEK293/R2 cells or MCF7-MX100 cells. ND = not determined. The chemical structures of these analogues are shown in the <a class="ref internalNav" href="#notes2" aria-label="Supporting Information">Supporting Information</a>.</p></div></div><div></div></div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">2.2.5.  Potent Flavonoid Dimers Showed No Synergistic Effect with Topotecan toward Normal L929 Cells</h4><div class="NLM_p">Our flavonoid dimers were found to enhance the cancer killing activity of topotecan in BCRP-overexpressing HEK293/R2 and MCF7-MX100 cells. We would like to know whether such a drug combination also shows a synergistic effect toward normal cells. Normal mouse fibroblast L929 or BCRP-overexpressing HEK293/R2 cells were incubated with different doses of topotecan and 1 μM of clicked flavonoid dimers together. A strong synergistic effect was only observed in BCRP-overexpressing HEK293/R2 cells with RF = 21.6–36.7 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Remarkably, no potentiation effect was observed in normal L929 cells with RF = 1.1–1.7 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), indicating that a combination of topotecan and the flavonoid dimers is safe and does not enhance the killing activity of topotecan toward normal cells.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potent Clicked Flavonoid Dimers Showed No Synergistic Effect with Topotecan toward Normal L929 Cells<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char=" " /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char=" "><b>L929</b></th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" align="center" char="."><b>HEK293/R2</b></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Cpds at 1 μM</b></th><th class="colsep0 rowsep0" align="center" char=" "><b>Mean IC</b><sub><b>50</b></sub><b>of topotecan (nM)</b></th><th class="colsep0 rowsep0" align="center" char="."><b>RF</b></th><th class="colsep0 rowsep0" align="center" char="."><b>Mean IC</b><sub><b>50</b></sub><b>of topotecan (nM)</b></th><th class="colsep0 rowsep0" align="center" char="."><b>RF</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1% DMSO</td><td class="colsep0 rowsep0" align="char" char=" ">1168 ± 109</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">531.5 ± 180</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ko143</td><td class="colsep0 rowsep0" align="char" char=" ">1040 ± 27</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">24.0 ± 6.7</td><td class="colsep0 rowsep0" align="char" char=".">22.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ac15(Az8)</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="char" char=" ">668 ± 72</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">14.5 ± 1.6</td><td class="colsep0 rowsep0" align="char" char=".">36.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ac22(Az8)</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="char" char=" ">783 ± 77</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">24.6 ± 2.2</td><td class="colsep0 rowsep0" align="char" char=".">21.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ac24(Az8)</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="char" char=" ">877 ± 78</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">19.1 ± 4.2</td><td class="colsep0 rowsep0" align="char" char=".">27.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Ac25(Az8)</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="char" char=" ">851 ± 130</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">20.2 ± 4.8</td><td class="colsep0 rowsep0" align="char" char=".">26.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Normal mouse fibroblast L929 cells or HEK293/R2 cells were incubated together with different dosages of topotecan and 1 μM of potent clicked flavonoid dimers. Relative fold (RF) was determined by dividing the IC<sub>50</sub> of topotecan of a cell line without modulators by that with modulators. <i>N</i> = 3 independent experiments. The IC<sub>50</sub> value was presented as mean ± standard deviation.</p></div></div></div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">2.2.6.  <b>Ac22(Az8)<sub>2</sub></b> Selectively Reverses Mitoxantrone Resistance in BCRP-Overexpressed Cell Line but not in MRP1- or P-gp-Overexpressed Cell Lines</h4><div class="NLM_p">Mitoxantrone is an overlap substrate between BCRP, MRP1, and P-gp transporters.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(55)</a> In order to further confirm the BCRP-selectivity of <b>Ac22(Az8)</b><sub><b>2</b></sub>, a mitoxantrone sensitization assay with or without <b>Ac22(Az8)</b><sub><b>2</b></sub> was carried out using BCRP-, MRP1-, and P-gp-overexpressed cell lines. Overexpression of BCRP, MRP1, or P-gp transporter resulted in 77-, 3.5-, and 40-fold higher mitoxantrone resistance (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>A). <b>Ac22(Az8)</b><sub><b>2</b></sub> and Ko143 markedly modulated BCRP-mediated mitoxantrone resistance in HEK293/R2 with EC<sub>50</sub> of 10.5 nM and 5.4 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>B). <b>Ac22(Az8)</b><sub><b>2</b></sub> did not exhibit any MRP1- or P-gp modulating activities as EC<sub>50</sub> greater than 2000 nM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>B). However, Ko143 showed weak MRP1- and P-gp modulating activities with EC<sub>50</sub> of 1800 nM and 943 nM (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>B). Once again, the mitoxantrone sensitization assay demonstrated that <b>Ac22(Az8)</b><sub><b>2</b></sub> was highly selective toward BCRP over MRP1 or P-gp.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Ac22(Az8)<sub>2</sub> Selectively Reverses Mitoxantrone Resistance in BCRP-Overexpressed Cell Line but not MRP1- or P-gp-Overexpressed Cell Lines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center"><b>Cell lines</b></th><th class="colsep0 rowsep0" align="center" char="."><b>IC</b><sub><b>50</b></sub><b>of mitoxantrone (nM)</b></th><th class="colsep0 rowsep0" align="center" char="."><b>Resistance factor</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">HEK293/R2</td><td class="colsep0 rowsep0" align="char" char=".">903.8 ± 517.4</td><td class="colsep0 rowsep0" align="char" char=".">77.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">HEK293/pcDNA3.1</td><td class="colsep0 rowsep0" align="char" char=".">11.7 ± 7.9</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">2008/MRP1</td><td class="colsep0 rowsep0" align="char" char=".">27.5 ± 16.8</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">2008</td><td class="colsep0 rowsep0" align="char" char=".">7.8 ± 5.7</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">LCC6MDR</td><td class="colsep0 rowsep0" align="char" char=".">1501.0 ± 750.9</td><td class="colsep0 rowsep0" align="char" char=".">40.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">LCC6</td><td class="colsep0 rowsep0" align="char" char=".">37.4 ± 23.5</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr></tbody></table><table class="table "><colgroup><col /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="."><b>EC</b><sub><b>50</b></sub><b>(nM) for reversing mitoxantrone resistance</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">B</th><th class="colsep0 rowsep0" align="center"><b>Compounds</b></th><th class="colsep0 rowsep0" align="center" char="."><b>BCRP-overexpressed HEK293/R2</b></th><th class="colsep0 rowsep0" align="center"><b>MRP1-overexpressed 2008/MRP1</b></th><th class="colsep0 rowsep0" align="center"><b>P-gp-overexpessed LCC6MDR</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left"><b>Ac22(Az8)</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="char" char=".">10.5 ± 5.6</td><td class="colsep0 rowsep0" align="left">>2000</td><td class="colsep0 rowsep0" align="left">>2000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0" align="left">Ko143</td><td class="colsep0 rowsep0" align="char" char=".">5.4 ± 1.8</td><td class="colsep0 rowsep0" align="left">1800.0 ± 282.8</td><td class="colsep0 rowsep0" align="left">942.5 ± 465.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Mitoxantrone is an overlap substrate between BCRP, MRP1, and P-gp transporters. (A) The IC<sub>50</sub> of mitoxantrone toward HEK293/R2, 2008MRP1, and LCC6MDR and their parental cells were determined. Resistance-fold was calculated by dividing the mean IC<sub>50</sub> of mitoxantrone of transporter-overexpressing cell lines by its parental cells. (B) The EC<sub>50</sub> of <b>Ac22(Az8)</b><sub><b>2</b></sub> and Ko143 for reversing mitoxantrone resistance in different cell lines was also determined. <i>N</i> = 2–4 independent experiments. The IC<sub>50</sub> and EC<sub>50</sub> values were presented as mean ± standard deviation.</p></div></div></div></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">2.2.7.  BCRP Inhibitor <b>Ac22(Az8)<sub>2</sub></b> Increases Topotecan Accumulation in HEK293/R2 Cells</h4><div class="NLM_p">The above results showed that these triazole linked flavonoid dimers were potent, nontoxic, and highly selective BCRP modulators. We determined whether the modulation of BCRP-mediated topotecan resistance was associated with a concomitant increase in drug accumulation. <b>Ac22(Az8)</b><sub><b>2</b></sub> was selected for further characterization. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, BCRP-overexpressing cell line HEK293/R2 significantly accumulated 11-fold (<i>P</i> < 0.01) less topotecan accumulation as compared to its wild type. Treatment of HEK293/R2 cells with 1 μM of compound <b>Ac22(Az8)</b><sub><b>2</b></sub> (<i>P</i> < 0.01) or Ko143 (<i>P</i> < 0.005) significantly resulted in 11–12-fold increase in intracellular topotecan accumulation. The result suggests that <b>Ac22(Az8)</b><sub><b>2</b></sub> inhibits the transport activity of BCRP and restores the intracellular topotecan concentration to a level similar to that of parental HEK293/pcDNA3.1.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on intracellular topotecan accumulation in HEK293/pcDNA3.1 and HEK293/R2 cells. The cells were incubated with 50 μM topotecan for 120 min at 37 °C with or without 1 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub>, and Ko143. 0.1% of DMSO was used as negative control. After incubation, cells were washed and intracellular accumulation of topotecan was measured by flow cytometry at the FL1 channel. (A) Flow cytometric histogram of HEK293/pcDNA3.1 and HEK293/R2 cells after incubating with topotecan in the absence or presence of modulators. (B) Fluorescence level of intracellular topotecan of cells after different treatments. Experiments were performed in duplicate and repeated thrice. The fluorescence units are presented as mean ± standard deviation. Student paired <i>t</i> test was conducted relative to HEK293/R2 cells incubated with 0.1% DMSO. **<i>P</i> < 0.01 and *** <i>P</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">2.2.8.  BCRP Inhibitor <b>Ac22(Az8)<sub>2</sub></b> Does Not Affect BCRP Protein Expression Levels in HEK293/R2 Cells</h4><div class="NLM_p">We characterized the effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on surface BCRP protein expression by flow cytometric detection (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). HEK293/R2 cells highly overexpressed surface BCRP protein with 42-fold higher than the wild type HEK293/pcDNA3.1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). After incubating with 1 or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days, the high BCRP protein expression in HEK293/R2 cells remained more or less unchanged, indicating that <b>Ac22(Az8)</b><sub><b>2</b></sub> did not down-regulate the surface BCRP protein expression to sensitize the cells to topotecan. After coincubating with <b>Ac22(Az8)</b><sub><b>2</b></sub>, the increased topotecan accumulation level observed in HEK293/R2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) might be due to the loss of functionality of BCRP.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on surface BCRP protein expression. The HEK293/R2 cells were incubated with 1 or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days, respectively. The surface BCRP protein level was measured by flow cytometer at the FL1 channel. (A) Flow cytometric histogram of BCRP protein expression in HEK293/pcDNA3.1 and HEK293/R2 cells after incubating with 0.3% of DMSO. (B) Surface BCRP protein level of HEK293/R2 cells detected after incubating with 1 or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days. <i>N</i> = 2 independent experiments. The fluorescence units were presented as mean ± standard deviation. 0.3% of DMSO was used as a solvent control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">2.2.9.  <b>Ac22(Az8)<sub>2</sub></b> Inhibits Topotecan Efflux in HEK293/R2 Cells</h4><div class="NLM_p">We then performed an experiment to determine whether the increased topotecan retention in HEK293/R2 cells caused by <b>Ac22(Az8)</b><sub><b>2</b></sub> was due to inhibition of topotecan efflux (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In the efflux experiments, the topotecan preloaded cells were incubated with or without <b>Ac22(Az8)</b><sub><b>2</b></sub>. After 0, 5, 10, and 15 min, the amount of topotecan remaining inside the cells was measured by flow cytometry. In the absence of <b>Ac22(Az8)</b><sub><b>2</b></sub>, the intracellular topotecan level of wild type HEK293/pcDNA3.1 cells was gradually diminished from 100% at 0 min to 67% at 15 min (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In contrast, the topotecan level of HEK293/R2 cells was reduced from 100% at 0 min to 44% at 15 min (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), indicating that the efflux rate of HEK293/R2 cells was higher than the wild type. This difference in efflux rate may explain why HEK293/R2 cells had less accumulation and were resistant to topotecan as compared to the wild type. In the presence of 5 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub>, the topotecan efflux rate remained unchanged in wild type, whereas in HEK293/R2 cells, the topotecan efflux rate was changed. After 10 and 15 min, the intracellular topotecan levels still retained 73% (<i>P</i> < 0.05) and 58% (<i>P</i> < 0.01) in HEK293/R2 cells, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The above results demonstrate that reversal of topotecan resistance by <b>Ac22(Az8)</b><sub><b>2</b></sub> is due to an inhibition of BCRP-mediated drug efflux, leading to an increased drug accumulation and thus restoring the drug sensitivity.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on topotecan efflux in HEK293/pcDNA3.1 and HEK293/R2 cells. Topotecan preloaded cells were incubated with or without compound <b>Ac22(Az8)<sub>2</sub></b> (5 μM) at 37 °C. At 0, 5, 10, and 15 min, cells were harvested and intracellular topotecan concentration was measured by flow cytometer at the FL-1 channel. The values were presented as mean ± standard deviation. Student paired <i>t</i> test was conducted at each time point in HEK293/R2 cells after incubating with or without <b>Ac22(Az8)</b><sub><b>2</b></sub>. *<i>P</i> < 0.05 and ** <i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">2.2.10.  <b>Ac22(Az8)<sub>2</sub></b> Inhibits BCRP-ATPase Activity</h4><div class="NLM_p">In order to study whether <b>Ac22(Az8)</b><sub><b>2</b></sub> can inhibit the ATPase activity of BCRP and then block transporter efflux, membrane microsome from BCRP-overexpressed S1M180 was purified and the effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on vanadate-sensitive BCRP-ATPase activity was investigated. It was found that both Ko143 and <b>Ac22(Az8)</b><sub><b>2</b></sub> inhibited vanadate-sensitive BCRP-ATPase activity in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The higher the concentration of <b>Ac22(Az8)</b><sub><b>2</b></sub>, the lower the BCRP-ATPase activity observed. These results suggested that <b>Ac22(Az8)</b><sub><b>2</b></sub> depletes the energy supply for BCRP-mediated drug efflux via BCRP-ATPase inhibition.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on vanadate-sensitive BCRP-ATPase activity. Membrane fraction of S1M180 was collected after sonication and ultracentrifugation. Ouabain (Na+/K+-ATPase inhibitor) and sodium azide were added to the microsome fraction to inhibit non-ABC transporter ATPase activities. Ko143 and <b>Ac22(Az8)</b><sub><b>2</b></sub> were preincubated at 37 °C for 30 min, followed by 1-h incubation of 2.5 mM ATP. After stopping the reaction, the phosphate level was determined using a colorimetry method. These data were shown as mean ± standard error of mean. <i>N</i> = 3–4 independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">2.2.11.  <i>In Silico</i> Docking Studies</h4><div class="NLM_p">Several high-resolution cryo-electron microscopy (cryo-EM) structures of human BCRP in complex with its substrate estrone-3-sulfate (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO">6HCO</a>)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(56)</a> and with potent inhibitors MZ29 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>) and MB136 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ">6FEQ</a>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(44)</a> have been reported recently, allowing a better understanding of how drug binding occurs in BCRP. It was observed that the drug-binding site in the central translocation pathway of inward-facing BCRP was optimally suited to bind flat, hydrophobic, and polyphenolic molecules of either BCRP substrates or inhibitors. It has been proposed that binding of an inhibitor blocks access for substrate and prevents conformational changes necessary for ATP hydrolysis, thus accounting for the inhibitory activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(56)</a> In this study, flavonoid dimer <b>Ac22(Az8)</b><sub><b>2</b></sub> is the most promising BCRP inhibitor in terms of its high potency, low cytotoxicity, and high specificity. We were therefore interested in interrogating its interaction with BCRP with <i>in silico</i> molecular docking studies to see if these BCRP models may account for its inhibitory activity. The BCRP substrates topotecan and mitoxantrone were similarly examined. In agreement with the cryo-EM observations,<a onclick="showRef(event, 'ref46 ref58'); return false;" href="javascript:void(0);" class="ref ref46 ref58">(44,56)</a> the binding poses with the top-ranked scores positioned the inhibitor <b>Ac22(Az8)</b><sub><b>2</b></sub> and the two substrates into the same drug-binding site, which was located at the central translocation pathway of BCRP and involved mainly six transmembrane helices 1b, 1b′, 2, 2′, 5a, and 5a′ (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). Top-ranked binding poses of <b>Ac22(Az8)</b><sub><b>2</b></sub>, mitoxantrone, and topotecan using the BCRP model (6ETI) are shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B–<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>D, respectively. For other BCRP models (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO">6HCO</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ">6FEQ</a>), top-ranked binding poses are described in <a class="ref internalNav" href="#notes2" aria-label="Figures S68–S69 of the Supporting Information">Figures S68–S69 of the Supporting Information</a>. As described in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, the top-ranked scores of flavonoid dimer <b>Ac22(Az8)</b><sub><b>2</b></sub> with all three BCRP models were generally much lower than that of mitoxantrone and topotecan, suggesting that <b>Ac22(Az8)</b><sub><b>2</b></sub> may bind preferentially to BCRP and block the access for the substrates topotecan or mitoxantrone.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Top-Ranked Scores of Ligands Using Different cryo-EM Structures of BCRP</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">Ligands docked</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PDB ID</th><th class="colsep0 rowsep0" align="center"><b>Ac22(Az8)</b><sub><b>2</b></sub></th><th class="colsep0 rowsep0" align="center">Topotecan</th><th class="colsep0 rowsep0" align="center">Mitoxantrone</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO">6HCO</a></td><td class="colsep0 rowsep0" align="left">–126</td><td class="colsep0 rowsep0" align="left">–80</td><td class="colsep0 rowsep0" align="left">–82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a></td><td class="colsep0 rowsep0" align="left">–137</td><td class="colsep0 rowsep0" align="left">–88</td><td class="colsep0 rowsep0" align="left">–92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ">6FEQ</a></td><td class="colsep0 rowsep0" align="left">–122</td><td class="colsep0 rowsep0" align="left">–81</td><td class="colsep0 rowsep0" align="left">–91</td></tr></tbody></table></div></div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In silico</i> docking study using the cryo-EM structure of BCRP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>). (A) Ribbon diagram of the overall human BCRP homodimer with labeled TMD, NBD, and “leucine plug”. The red square indicates the location of the binding pocket of estrone-3-sulfate, MZ29, MB136, mitoxantrone, topotecan, and <b>Ac22(Az8)</b><sub><b>2</b></sub>. Top-ranked binding poses of (B) inhibitor <b>Ac22(Az8)</b><sub><b>2</b></sub> (blue sticks), (C) substrate mitoxantrone (deep green sticks), and (D) substrate topotecan (brown sticks). Transmembrane helices 1b, 1b′, 2, 2′, 5a, and 5a′ are labeled in red. Important amino acid residues (gray sticks) are highlighted in black, and hydrogen bonding interactions are indicated as dotted blue lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Detailed analysis of binding poses of <b>Ac22(Az8)</b><sub><b>2</b></sub> with the BCRP model (6ETI) revealed that strong π–π interactions were formed between the linker part 1,3-<i>bis</i>-(triazol-4-yl)benzene of <b>Ac22(Az8)</b><sub><b>2</b></sub> and Phe439 of helix 2′ as well as between one of the benzyl groups of <b>Ac22(Az8)</b><sub><b>2</b></sub> and Phe547 of helix 5a (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Although there was no hydrogen bonding interaction predicted to occur between <b>Ac22(Az8)</b><sub><b>2</b></sub> and BCRP; there were, however, extensive networks of van der Waals contacts with many amino acid residues inside the drug-binding site of BCRP, thus providing strong interaction with BCRP. Particularly, this interaction involved amino acid residues of helix 5a (Phe551, Met549, Val546, Ile543, Thr542, Thr538, Val534), helix 2 (Phe432, Ser440, Phe439, Thr435, Ser443, Val442, Glu446, Val445), helix 1b (Val401, Gln398), helix 2′ (Phe432, Asn436, Thr435, Ser440), helix 1b′ (Ile412, Val408, Val404, Leu405, Val401, Ile400), and helix 5a′ (Met549, Val546, Ile543, Thr542, Thr538, Leu539). It has been proposed by Locher’s group that a “leucine plug” (Leu554 and Leu555), which was located in a flexible loop between helix 5a and 5b, acts as a gate to allow BCRP substrate moving outside (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(56)</a> Interestingly, one of the flavonoid moieties of <b>Ac22(Az8)</b><sub><b>2</b></sub> is predicted to insert into a cavity between helix 5a and 5b and form van der Waals contacts with amino acid residues of helix 5a and 5b (Leu568, Leu565). We, therefore, believed that by occupying the cavity, this flavonoid moiety might reduce the flexibility of this loop and allow only very limited movement of the “leucine plug”. This may obstruct the gate-opening function of the “leucine plug” and account for its inhibitory activity. More importantly, structural comparison between transporters P-gp, MRP1, and BCRP revealed that such cavity exists only in BCRP but not in P-gp or MRP1.<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(57−59)</a> We, therefore, reasoned that the high BCRP specificity of <b>Ac22(Az8)</b><sub><b>2</b></sub> over P-gp and MRP1 may be attributed to this structural difference. Careful evaluation of binding poses of BCRP substrates topotecan and mitoxantrone revealed that both ligands occupied exactly the same drug-binding area as the linker part 1,3-<i>bis</i>-(triazol-4-yl)benzene of <b>Ac22(Az8)</b><sub><b>2</b></sub> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a><b>C–D</b>). As both ligands are flat and polyaromatic molecules, strong π–π interactions were predicted to form between the ligands and Phe439 of helix 2′ and helix 2. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C, multiple hydrogen bonding interactions were also observed between the mitoxantrone (amino-alcohol side chains and phenol group) and amino acid residues (Thr435 of helix 2 and 2′, Phe439 of helix 2′) of BCRP. On the contrary, only one hydrogen bonding interaction was observed between the phenyl group of topotecan and Thr435 of helix 2 of BCRP (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D).</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">3.  Discussions and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71867" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71867" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several clinical trials using P-gp inhibitors together with anticancer drug had been evaluated to overcome MDR but led to disappointing outcomes,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> possibly due to the effect of the inhibitor on the pharmacokinetics of the anticancer drug.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, there is still a need to develop MDR inhibitors for clinical use to reverse MDR in cancer patients. Further improvement of inhibitors of ABC transporters should not only focus on potency but also improve specificity to minimize such potential drug–drug interaction.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">In this study, we have successfully used the CuAAC reaction to rapidly synthesize various flavonoid dimers. In a 74-member homo- and hetero-flavonoid dimer library, we found that many of these dimers generally displayed no cytotoxicity and strong inhibition against BCRP (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Fifteen of them displayed higher BCRP inhibitory potency than Ko143, the most potent BCRP-specific inhibitor thus far reported,<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(36,37)</a> with EC<sub>50</sub> values less than 10 nM for reversing topotecan resistance (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_p">Some information was drawn regarding the SAR for BCRP-inhibition and selectivity. Structural features which can enhance BCRP-inhibition activity are (1) two flavonoid moieties, (2) a benzyloxy substitution at the C-3 of the C-ring of the flavone (<b>Az5-</b>, <b>Az8</b>-, <b>Az9</b>-, and <b>Az10</b>- dimers), and (3) 7-fluoro substitution on the A-ring of the flavone (<b>Ac3</b>-clicked dimers). To make a highly selective BCRP inhibitor, we demonstrated that extending the linker length using <i>bis</i>-triazole (<b>Ac15</b>-clicked dimers) between two flavones is a simple and promising approach. We previously showed that potent P-gp and MRP1 inhibitors required an optimal linker length between the two flavones, with about 13–15 atoms and 13–17 atoms, respectively. In contrast, the linker length needed for active BCRP inhibitor appeared to be more flexible, with about 13–27 atoms. Thus, <b>Ac15(Az8)</b><sub><b>2</b></sub> (linker length with 21 atoms) and <b>Ac15(Az9)</b><sub><b>2</b></sub> (linker length with 27 atoms) with <i>bis</i>-triazole in the linker resulted in very low inhibitory activity toward P-gp and MRP1 and therefore high BCRP selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Further modification of the <i>bis</i>-triazole structure led to several compounds with high potency, low cytotoxicity, and high specificity. In particular, <b>Ac22(Az8)</b><sub><b>2</b></sub> was found to have low toxicity toward L929, 3T3, and HFF-1 cells (IC<sub>50</sub> > 100 μM), high potency in BCRP inhibitory activity (EC<sub>50</sub> = 1–2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp > 455–909) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It had about 5- to 8-fold and 2- to 8-fold higher BCRP-modulating activity and selectivity than Ko143, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It was found to inhibit the BCRP-ATPase activity <b>(</b><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a><b>)</b> and block the efflux activity of BCRP (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), thus elevating the intracellular drug accumulation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) and finally restoring the drug sensitivity of the BCRP-overexpressing cells (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It did not down-regulate the surface BCRP protein expression to enhance the drug retention (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Interestingly, an <i>in silico</i> docking study shows that it binds to the same drug-binding site, consistent with the cryo-EM structures revealed for BCRP in complex with substrate/inhibitor.</div><div class="NLM_p last">Because these flavonoid dimers have high molecular weights (e.g., MW: 1156 for <b>Ac22(Az8)</b><sub><b>2</b></sub>) and hydrophobic linker, there is concern about the druggability of these flavonoid dimers. <i>In vivo</i> experiments regarding the pharmacokinetics and efficacy to overcome MDR cancers with BCRP overexpression are needed. Such experiments will be reported in due course.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(60)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.1.  Materials and Methods</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.1.1.  General</h4><div class="NLM_p last">All NMR spectra were recorded on a Bruker Advance-III 400 MHz spectrometer at 400 MHz for <sup>1</sup>H and 101 MHz for <sup>13</sup>C, Varian Unity Inova 500 MHz NMR Spectrometer at 500 MHz for <sup>1</sup>H and 101 MHz for <sup>13</sup>C or Bruker Advance-III 600 MHz spectrometer at 600 MHz for <sup>1</sup>H and 151 MHz for <sup>13</sup>C. All NMR measurements were carried out at room temperature, and the chemical shifts are reported as parts per million (ppm) in unit relative to the resonance of CDCl<sub>3</sub> (7.26 ppm in the <sup>1</sup>H, 77.0 ppm for the central line of the triplet in the <sup>13</sup>C modes, respectively). Low-resolution and high-resolution mass spectra were obtained on a Micromass Q-TOF-2 by electron spray ionization (ESI) mode or on Finnigan MAT95 ST by electron ionization (EI) mode. All reagents and solvents were reagent grade and were used without further purification unless otherwise stated. The plates used for thin-layer chromatography (TLC) were E. Merck Silica Gel 60F<sub>254</sub> (0.25 mm thickness), and they were visualized under short (254 nm) and long (365 nm) UV light. Chromatographic purifications were carried out using MN silica gel 60 (230–400 mesh). The purity of tested compounds was determined by HPLC, which was performed by using Agilent 1100 series installed with an analytic column of Agilent Prep-Sil Scalar column (4.6 mm × 250 mm, 5-μm) at UV detection of 254 nm (reference at 450 nm) with gradient elution of dichloromethane (10%)/methanol (90%) to dichloromethane (1%)/methanol (99%) at a flow rate of 1.0 mL/min. All tested compounds were shown to have >95% purity according to HPLC.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.2.  <b>Procedure for the Synthesis of Ac1, Ac2, Ac3, Ac5, Ac12, Ac13, Ac15, Ac16, Ac22, Ac23, Ac24, Ac25, Ac26, Ac28, Ac29, Ac30</b>, and <b>Ac31</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">4.2.1.  Synthesis of 2-(4-(Pent-4-yn-1-yloxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">4.2.2.  Synthesis of 7-(Pent-4-yn-1-yloxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac2</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35">4.2.3.  Synthesis of 7-Fluoro-2-(4-(pent-4-yn-1-yloxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac3</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36">4.2.4.  Synthesis of 7-(Hex-5-yn-1-yloxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac12</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37">4.2.5.  Synthesis of 2-Phenyl-7-(2-(prop-2-yn-1-yloxy)ethoxy)-4<i>H</i>-chromen-4-one (<b>Ac13</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38">4.2.6.  <i>N</i>-Benzyl-<i>N</i>,<i>N</i>-di(prop-2-yn-1-yl)amine (<b>Ac15</b>)</h4><div class="NLM_p last">This compound was commercially available.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">4.2.7.  Synthesis of 7-(2-(Benzyl(prop-2-yn-1-yl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">4.2.8.  -<i>m</i>-Diethynylbenzene (<b>Ac22</b>)</h4><div class="NLM_p last">This compound was commercially available.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41">4.2.9.  1,4-Diethynylbenzene (<b>Ac23</b>)</h4><div class="NLM_p last">This compound was commercially available.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42">4.2.10.  Hepta-1,6-diyne (<b>Ac24</b>)</h4><div class="NLM_p last">This compound was commercially available.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43">4.2.11.  3-(Prop-2-yn-1-yloxy)prop-1-yne (<b>Ac25</b>)</h4><div class="NLM_p last">This compound was commercially available.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44">4.2.12.  Synthesis of <i>N</i>,<i>N</i>-Di(prop-2-yn-1-yl)aniline (<b>Ac26</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(54)</a></div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45">4.2.13.  Synthesis of <i>N</i>-(Prop-2-yn-1-yl)-<i>N</i>-(pyridin-4-ylmethyl)prop-2-yn-1-amine (<b>Ac28</b>)</h4><div class="NLM_p last">To a solution of <b>3a</b> (1.00 g, 9.26 mmol) in acetone (25 mL) at room temperature was added excess propargyl bromide (2.20 g, 18.52 mmol) solution. The reaction mixture was then stirred at room temperature for 12 h. The solution was rotary evaporated followed by column chromatography on silica gel using hexane and EA in 3:1 to afford the desired compound (0.652g, 3.37 mmol, 38.3%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29 (t, <i>J</i> = 2.20 Hz, 1 H), 3.43 (d, <i>J</i> = 2.45 Hz, 2 H), 3.72 (s, 1 H), 7.32 (d, <i>J</i> = 5.38 Hz, 1 H), 8.57 (d, <i>J</i> = 5.62 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 42.1, 55.8, 73.5, 78.3, 123.8, 147.0, 149.9; LRMS (ESI) <i>m</i>/<i>z</i> 185 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub> [M + H]<sup>+</sup> 185.2450, found 185.2469.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46">4.2.14.  Synthesis of 1,4-Di(prop-2-yn-1-yl)piperazine (<b>Ac29</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47">4.2.15.  Synthesis of 1,4-Di(prop-2-yn-1-yl)-1,4-diazepane (<b>Ac30</b>)</h4><div class="NLM_p last">To a solution of <b>3b</b> (1.00g, 10.00 mmol) in acetone (25 mL) at room temperature, was added excess propargyl bromide (3.57g, 30.00 mmol) solution. The reaction mixture was then stirred at room temperature for 12 h. The solution was rotary evaporated followed by column chromatography on silica gel using hexane and EA in 100:1 to afford the desired compound (0.972 g, 5.52 mmol, 55.2%); <sup>1</sup>H NMR (400 MHz, CHLOROFORM-d) d 1.87 (quin, <i>J</i> = 5.99 Hz, 2 H), 2.21 (t, <i>J</i> = 2.32 Hz, 2 H), 2.75–2.85 (m, 8 H), 3.40 (d, <i>J</i> = 2.45 Hz, 4 H) ; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 27.7, 47.6, 53.5, 54.4, 72.3, 79.8; LRMS (ESI) <i>m</i>/<i>z</i> 177 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>11</sub>H<sub>17</sub>N<sub>2</sub> [M + H]<sup>+</sup> 177.2661, found 177.2678.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48">4.2.16.  Synthesis of <i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-Dimethyl-<i>N</i><sup>1</sup>,<i>N</i><sup>2</sup>-di(prop-2-yn-1-yl)ethane-1,2-diamine (<b>Ac31</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">4.3.  Procedure for the Synthesis of <b>Az1</b>, <b>Az2</b>, <b>Az3</b>, <b>Az4</b>, <b>Az5</b>, <b>Az7</b>, <b>Az10</b>, <b>Az11</b>, <b>Az12</b>, <b>Az13</b>, <b>Az14</b>, <b>Az16</b>, and <b>Az17</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">4.3.1.  Synthesis of 2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">4.3.2.  Synthesis of 2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Az2</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">4.3.3.  Synthesis of 2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-6-methyl-4<i>H</i>-chromen-4-one (<b>Az3</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">4.3.4.  Synthesis of 2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-6-fluoro-4<i>H</i>-chromen-4-one (<b>Az4</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54">4.3.5.  Synthesis of 2-(4-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)phenyl)-3-(benzyloxy)-4<i>H</i>-chromen-4-one (<b>Az5</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55">4.3.6.  Synthesis of 2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-6-fluoro-4<i>H</i>-chromen-4-one (<b>Az7</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56">4.3.7.  Synthesis of Methyl 3-(((2-(4-(2-(2-azidoethoxy)ethoxy)phenyl)-4-oxo-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Az8</b>)</h4><div class="NLM_p last">The starting material <b>1a</b> was prepared according the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> A round-bottom flask was charged with <b>1a</b> (5 mmol, 2.2 g), a catalytic amount of Pd(OH)<sub>2</sub> and THF/MeOH (1:1–10 mL). The reaction mixture was stirred vigorously under H<sub>2</sub> atmosphere at balloon pressure and room temperature for 14 h. When TLC indicated complete consumption of the starting material, the charcoal was removed by suction filtration. The pale-yellow filtrate was purified by passing through a short pad of silica gel to furnish debenzylated product 3-hydroxy-2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (76%, 1.3 g). To a round-bottom flask was charged the debenzylated product, methyl 3-(bromomethyl)benzoate (4 mmol, 0.92 g), K<sub>2</sub>CO<sub>3</sub> (4 mmol, 0.55 g), and acetone (10 mL). The reaction mixture was stirred at refluxing temperature for 12 h. When TLC indicated complete consumption of starting material, solvent was rotary evaporated to dryness. Purification was performed by flash column chromatography on silica gel with acetone in DCM as eluent to furnish <b>1c</b> (86%, 1.6 g). The hydroxylated flavone <b>1c</b> was then dissolved in a solution of DCM (10 mL) and triethylamine (2 mL) at 0 °C. Methanesulfonyl chloride (5 mmol, 0.56 g) was then added dropwise, and the reaction mixture was stirred for 1 h at room temperature. When TLC indicated complete consumption of the starting material, the white precipitate formed was removed by passing through a short pad of silica gel to furnish the mesylated product which was sufficiently pure for the next step. To a solution of the mesylate in ACN (15 mL) was added excess sodium azide (15 mmol, 0.98 g). The solution was kept for reflux at 80 °C for 15 h. The resulting solution was treated with water and then extracted with DCM. The combined organic layer was dried over MgSO<sub>4</sub> and concentrated at reduced pressure to give pale yellow viscous liquid. Purification was performed by flash column chromatography on silica gel with acetone in DCM as eluent to furnish desired product <b>Az8</b> (0.29 g, 57%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.44 (t, <i>J</i> = 4.88 Hz, 2 H), 3.76–3.79 (m, 2 H), 3.89 (s, 3 H), 3.90–3.94 (m, 2 H), 4.20–4.25 (m, 2 H), 5.15 (s, 2 H), 6.99 (d, <i>J</i> = 8.79 Hz, 2 H), 7.35 (t, <i>J</i> = 7.81 Hz, 1 H), 7.41 (t, <i>J</i> = 7.57 Hz, 1 H), 7.52 (d, <i>J</i> = 8.30 Hz, 1 H), 7.59 (d, <i>J</i> = 7.32 Hz, 1 H), 7.65–7.71 (m, 1 H), 7.93 (d, <i>J</i> = 7.81 Hz, 1 H), 7.96–8.01 (m, 3 H), 8.29 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.73, 52.03, 67.52, 69.64, 70.31, 73.36, 114.41, 117.93, 123.46, 124.19, 124.65, 125.77, 128.29, 129.27, 129.81, 130.13, 130.54, 133.24, 133.30, 137.18, 139.07, 155.22, 156.51, 160.62, 166.82, 174.87; LRMS (ESI) <i>m</i>/<i>z</i> 516 [M + H]<sup>+</sup>, 538 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>28</sub>H<sub>26</sub>N<sub>3</sub>O<sub>7</sub> [M + H]<sup>+</sup> 516.1771, found 516.1783; calcd for C<sub>28</sub>H<sub>25</sub>N<sub>3</sub>O<sub>7</sub>Na [M + Na]<sup>+</sup> 538.1590, found 538.1583.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57">4.3.8.  Synthesis of Methyl 3-(((2-(4-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)phenyl)-4-oxo-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Az9</b>)</h4><div class="NLM_p last">The starting material <b>1b</b> was prepared according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a> The title compound <b>Az9</b> (0.62g, 37%) was obtained from <b>1b</b> (3 mmol, 1.5 g) according to the procedure for the synthesis of <b>Az8</b> described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.40 (t, <i>J</i> = 4.39 Hz, 2 H), 3.67–3.74 (m, 5 H), 3.74–3.79 (m, 2 H), 3.89 (s, 3 H), 3.92 (t, <i>J</i> = 4.15 Hz, 2 H), 4.22 (t, <i>J</i> = 4.15 Hz, 2 H), 5.15 (s, 2 H), 6.98 (d, <i>J</i> = 8.79 Hz, 2 H), 7.35 (t, <i>J</i> = 7.81 Hz, 1 H), 7.42 (t, <i>J</i> = 7.57 Hz, 1 H), 7.52 (d, <i>J</i> = 8.79 Hz, 1 H), 7.59 (d, <i>J</i> = 6.34 Hz, 1 H), 7.65–7.70 (m, 1 H), 7.93 (d, <i>J</i> = 7.50 Hz, 1 H), 7.96–8.01 (m, 3 H), 8.29 (d, <i>J</i> = 8.30 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.71, 52.04, 67.55, 69.71, 70.12, 70.78, 70.94, 73.35, 114.41, 117.92, 123.36, 124.20, 124.64, 125.78, 128.29, 129.28, 129.80, 130.14, 130.52, 133.23, 133.30, 137.19, 139.07, 155.23, 156.53, 160.73 166.82, 174.87; LRMS (ESI) <i>m</i>/<i>z</i> 560 [M + H]<sup>+</sup>, 582 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>30</sub>H<sub>30</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 560.2033, found 560.2028; calcd for C<sub>30</sub>H<sub>29</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 582.1852, found 582.1831.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58">4.3.9.  Synthesis of 2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-3-(benzyloxy)-4<i>H</i>-chromen-4-one (<b>Az10</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59">4.3.10.  Synthesis of 7-(2-(2-Azidoethoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Az11</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60">4.3.11.  Synthesis of 7-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Az12</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61">4.3.12.  Synthesis of 7-(2-Azidoethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Az13</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62">4.3.13.  Synthesis of 2-(4-(2-((2-Azidoethyl)(benzyl)amino)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Az14</b>)</h4><div class="NLM_p last">The starting material <b>2b</b> was prepared according the procedure as described.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(48)</a> To a well stirred solution of <b>2b</b> (3 mmol, 0.71g), <i>N</i>-benzyl-<i>N</i>,<i>N</i>-di(2-hydroxyethyl)amine (3 mmol, 0.6 g), and PPh<sub>3</sub> (3 mmol, 0.79g) in THF (20 mL) at room temperature was added DIAD (3 mmol, 0.59 mL) dropwise. The reaction mixture was then stirred for 12 h at room temperature. When TLC indicated complete consumption of starting material, the reaction mixture was evaporated to give a brown crude reaction mixture. Purification was performed by flash column chromatography on silica gel with acetone in DCM (1:10) as eluent to furnish intermediate compound 2-(4-(2-(benzyl(2-hydroxyethyl)amino)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (0.13g, 10.4%). The hydroxylated flavone was then dissolved in a solution of DCM (2 mL) and triethylamine (0.5 mL) at 0 °C. Methanesulfonyl chloride (0.5 mmol, 0.06 g) was then added dropwise and stirred for 1 h at room temperature. When TLC indicated complete consumption of the starting material, the white precipitate formed was removed by passing through a short pad of silica gel to furnish the mesylated product which was sufficiently pure for the next step. To a solution of the mesylate in ACN (2 mL) was added excess sodium azide (5 mmol, 0.32 g). The solution was kept for reflux at 80 °C for 15 h. The resulting solution was treated with water and then extracted with DCM. The combined organic layer was dried over MgSO<sub>4</sub> and concentrated at reduced pressure to give a pale yellow viscous liquid. Purification was performed by flash column chromatography on silica gel with acetone in DCM as eluent to furnish the desired product <b>Az14</b> (10 mg, 17%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.91 (br. s., 2 H), 3.03 (br. s., 2 H), 3.32 (br. s., 2 H), 3.80 (br. s., 2 H), 4.15 (br. s., 2 H), 6.77 (s, 1 H), 6.92–6.96 (m, 2 H), 7.27–7.37 (m, 5 H), 7.49–7.56 (m, 3 H), 7.89–7.93 (m, 2 H), 8.13 (d, <i>J</i> = 8.30 Hz, 1 H); LRMS (ESI) <i>m</i>/<i>z</i> 441 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>26</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 441.1927, found 441.1909.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63">4.3.14.  7-(2-((2-Azidoethyl)(benzyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Az15</b>)</h4><div class="NLM_p last">The starting material <b>2c</b> was commercially available. The titled compound <b>Az15</b> (12 mg, 22%) was obtained from <b>2c</b> according to the procedure for the synthesis of <b>Az14</b> described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.90 (br. s., 2 H), 3.00 (br. s., 2 H), 3.32 (br. s., 2 H), 3.79 (s, 2 H), 4.11 (br. s., 2 H), 6.75 (s, 1 H), 6.98 (m, <i>J</i> = 8.79 Hz, 2 H), 7.26–7.44 (m, 6 H), 7.54–7.58 (m, 1 H), 7.66–7.71 (m, 1 H), 7.84–7.91 (m, 2 H), 8.23 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); LRMS (ESI) <i>m</i>/<i>z</i> 441 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>26</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 441.1927, found 441.1908.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64">4.3.15.  Synthesis of 2-(2-Azidoethoxy)ethanol (<b>Az16</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(61)</a></div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65">4.3.16.  Synthesis of 2-(4-(2-(2-Azidoethoxy)ethoxy)phenyl)-3-((3-methoxybenzyl)oxy)-4H-chromen-4-one (<b>Az17</b>)</h4><div class="NLM_p">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div><div class="NLM_p last">Synthesis of <i>anti</i>-triazole bridged flavonoid dimers.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66">4.4.  General Procedure for the Synthesis of Antitriazole Bridged Flavonoid Dimers Catalyzed by Cu(I)</h3><div class="NLM_p">The Cu(PPh<sub>3</sub>)<sub>3</sub>Br catalyst (MW = 929) (0.05 mmol), prepared according to the literature,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(62)</a> was added to a THF solution (2 mL) containing the azide (<b>Az,</b> 0.1 mmol for Ac with one acetylene or 0.2 mmol for Ac with two acetylenes) and the alkyne (<b>Ac</b>, 0.1 mmol). The reaction mixture was stirred overnight under reflux conditions. The crude residue was purified by flash chromatography on silica gel using a gradient of 10–50% of acetone with CH<sub>2</sub>Cl<sub>2</sub> to afford the desired compound.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67">4.4.1.  Synthesis of 2-(4-(3-(1-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac1Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68">4.4.2.  Synthesis of 7-(3-(1-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac2Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69">4.4.3.  Synthesis of 7-(3-(1-(2-(2-(2-(4-(4-Oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)-2-phenyl-4H-chromen-4-one (<b>Ac2Az2</b>)</h4><div class="NLM_p last">This compound (50 mg) was obtained from <b>Ac2</b> and <b>Az2</b> in 72% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.17–2.26 (m, 2 H), 2.90 (t, <i>J</i> = 7.5 Hz, 2 H), 3.59–3.70 (m, 4 H), 3.78–3.90 (m, 4 H), 4.07 (t, <i>J</i> = 6.3 Hz, 2 H), 4.12–4.19 (m, 2 H), 4.52 (t, <i>J</i> = 5.0 Hz, 2 H), 6.70 (s, 1 H), 6.72 (s, 1 H), 6.87–7.03 (m, 4 H), 7.32–7.41 (m, 1 H), 7.42–7.56 (m, 5 H), 7.60–7.69 (m, 1 H), 7.78–7.90 (m, 4 H), 8.08 (d, <i>J</i> = 8.8 Hz, 1 H), 8.17 (dd, <i>J</i> = 7.9, 1.7 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 22.14, 28.77, 50.28, 67.70, 67.71, 69.64, 69.73, 70.64, 70.85, 100.98, 106.30, 107.56, 114.88, 115.08, 117.85, 118.05, 122.35, 123.97, 124.37, 125.23, 125.74, 126.24, 127.09, 128.10, 129.12, 131.56, 131.86, 133.73, 146.82, 156.22, 158.06, 161.59, 163.09, 163.29, 163.63, 177.96, 178.46. LRMS (ESI) <i>m</i>/<i>z</i> 700 [M + H]<sup>+</sup>, 722 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>38</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 700.2659, found 700.2637; calcd for C<sub>41</sub>H<sub>37</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 722.2478, found 722.2461.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70">4.4.4.  Synthesis of 6-Methyl-2-(4-(2-(2-(2-(4-(3-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (<b>Ac2Az3</b>)</h4><div class="NLM_p last">This compound (63 mg) was obtained from <b>Ac2</b> and <b>Az3</b> in 88% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.14–2.24 (m, 2 H), 2.38 (s, 3 H), 2.87 (t, <i>J</i> = 7.5 Hz, 2 H), 3.57–3.68 (m, 4 H), 3.79 (t, <i>J</i> = 4.6 Hz, 2 H), 3.84 (t, <i>J</i> = 5.0 Hz, 2 H), 4.03 (t, <i>J</i> = 6.2 Hz, 2 H), 4.12 (t, <i>J</i> = 4.6 Hz, 2 H), 4.50 (t, <i>J</i> = 5.0 Hz, 2 H), 6.63 (s, 1 H), 6.67 (s, 1 H), 6.85 (d, <i>J</i> = 2.3 Hz, 1 H), 6.89 (dd, <i>J</i> = 8.8, 2.4 Hz, 1 H), 6.92–6.98 (m, 2 H), 7.33 (d, <i>J</i> = 8.5 Hz, 1 H), 7.40 (s, 1 H), 7.42–7.49 (m, 3 H), 7.53 (s, 1 H), 7.74–7.80 (m, 2 H), 7.80–7.85 (m, 2 H), 7.90 (s, 1 H), 8.04 (d, <i>J</i> = 8.8 Hz, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ ppm 22.05, 28.68, 50.16, 67.60, 67.64, 69.54, 69.62, 70.53, 70.74, 100.86, 105.99, 107.38, 114.76, 114.94, 117.69, 117.72, 122.23, 123.48, 124.32, 124.94, 126.10, 126.91, 127.92, 129.00, 131.44, 131.71, 134.81, 135.03, 146.71, 154.35, 157.91, 161.42, 162.91, 163.00, 163.51, 177.76, 178.38; LRMS (ESI) <i>m</i>/<i>z</i> 714 [M + H]<sup>+</sup>, 736 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>42</sub>H<sub>40</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 714.2815, found 714.2808; calcd for C<sub>42</sub>H<sub>39</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 736.2635, found 736.2615.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71">4.4.5.  Synthesis of 6-Fluoro-2-(4-(2-(2-(2-(4-(3-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (<b>Ac2Az4</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72">4.4.6.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(3-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (<b>Ac2Az5</b>)</h4><div class="NLM_p last">This compound (51 mg) was obtained from <b>Ac2</b> and <b>Az5</b> in 63% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CHLOROFORM-<i>d</i>) δ ppm 2.16–2.30 (m, 2H), 2.91 (t, <i>J</i> = 7.5 Hz, 2H), 3.55–3.73 (m, 4H), 3.79–3.95 (m, 4H), 4.08 (t, <i>J</i> = 6.2 Hz, 2H), 4.17 (t, <i>J</i> = 4.6 Hz, 2H), 4.53 (t, <i>J</i> = 5.0 Hz, 2H), 5.10 (s, 2H), 6.73 (s, 1H), 6.94 (m, 4H), 7.28 (dt, <i>J</i> = 7.0, 2.3 Hz, 3H), 7.37 (td, <i>J</i> = 6.3, 5.1, 3.1 Hz, 3H), 7.44–7.52 (m, 4H), 7.56 (s, 1H), 7.61–7.67 (m, 1H), 7.83–7.91 (m, 2H), 7.99–8.06 (m, 2H), 8.08 (d, <i>J</i> = 8.7 Hz, 1H), 8.24 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 22.04, 28.67, 50.17, 67.50, 67.64, 69.60, 69.63, 70.54, 70.73, 73.92, 100.88, 107.42, 114.31, 114.83, 117.71, 117.92, 122.29, 123.59, 124.12, 124.66, 125.71, 126.15, 126.94, 128.14, 128.28, 128.82, 129.03, 130.56, 131.47, 131.74, 133.34, 136.78, 139.30, 146.73, 155.12, 156.09, 157.96, 160.55, 163.01, 163.55, 174.96, 177.88. LRMS (ESI) <i>m</i>/<i>z</i> 806 [M + H]<sup>+</sup>, 828 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>44</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 806.3078, found 806.3089; calcd for C<sub>48</sub>H<sub>43</sub>N<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 828.2897, found 828.2889.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73">4.4.7.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(4-(3-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate (<b>Ac2Az8</b>)</h4><div class="NLM_p last">This compound (58 mg) was obtained from <b>Ac2</b> and <b>Az8</b> in 71% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.23 (s, 2 H), 3.00 (s, 2 H), 3.78–3.96 (m, 5 H), 3.95–4.17 (m, 6 H), 4.65 (s, 2 H), 5.10 (s, 2 H), 6.72 (s, 1 H), 6.96–6.83 (m, 4 H), 7.28–7.38 (m, 2 H), 7.39–7.52 (m, 4 H), 7.56 (d, <i>J</i> = 7.5 Hz, 1 H), 7.59–7.65 (m, 1 H), 7.80–7.87 (m, 3 H), 7.89 (d, <i>J</i> = 7.7 Hz, 1 H), 7.92–8.10 (m, 4 H), 8.21 (dd, <i>J</i> = 8.0, 1.5 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 21.80, 28.49, 52.22, 67.38, 67.71, 69.49, 69.66, 73.41, 101.01, 107.23, 114.35, 114.92, 117.99, 123.54, 124.09, 124.82, 125.75, 126.27, 126.91, 128.43, 129.09, 129.36, 129.88, 130.11, 130.65, 131.59, 131.61, 133.35, 133.51, 137.17, 139.08, 155.17, 156.36, 157.95, 160.48, 163.24, 163.58, 166.89, 174.91, 177.98. LRMS (ESI) <i>m</i>/<i>z</i> 820 [M + H]<sup>+</sup>, 842 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>42</sub>N<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup> 820.2870, found 820.2883; calcd for C<sub>48</sub>H<sub>41</sub>N<sub>3</sub>O<sub>10</sub>Na [M + Na]<sup>+</sup> 842.2690, found 842.2665.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74">4.4.8.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(2-(4-(3-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-3-yl)oxy)methyl)benzoate (<b>Ac2Az9</b>)</h4><div class="NLM_p last">This compound (24 mg) was obtained from <b>Ac2</b> and <b>Az9</b> in 68% yield according to the general procedure described above. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 8.27 (d, <i>J</i> = 8.80 Hz, 1H), 8.11 (d, <i>J</i> = 8.80 Hz, 1H), 7.97–8.01 (m, 3H), 7.94 (d, <i>J</i> = 8.80 Hz, 1H), 7.90 (d, <i>J</i> = 7.34 Hz, 2H), 7.65–7.70 (m, 1H), 7.61 (d, <i>J</i> = 7.34 Hz, 1H), 7.46–7.58 (m, 5H), 7.41 (t, <i>J</i> = 7.34 Hz, 1H), 7.37 (t, <i>J</i> = 7.34 Hz, 1H), 6.92–7.00 (m, 4H), 6.76 (s, 1H), 5.15 (s, 2H), 4.57 (br. s., 2H), 4.19 (t, <i>J</i> = 4.40 Hz, 2H), 4.12 (br. s., 2H), 3.89–3.94 (m, 5H), 3.85–3.88 (m, 2H), 3.71 (d, <i>J</i> = 2.93 Hz, 2H), 3.66 (d, <i>J</i> = 2.93 Hz, 2H), 2.95 (br. s., 2H), 2.27 (br. s., 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 21.89, 29.20, 30.91, 31.71, 52.06, 53.70, 67.38, 67.52, 69.44, 69.52, 70.46, 70.64, 73.25, 100.81, 107.37, 114.24, 114.73, 117.86, 123.36, 124.02, 124.65, 125.66, 126.10, 126.90, 128.29,128.96, 129.22, 129.72, 130.00, 130.48, 131.39, 131.68, 133.21, 133.34, 137.09, 138.98, 155.07, 156.26, 157.89, 160.48, 162.94, 163.44, 166.79, 174.78, 177.78; LRMS (ESI) <i>m</i>/<i>z</i> 864 [M + H]<sup>+</sup>, 886 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>50</sub>H<sub>46</sub>N<sub>3</sub>O<sub>11</sub> [M + H]<sup>+</sup> 864.3132, found 864.3145; calcd for C<sub>50</sub>H<sub>45</sub>N<sub>3</sub>O<sub>11</sub>Na [M + Na]<sup>+</sup> 886.2952, found 886.2927.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75">4.4.9.  Synthesis of 7-(3-(1-(2-(2-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)-2-phenyl-4H-chromen-4-one (<b>Ac2Az11</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76">4.4.10.  Synthesis of 7-(3-(1-(2-(2-(2-((4-Oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)-2-phenyl-4H-chromen-4-one (<b>Ac2Az12</b>)</h4><div class="NLM_p last">This compound (62 mg) was obtained from <b>Ac2</b> and <b>Az12</b> in 89% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.14–2.26 (m, 2 H), 2.89 (t, <i>J</i> = 7.4 Hz, 2 H), 3.58–3.70 (m, 4 H), 3.79–3.90 (m, 4 H), 4.05 (t, <i>J</i> = 6.1 Hz, 2 H), 4.18 (t, <i>J</i> = 4.6 Hz, 2 H), 4.51 (t, <i>J</i> = 5.0 Hz, 2 H), 6.69 (d, <i>J</i> = 2.3 Hz, 2 H), 6.84–6.98 (m, 4 H), 7.40–7.56 (m, 7 H), 7.78–7.88 (m, 4 H), 8.06 (dd, <i>J</i> = 11.8, 8.7 Hz, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 22.07, 28.68, 50.23, 67.65, 68.09, 69.43, 69.64, 70.57, 70.81, 100.92, 101.15, 107.44, 107.50, 114.72, 114.77, 117.77, 118.02, 126.13, 126.16, 126.97, 127.11, 129.04, 131.47, 131.51, 131.71, 131.78, 157.88, 157.96, 162.98, 163.04, 163.27, 163.53, 177.75, 177.82; LRMS (ESI) <i>m</i>/<i>z</i> 700 [M + H]<sup>+</sup>, 722 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>38</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 700.2659, found 700.2651; calcd for C<sub>41</sub>H<sub>37</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 722.2478, found 722.2490.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77">4.4.11.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)propoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac3Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78">4.4.12.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-(2-(4-(4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az2</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79">4.4.13.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-(2-(4-(6-methyl-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az3</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80">4.4.14.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-(2-(4-(6-fluoro-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az4</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81">4.4.15.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(3-(4-(7-fluoro-4-oxo-4H-chromen-2-yl)phenoxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az5</b>)</h4><div class="NLM_p last">This compound (49 mg) was obtained from <b>Ac3</b> and <b>Az5</b> in 60% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.13–2.26 (m, 2 H), 2.89 (t, <i>J</i> = 7.6 Hz, 2 H), 3.60–3.78 (m, 4 H), 3.82–3.92 (m, 4 H), 4.02 (t, <i>J</i> = 6.2 Hz, 2 H), 4.15–4.22 (m, 2 H), 4.54 (t, <i>J</i> = 5.1 Hz, 2 H), 5.11 (s, 2 H), 6.65 (s, 1 H), 6.91–7.00 (m, 4 H), 7.09–7.15 (m, 1 H), 7.18–7.23 (m, 1 H), 7.24–7.31 (m, 3 H), 7.32–7.41 (m, 3 H), 7.47 (d, <i>J</i> = 8.4 Hz, 1 H), 7.56 (s, 1 H), 7.63 (t, <i>J</i> = 7.8 Hz, 1 H), 7.77 (d, <i>J</i> = 8.4 Hz, 2 H), 8.02 (d, <i>J</i> = 8.5 Hz, 2 H), 8.16–8.27 (m, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 22.14, 28.84, 50.17, 67.24, 67.53, 69.63, 70.56, 70.75, 73.92, 104.64, 104.89, 106.02, 113.68, 113.90, 114.31, 114.97, 117.91, 120.75, 120.78, 122.22, 123.40, 123.61, 124.15, 124.65, 125.72, 127.93, 128.03, 128.14, 128.16, 128.29, 128.84, 130.57, 133.33, 136.80, 139.32, 146.89, 155.13, 156.05, 157.02, 157.16, 160.57, 161.93, 163.66, 164.33, 166.86, 174.95, 177.37; LRMS (ESI) <i>m</i>/<i>z</i> 824 [M + H]<sup>+</sup>, 846 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>43</sub>FN<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 824.2983, found 824.3005; calcd for C<sub>48</sub>H<sub>42</sub>FN<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 846.2803, found 846.2829.</div></div><div id="sec4_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82">4.4.16.  Synthesis of Methyl 3-(((2-(4-(2-(2-(4-(3-(4-(7-Fluoro-4-oxo-4H-chromen-2-yl)phenoxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate (<b>Ac3Az8</b>)</h4><div class="NLM_p last">This compound (54 mg) was obtained from <b>Ac3</b> and <b>Az8</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.17 (m, 2 H), 2.90 (m, 2 H), 3.91–3.80 (m, 5 H), 3.96 (t, <i>J</i> = 4.7 Hz, 2 H), 4.05 (t, <i>J</i> = 5.6 Hz, 2 H), 4.14 (t, <i>J</i> = 4.4 Hz, 2 H), 4.57 (s, 2 H), 5.13 (s, 2 H), 6.66 (s, 1 H), 7.01–6.90 (m, 4 H), 7.12 (td, <i>J</i> = 8.5, 2.4 Hz, 1 H), 7.21 (dd, <i>J</i> = 9.0, 2.4 Hz, 1 H), 7.42–7.30 (m, 2 H), 7.47 (d, <i>J</i> = 8.5 Hz, 1 H), 7.50–7.56 (m, 1 H), 7.59 (d, <i>J</i> = 7.6 Hz, 1 H), 7.64 (td, <i>J</i> = 7.7, 7.1, 1.7 Hz, 1 H), 7.76 (d, <i>J</i> = 8.3 Hz, 2 H), 7.88–8.01 (m, 4 H), 8.16–8.28 (m, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 22.18, 22.82, 29.83, 30.30, 31.56, 52.21, 67.32, 67.40, 69.71, 69.90, 73.45, 104.70, 104.95, 106.16, 113.77, 114.00, 114.37, 115.03, 118.01, 123.54, 123.67, 124.21, 124.84, 125.87, 128.03, 128.15, 128.25, 128.45, 129.40, 129.94, 130.18, 130.69, 133.39, 133.51, 137.25, 139.17, 155.25, 156.36, 157.12, 157.25, 160.52, 161.99, 163.76, 164.42, 166.93, 166.95, 174.94, 177.49; LRMS (ESI) <i>m</i>/<i>z</i> 838 [M + H]<sup>+</sup>, 860 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>41</sub>FN<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup> 838.2776, found 838.2755; calcd for C<sub>48</sub>H<sub>40</sub>FN<sub>3</sub>O<sub>10</sub>Na [M + Na]<sup>+</sup> 860.2595, found 860.2590.</div></div><div id="sec4_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83">4.4.17.  Synthesis of Methyl 3-(((2-(4-(2-(2-(2-(4-(3-(4-(7-Fluoro-4-oxo-4H-chromen-2-yl)phenoxy)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4-oxo-4H-chromen-3-yl)oxy)methyl)benzoate (<b>Ac3Az9</b>)</h4><div class="NLM_p last">This compound (24 mg) was obtained from <b>Ac3</b> and <b>Az9</b> in 75% yield according to the general procedure described above. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 2.21–2.25 (m, 2H), 2.96 (t, <i>J</i> = 7.47 Hz, 2H), 3.65–3.69 (m, 2H), 3.71 (dd, <i>J</i> = 3.11, 5.61 Hz, 2H), 3.84–3.88 (m, 2H), 3.89 (s, 3H), 3.92 (t, <i>J</i> = 4.98 Hz, 2H), 4.04 (t, <i>J</i> = 5.61 Hz, 2H), 4.17–4.22 (m, 2H), 4.59 (t, <i>J</i> = 4.98 Hz, 2H), 5.14 (s, 2H), 6.67 (s, 1H), 6.96 (dd, <i>J</i> = 4.98, 8.72 Hz, 4H), 7.11–7.16 (m, 1H), 7.20–7.24 (m, 1H), 7.33–7.41 (m, 2H), 7.49 (d, <i>J</i> = 7.47 Hz, 1H), 7.61 (d, <i>J</i> = 7.47 Hz, 1H), 7.63–7.71 (m, 2H), 7.78 (d, <i>J</i> = 8.72 Hz, 2H), 7.93 (d, <i>J</i> = 7.47 Hz, 1H), 7.95–8.00 (m, 3H), 8.21 (dd, <i>J</i> = 6.23, 8.72 Hz, 1H), 8.25 (d, <i>J</i> = 6.23 Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ ppm 21.54, 28.49, 29.17, 52.04, 66.96, 67.37, 69.14, 69.49, 70.42, 70.56, 73.21, 104.56, 104.73, 105.89, 113.64, 113.79, 114.19, 114.82, 117.83, 120.58, 123.35, 123.97, 124.64, 125.60, 127.84, 127.88, 127.93, 128.00, 128.27, 129.20, 129.70, 129.97, 130.47, 133.19, 133.33, 137.05, 138.94, 155.03, 156.19, 156.92, 157.01, 160.44, 161.68, 163.55, 164.65, 166.34, 166.76, 174.75, 177.29; LRMS (ESI) <i>m</i>/<i>z</i> 882 [M + H]<sup>+</sup>, 904 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>50</sub>H<sub>45</sub>N<sub>3</sub>O<sub>11</sub>F [M + H]<sup>+</sup> 882.3038, found 882.3051; calcd for C<sub>50</sub>H<sub>44</sub>N<sub>3</sub>O<sub>11</sub>FNa [M + Na]<sup>+</sup> 904.2858, found 904.2833.</div></div><div id="sec4_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84">4.4.18.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az11</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85">4.4.19.  Synthesis of 7-Fluoro-2-(4-(3-(1-(2-(2-(2-((4-oxo-3-phenyl-4H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)propoxy)phenyl)-4H-chromen-4-one (<b>Ac3Az12</b>)</h4><div class="NLM_p last">This compound (26 mg) was obtained from <b>Ac3</b> and <b>Az12</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ ppm 2.20 (br. s., 2H), 2.91 (br. s., 2H), 3.65 (d, <i>J</i> = 3.74 Hz, 2H), 3.67–3.71 (m, 2H), 3.83–3.88 (m, 2H), 3.90 (br. s., 2H), 4.01 (br. s., 2H), 4.17–4.23 (m, 2H), 4.56 (br. s., 2H), 6.60–6.65 (m, 1H), 6.70 (s, 1H), 6.88–6.97 (m, 4H), 7.09 (t, <i>J</i> = 8.10 Hz, 1H), 7.17 (dd, <i>J</i> = 2.49, 8.72 Hz, 1H), 7.43–7.50 (m, 3H), 7.57–7.69 (m, 1H), 7.74 (d, <i>J</i> = 8.72 Hz, 2H), 7.83 (d, <i>J</i> = 7.47 Hz, 2H), 8.07 (d, <i>J</i> = 8.72 Hz, 1H), 8.14–8.20 (m, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ ppm 21.74, 28.45, 29.11, 66.95, 67.87, 69.20 (s), 69.25 (s), 70.34 (s), 70.55 (s), 100.88 (s), 104.44 (s), 104.61 (s), 105.71 (s), 107.16 (s), 113.51 (s), 113.66 (s), 114.55 (s), 114.71 (s), 117.71 (s), 120.49 (s), 123.14 (s), 125.91 (s), 126.83 (s), 127.72 (s), 127.80 (s), 127.87 (s), 128.82 (s), 131.34 (s), 131.39 (s), 156.79 (s), 156.88 (s), 157.63 (s), 161.65 (s), 162.83 (s), 163.05 (s), 163.44 (s), 164.52 (s), 166.20 (s), 177.15 (s), 177.55 (s); LRMS (ESI) <i>m</i>/<i>z</i> 718 [M + H]<sup>+</sup>, 740 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>37</sub>N<sub>3</sub>O<sub>8</sub>F [M + H]<sup>+</sup> 718.2565, found 718.2540; calcd for C<sub>41</sub>H<sub>36</sub>N<sub>3</sub>O<sub>8</sub>FNa [M + Na]<sup>+</sup> 740.2384, found 740.2410.</div></div><div id="sec4_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86">4.4.20.  Synthesis of 6-Methyl-2-(4-(4-(1-(2-(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87">4.4.21.  Synthesis of 6-Methyl-2-(4-(4-(1-(2-(2-(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az2</b>)</h4><div class="NLM_p last">This compound (63 mg) was obtained from <b>Ac5</b> and <b>Az2</b> in 86% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.86 (br. s., 3 H), 2.42–2.47 (m, 2 H), 2.78 (br. s., 1 H), 3.63–3.66 (m, 2 H), 3.68–3.72 (m, 2 H), 3.86 (dt, <i>J</i> = 17.81, 4.76 Hz, 4 H), 3.99–4.03 (m, 1 H), 4.15–4.19 (m, 2 H), 4.52 (t, <i>J</i> = 5.12 Hz, 1 H), 6.68 (s, 1 H), 6.71 (s, 1 H), 6.94 (d, <i>J</i> = 8.79 Hz, 2 H), 7.00 (d, <i>J</i> = 8.79 Hz, 2 H), 7.34–7.40 (m, 1 H), 7.40–7.43 (m, 1 H), 7.44–7.48 (m, 1 H), 7.48–7.53 (m, 2 H), 7.63–7.68 (m, 1 H), 7.80 (d, <i>J</i> = 8.79 Hz, 2 H), 7.85 (d, <i>J</i> = 9.27 Hz, 2 H), 7.97 (s, 1 H), 8.19 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.73, 25.18, 25.77, 28.48, 49.94, 67.44, 67.65, 69.35, 69.44, 70.36, 70.45, 70.55, 71.15, 105.66, 105.93, 114.63, 114.80, 117.52, 117.76, 121.80, 123.35, 123.66, 123.70, 123.99, 124.73, 124.87, 125.36, 127.68, 127.76, 133.38, 134.55, 134.77, 147.38, 154.19, 155.91, 161.33, 161.57, 162.97, 163.00, 178.16; LRMS (ESI) <i>m</i>/<i>z</i> 728 [M + H]<sup>+</sup>, 750 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>43</sub>H<sub>42</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 728.2972, found 728.2955; calcd for C<sub>43</sub>H<sub>41</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 750.2791, found 750.2815.</div></div><div id="sec4_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88">4.4.22.  Synthesis of 6-Methyl-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az3</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89">4.4.23.  Synthesis of 6-Fluoro-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az4</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90">4.4.24.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az5</b>)</h4><div class="NLM_p last">This compound (56 mg) was obtained from <b>Ac5</b> and <b>Az5</b> in 63% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.81 (br. s., 4 H), 2.38 (s, 3 H), 2.74 (br. s., 2 H), 3.59–3.63 (m, 2 H), 3.78–3.82 (m, 2 H), 3.84 (t, <i>J</i> = 5.07 Hz, 2 H), 3.91–3.97 (m, 2 H), 4.09–4.15 (m, 2 H), 4.48 (t, <i>J</i> = 4.88 Hz, 2 H), 5.07 (s, 2 H), 6.62 (s, 1 H), 6.85–6.93 (m, 4 H), 7.20–7.26 (m, 3 H), 7.28–7.37 (m, 4 H), 7.38–7.44 (m, 2 H), 7.50 (br. s., 1 H), 7.58 (ddd, <i>J</i> = 8.59, 7.03, 1.56 Hz, 1 H), 7.70–7.77 (m, 2 H), 7.91 (br. s., 1 H), 7.98 (d, <i>J</i> = 8.0, 2 H), 8.19 (dd, <i>J</i> = 8.20, 1.56 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.74, 25.21, 25.76, 28.49, 49.98, 67.36, 67.66, 69.44, 70.38, 70.56, 73.70, 105.70, 114.14, 114.66, 117.54, 117.71, 121.80, 123.37, 123.40, 123.70, 123.97, 124.40, 124.75, 125.48, 127.69, 127.91, 128.06, 128.60, 130.34, 133.08, 134.54, 134.76, 136.65, 139.14, 154.21, 154.93, 155.81, 160.39, 161.58, 163.01, 174.69, 178.18; LRMS (ESI) <i>m</i>/<i>z</i> 834 [M + H]<sup>+</sup>, 856 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>50</sub>H<sub>48</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 834.3391, found 834.3367; calcd for C<sub>50</sub>H<sub>47</sub>N<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 856.3210, found 856.3195.</div></div><div id="sec4_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91">4.2.25.  Synthesis of 6-Fluoro-2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az7</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92">4.4.26.  Synthesis of Methyl 3-(((2-(4-(2-(2-(4-(4-(4-(6-Methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4-oxo-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac5Az8</b>)</h4><div class="NLM_p last">This compound (44 mg) was obtained from <b>Ac5</b> and <b>Az8</b> in 51% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.84 (br. s., 4 H), 2.43 (s, 3 H), 2.77 (br. s., 2 H), 3.82–3.84 (m, 2 H), 3.86 (s, 3 H), 3.94 (t, <i>J</i> = 4.88 Hz, 2 H), 3.98 (br. s., 2 H), 4.11–4.17 (m, 2 H), 4.54 (t, <i>J</i> = 4.88 Hz, 2 H), 5.13 (s, 2 H), 6.65 (s, 1 H), 6.92 (t, <i>J</i> = 8.30 Hz, 4 H), 7.32–7.37 (m, 2 H), 7.40 (d, <i>J</i> = 5 Hz, 1 H), 7.45 (d, <i>J</i> = 8.79 Hz, 2 H), 7.50 (br. s., 1 H), 7.58 (d, <i>J</i> = 6.83 Hz, 1 H), 7.60–7.64 (m, 1 H), 7.77 (d, <i>J</i> = 8.30 Hz, 2 H), 7.86–8.01 (m, 5 H), 8.22 (d, <i>J</i> = 7.81 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.86, 25.29, 25.83, 28.58, 50.07, 51.98, 67.29, 67.76, 69.56, 69.79, 73.26, 105.86, 114.25, 114.77, 117.65, 117.81, 121.88, 123.51, 123.86, 124.07, 124.61, 124.91, 125.66, 127.81, 128.25, 129.20, 129.73, 130.07, 130.49, 133.15, 133.29, 134.65, 134.90, 137.15, 139.03, 147.58, 154.35, 155.08, 156.15, 160.40, 161.68, 163.13, 166.72, 174.72, 178.33; LRMS (ESI) <i>m</i>/<i>z</i> 848 [M + H]<sup>+</sup>, 870 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>50</sub>H<sub>46</sub>N<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup> 848.3183, found 848.3145; calcd for C<sub>50</sub>H<sub>45</sub>N<sub>3</sub>O<sub>10</sub>Na [M + Na]<sup>+</sup> 870.3003, found 870.2966.</div></div><div id="sec4_4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93">4.4.27.  Synthesis of Methyl 3-(((2-(4-(2-(2-(2-(4-(4-(4-(6-Methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4-oxo-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac5Az9</b>)</h4><div class="NLM_p last">This compound (83 mg) was obtained from <b>Ac5</b> and <b>Az9</b> in 93% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.86 (br. s., 4 H), 2.44 (s, 3 H), 2.78 (br. s., 2 H), 3.62–3.67 (m, 2 H), 3.68–3.72 (m, 2 H), 3.81–3.90 (m, 7 H), 4.01 (br. s., 2 H), 4.17 (t, <i>J</i> = 4.39 Hz, 2 H), 4.52 (t, <i>J</i> = 4.88 Hz, 2 H), 5.14 (s, 2 H), 6.69 (s, 1 H), 6.91–6.97 (m, 4 H), 7.34 (t, <i>J</i> = 7.81 Hz, 1 H), 7.36–7.40 (m, 1 H), 7.42 (d, <i>J</i> = 10 Hz, 1 H), 7.44–7.50 (m, 2 H), 7.51 (br. s., 1 H), 7.60 (d, <i>J</i> = 5 Hz, 1 H), 7.61–7.68 (m, 1 H), 7.80–7.82 (d, <i>J</i> = 10 Hz, 2 H), 7.87–8.02 (m, 5 H), 8.25 (d, <i>J</i> = 10, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.76, 25.22, 25.79, 28.51, 29.17, 49.99, 51.91, 67.36, 67.69, 69.45, 69.49, 70.41, 70.59, 73.15, 105.74, 114.20, 114.68, 117.56, 117.77, 121.81, 123.26, 123.40, 123.74, 123.97, 124.50, 124.79, 125.53, 127.72, 128.17, 129.12, 129.61, 129.99, 130.36, 133.05, 133.19, 134.56, 134.80, 137.08, 138.92, 154.24, 154.99, 156.11, 160.46, 161.61, 163.04, 166.63, 174.62, 178.20; LRMS (ESI) <i>m</i>/<i>z</i> 892 [M + H]<sup>+</sup>, 914 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>52</sub>H<sub>50</sub>N<sub>3</sub>O<sub>11</sub> [M + H]<sup>+</sup> 892.3445, found 892.3410; calcd for C<sub>52</sub>H<sub>49</sub>N<sub>3</sub>O<sub>11</sub>Na [M + Na]<sup>+</sup> 914.3265, found 914.3301.</div></div><div id="sec4_4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94">4.4.28.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(4-(4-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az10</b>)</h4><div class="NLM_p last">This compound (77 mg) was obtained from <b>Ac5</b> and <b>Az10</b> in 98% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.83 (br. s., 3 H), 2.41 (s, 2 H), 2.67–2.81 (m, 2 H), 3.78–3.85 (m, 2 H), 3.89–3.98 (m, 4 H), 4.09–4.17 (m, 2 H), 4.53 (t, <i>J</i> = 5.07 Hz, 2 H), 5.09 (s, 2 H), 6.63 (s, 1 H), 6.92 (d, <i>J</i> = 9.37 Hz, 2 H), 6.89 (d, <i>J</i> = 8.98 Hz, 2 H), 7.22–7.28 (m, 3 H), 7.29–7.46 (m, 6 H), 7.48 (s, 1 H), 7.59 (ddd, <i>J</i> = 8.59, 7.03, 1.56 Hz, 1 H), 7.75 (d, <i>J</i> = 10 Hz, 2 H), 7.95 (s, 1 H), 8.0 (d, <i>J</i> = 10 Hz, 2 H), 8.21 (d, <i>J</i> = 10.0 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.84, 25.27, 25.81, 28.56, 50.05, 67.29, 67.73, 69.53, 69.76, 73.81, 105.83, 114.20, 114.75, 117.63, 117.76, 121.89, 123.47, 123.67, 123.82, 124.07, 124.51, 124.87, 125.62, 127.79, 128.01, 128.15, 128.68, 130.46, 133.18, 134.63, 134.87, 136.74, 139.27, 147.55, 154.32, 155.02, 155.81, 160.34, 161.66, 163.11, 174.78, 178.30; LRMS (ESI) <i>m</i>/<i>z</i> 790 [M + H]<sup>+</sup>, 812 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>44</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 790.3128, found 790.3140; calcd for C<sub>48</sub>H<sub>43</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 812.2948, found 812.2961.</div></div><div id="sec4_4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95">4.4.29.  Synthesis of 6-Methyl-2-(4-(4-(1-(2-(2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az11</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96">4.4.30.  Synthesis of 6-Methyl-2-(4-(4-(1-(2-(2-(2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac5Az12</b>)</h4><div class="NLM_p last">This compound (33 mg) was obtained from <b>Ac5</b> and <b>Az12</b> in 46% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.83–1.89 (m, 4 H), 2.45 (s, 3 H), 2.76–2.81 (m, 2 H), 3.62–3.67 (m, 2 H), 3.68–3.73 (m, 2 H), 3.86–3.90 (m, 4 H), 4.00–4.02 (m, 2 H), 4.19–4.24 (m, 2 H), 4.52 (t, <i>J</i> = 4.88 Hz, 2 H), 6.70 (s, 1 H), 6.74 (s, 1 H), 6.91–7.02 (m, 4 H), 7.40–7.54 (m, 6 H), 7.82 (d, <i>J</i> = 9.0 Hz, 2 H), 7.87 (dd, <i>J</i> = 7.57, 1.71 Hz, 2 H), 7.99 (s, 1 H), 8.13 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.90, 25.21, 25.89, 28.62, 50.29, 67.80, 68.07, 69.41, 69.55, 70.56, 70.78, 101.19, 105.94, 107.53, 114.59, 114.84, 117.68, 118.04, 122.03, 123.54, 123.97, 125.00, 126.12, 127.15, 127.91, 128.99, 131.44, 131.76, 134.73, 135.00, 154.44, 157.87, 161.74, 163.06, 163.23, 163.27, 177.70, 178.44; LRMS (ESI) <i>m</i>/<i>z</i> 728 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>43</sub>H<sub>42</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 728.2972, found 728.3006.</div></div><div id="sec4_4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97">4.4.31.  Synthesis of 6-Methyl-2-(4-(4-(1-(2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)ethyl)-1H-1,2,3-triazol-4-yl)butoxy)phenyl)-4H-chromen-4-one (<b>Ac5Az13</b>)</h4><div class="NLM_p last">This compound (23 mg) was obtained from <b>Ac5</b> and <b>Az13</b> in 67% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.82 (br. s., 4 H), 2.36 (s, 3 H), 2.79 (t, <i>J</i> = 4.58 Hz, 2 H), 3.94 (t, <i>J</i> = 4.60, 2 H), 4.42 (t, <i>J</i> = 4.68 Hz, 2 H), 4.75 (t, <i>J</i> = 4.68 Hz, 2 H), 6.63 (s, 1 H), 6.59 (s, 1 H), 6.81–6.89 (m, 4 H), 7.29–7.37 (m, 1 H), 7.37–7.46 (m, 4 H), 7.51 (s, 1 H), 7.72 (d, <i>J</i> = 8.20 Hz, 2 H), 7.77 (d, <i>J</i> = 7.81 Hz, 2 H), 7.89 (s, 1 H), 8.01 (d, <i>J</i> = 8.98 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.8, 25.1, 25.7, 28.4, 49.2, 66.8, 67.6, 101.2, 105.7, 107.3, 114.1, 114.7, 117.6, 118.3, 121.9, 123.3, 123.7, 124.7, 125.9, 127.1, 127.7, 128.9, 131.4, 134.6, 134.8, 147.8, 154.2, 157.5, 161.6, 162.1, 162.9, 163.1, 177.4, 178.2; LRMS (ESI) <i>m</i>/<i>z</i> 640.3 base peak: 640.3 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>39</sub>H<sub>34</sub>N<sub>3</sub>O<sub>6</sub>[M + H]<sup>+</sup> 640.2448, found 640.2471.</div></div><div id="sec4_4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98">4.4.32.  Synthesis of 2-(4-(4-(1-(2-(Benzyl(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethyl)amino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-6-methyl-4<i>H</i>-chromen-4-one (<b>Ac5Az14</b>)</h4><div class="NLM_p last">This compound (38 mg) was obtained from <b>Ac5</b> and <b>Az14</b> in 49% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.81 (br. s., 4 H), 2.44 (s, 3 H), 2.71 (br. s., 2 H), 2.97–3.00 (m, 2 H), 3.11 (br. s., 2 H), 3.76 (s, 2 H), 3.89–4.03 (m, 4 H), 4.40 (br. s., 2 H), 6.66 (s, 1 H), 6.72 (s, 1 H), 6.84–6.94 (m, 4 H), 7.20–7.32 (m, 5 H), 7.33–7.53 (m, 6 H), 7.74–7.81 (m, 2 H), 7.82–7.88 (m, 2 H), 7.97 (d, <i>J</i> = 0.78 Hz, 1 H), 8.09 (d, <i>J</i> = 8.98 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.9, 25.3, 25.9, 28.6, 48.7, 52.9, 54.8, 59.8, 67.1, 67.8, 100.9, 105.9, 107.5, 114.5, 114.8, 117.7, 117.9, 121.5, 123.6, 123.9, 124.9, 126.1, 127.1, 127.5, 127.9, 128.5, 128.7, 128.9, 131.4, 131.7, 134.7, 134.9, 138.4, 154.4, 157.9, 161.7, 162.9, 163.0, 163.2, 177.6, 178.4; LRMS (ESI) <i>m</i>/<i>z</i> 773 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>45</sub>N<sub>4</sub>O<sub>6</sub> [M + H]<sup>+</sup> 773.3339, found 773.3314.</div></div><div id="sec4_4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99">4.4.33.  Synthesis of 2-(4-(4-(1-(2-(Benzyl(2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethyl)amino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)phenyl)-6-methyl-4<i>H</i>-chromen-4-one (<b>Ac5Az15</b>)</h4><div class="NLM_p last">This compound (41 mg) was obtained from <b>Ac5</b> and <b>Az15</b> in 53% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.84 (br. s., 4 H), 2.46 (s, 3 H), 2.73 (br. s., 2 H), 2.97 (br. s., 2 H), 3.11 (br. s., 2 H), 3.77 (br. s., 2 H), 3.89–4.05 (m, 4 H), 4.40 (br. s., 2 H), 6.68 (s, 1 H), 6.72 (s, 1 H), 6.88–6.97 (m, 4 H), 7.21–7.33 (m, 5 H), 7.33–7.40 (m, 2 H), 7.40–7.44 (m, 1 H), 7.45–7.52 (m, 2 H), 7.61–7.67 (m, 1 H), 7.76–7.81 (m, 2 H), 7.84 (d, <i>J</i> = 8.79 Hz, 2 H), 7.99 (s, 1 H), 8.18 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.9, 25.3, 25.9, 28.7, 48.7, 53.1, 54.8, 59.9, 66.8, 67.8, 105.9, 106.3, 114.8, 114.9, 117.7, 117.9, 123.6, 123.9, 123.9, 124.2, 125.0, 125.1, 125.7, 127.5, 127.9, 128.0, 128.5, 128.7, 133.6, 134.7, 134.9, 154.4, 156.1, 161.3, 161.7, 163.2, 163.2, 178.3, 178.4; LRMS (ESI) <i>m</i>/<i>z</i> 773 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>45</sub>N<sub>4</sub>O<sub>6</sub> [M + H]<sup>+</sup> 773.3339, found 773.3353.</div></div><div id="sec4_4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100">4.4.34.  Synthesis of 7-(4-(1-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac12Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101">4.4.35.  Synthesis of 7-(4-(1-(2-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)butoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac12Az2</b>)</h4><div class="NLM_p last">This compound (70 mg) was obtained from <b>Ac12</b> and <b>Az2</b> in 98% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.89 (br. s., 4 H), 2.80 (br. s., 2 H), 3.62–3.68 (m, 2 H), 3.68–3.75 (m, 2 H), 3.85 (t, <i>J</i> = 4.15 Hz, 2 H), 3.89 (t, <i>J</i> = 5.12 Hz, 2 H), 4.07 (br. s., 2 H), 4.18 (t, <i>J</i> = 4.39 Hz, 2 H), 4.53 (t, <i>J</i> = 4.88 Hz, 2 H), 6.72 (s, 1 H), 6.74 (s, 1 H), 6.91 (s, 1 H), 6.94 (dd, <i>J</i> = 9.03, 1.22 Hz, 1 H), 7.01 (d, <i>J</i> = 8.30 Hz, 2 H), 7.39 (t, <i>J</i> = 7.57 Hz, 1 H), 7.52 (d, <i>J</i> = 4.88 Hz, 5 H), 7.66 (t, <i>J</i> = 7.57 Hz, 1 H), 7.82–7.93 (m, 4 H), 8.10 (d, <i>J</i> = 8.79 Hz, 1 H), 8.20 (d, <i>J</i> = 7.81 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.13, 25.73, 28.31, 49.93, 67.44, 68.13, 69.35, 69.44, 70.35, 70.55, 100.65, 105.92, 107.19, 114.52, 114.79, 117.48, 117.74, 121.76, 123.67, 123.98, 124.86, 125.35, 125.89, 126.67, 127.74, 128.78, 131.20, 131.56, 133.36, 147.28, 155.89, 157.71, 161.33, 162.68, 162.94, 163.36, 177.50, 177.98; LRMS (ESI) <i>m</i>/<i>z</i> 714 [M + H]<sup>+</sup>, 736 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>42</sub>H<sub>40</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 714.2815, found 714.2804; calcd for C<sub>42</sub>H<sub>39</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 736.2635, found 736.2625.</div></div><div id="sec4_4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102">4.4.36.  Synthesis of 6-Methyl-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac12Az3</b>)</h4><div class="NLM_p last">This compound (62 mg) was obtained from <b>Ac12</b> and <b>Az3</b> in 85% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.83 (br. s., 4 H), 2.37 (s, 3 H), 2.74 (br. s., 2 H), 3.61 (br. s., 2 H), 3.63–3.70 (m, 2 H), 3.80 (br. s., 2 H), 3.84 (t, <i>J</i> = 4.88 Hz, 2 H), 4.00 (br. s., 2 H), 4.12 (br. s., 2 H), 4.48 (t, <i>J</i> = 4.88 Hz, 2 H), 6.63 (s, 1 H), 6.67 (s, 1 H), 6.83 (s, 1 H), 6.86 (d, <i>J</i> = 9.27 Hz, 1 H), 6.94 (d, <i>J</i> = 8.30 Hz, 2 H), 7.33 (d, <i>J</i> = 8.30 Hz, 1 H), 7.39 (d, <i>J</i> = 8.79 Hz, 1 H), 7.41–7.48 (m, 3 H), 7.50 (s, 1 H), 7.77 (d, <i>J</i> = 8.30 Hz, 2 H), 7.81 (d, <i>J</i> = 6.83 Hz, 2 H), 7.90 (s, 1 H), 8.02 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.76, 25.18, 25.77, 28.36, 49.96, 67.48, 68.17, 69.40, 69.48, 70.39, 70.59, 100.70, 105.85, 107.24, 114.55, 114.81, 117.53, 121.80, 123.36, 124.21, 124.79, 125.95, 126.74, 127.75, 128.82, 131.23, 131.62, 134.61, 134.86, 147.32, 154.22, 157.77, 161.28, 162.75, 162.85, 163.41, 177.57, 178.18; LRMS (ESI) <i>m</i>/<i>z</i> 728 [M + H]<sup>+</sup>, 750 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>43</sub>H<sub>42</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 728.2972, found 728.2949; calcd for C<sub>43</sub>H<sub>41</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 750.2791, found 750.2790.</div></div><div id="sec4_4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103">4.4.37.  Synthesis of 6-Fluoro-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac12Az4</b>)</h4><div class="NLM_p last">This compound (53 mg) was obtained from <b>Ac12</b> and <b>Az4</b> in 73% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.89 (br. s., 4 H), 2.79 (br. s., 2 H), 3.61–3.67 (m, 2 H), 3.67–3.71 (m, 2 H), 3.81–3.86 (m, 2 H), 3.88 (t, <i>J</i> = 5.12 Hz, 2 H), 4.06 (br. s., 2 H), 4.13–4.20 (m, 2 H), 4.52 (t, <i>J</i> = 4.39 Hz, 2 H), 6.69 (s, 1 H), 6.73 (s, 1 H), 6.90 (s, 1 H), 6.93 (d, <i>J</i> = 8.79 Hz, 1 H), 6.99 (d, <i>J</i> = 8.79 Hz, 2 H), 7.34–7.40 (m, 1 H), 7.46–7.55 (m, 5 H), 7.80–7.85 (m, 3 H), 7.85–7.90 (m, 2 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.07, 25.63, 28.22, 49.94, 67.38, 68.05, 69.24, 69.31, 70.26, 70.47, 100.56, 105.04, 107.03, 110.13 (d, <i>J</i> = 23.63 Hz, C5), 114.42, 114.73, 117.37, 119.77 (d, <i>J</i> = 8.08 Hz, C8), 121.30 (d, <i>J</i> = 25.15 Hz, C7), 123.49, 124.75 (d, <i>J</i> = 6.67 Hz, C10), 125.77, 126.52, 127.67, 128.68, 131.11, 131.40, 151.94 (d, <i>J</i> = 2.02 Hz, C9), 157.59, 159.18 (d, <i>J</i> = 247.85 Hz, C6), 161.39, 162.54, 163.11, 163.26, 176.94 (d, <i>J</i> = 3.03 Hz, C4), 177.32; LRMS (ESI) <i>m</i>/<i>z</i> 732 [M + H]<sup>+</sup>, 754 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>42</sub>H<sub>39</sub>N<sub>3</sub>O<sub>8</sub>F [M + H]<sup>+</sup> 732.2721, found 732.2712; calcd for C<sub>42</sub>H<sub>38</sub>N<sub>3</sub>O<sub>8</sub>FNa [M + Na]<sup>+</sup> 754.2541, found 754.2524.</div></div><div id="sec4_4_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104">4.4.38.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac12Az5</b>)</h4><div class="NLM_p last">This compound (58 mg) was obtained from <b>Ac12</b> and <b>Az5</b> in 71% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.83–1.94 (m, 4 H), 2.77–2.80 (m, 2 H), 3.62–3.68 (m, 2 H), 3.68–3.74 (m, 2 H), 3.84–3.86 (m, 2 H), 3.88 (t, <i>J</i> = 5.12 Hz, 2 H), 4.01–4.08 (m, 2 H), 4.17–4.19 (m, 2 H), 4.52 (t, <i>J</i> = 5.12 Hz, 2 H), 5.11 (s, 2 H), 6.74 (s, 1 H), 6.89–6.97 (m, 4 H), 7.25–7.30 (m, 3 H), 7.34–7.41 (m, 3 H), 7.45–7.54 (m, 5 H), 7.61–7.67 (m, 1 H), 7.85–7.91 (m, 2 H), 8.00–8.05 (m, 2 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H), 8.26 (dd, <i>J</i> = 8.30, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.13, 25.73, 28.32, 49.94, 67.35, 68.14, 69.42, 69.44, 70.36, 70.56, 73.71, 100.68, 107.24, 114.14, 114.55, 117.49, 117.71, 121.79, 123.40, 123.95, 124.41, 125.48, 125.94, 126.71, 127.91, 128.05, 128.58, 128.79, 130.33, 131.21, 131.60, 133.08, 136.64, 139.13, 147.30, 154.91, 155.84, 157.75, 160.38, 162.74, 162.76, 163.39, 174.71, 177.58; LRMS (ESI) <i>m</i>/<i>z</i> 820 [M + H]<sup>+</sup>, 842 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>49</sub>H<sub>46</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 820.3234, found 820.3246; calcd for C<sub>49</sub>H<sub>45</sub>N<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 842.3054, found 842.3068.</div></div><div id="sec4_4_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105">4.4.39.  Synthesis of 6-Fluoro-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac12Az7</b>)</h4><div class="NLM_p last">This compound (63 mg) was obtained from <b>Ac12</b> and <b>Az7</b> in 91% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.82–1.94 (m, 5 H), 2.78–2.80 (m, 2 H), 3.80–3.86 (m, 2 H), 3.95 (t, <i>J</i> = 5.00, 2 H), 4.01–4.09 (m, 2 H), 4.15–4.16 (m, 2 H), 4.55 (t, <i>J</i> = 5.12 Hz, 2 H), 6.70 (s, 1 H), 6.73 (s, 1 H), 6.88–6.93 (m, 2 H), 6.97–7.02 (m, 2 H), 7.37 (ddd, <i>J</i> = 9.15, 7.69, 3.17 Hz, 1 H), 7.47–7.54 (m, 5 H), 7.78–7.89 (m, 5 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.07, 25.64, 28.24, 49.89, 67.28, 68.08, 69.28, 69.61, 100.58, 105.15, 107.08, 110.16 (d, <i>J</i> = 23.23 Hz, C5), 114.48, 114.76, 117.39, 119.78 (d, <i>J</i> = 8.08 Hz, C8), 121.38 (d, <i>J</i> = 25.25 Hz, C7), 121.77, 123.67, 124.78 (d, <i>J</i> = 6.06 Hz, C10), 125.82, 126.57, 127.73, 128.73, 131.17, 131.44, 147.29, 151.97, 157.63, 159.23 (d, <i>J</i> = 248.46 Hz, C6), 161.31, 162.61, 163.09, 163.30, 177.00, 177.41; LRMS (ESI) <i>m</i>/<i>z</i> 688 [M + H]<sup>+</sup>, 710 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>40</sub>H<sub>35</sub>N<sub>3</sub>O<sub>7</sub>F [M + H]<sup>+</sup> 688.2459, found 688.2454; calcd for C<sub>40</sub>H<sub>34</sub>N<sub>3</sub>O<sub>7</sub>FNa [M + Na]<sup>+</sup> 710.2278, found 710.2261.</div></div><div id="sec4_4_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106">4.4.40.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac12Az8</b>)</h4><div class="NLM_p last">This compound (63 mg) was obtained from <b>Ac12</b> and <b>Az8</b> in 76% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.84–1.92 (m, 4 H), 2.77–2.80 (m, 2 H), 3.82–3.86 (m, 2 H), 3.87 (s, 3 H), 3.96 (t, <i>J</i> = 4.88 Hz, 2 H), 4.03–4.07 (m, 2 H), 4.14–4.18 (m, 2 H), 4.55 (t, <i>J</i> = 4.88 Hz, 2 H), 5.13 (s, 2 H), 6.73 (s, 1 H), 6.89–6.96 (m, 4 H), 7.34 (t, <i>J</i> = 7.57 Hz, 1 H), 7.36–7.41 (m, 1 H), 7.45–7.53 (m, 5 H), 7.59 (d, <i>J</i> = 7.81 Hz, 1 H), 7.64 (ddd, <i>J</i> = 8.42, 6.95, 1.71 Hz, 1 H), 7.85–7.90 (m, 2 H), 7.92 (dd, <i>J</i> = 7.56, 1.22 Hz, 1 H), 7.95–8.00 (m, 3 H), 8.08 (d, <i>J</i> = 8.79 Hz, 1 H), 8.25 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.18, 25.74, 28.37, 50.02, 51.93, 67.25, 68.18, 69.50, 69.73, 73.21, 100.73, 107.33, 114.21, 114.61, 117.57, 117.77, 121.88, 123.44, 124.00, 124.57, 125.59, 126.00, 126.79, 128.19, 128.86, 129.14, 129.66, 130.01, 130.42, 131.25, 131.69, 133.08, 133.24, 137.10, 138.97, 147.44, 155.02, 156.08, 157.81, 160.36, 162.80, 163.44, 166.67, 174.65, 177.61; LRMS (ESI) <i>m</i>/<i>z</i> 834 [M + H]<sup>+</sup>, 856 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>49</sub>H<sub>44</sub>N<sub>3</sub>O<sub>10</sub> [M + H]<sup>+</sup> 834.3027, found 834.3041; calcd for C<sub>49</sub>H<sub>43</sub>N<sub>3</sub>O<sub>10</sub>Na [M + Na]<sup>+</sup> 856.2846, found 856.2834.</div></div><div id="sec4_4_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107">4.4.41.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac12Az9</b>)</h4><div class="NLM_p last">This compound (78 mg) was obtained from <b>Ac12</b> and <b>Az9</b> in 89% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.84–1.93 (m, 4 H), 2.74–2.82 (m, 2 H), 3.63–3.67 (m, 2 H), 3.68–3.73 (m, 2 H), 3.84–3.87 (m, 2 H), 3.87–3.90 (m, 5 H), 4.04–4.09 (m, 2 H), 4.15–4.20 (m, 2 H), 4.52 (t, <i>J</i> = 5.12 Hz, 2 H), 5.14 (s, 2 H), 6.74 (s, 1 H), 6.89–6.97 (m, 4 H), 7.34 (t, <i>J</i> = 7.56 Hz, 1 H), 7.39 (t, <i>J</i> = 7.57 Hz, 1 H), 7.46–7.54 (m, 5 H), 7.59 (d, <i>J</i> = 7.81 Hz, 1 H), 7.65 (ddd, <i>J</i> = 8.54, 7.08, 1.46 Hz, 1 H), 7.86–7.90 (m, 2 H), 7.92 (d, <i>J</i> = 7.81 Hz, 1 H), 7.95–8.01 (m, 3 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H), 8.26 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.19, 25.80, 28.39, 50.00, 51.93, 67.39, 68.20, 69.49, 69.52, 70.44, 70.62, 73.19, 100.75, 107.33, 114.23, 114.60, 117.60, 117.79, 121.81, 123.31, 124.00, 124.55, 125.59, 126.01, 126.80, 128.20, 128.86, 129.14, 129.64, 130.01, 130.40, 131.26, 131.69, 133.08, 133.23, 137.10, 138.96, 147.36, 155.03, 156.17, 157.83, 160.49, 162.83, 163.47, 166.68, 174.68, 177.63; LRMS (ESI) <i>m</i>/<i>z</i> 878 [M + H]<sup>+</sup>, 900 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>51</sub>H<sub>48</sub>N<sub>3</sub>O<sub>11</sub> [M + H]<sup>+</sup> 878.3289, found 878.3313; calcd for C<sub>51</sub>H<sub>47</sub>N<sub>3</sub>O<sub>11</sub>Na [M + Na]<sup>+</sup> 900.3108, found 900.3151.</div></div><div id="sec4_4_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108">4.4.42.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(4-(4-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac12Az10</b>)</h4><div class="NLM_p last">This compound (74 mg) was obtained from <b>Ac12</b> and <b>Az10</b> in 96% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.82–1.94 (m, 4 H), 2.78–2.80 (m, 2 H), 3.81–3.87 (m, 2 H), 3.96 (t, <i>J</i> = 4.88 Hz, 2 H), 4.01–4.08 (m, 2 H), 4.13–4.20 (m, 2 H), 4.55 (t, <i>J</i> = 4.88 Hz, 2 H), 5.12 (s, 2 H), 6.73 (s, 1 H), 6.88–6.98 (m, 4 H), 7.25–7.30 (m, 3 H), 7.34–7.41 (m, 3 H), 7.44–7.54 (m, 5 H), 7.61–7.67 (m, 1 H), 7.85–7.91 (m, 2 H), 8.01–8.06 (m, 2 H), 8.09 (d, <i>J</i> = 8.75, 1 H), 8.25 (dd, <i>J</i> = 8.54, 1.22 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.22, 25.79, 28.40, 50.05, 67.30, 68.20, 69.55, 69.77, 73.82, 100.76, 107.40, 114.21, 114.64, 117.63, 117.77, 121.87, 123.70, 124.07, 124.53, 125.64, 126.05, 126.85, 128.00, 128.15, 128.66, 128.90, 130.46, 131.28, 131.76, 133.18, 136.75, 139.28, 147.47, 155.03, 155.80, 157.86, 160.33, 162.85, 163.48, 174.78, 177.66; LRMS (ESI) <i>m</i>/<i>z</i> 776 [M + H]<sup>+</sup>, 798 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>47</sub>H<sub>42</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 776.2972, found 776.2946; calcd for C<sub>47</sub>H<sub>41</sub>N<sub>3</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 798.2791, found 798.2767.</div></div><div id="sec4_4_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109">4.4.43.  Synthesis of 7-(2-(2-(4-(4-((4-Oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac12Az11</b>)</h4><div class="NLM_p last">This compound (30 mg) was obtained from <b>Ac12</b> and <b>Az11</b> in 45% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.87 (br. s., 4 H), 2.78 (br. s., 2 H), 3.85–3.87 (m, 2 H), 3.96 (t, <i>J</i> = 4.88 Hz, 2 H), 4.04 (br. s., 2 H), 4.18–4.22 (m, 2 H), 4.55 (t, <i>J</i> = 4.39 Hz, 2 H), 6.72 (s, 1 H), 6.73 (s, 1 H), 6.86–7.00 (m, 4 H), 7.45–7.55 (m, 7 H), 7.83–7.90 (m, 4 H), 8.07 (d, <i>J</i> = 8.79 Hz, 1 H), 8.13 (d, <i>J</i> = 8.78 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.17, 25.71, 28.36, 50.10, 67.75, 68.18, 69.28, 69.74, 100.73, 101.08, 107.31, 107.36, 114.41, 114.62, 117.58, 117.97, 125.97, 126.02, 126.77, 127.01, 128.87, 128.89, 131.28, 131.37, 131.55, 131.70, 157.71, 157.81, 162.81, 162.92, 162.99, 163.45, 177.50, 177.64; LRMS (ESI) <i>m</i>/<i>z</i> 670 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>40</sub>H<sub>36</sub>N<sub>3</sub>O<sub>7</sub> [M + H]<sup>+</sup> 670.2553, found 670.2565.</div></div><div id="sec4_4_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110">4.4.44.  Synthesis of 7-(2-(2-(2-(4-(4-((4-Oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)butyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac12Az12</b>)</h4><div class="NLM_p last">This compound (17 mg) was obtained from <b>Ac12</b> and <b>Az12</b> in 24% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.85–1.91 (m, 4 H), 2.80 (br. s., 2 H), 3.62–3.68 (m, 2 H), 3.68–3.72 (m, 2 H), 3.86–3.90 (m, 4.70 Hz, 4 H), 4.06 (s, 2 H), 4.19–4.23 (m, 2 H), 4.52 (t, <i>J</i> = 5.12 Hz, 2 H), 6.73 (s, 1 H), 6.74 (s, 1 H), 6.88–7.01 (m, 4 H), 7.46–7.55 (m, 7 H), 7.84–7.91 (m, 4 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H), 8.12 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.26, 25.90, 28.48, 50.16, 68.05, 68.27, 69.41, 69.61, 70.54, 70.79, 100.84, 101.18, 107.48, 107.54, 114.59, 114.72, 117.73, 118.04, 121.92, 126.12, 126.14, 126.97, 127.15, 128.98, 128.99, 131.37, 131.44, 131.77, 131.85, 157.86, 157.97, 162.97, 163.05, 163.22, 163.57, 177.70, 177.80; LRMS (ESI) <i>m</i>/<i>z</i> 714 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>42</sub>H<sub>40</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 714.2815, found 714.2818.</div></div><div id="sec4_4_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111">4.4.45.  Synthesis of 7-(2-((1-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac13Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112">4.4.46.  Synthesis of 7-(2-((1-(2-(2-(2-(4-(4-Oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac13Az2</b>)</h4><div class="NLM_p last">This compound (54 mg) was obtained from <b>Ac13</b> and <b>Az2</b> in 76% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.69 (m, 4 H), 3.80–3.82 (m, 2 H), 3.86–3.88 (m, 2 H), 3.92–3.93 (m, 2 H), 4.13–4.15 (m, 2 H), 4.20–4.22 (m, 2 H), 4.53 (t, <i>J</i> = 4.88 Hz, 2 H), 4.73 (s, 2 H), 6.69 (d, <i>J</i> = 11.2 Hz, 2 H), 6.90 (s, 1 H), 6.92–7.00 (m, 3 H), 7.36 (t, <i>J</i> = 7.57 Hz, 1 H), 7.43–7.51 (m, 4 H), 7.61–7.67 (m, 1 H), 7.76–7.87 (m, 5 H), 8.07 (d, <i>J</i> = 8.79, 1 H), 8.17 (d, <i>J</i> = 8.0, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.22, 64.76, 67.54, 67.93, 68.40, 69.40, 69.48, 70.50, 70.66, 101.06, 106.13, 107.42, 114.65, 114.94, 117.86, 117.92, 123.77, 123.85, 124.19, 125.00, 125.56, 126.05, 126.96, 127.88, 128.92, 131.35, 131.70, 133.48, 144.57, 156.06, 157.77, 161.43, 162.93, 163.12, 163.19, 177.63, 178.18; LRMS (ESI) <i>m</i>/<i>z</i> 716 [M + H]<sup>+</sup>, 738 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>38</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 716.2608, found 716.2574; calcd for C<sub>41</sub>H<sub>37</sub>N<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 738.2427, found 738.2396.</div></div><div id="sec4_4_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113">4.4.47.  Synthesis of 6-Methyl-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac13Az3</b>)</h4><div class="NLM_p last">This compound (47 mg) was obtained from <b>Ac13</b> and <b>Az3</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.69 (m, 4 H), 3.78–3.83 (m, 2 H), 3.87 (t, <i>J</i> = 4.88 Hz, 2 H), 3.90–3.92 (m, 2 H), 4.11–4.16 (m, 2 H), 4.18–4.22 (m, 2 H), 4.53 (t, <i>J</i> = 4.88 Hz, 2 H), 4.73 (s, 2 H), 6.65 (s, 1 H), 6.69 (s, 1 H), 6.88–6.99 (m, 4 H), 7.34–7.39 (m, 1 H), 7.41–7.51 (m, 4 H), 7.76–7.86 (m, 5 H), 7.94 (s, 1 H), 8.06 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.83, 50.21, 64.75, 67.52, 67.91, 68.37, 69.39, 69.47, 70.49, 70.64, 101.05, 105.97, 107.39, 114.63, 114.90, 117.60, 117.90, 123.46, 123.76, 124.30, 124.90, 126.03, 126.93, 127.83, 128.90, 131.33, 131.68, 134.67, 134.94, 144.55, 154.32, 157.75, 161.34, 162.91, 162.97, 163.18, 177.62, 178.29; LRMS (ESI) <i>m</i>/<i>z</i> 730 [M + H]<sup>+</sup>, 752 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>42</sub>H<sub>40</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 730.2765, found 730.2753; calcd for C<sub>42</sub>H<sub>40</sub>N<sub>3</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 752.2584, found 752.2604.</div></div><div id="sec4_4_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114">4.4.48.  Synthesis of 6-Fluoro-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac13Az4</b>)</h4><div class="NLM_p last">This compound (48 mg) was obtained from <b>Ac13</b> and <b>Az4</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.70 (m, 4 H), 3.78–3.83 (m, 2 H), 3.88–3.89 (m, 2 H), 3.95 (br. s., 2 H), 4.11–4.17 (m, 2 H), 4.22 (br. s., 2 H), 4.50–4.58 (m, 2 H), 4.73 (br. s., 2 H), 6.66 (s, 1 H), 6.71 (s, 1 H), 6.88–6.99 (m, 4 H), 7.32–7.38 (m, 1 H), 7.43–7.51 (m, 4 H), 7.76–7.86 (m, 6 H), 8.07 (d, <i>J</i> = 8.78 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 64.80, 64.82, 67.57, 67.94, 68.40, 69.36, 69.47, 70.50, 70.67, 101.05, 105.42, 107.41, 110.50 (d, <i>J</i> = 23.23 Hz, C5), 114.66, 114.99, 119.92 (d, <i>J</i> = 8.08 Hz, C8), 121.56 (d, <i>J</i> = 25.25 Hz, C7), 123.86, 126.04, 126.95, 127.93, 128.92, 131.37, 131.67, 152.24 (d, <i>J</i> = 2.22 Hz, C9), 157.78, 159.46 (d, <i>J</i> = 247.45 Hz, C6), 161.58, 162.92, 163.19, 163.41, 177.31 (d, <i>J</i> = 2.53 Hz, C4), 177.61; LRMS (ESI) <i>m</i>/<i>z</i> 734 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>37</sub>N<sub>3</sub>O<sub>9</sub>F [M + H]<sup>+</sup> 734.2514, found 734.2546.</div></div><div id="sec4_4_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115">4.4.49.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac13Az5</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116">4.4.50.  Synthesis of 6-Fluoro-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac13Az7</b>)</h4><div class="NLM_p last">This compound (30 mg) was obtained from <b>Ac13</b> and <b>Az7</b> in 44% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.83–3.83 (m, 2 H), 3.95–3.97 (m, 4 H), 4.14–4.15 (m, 2 H), 4.22 (br. s., 2 H), 4.59 (t, <i>J</i> = 4.88 Hz, 2 H), 4.75 (br. s., 2 H), 6.69 (s, 1 H), 6.72 (s, 1 H), 6.90–7.01 (m, 4 H), 7.36 (ddd, <i>J</i> = 9.15, 7.44, 2.93 Hz, 1 H), 7.47–7.52 (m, 4 H), 7.78–7.87 (m, 6 H), 8.08 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.37, 64.85, 67.43, 67.96, 68.44, 69.55, 69.66, 101.09, 105.57, 107.48, 110.59 (d, <i>J</i> = 24.24 Hz, C5), 114.72, 115.01, 119.94 (d, <i>J</i> = 8.08 Hz, C8), 121.63 (d, <i>J</i> = 26.26 Hz, C7), 124.14, 126.09, 127.01, 128.01, 128.98, 131.41, 131.74, 152.28 (d, <i>J</i> = 1.46 Hz, C9), 157.81, 159.53 (d, <i>J</i> = 247.45 Hz, C6), 161.45, 162.98, 163.23, 163.36, 177.34, 177.35 (d, <i>J</i> = 2.02 Hz, C4), 177.66; LRMS (ESI) <i>m</i>/<i>z</i> 690 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>39</sub>H<sub>33</sub>N<sub>3</sub>O<sub>8</sub>F [M + H]<sup>+</sup> 690.2252, found 690.2220.</div></div><div id="sec4_4_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117">4.4.51.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac13Az8</b>)</h4><div class="NLM_p last">This compound (78 mg) was obtained from <b>Ac13</b> and <b>Az8</b> in 94% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.80–3.84 (m, 2 H), 3.85 (s, 3 H), 3.89–3.93 (m, 2 H), 3.95 (t, <i>J</i> = 4.88 Hz, 2 H), 4.10–4.16 (m, 2 H), 4.16–4.21 (m, 2 H), 4.57 (t, <i>J</i> = 4.88 Hz, 2 H), 4.73 (s, 2 H), 5.11 (s, 2 H), 6.70 (s, 1 H), 6.88–6.96 (m, 4 H), 7.32 (t, <i>J</i> = 7.57 Hz, 1 H), 7.37 (t, <i>J</i> = 7.57 Hz, 1 H), 7.43–7.51 (m, 4 H), 7.57 (d, <i>J</i> = 7.81 Hz, 1 H), 7.63 (ddd, <i>J</i> = 8.54, 7.08, 1.95 Hz, 1 H), 7.78 (br. s., 1 H), 7.81–7.86 (m, 2 H), 7.90 (d, <i>J</i> = 7.81 Hz, 1 H), 7.92–7.98 (m, 3 H), 8.06 (d, <i>J</i> = 9.27 Hz, 1 H), 8.23 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.51, 52.23, 65.01, 67.50, 68.15, 68.64, 69.83, 69.87, 73.51, 76.95, 77.26, 77.47, 77.58, 101.32, 107.70, 114.52, 114.94, 118.09, 123.78, 124.33, 124.88, 125.93, 126.32, 127.18, 128.51, 129.18, 129.44, 129.96, 130.33, 130.73, 131.59, 131.99, 133.40, 133.54, 137.42, 139.29, 155.35, 156.40, 158.02, 160.62, 163.18, 163.46, 166.99, 174.97, 177.87; LRMS (ESI) <i>m</i>/<i>z</i> 836 [M + H]<sup>+</sup>, 858 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>42</sub>N<sub>3</sub>O<sub>11</sub> [M + H]<sup>+</sup> 836.2819, found 836.2792; calcd for C<sub>48</sub>H<sub>42</sub>N<sub>3</sub>O<sub>11</sub>Na [M + Na]<sup>+</sup> 858.2639, found 858.2606.</div></div><div id="sec4_4_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118">4.4.52.  Synthesis of Methyl 3-(((4-Oxo-2-(4-(2-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-3-yl)oxy)methyl)benzoate (<b>Ac13Az9</b>)</h4><div class="NLM_p last">This compound (47 mg) was obtained from <b>Ac13</b> and <b>Az9</b> in 53% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.62–3.66 (m, 2 H), 3.66–3.70 (m, 2 H), 3.81–3.85 (m, 2 H), 3.87 (s, 3 H), 3.88 (t, <i>J</i> = 4.75 Hz, 2 H), 3.91–3.95 (m, 2 H), 4.14–4.17 (m, 2 H), 4.19–4.23 (m, 2 H), 4.54 (t, <i>J</i> = 5.12 Hz, 2 H), 4.74 (s, 2 H), 5.13 (s, 2 H), 6.72 (s, 1 H), 6.90–6.99 (m, 4 H), 7.33 (t, <i>J</i> = 7.57 Hz, 1 H), 7.36–7.41 (m, 1 H), 7.45–7.52 (m, 4 H), 7.58 (d, <i>J</i> = 7.32 Hz, 1 H), 7.64 (ddd, <i>J</i> = 8.42, 6.95, 1.71 Hz, 1 H), 7.79 (br. s., 1 H), 7.83–7.87 (m, 2 H), 7.91 (d, <i>J</i> = 7.81 Hz, 1 H), 7.93–7.98 (m, 3 H), 8.09 (d, <i>J</i> = 8.79 Hz, 1 H), 8.25 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.29, 52.00, 64.76, 67.44, 67.93, 68.40, 69.42, 69.56, 70.53, 70.68, 73.27, 101.10, 107.48, 114.31, 114.69, 117.86, 123.39, 124.11, 124.62, 125.70, 126.09, 126.99, 128.27, 128.95, 129.21, 129.70, 130.09, 130.46, 131.36, 131.77, 133.16, 133.28, 137.18, 139.04, 155.12, 156.26, 157.81, 160.55, 162.97, 163.22, 166.76, 174.76, 177.66; LRMS (ESI) <i>m</i>/<i>z</i> 880 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>50</sub>H<sub>46</sub>N<sub>3</sub>O<sub>12</sub> [M + H]<sup>+</sup> 880.3081, found 880.3043.</div></div><div id="sec4_4_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119">4.4.53.  Synthesis of 3-(Benzyloxy)-2-(4-(2-(2-(4-((2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)phenyl)-4<i>H</i>-chromen-4-one (<b>Ac13Az10</b>)</h4><div class="NLM_p last">This compound (39 mg) was obtained from <b>Ac13</b> and <b>Az10</b> in 50% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.79–3.84 (m, 2 H), 3.88–3.93 (m, 2 H), 3.95 (t, <i>J</i> = 4.88 Hz, 2 H), 4.10–4.15 (m, 2 H), 4.15–4.21 (m, 2 H), 4.57 (t, <i>J</i> = 4.88 Hz, 2 H), 4.73 (s, 2 H), 5.10 (s, 2 H), 6.71 (s, 1 H), 6.87–6.96 (m, 4 H), 7.22–7.29 (m, 3 H), 7.33–7.39 (m, 3 H), 7.43–7.51 (m, 4 H), 7.59–7.65 (m, 1 H), 7.77 (br. s., 1 H), 7.80–7.86 (m, 2 H), 7.98–8.04 (m, 2 H), 8.06 (d, <i>J</i> = 8.75, 1 H), 8.23 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.27, 64.76, 67.26, 67.89, 68.40, 69.57, 69.61, 73.83, 101.07, 107.45, 114.23, 114.70, 117.80, 123.73, 124.11, 124.55, 125.67, 126.07, 126.94, 128.02, 128.18, 128.69, 128.92, 130.48, 131.34, 131.74, 133.20, 136.77, 139.30, 155.07, 155.84, 157.78, 160.31, 162.95, 163.21, 174.82, 177.63; LRMS (ESI) <i>m</i>/<i>z</i> 778 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>46</sub>H<sub>40</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 778.2765, found 778.2791.</div></div><div id="sec4_4_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120">4.4.54.  Synthesis of 7-(2-((1-(2-(2-((4-Oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac13Az11</b>)</h4><div class="NLM_p last">This compound (38 mg) was obtained from <b>Ac13</b> and <b>Az11</b> in 57% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.80–3.85 (m, 2 H), 3.91 (br. s., 2 H), 3.94 (t, <i>J</i> = 4.88 Hz, 2 H), 4.12–4.19 (m, 4 H), 4.57 (t, <i>J</i> = 4.88 Hz, 2 H), 4.72 (s, 2 H), 6.65 (s, 1 H), 6.67 (s, 1 H), 6.85 (dd, <i>J</i> = 7.32, 2.44 Hz, 2 H), 6.90 (dd, <i>J</i> = 9.03, 2.20 Hz, 1 H), 6.93 (dd, <i>J</i> = 8.79, 1.95 Hz, 1 H), 7.41–7.51 (m, 6 H), 7.80 (ddd, <i>J</i> = 7.69, 3.29, 1.71 Hz, 5 H), 8.03 (d, <i>J</i> = 8.78 Hz, 1 H), 8.07 (d, <i>J</i> = 9.27 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.24, 64.76, 67.69, 67.87, 68.41, 69.28, 69.59, 100.97, 101.03, 107.34, 107.37, 114.51, 114.68, 117.82, 117.97, 126.00, 126.02, 126.82, 127.00, 128.88, 128.90, 131.33, 131.37, 131.58, 131.64, 157.70, 162.86, 162.92, 162.95, 163.14, 177.52, 177.59; LRMS (ESI) <i>m</i>/<i>z</i> 672 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>39</sub>H<sub>34</sub>N<sub>3</sub>O<sub>8</sub> [M + H]<sup>+</sup> 672.2346, found 672.2317.</div></div><div id="sec4_4_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121">4.4.55.  Synthesis of 7-(2-((1-(2-(2-(2-((4-Oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac13Ac12</b>)</h4><div class="NLM_p last">This compound (32 mg) was obtained from <b>Ac13</b> and <b>Az12</b> in 45% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.66 (m, 2 H), 3.66–3.70 (m, 2 H), 3.81–3.86 (m, 2 H), 3.88–3.90 (m, 2 H), 3.94 (br. s., 2 H), 4.17–4.25 (m, 4 H), 4.53–4.55 (m, 2 H), 4.73 (br. s., 2 H), 6.71 (s, 2 H), 6.87–6.98 (m, 4 H), 7.43–7.54 (m, 6 H), 7.80–7.88 (m, 5 H), 8.08 (t, <i>J</i> = 8.54 Hz, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.45, 64.80, 67.93, 67.99, 68.43, 69.36, 69.37, 70.51, 70.71, 101.07, 101.16, 107.44, 107.45, 114.58, 114.68, 118.01, 126.08, 126.96, 127.04, 128.94, 131.37, 131.72, 157.79, 157.80, 162.97, 163.18, 163.20, 177.63; LRMS (ESI) <i>m</i>/<i>z</i> 716 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>41</sub>H<sub>38</sub>N<sub>3</sub>O<sub>9</sub> [M + H]<sup>+</sup> 716.2608, found 716.2577.</div></div><div id="sec4_4_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122">4.4.56.  Synthesis of 2,2′-((((((4,4′-((Benzylazanediyl)bis(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))bis(4,1-phenylene))<i>bis</i>(4H-chromen-4-one) (<b>Ac15(Az1)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (88 mg) was obtained from <b>Ac15</b> and <b>Az1</b> in 99% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.62–3.74 (m, 2 H), 3.75–3.81 (m, 2 H), 3.93 (br. s., 2 H), 4.06–4.12 (m, 2 H), 4.52–4.54 (m, 2 H), 6.65 (s, 1 H), 6.91 (d, <i>J</i> = 9.27 Hz, 2 H), 7.11–7.18 (m, 1 H), 7.22 (t, <i>J</i> = 7.08 Hz, 1 H), 7.29–7.39 (m, 2 H), 7.48 (d, <i>J</i> = 8.30 Hz, 1 H), 7.63 (ddd, <i>J</i> = 8.54, 7.08, 1.46 Hz, 1 H), 7.68–7.79 (m, 3 H), 8.15 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.11, 67.34, 69.37, 69.55, 106.00, 114.84, 117.83, 123.74, 124.08, 124.94, 125.41, 126.89, 127.83, 127.89, 128.13, 128.73, 133.44, 155.97, 161.22, 163.06, 178.10; LRMS (ESI) <i>m</i>/<i>z</i> 886 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>51</sub>H<sub>48</sub>N<sub>7</sub>O<sub>8</sub> [M + H]<sup>+</sup> 886.3564, found 886.3524.</div></div><div id="sec4_4_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123">4.4.57.  Synthesis of 2,2′-((((((((4,4′-((Benzylazanediyl)bis(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))bis(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4<i>H</i>-chromen-4-one) (<b>Ac15(Az2)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (48 mg) was obtained from <b>Ac15</b> and <b>Az2</b> in 49% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.90 (m, 10 H), 4.10–4.18 (m, 2 H), 4.53 (br. s., 2 H), 6.72 (s, 1 H), 6.99 (d, <i>J</i> = 8.79 Hz, 2 H), 7.17–7.33 (m, 2 H), 7.33–7.43 (m, 2 H), 7.50–7.56 (m, 1 H), 7.64–7.70 (m, 1 H), 7.72–7.89 (m, 3 H), 8.20 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 67.62, 69.53, 70.59, 70.72, 106.19, 115.01, 117.93, 124.19, 125.04, 125.60, 127.12, 127.94, 128.32, 133.52, 156.14, 161.50, 163.25, 178.26; LRMS (ESI) <i>m</i>/<i>z</i> 974 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>55</sub>H<sub>56</sub>N<sub>7</sub>O<sub>10</sub> [M + H]<sup>+</sup> 974.4089, found 974.4064.</div></div><div id="sec4_4_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124">4.4.58.  Synthesis of 2,2′-((((((((4,4′-((Benzylazanediyl)bis(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))bis(4,1-phenylene))<i>bis</i>(6-methyl-4<i>H</i>-chromen-4-one) (<b>Ac15(Az3)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (99 mg) was obtained from <b>Ac15</b> and <b>Az3</b> in 99% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.41 (s, 3 H), 3.59–3.70 (m, 5 H), 3.73 (br. s., 1 H), 3.76–3.81 (m, 2 H), 3.87 (br. s., 2 H), 4.10–4.12 (m, 2 H), 4.51 (br. s., 2 H), 6.66 (s, 1 H), 6.95 (d, <i>J</i> = 8.79 Hz, 2 H), 7.14–7.23 (m, 1 H), 7.23–7.31 (m, 1 H), 7.31–7.47 (m, 3 H), 7.70–7.82 (m, 3 H), 7.95 (s, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.80, 67.50, 69.37, 69.43, 70.50, 70.62, 105.90, 114.87, 117.60, 123.43, 124.16, 124.83, 126.95, 127.80, 128.20, 128.84, 134.64, 134.89, 154.29, 161.33, 163.01, 178.27; LRMS (ESI) <i>m</i>/<i>z</i> 1002 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>57</sub>H<sub>60</sub>N<sub>7</sub>O<sub>10</sub> [M + H]<sup>+</sup> 1002.4402, found 1002.4353.</div></div><div id="sec4_4_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125">4.4.59.  Synthesis of 2,2′-((((((((4,4′-((Benzylazanediyl)bis(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))bis(4,1-phenylene))<i>bis</i>(3-(benzyloxy)-4<i>H</i>-chromen-4-one) (<b>Ac15(Az5)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (110 mg) was obtained from <b>Ac15</b> and <b>Az5</b> in 92% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.61–3.66 (m, 2 H), 3.66–3.72 (m, 2 H), 3.76 (br. s., 2 H), 3.80–3.86 (m, 2 H), 3.88 (t, <i>J</i> = 5.12 Hz, 2 H), 4.12–4.19 (m, 2 H), 4.53 (t, <i>J</i> = 4.88 Hz, 2 H), 5.11 (s, 2 H), 6.94 (d, <i>J</i> = 9.27 Hz, 2 H), 7.24–7.30 (m, 4 H), 7.35–7.42 (m, 4 H), 7.51 (d, <i>J</i> = 7.81 Hz, 1 H), 7.66 (ddd, <i>J</i> = 8.54, 7.08, 1.95 Hz, 1 H), 7.74 (br. s., 1 H), 7.99–8.05 (m, 2 H), 8.28 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.10, 67.44, 69.47, 69.54, 70.56, 70.68, 73.83, 114.26, 117.83, 123.47, 124.11, 124.52, 125.64, 126.98, 127.99, 128.14, 128.23, 128.71, 128.88, 130.44, 133.17, 136.71, 139.23, 155.08, 156.09, 160.50, 174.85; LRMS (ESI) <i>m</i>/<i>z</i> 1186 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>69</sub>H<sub>68</sub>N<sub>7</sub>O<sub>12</sub> [M + H]<sup>+</sup> 1186.4926, found 1186.4880.</div></div><div id="sec4_4_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126">4.4.60.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4<i>H</i>-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac15(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (120 mg) was obtained from <b>Ac15</b> and <b>Az8</b> in 98% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.74 (br. s., 2 H), 3.80–3.82 (m, 2 H), 3.86 (s, 3 H), 3.94 (t, <i>J</i> = 5.12 Hz, 2 H), 4.10–4.15 (m, 2 H), 4.54 (t, <i>J</i> = 5.12 Hz, 2 H), 5.12 (s, 2 H), 6.87–6.93 (m, 2 H), 7.17 (d, <i>J</i> = 7.32 Hz, 1 H), 7.24 (t, <i>J</i> = 7.57 Hz, 1 H), 7.32 (t, <i>J</i> = 7.81 Hz, 1 H), 7.35–7.42 (m, 2 H), 7.49 (d, <i>J</i> = 7.81 Hz, 1 H), 7.56–7.60 (m, 1 H), 7.65 (ddd, <i>J</i> = 8.54, 7.08, 1.46 Hz, 1 H), 7.75 (br. s., 1 H), 7.89–7.98 (m, 4 H), 8.26 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 47.53, 50.11, 51.98, 57.43, 67.30, 69.55, 69.69, 73.27, 114.28, 117.88, 123.43, 124.10, 124.22, 124.63, 125.68, 126.99, 128.21, 128.25, 128.89, 129.20, 129.72, 130.07, 130.48, 133.16, 133.30, 137.14, 139.02, 144.38, 155.13, 156.31, 160.39, 166.73, 174.78; LRMS (ESI) <i>m</i>/<i>z</i> 1214 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>69</sub>H<sub>64</sub>N<sub>7</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1214.4511, found 1214.4476.</div></div><div id="sec4_4_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127">4.4.61.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4<i>H</i>-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac15(Az9)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (120 mg) was obtained from <b>Ac15</b> and <b>Az9</b> in 90% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.60–3.65 (m, 3 H), 3.65–3.70 (m, 3 H), 3.77 (br. s., 2 H), 3.80–3.84 (m, 2 H), 3.85–3.90 (m, 5 H), 4.14 (t, <i>J</i> = 4.64 Hz, 2 H), 4.52 (t, <i>J</i> = 5.12 Hz, 2 H), 5.13 (s, 2 H), 6.93 (d, <i>J</i> = 8.79 Hz, 2 H), 7.20–7.22 (d, <i>J</i> = 6.83 Hz, 1 H), 7.29 (t, <i>J</i> = 7.08 Hz, 1 H), 7.33 (t, <i>J</i> = 7.81 Hz, 1 H), 7.40 (t, <i>J</i> = 7.57 Hz, 2 H), 7.50 (d, <i>J</i> = 8.79 Hz, 1 H), 7.58 (d, <i>J</i> = 7.32 Hz, 1 H), 7.63–7.69 (m, 1 H), 7.75 (br. s., 1 H), 7.91 (d, <i>J</i> = 7.81 Hz, 1 H), 7.93–7.99 (m, 3 H), 8.27 (d, <i>J</i> = 7.81 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.20, 52.03, 67.49, 69.56, 69.61, 70.64, 70.75, 73.32, 114.36, 117.92, 123.38, 124.16, 124.66, 125.75, 128.29, 129.25, 129.76, 130.12, 130.51, 133.21, 133.31, 137.19, 139.07, 155.19, 156.42, 160.62, 166.80, 174.84; LRMS (ESI) <i>m</i>/<i>z</i> 1302 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>73</sub>H<sub>72</sub>N<sub>7</sub>O<sub>16</sub> [M + H]<sup>+</sup> 1302.4980, found 1302.5036.</div></div><div id="sec4_4_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128">4.4.62.  Synthesis of 7,7′-(((((4,4′-((Benzylazanediyl)bis(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl)) <i>s</i> (ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(2-phenyl-4<i>H</i>-chromen-4-one) (<b>Ac15(Az11)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (88 mg) was obtained from <b>Ac15</b> and <b>Az11</b> in 99% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.61–4.17 (m, 8 H), 4.56 (br. s., 2 H), 6.73 (s, 1 H), 6.92 (br. s., 2 H), 7.16 (br. s., 1 H), 7.26 (d, <i>J</i> = 1.46 Hz, 1 H), 7.44–7.56 (m, 3 H), 7.86 (d, <i>J</i> = 7.81 Hz, 2 H), 8.07 (d, <i>J</i> = 8.30 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 67.89, 69.36, 101.25, 107.51, 114.56, 126.16, 127.10, 128.99, 131.42, 131.78, 157.83, 163.05, 177.68; LRMS (ESI) <i>m</i>/<i>z</i> 886 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>51</sub>H<sub>48</sub>N<sub>7</sub>O<sub>8</sub> [M + H]<sup>+</sup> 886.3564, found 886.3521.</div></div><div id="sec4_4_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129">4.4.63.  Synthesis of 7,7′-(((((((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(2-phenyl-4<i>H</i>-chromen-4-one) (<b>Ac15(Az12)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (58 mg) was obtained from <b>Ac15</b> and <b>Az12</b> in 60% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.59–3.65 (m, 2 H), 3.65–3.71 (m, 2 H), 3.77 (br. s., 2 H), 3.81–3.86 (m, 2 H), 3.87–3.89 (m, 2 H), 4.16–4.22 (m, 2 H), 4.52 (t, <i>J</i> = 4.88 Hz, 2 H), 6.74 (s, 1 H), 6.91–6.99 (m, 2 H), 7.19–7.22 (m, 1 H), 7.28 (t, <i>J</i> = 7.08 Hz, 1 H), 7.39 (br. s., 1 H), 7.46–7.55 (m, 3 H), 7.77 (br. s., 1 H), 7.85–7.91 (m, 2 H), 8.10 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.21, 68.06, 69.42, 69.52, 70.64, 70.79, 101.20, 107.53, 114.65, 117.98, 126.15, 127.05, 128.33, 128.98, 131.40, 131.83, 157.86, 163.04, 163.26, 177.74; LRMS (ESI) <i>m</i>/<i>z</i> 974 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>55</sub>H<sub>56</sub>N<sub>7</sub>O<sub>10</sub> [M + H]<sup>+</sup> 974.4089, found 974.4063.</div></div><div id="sec4_4_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130">4.4.64.  Synthesis of 7,7′-(((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1<i>H</i>-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(2-phenyl-4<i>H</i>-chromen-4-one) (<b>Ac15(Az13)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (69 mg) was obtained from <b>Ac15</b> and <b>Az13</b> in 87% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.75 (br. s., 2 H), 4.50 (br. s., 2 H), 4.83 (br. s., 2 H), 6.73 (s, 1 H), 6.94 (br. s., 2 H), 7.31 (br. s., 1 H), 7.46–7.56 (m, 3 H), 7.86 (d, <i>J</i> = 7.81 Hz, 2 H), 8.10 (d, <i>J</i> = 8.30 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 53.84, 69.47, 101.42, 107.51, 114.28, 126.14, 127.36, 128.48, 128.99, 131.49, 131.61, 157.71, 162.13, 163.14, 177.52; LRMS (ESI) <i>m</i>/<i>z</i> 798 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>47</sub>H<sub>40</sub>N<sub>7</sub>O<sub>6</sub> [M + H]<sup>+</sup> 798.3040, found 798.3013.</div></div><div id="sec4_4_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131">4.4.65.  Synthesis of 2,2′-(((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))diethanol (<b>Ac15(Az16)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (28.5 mg) was obtained from <b>Ac15</b> and <b>Az16</b> in 64% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.54–3.59 (m, 4 H) 3.68–3.75 (m, 10 H) 3.82–3.88 (m, 4 H) 4.51 (t, <i>J</i> = 4.88 Hz, 4 H) 7.19–7.24 (m, 1 H) 7.30 (t, <i>J</i> = 7.57 Hz, 2 H) 7.40 (d, <i>J</i> = 7.32 Hz, 2 H) 7.84 (s, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 47.55 (s) 50.14 (s) 58.38 (s) 61.40 (s) 69.13 (s) 72.61 (s) 124.55 (s) 127.06 (s) 128.27 (s) 128.90 (s) 138.67 (s) 144.44 (s). LRMS (ESI) <i>m</i>/<i>z</i> 446 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>21</sub>H<sub>32</sub>N<sub>7</sub>O<sub>4</sub> [M + H]<sup>+</sup> 446.5153, found 446.5258.</div></div><div id="sec4_4_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132">4.4.66.  Synthesis of 2,2′-((((((4,4′-((Benzylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(3-((3-methoxybenzyl)oxy)-4H-chromen-4-one) (<b>Ac15(Az17)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (30.6 mg) was obtained from <b>Ac15</b> and <b>Az17</b> in 49% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.63 (br. s., 1 H), 3.70 (s, 3 H), 3.74 (br. s., 2 H), 3.81 (t, <i>J</i> = 4.88 Hz, 2 H), 3.94 (t, <i>J</i> = 4.88 Hz, 2 H), 4.11 (t, <i>J</i> = 4.89 Hz, 2 H), 4.53 (t, <i>J</i> = 4.89 Hz, 2 H), 5.09 (s, 2 H), 6.76–6.81 (m, 1 H), 6.88–6.95 (m, 4 H), 7.16 (t, <i>J</i> = 7.70 Hz, 2 H), 7.23 (t, <i>J</i> = 7.34 Hz, 1 H), 7.31–7.43 (m, 2 H), 7.50 (d, <i>J</i> = 8.56 Hz, 1 H), 7.65 (ddd, <i>J</i> = 8.50, 7.03, 1.59 Hz, 1 H), 7.73 (br. s., 1 H), 8.00 (d, <i>J</i> = 8.80 Hz, 2 H), 8.27 (dd, <i>J</i> = 8.07, 1.47 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 47.6, 50.2, 55.1, 57.6, 67.3, 69.6, 69.7, 73.8, 113.7, 114.2, 114.3, 117.9, 121.0, 123.7, 124.2, 124.6, 125.7, 127.0, 128.2, 128.9, 129.2, 130.5, 133.2, 138.3, 139.3, 155.1, 156.1, 159.5, 160.4, 174.9<b>;</b> LRMS (ESI) <i>m</i>/<i>z</i> 1158.5 base peak: 1158.5 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>67</sub>H<sub>64</sub>N<sub>7</sub>O<sub>12</sub>[M + H]<sup>+</sup> 1158.4613, found 1158.4630.</div></div><div id="sec4_4_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133">4.4.67.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az1</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134">4.4.68.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(2-(4-(4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az2</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135">4.4.69.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(2-(4-(6-methyl-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az3</b>)</h4><div class="NLM_p last">This compound (28 mg) was obtained from <b>Ac16</b> and <b>Az3</b> in 34% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.38 (s, 3 H), 2.94 (br. s., 2 H), 3.45–3.68 (m, 6 H), 3.68–3.76 (m, 3 H), 3.82 (br. s., 3 H), 4.05 (m, 2 H), 4.11 (br. s., 2 H), 4.48 (br. s., 2 H), 6.62 (s, 1 H), 6.67 (s, 1 H), 6.81–6.92 (m, 4 H), 7.16–7.21 (m, 2 H), 7.26 (br. s., 2 H), 7.31–7.37 (m, 2 H), 7.37–7.48 (m, 5 H), 7.74 (d, <i>J</i> = 8.79 Hz, 2 H), 7.78–7.83 (m, 2 H), 7.91 (s, 1 H), 8.02 (d, <i>J</i> = 8.79 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 20.90, 67.58, 69.52, 69.55, 70.59, 70.76, 101.05, 106.10, 107.48, 114.66, 114.95, 117.67, 124.41, 125.01, 126.13, 127.03, 127.91, 128.44, 128.98, 131.40, 131.78, 134.75, 135.02, 154.42, 157.91, 161.37, 162.99, 163.05, 177.72, 178.39; LRMS (ESI) <i>m</i>/<i>z</i> 819 [M + H]<sup>+</sup>, 841 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>49</sub>H<sub>47</sub>N<sub>4</sub>O<sub>8</sub> [M + H]<sup>+</sup> 819.3394, found 819.3392; calcd for C<sub>49</sub>H<sub>46</sub>N<sub>4</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 841.3213, found 841.3220.</div></div><div id="sec4_4_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136">4.4.70.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(2-(4-(6-fluoro-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4H-chromen-4-one (<b>Ac16Az4</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137">4.4.71.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(2-(4-(3-(benzyloxy)-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az5</b>)</h4><div class="NLM_p last">This compound (29 mg) was obtained from <b>Ac16</b> and <b>Az5</b> in 31% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.00 (br. s., 2 H), 3.57–3.70 (m, 4 H), 3.70–3.85 (m, 4 H), 3.88–3.98 (m, 4 H), 4.09–4.23 (m, 4 H), 4.53 (t, <i>J</i> = 4.88 Hz, 2 H), 5.10 (s, 2 H), 6.73 (s, 1 H), 6.87–6.95 (m, 4 H), 7.20–7.42 (m, 11 H), 7.45–7.52 (m, 4 H), 7.64 (td, <i>J</i> = 7.81, 1.46 Hz, 1 H), 7.70 (br. s., 1 H), 7.86–7.59 (m, 2 H), 8.00 (d, <i>J</i> = 8.75 Hz, 2 H), 8.08 (d, <i>J</i> = 8.79 Hz, 1 H), 8.25 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.33, 67.44, 69.51, 69.57, 70.55, 70.72, 73.85, 100.98, 107.45, 114.26, 114.67, 117.83, 123.58, 124.14, 124.55, 125.70, 126.11, 126.94, 127.18, 128.02, 128.17, 128.34, 128.72, 128.79, 128.94, 130.47, 131.36, 131.77, 133.19, 136.77, 139.29, 155.10, 156.01, 157.89, 160.46, 162.95, 163.28, 174.87, 177.70; LRMS (ESI) <i>m</i>/<i>z</i> 911 [M + H]<sup>+</sup>, 933 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>55</sub>H<sub>51</sub>N<sub>4</sub>O<sub>9</sub> [M + H]<sup>+</sup> 911.3656, found 911.3662; calcd for C<sub>55</sub>H<sub>50</sub>N<sub>4</sub>O<sub>9</sub>Na [M + Na]<sup>+</sup> 933.3475, found 933.3487.</div></div><div id="sec4_4_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138">4.4.72.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(4-(6-fluoro-4-oxo-4<i>H</i>-chromen-2-yl)phenoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az7</b>)</h4><div class="NLM_p last">This compound was obtained according to the procedure as described.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(52)</a></div></div><div id="sec4_4_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139">4.4.73.  Synthesis of 7-(2-(Benzyl((1-(2-(2-(2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az12</b>)</h4><div class="NLM_p last">This compound (33 mg) was obtained from <b>Ac16</b> and <b>Az12</b> in 41% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 2.99 (br. s., 2 H), 3.58–3.69 (m, 4 H), 3.71–3.84 (m, 4 H), 3.88 (t, <i>J</i> = 5.12 Hz, 2 H), 3.93 (br. s., 2 H), 4.11–4.20 (m, 4 H), 4.53 (t, <i>J</i> = 5.12 Hz, 2 H), 6.72 (s, 1 H), 6.72 (s, 1 H), 6.87–6.96 (m, 4 H), 7.20–7.25 (m, 1 H), 7.30 (t, <i>J</i> = 7.57 Hz, 2 H), 7.33–7.41 (m, 2 H), 7.45–7.54 (m, 6 H), 7.68 (br. s., 1 H), 7.82–7.89 (m, 4 H), 8.08 (dd, <i>J</i> = 8.79, 2.93 Hz, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 49.28, 50.25, 51.69, 58.83, 67.24, 67.99, 69.38, 69.55, 70.57, 70.78, 100.97, 101.14, 107.45, 107.51, 114.56, 114.67, 117.83, 118.00, 123.80, 126.11, 126.96, 127.06, 127.20, 128.36, 128.78, 128.96, 131.37, 131.39, 131.77, 138.96, 157.80, 157.88, 162.95, 162.97, 163.16, 163.25, 177.65, 177.69; LRMS (ESI) <i>m</i>/<i>z</i> 805 [M + H]<sup>+</sup>, 827 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>48</sub>H<sub>45</sub>N<sub>4</sub>O<sub>8</sub> [M + H]<sup>+</sup> 805.3237, found 805.3265; calcd for C<sub>48</sub>H<sub>44</sub>N<sub>4</sub>O<sub>8</sub>Na [M + Na]<sup>+</sup> 827.3057, found 827.3078.</div></div><div id="sec4_4_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140">4.4.74.  Synthesis of 7-(2-(Benzyl((1-(2-((4-oxo-2-phenyl-4<i>H</i>-chromen-7-yl)oxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)amino)ethoxy)-2-phenyl-4<i>H</i>-chromen-4-one (<b>Ac16Az13</b>)</h4><div class="NLM_p last">This compound (18 mg) was obtained from <b>Ac16</b> and <b>Az13</b> in 25% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.00 (br. s., 2 H), 3.75 (br. s., 2 H), 3.97 (br. s., 2 H), 4.16 (br. s., 2 H), 4.47 (t, <i>J</i> = 4.88 Hz, 2 H), 4.81 (t, <i>J</i> = 4.64 Hz, 2 H), 6.99 (s, 1 H), 6.70 (s, 1 H), 6.84–6.93 (m, 4 H), 7.20–7.25 (m, 1 H), 7.30 (t, <i>J</i> = 7.32 Hz, 2 H), 7.36 (br. s., 2 H), 7.44–7.53 (m, 6 H), 7.73 (br. s., 1 H), 7.85 (dd, <i>J</i> = 7.56, 1.71 Hz, 2 H), 7.82 (dd, <i>J</i> = 8.05, 1.22 Hz, 2 H), 8.06 (dd, <i>J</i> = 9.03, 2.20 Hz, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 49.48, 51.83, 58.83, 66.84, 67.21, 101.02, 101.34, 107.44, 107.51, 114.08, 114.59, 117.84, 118.54, 124.00, 126.09, 126.11, 126.96, 127.28, 127.39, 128.38, 128.73, 128.95, 128.98, 131.38, 131.49, 131.58, 131.76, 138.71, 157.67, 157.85, 162.08, 162.93, 163.09, 163.21, 177.44, 177.66; LRMS (ESI) <i>m</i>/<i>z</i> 717 [M + H]<sup>+</sup>, 739 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>44</sub>H<sub>37</sub>N<sub>4</sub>O<sub>6</sub> [M + H]<sup>+</sup> 717.2713, found 717.2729; calcd for C<sub>44</sub>H<sub>36</sub>N<sub>4</sub>O<sub>6</sub>Na [M + Na]<sup>+</sup> 739.2533, found 739.2541.</div></div><div id="sec4_4_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141">4.4.75.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(1,3-Phenylene)<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))bis(oxy))<i>bis</i>(ethane-2,1-diyl))bis(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac22(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (72.0 mg) was obtained from <b>Ac22</b> and <b>Az8</b> in 75% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.78–3.87 (m, 5 H), 3.92–3.97 (m, 2 H), 4.09–4.15 (m, 2 H), 4.55 (t, <i>J</i> = 4.88 Hz, 2 H), 5.08 (s, 2 H), 6.84–6.91 (m, 1 H), 6.85–6.90 (m, 2 H), 7.27–7.39 (m, 2 H), 7.46 (d, <i>J</i> = 8.30 Hz, 1 H), 7.54 (d, <i>J</i> = 7.81 Hz, 1 H), 7.63 (ddd, <i>J</i> = 8.54, 7.08, 1.46 Hz, 1 H), 7.70 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H), 7.84–7.91 (m, 3 H), 7.92–8.00 (m, 2 H), 8.24 (dd, <i>J</i> = 8.30, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.3, 51.9, 67.2, 69.4, 69.5, 69.6, 73.2, 114.2, 117.9, 121.1, 122.7, 123.3, 124.0, 124.6, 125.2, 125.6, 128.2, 129.1, 129.7, 130.0, 130.4, 131.1, 133.1, 133.3, 137.1, 138.9, 147.2, 155.1, 156.3, 160.4, 166.7, 174.7; LRMS (ESI) <i>m</i>/<i>z</i> 1157 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>66</sub>H<sub>57</sub>N<sub>6</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1157.3933, found 1157.3907.</div></div><div id="sec4_4_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142">4.4.76.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(1,4-Phenylene)<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))bis(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac23(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (52.0 mg) was obtained from <b>Ac23</b> and <b>Az8</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.83–3.89 (m, 5 H), 3.96–4.02 (m, 2 H), 4.14 (dd, <i>J</i> = 5.12, 3.66 Hz, 2 H), 4.60 (t, <i>J</i> = 4.88 Hz, 2 H), 5.12 (s, 2 H), 6.87–6.91 (m, 2 H), 7.32 (t, <i>J</i> = 7.81 Hz, 1 H), 7.37–7.44 (m, 1 H), 7.50 (d, <i>J</i> = 8.30 Hz, 1 H), 7.55–7.58 (m, 1 H), 7.62–7.69 (m, 1 H), 7.76 (s, 2 H), 7.89–7.94 (m, 4 H), 7.95–7.98 (m, 1 H), 8.26 (dd, <i>J</i> = 8.05, 1.71 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.4, 52.0, 67.4, 69.7, 69.8, 73.3, 114.3, 118.0, 120.9, 123.5, 124.1, 124.6, 125.6, 126.0, 128.3, 129.2, 129.8, 130.1, 130.3, 130.5, 133.2, 133.3, 137.1, 139.0, 147.3, 155.2, 156.3, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1157 [M + H]<sup>+</sup> ; HRMS (ESI) calcd for C<sub>66</sub>H<sub>57</sub>N<sub>6</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1157.3933, found 1157.3942.</div></div><div id="sec4_4_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143">4.4.77.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(Propane-1,3-diyl)<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))bis(oxy))<i>bis</i>(ethane-2,1-diyl))bis(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac24(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (55.0 mg) was obtained from <b>Ac24</b> and <b>Az8</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 1.99–2.07 (m, 1 H), 2.74 (t, <i>J</i> = 7.57 Hz, 2 H), 3.80–3.84 (m, 2 H), 3.87 (s, 3 H), 3.91–3.95 (m, 2 H), 4.13–4.16 (m, 2 H), 4.51 (t, <i>J</i> = 5.12 Hz, 2 H), 5.14 (s, 2 H), 6.92–6.95 (m, 2 H), 7.34 (t, <i>J</i> = 7.81 Hz, 1 H), 7.41 (ddd, <i>J</i> = 8.05, 7.08, 0.98 Hz, 1 H), 7.47 (s, 1 H), 7.52 (d, <i>J</i> = 8.30 Hz, 1 H), 7.58–7.61 (m, 1 H), 7.65–7.69 (m, 1 H), 7.92 (dt, <i>J</i> = 7.81, 1.46 Hz, 1 H), 7.95–8.00 (m, 3 H), 8.28 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 25.0, 29.1, 50.0, 52.0, 67.3, 69.6, 69.8, 73.3, 114.3, 117.9, 122.0, 123.5, 124.1, 124.7, 125.7, 128.3, 129.2, 129.8, 130.1, 130.5, 133.2, 133.3, 137.2, 139.1, 147.4, 155.2, 156.3, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1123 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>63</sub>H<sub>59</sub>N<sub>6</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1123.4089, found 1123.4125</div></div><div id="sec4_4_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144">4.4.78.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(Oxy<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))bis(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac25(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (45.0 mg) was obtained from <b>Ac25</b> and <b>Az8</b> in 57% yield according to the general procedure described above. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ ppm 3.81 (dd, <i>J</i> = 5.37, 3.90 Hz, 3 H), 3.84–3.88 (m, 3 H), 3.93 (t, <i>J</i> = 5.12 Hz, 2 H), 4.13 (dd, <i>J</i> = 5.12, 3.66 Hz, 2 H), 4.54 (t, <i>J</i> = 5.12 Hz, 2 H), 4.68 (s, 2 H), 5.13 (s, 2 H), 6.93 (d, <i>J</i> = 8.79 Hz, 2 H), 7.33 (t, <i>J</i> = 7.57 Hz, 1 H), 7.37–7.41 (m, 1 H), 7.51 (d, <i>J</i> = 7.81 Hz, 1 H), 7.56–7.60 (m, 1 H), 7.62–7.69 (m, 1 H), 7.76 (s, 1 H), 7.91 (d, <i>J</i> = 7.81 Hz, 1 H), 7.94–7.99 (m, 3 H), 8.26 (dd, <i>J</i> = 7.81, 1.46 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 51.3, 53.2, 64.7, 68.4, 70.7, 70.8, 74.4, 106.7, 115.4, 119.1, 124.6, 125.3, 125.8, 126.8, 129.4, 130.4, 130.9, 131.2, 131.7, 134.3, 134.5, 138.3, 140.2, 156.3, 157.5, 161.6, 167.9, 176.0; LRMS (ESI) <i>m</i>/<i>z</i> 1125 [M + H]<sup>+</sup> (ditto); HRMS (ESI) calcd for C<sub>62</sub>H<sub>57</sub>N<sub>6</sub>O<sub>15</sub> [M + H]<sup>+</sup> 1125.3882, found 1125.3889.</div></div><div id="sec4_4_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145">4.4.79.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-((Phenylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac26(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (34.0 mg) was obtained from <b>Ac26</b> and <b>Az8</b> in 58% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.69–3.80 (m, 4 H), 3.85–3.96 (m, 10 H), 4.02–4.11 (m, 4 H), 4.42–4.53 (m, 4 H), 4.64 (s, 4 H), 5.14 (s, 4 H), 6.61–6.72 (m, 1 H), 6.83 (d, <i>J</i> = 8.31 Hz, 2 H), 6.91 (d, <i>J</i> = 9.05 Hz, 4 H), 7.13 (t, <i>J</i> = 7.82 Hz, 2 H), 7.34 (t, <i>J</i> = 7.70 Hz, 2 H), 7.41 (t, <i>J</i> = 7.58 Hz, 2 H), 7.49–7.62 (m, 6 H), 7.63–7.71 (m, 2 H), 7.88–8.03 (m, 8 H), 8.25–8.31 (m, 2 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 46.8, 50.2, 52.0, 67.3, 69.6, 69.7, 73.3, 113.7, 114.3, 117.7, 117.9, 123.1, 123.5, 124.1, 124.7, 125.7, 128.3, 129.1, 129.2, 129.8, 130.1, 130.5, 133.2, 133.3, 137.2, 139.0, 147.9, 155.2, 156.3, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1200 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>68</sub>H<sub>62</sub>N<sub>7</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1200.4355, found 1200.4362.</div></div><div id="sec4_4_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146">4.4.80.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(((Pyridin-4-ylmethyl)azanediyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac28(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (23.0 mg) was obtained from <b>Ac28</b> and <b>Az8</b> in 54% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.65 (s, 1 H), 3.74 (s, 2 H), 3.81–3.86 (m, 2 H), 3.88 (s, 3 H), 3.93–3.99 (m, 2 H), 4.11–4.19 (m, 2 H), 4.56 (t, <i>J</i> = 5.14 Hz, 2 H), 5.15 (s, 2 H), 6.93 (d, <i>J</i> = 9.05 Hz, 2 H), 7.29–7.37 (t, <i>J</i> = 7.90 Hz 2 H), 7.39–7.44 (t, <i>J</i> = 8.28 Hz 1 H), 7.52 (d, <i>J</i> = 8.56 Hz, 1 H), 7.60 (d, <i>J</i> = 7.58 Hz, 1 H), 7.63–7.72 (m, 1 H), 7.74 (s, 1 H), 7.87–8.01 (m, 4 H), 8.29 (d, <i>J</i> = 6.60 Hz, 1 H), 8.49 (br. s., 1 H) ; <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ ppm 50.6, 52.1, 67.4, 69.2, 69.6, 73.3, 114.3, 118.0, 123.5, 124.1, 124.8, 125.7, 128.4, 129.3, 129.8, 130.0, 130.5, 133.3, 133.5, 137.1, 139.0, 155.1, 156.3, 160.3, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1215 [M + H]<sup>+</sup> (ditto) ; HRMS (ESI) calcd for C<sub>68</sub>H<sub>63</sub>N<sub>8</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1215.4467, found 1215.4521.</div></div><div id="sec4_4_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147">4.4.81.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-(Piperazine-1,4-diyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac29(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (25.0 mg) was obtained from <b>Ac29</b> and <b>Az8</b> in 52% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.91 (br. s., 4 H), 3.79–3.93 (m, 7 H), 3.96 (t, <i>J</i> = 5.01 Hz, 2 H), 4.13–4.21 (m, 2 H), 4.56 (t, <i>J</i> = 5.01 Hz, 2 H), 5.15 (s, 2 H), 6.95 (d, <i>J</i> = 9.05 Hz, 2 H), 7.30–7.48 (m, 2 H), 7.52 (d, <i>J</i> = 8.31 Hz, 1 H), 7.59 (d, <i>J</i> = 7.34 Hz, 1 H), 7.63–7.73 (m, 1 H), 7.86–7.95 (m, 2 H), 7.95–8.02 (m, 3 H), 8.28 (d, <i>J</i> = 7.82 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.1, 52.5, 67.3, 69.6, 73.3, 114.3, 117.9, 124.1, 125.7, 128.3, 129.9, 133.3, 137.1, 139.0, 143.8, 155.2, 156.4, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1193 [M + H]<sup>+</sup> (ditto); HRMS (ESI) calcd for C<sub>66</sub>H<sub>65</sub>N<sub>8</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1193.4620, found 1193.4635.</div></div><div id="sec4_4_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148">4.4.82.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-((1,4-Diazepane-1,4-diyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac30(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (30.0 mg) was obtained from <b>Ac30</b> and <b>Az8</b> in 59% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 1.95 (br. s., 2 H), 2.91 (br. s., 4 H), 3.83–3.91 (m, 6 H), 3.97 (t, <i>J</i> = 5.14 Hz, 2 H), 4.14–4.21 (m, 2 H), 4.57 (t, <i>J</i> = 5.01 Hz, 2 H), 5.15 (s, 2 H), 6.96 (d, <i>J</i> = 8.80 Hz, 2 H), 7.33–7.38 (t, <i>J</i> = 7.60 Hz 1 H), 7.39–7.44 (t, <i>J</i> = 7.60 Hz 1 H), 7.53 (d, <i>J</i> = 8.31 Hz, 1 H), 7.60 (d, <i>J</i> = 7.83 Hz, 1 H), 7.63–7.72 (m, 1 H), 7.87–7.95 (m, 2 H), 7.95–8.03 (m, 3 H), 8.28 (d, <i>J</i> = 7.34 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.3, 52.0, 52.5, 53.2, 67.4, 69.6, 73.3, 114.3, 117.9, 123.5, 124.1, 124.7, 125.0, 125.7, 129.6, 133.3, 137.0, 139.1, 155.0, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1207 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>67</sub>H<sub>67</sub>N<sub>8</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1207.4777, found 1207.4761.</div></div><div id="sec4_4_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149">4.4.83.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((4,4′-((Ethane-1,2-diyl)<i>bis</i>(methylazanediyl))bis(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac31(Az8)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (32.0 mg) was obtained from <b>Ac31</b> and <b>Az8</b> in 69% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.22 (s, 3 H), 2.54 (s, 2 H), 3.68 (s, 2 H), 3.80–3.85 (m, 2 H), 3.88 (s, 3 H), 3.92–4.00 (m, 2 H), 4.09–4.18 (m, 2 H), 4.55 (t, <i>J</i> = 5.01 Hz, 2 H), 5.15 (s, 2 H), 6.94 (d, <i>J</i> = 8.80 Hz, 2 H), 7.32–7.37 (t, <i>J</i> = 7.60 Hz, 1 H), 7.38–7.43 (t, <i>J</i> = 6.80 Hz, 1 H), 7.51 (d, <i>J</i> = 8.31 Hz, 1 H), 7.59 (d, <i>J</i> = 7.82 Hz, 1 H), 7.63–7.71 (m, 2 H), 7.92 (d, <i>J</i> = 7.82 Hz, 1 H), 7.95–8.01 (m, 3 H), 8.28 (d, <i>J</i> = 8.07 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 42.4, 50.1, 52.0, 52.6, 54.4, 67.3, 69.6, 69.7, 73.3, 114.3, 117.9, 123.5, 123.7, 124.1, 124.7, 125.7, 128.3, 129.2, 129.8, 130.1, 130.5, 133.2, 133.3, 137.2, 139.1, 144.6, 155.2, 156.4, 160.4, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1195 [M + H]<sup>+</sup>; HRMS (ESI) calcd for C<sub>66</sub>H<sub>67</sub>N<sub>8</sub>O<sub>14</sub> [M + H]<sup>+</sup> 1195.4777, found 1195.4814.</div></div><div id="sec4_4_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150">4.4.84.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((((4,4′-(1,3-Phenylene)<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac22(Az9)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (22.0 mg) was obtained from <b>Ac22</b> and <b>Az9</b> in 65% yield according to the general procedure described above.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.61–3.70 (m, 4 H), 3.81 (t, <i>J</i> = 5.08 Hz, 2 H), 3.85 (s, 3 H), 3.89 (t, <i>J</i> = 5.08 Hz, 2 H), 4.11(t, <i>J</i> = 4.96 Hz, 2 H), 4.55 (t, <i>J</i> = 4.96 Hz, 2 H), 5.10 (s, 2 H), 6.83–6.88 (m, 2 H), 7.31 (t, <i>J</i> = 7.61 Hz, 1 H), 7.34–7.40 (m, 2 H), 7.48 (d, <i>J</i> = 8.20 Hz, 1 H), 7.55 (d, <i>J</i> = 7.42 Hz, 1 H), 7.61–7.67 (m, 1 H), 7.75 (dd, <i>J</i> = 7.81, 1.56 Hz, 1 H), 7.86–7.92 (m, 3 H), 7.95 (s, 1 H), 8.02 (s, 1 H), 8.22–8.27 (m, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.4, 52.0, 67.5, 69.5, 69.5, 69.6, 70.6, 70.7, 73.3, 114.3, 117.9, 121.2, 122.7, 123.2, 124.1, 124.6, 125.2, 125.7, 128.3, 129.2, 129.3, 129.7, 130.1, 130.4, 131.3, 133.2, 133.3, 137.1, 139.0, 147.3, 155.1, 156.4, 160.6, 166.8, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1245.5[M + H]<sup>+</sup> base peak: 1267.5 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>70</sub>H<sub>65</sub>N<sub>6</sub>O<sub>16</sub>[M + H]<sup>+</sup> 1245.4457, found 1245.4473.</div></div><div id="sec4_4_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151">4.4.85.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((((4,4′-(1,4-Phenylene)<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))bis(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac23(Az9)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (22.0 mg) was obtained from <b>Ac23</b> and <b>Az9</b> in 65% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.57–3.67 (m, 4 H), 3.76 (t, <i>J</i> = 4.68 Hz, 2 H), 3.85 (s, 3 H), 3.86 (t, <i>J</i> = 4.68 Hz, 2 H), 4.05(t, <i>J</i> = 4.88 Hz, 2 H), 4.51 (t, <i>J</i> = 4.88 Hz, 2 H), 5.08 (s, 2 H), 6.84 (dd, <i>J</i> = 8.98, 1.17 Hz, 2 H), 7.26–7.32 (m, 1 H), 7.35 (t, <i>J</i> = 7.42 Hz, 1 H), 7.46 (d, <i>J</i> = 8.20 Hz, 1 H), 7.50–7.55 (m, 1 H), 7.58–7.65 (m, 1 H), 7.79 (d, <i>J</i> = 1.56 Hz, 2 H), 7.84–7.91 (m, 3 H), 7.91–7.95 (m, 2 H), 8.22 (d, <i>J</i> = 8.20 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.2, 51.9, 67.3, 69.3, 69.4, 70.5, 70.5, 73.2, 114.2, 117.9, 120.9, 123.2, 124.0, 124.6, 125.5, 125.9, 128.2, 129.2, 129.7, 130.0, 130.3, 130.4, 133.1, 133.2, 137.1, 138.9, 147.0, 155.1, 156.4, 160.5, 166.7, 174.7; LRMS (ESI) <i>m</i>/<i>z</i> 1245.5 [M + H]<sup>+</sup> base peak: 1267.5 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>70</sub>H<sub>65</sub>N<sub>6</sub>O<sub>16</sub>[M + H]<sup>+</sup> 1245.4457, found 1245.4454.</div></div><div id="sec4_4_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152">4.4.86.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((((4,4′-((Phenylazanediyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac26(Az9)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (21.0 mg) was obtained from <b>Ac26</b> and <b>Az9</b> in 55% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 3.50–3.60 (m, 4 H), 3.75 (t, <i>J</i> = 4.48 Hz, 2 H), 3.80 (t, <i>J</i> = 4.48 Hz, 2 H), 3.84 (s, 3 H), 4.08 (t, <i>J</i> = 4.46 Hz, 2 H), 4.43 (t, <i>J</i> = 4.46 Hz, 2 H), 4.63 (br. s., 2 H), 5.10 (s, 2 H), 6.67 (t, <i>J</i> = 7.22 Hz, 1 H), 6.82 (d, <i>J</i> = 7.81 Hz, 1 H), 6.90 (d, <i>J</i> = 7.81 Hz, 2 H), 7.06–7.16 (m, 1 H), 7.30 (t, <i>J</i> = 7.61 Hz, 1 H), 7.33–7.41 (m, 1 H), 7.47 (d, <i>J</i> = 8.20 Hz, 1 H), 7.55 (d, <i>J</i> = 6.25 Hz, 2 H), 7.59–7.67 (m, 1 H), 7.86–7.91 (m, 1 H), 7.91–7.99 (m, 3 H), 8.23 (d, <i>J</i> = 7.81 Hz, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 46.6, 50.2, 52.0, 67.4, 69.4, 69.5, 70.5, 70.6, 73.2, 113.6, 114.3, 117.7, 117.9, 123.1, 123.3, 124.0, 124.6, 125.6, 128.2, 129.1, 129.2, 129.7, 130.0, 130.4, 133.1, 133.3, 137.1, 139.0, 147.9, 155.1, 156.4, 160.5, 166.7, 174.8; LRMS (ESI) <i>m</i>/<i>z</i> 1288.5[M + H]<sup>+</sup> base peak: 1310.5 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>72</sub>H<sub>70</sub>N<sub>7</sub>O<sub>16</sub>[M + H]<sup>+</sup> 1288.4879, found 1288.4938.</div></div><div id="sec4_4_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153">4.4.87.  Synthesis of Dimethyl 3,3′-(((2,2′-((((((((4,4′-(Piperazine-1,4-diyl)<i>bis</i>(methylene))<i>bis</i>(1H-1,2,3-triazole-4,1-diyl))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(ethane-2,1-diyl))<i>bis</i>(oxy))<i>bis</i>(4,1-phenylene))<i>bis</i>(4-oxo-4H-chromene-3,2-diyl))<i>bis</i>(oxy))<i>bis</i>(methylene))dibenzoate (<b>Ac29(Az9)<sub>2</sub></b>)</h4><div class="NLM_p last">This compound (41.0 mg) was obtained from <b>Ac29</b> and <b>Az9</b> in 45% yield according to the general procedure described above. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.48 (br. s., 4 H), 3.59 (s, 4 H), 3.64 (t, <i>J</i> = 4.59 Hz, 2 H), 3.75–3.86 (m, 7 H), 4.12 (t, <i>J</i> = 4.86 Hz, 2 H), 4.46 (t, <i>J</i> = 5.07 Hz, 2 H), 5.09 (s, 2 H), 6.87–6.95 (m, 2 H), 7.29 (t, <i>J</i> = 7.81 Hz, 1 H), 7.35 (t, <i>J</i> = 7.61 Hz, 1 H), 7.46 (d, <i>J</i> = 8.20 Hz, 1 H), 7.54 (d, <i>J</i> = 7.81 Hz, 1 H), 7.57–7.66 (m, 2 H), 7.87 (d, <i>J</i> = 7.81 Hz, 1 H), 7.90–7.97 (m, 3 H), 8.17–8.26 (m, 1 H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 50.1, 51.9, 52.5, 53.0, 67.4, 69.4, 69.5, 70.4, 70.6, 73.2, 114.3, 117.9, 123.3, 123.7, 124.0, 124.6, 125.6, 128.2, 129.2, 129.7, 130.0, 130.4, 133.1, 133.3, 137.1, 138.9, 143.9, 155.1, 156.4, 160.5, 166.7, 174.7; LRMS (ESI) <i>m</i>/<i>z</i> 1281.6 [M + H]<sup>+</sup> base peak: 1303.5 [M + Na]<sup>+</sup>; HRMS (ESI) calcd for C<sub>70</sub>H<sub>73</sub>N<sub>8</sub>O<sub>16</sub>[M + H]<sup>+</sup> 1281.5145, found 1281.5099.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154">4.5.  Materials for Biological Studies</h3><div class="NLM_p last">Dimethyl sulfoxide (DMSO), paclitaxel, topotecan, DOX, mitoxantrone, cyclosporine A, Ko143, and phenazine methosulfate (PMS) were purchased from Sigma-Aldrich. Dulbecco’s Modified Eagle’s Medium (DMEM), trypsin-ethylenediaminetetraacetic acid (EDTA), and penicillin/streptomycin were purchased from Gibco BRL. Roswell Park Memorial Institute (RPMI) 1640 medium and fetal bovine serum (FBS) were purchased from HyClone Laboratories. 3-(4,5-Dimethylthiazol-2-yl)-5-[3-(carboxymethoxy)phenyl]-2-(4-sulfo-phenyl)-2H-tetrazolium (MTS) was purchased from Promega. The human breast cancer cell lines LCC6 and P-gp transfectant LCC6MDR were kindly provided by Prof. R. Clarke (Georgetown University Medical School, USA). The human ovarian carcinoma cell line 2008/MRP1 was a generous gift from Prof. P. Borst (The Netherlands Cancer Institute, Amsterdam, Netherlands). The human embryonic kidney cell lines HEK293/pcDNA3.1, BCRP-transfectant HEK293/R2, MCF7-MX100, and S1M180 cells were generously provided by Dr. Kenneth To (The Chinese University of Hong Kong, Hong Kong). L929, 3T3, and HFF-1 cell lines were purchased from ATCC.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155">4.6.  Cell Culture</h3><div class="NLM_p last">HEK293/R2, HEK293/pcDNA3.1, MCF7-MX100, 2008/MRP1, and S1M180 cells were cultured in RPMI 1640 medium with 10% FBS and 100 U/mL penicillin and 100 μg/mL of streptomycin and maintained at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. The L929, 3T3, HFF-1, and LCC6MDR cells were cultured in DMEM supplemented with 10% FBS and 100 U/mL penicillin and 100 μg/mL of streptomycin and maintained at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. For each passage of HEK293pcDNA3.1 or HEK293/R2, 1 mg/mL G418 was added to the culture. The cells were split constantly after a confluent monolayer had been formed. To split cells, the plate was washed briefly with phosphate-buffered saline (PBS), treated with 0.05% trypsin-EDTA, and harvested by centrifugation.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i156" class="anchor-spacer"></div><h3 class="article-section__title" id="_i156">4.7.  EC<sub>50</sub> Determination</h3><div class="NLM_p">5,000 cells of HEK293/R2 in each well of the 96-well plate were incubated with different concentrations of topotecan (0, 8, 25, 74, 222, 667, and 2000 nM) and modulators (0, 1.6, 8, 40, 200, and 1000 nM). 7,500 cells of MCF7-MX100 were incubated with different concentrations of topotecan (0, 0.41, 1.2, 3.7, 11, 33, and 100 μM) and modulators (0, 1.6, 8, 40, 200, and 1000 nM). 4,000 cells of 2008/MRP1 were incubated with various doses of DOX (0, 8, 25, 74, 222, 667, and 2000 nM) and modulators (0, 62.5, 125, 250, 500, and 1000 nM). 6,500 cells of LCC6MDR were incubated with various doses of paclitaxel (0, 1.6, 5, 15, 15, 44, 133, and 400 nM) and modulators (0, 62.5, 125, 250, 500, and 1000 nM). The final volume in each well of 96-well plates was 200 μL. The plates were then incubated for 5 days at 37 °C.</div><div class="NLM_p last">The CellTiter 96 AQ<sub>ueous</sub> Assay (Promega) was used to measure the cell proliferation according to the manufacturer’s instructions. MTS (2 mg/mL) and PMS (0.92 mg/mL) were mixed in a ratio of 20:1. An aliquot (10 μL) of the freshly prepared MTS/PMS mixture was added into each well, and the plate was incubated for 2 h at 37 °C. Optical absorbance at 490 nm was recorded with a microplate absorbance reader (Bio-Rad). All experiments were performed in triplicate and repeated at least twice, and the results were represented as mean ± standard error of mean. The EC<sub>50</sub> value was determined by PRISM software.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i157" class="anchor-spacer"></div><h3 class="article-section__title" id="_i157">4.8.  Mitoxantrone Sensitization Assay</h3><div class="NLM_p last">5,000 cells of HEK293/R2, 4,000 cells of 2008MRP1, or 6,500 cells of LCC6MDR were incubated with different doses of mitoxantrone with or without 1 μM <b>Ac22(Az8)</b><sub><b>2</b></sub> or Ko143 for 5 days. The final volume in each well of 96-well plates was 200 μL. For determining the EC<sub>50</sub> value, the cells were incubated with different doses of mitoxantrone and modulators together. The % of survival and EC<sub>50</sub> values were determined as mentioned previously.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i158" class="anchor-spacer"></div><h3 class="article-section__title" id="_i158">4.9.  Topotecan Accumulation Assay</h3><div class="NLM_p last">The topotecan accumulation assay was done in a 1 mL volume. 5 × 10<sup>5</sup> cells of HEK293/pcDNA3.1 or HEK293/R2 were added in an Eppendorf tube and incubated with 50 μM topotecan and 1 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> or Ko143 at 37 °C for 120 min. A 0.1% DMSO solution was used as a negative control. After incubation, the cells were spun down and washed with cold PBS, pH 7.4, for one time and then resuspended with 200 μL of cold FACS buffer (1% BSA and 1 mM EDTA in PBS). The intracellular topotecan level was analyzed by BD C6 Accuri flow cytometer using FL1 channel EX 480 nm and EM 533/30 nm. For each sample, a total of 30,000 events was collected.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159">4.10.  Determination of Surface BCRP Protein Expression</h3><div class="NLM_p last">40,000 cells of HEK293/pcDNA3.1 and HEK293/R2 cells were seeded in a 6-well plate and incubated with 0, 1, or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days, respectively. After 4 days, the cells were trypsinized and washed once with 1X PBS. After spinning, the cells were resuspended in 50 μL of FACS buffer (1% BSA and 1 mM EDTA in PBS) and stained with 2.5 μL of FITC mouse antihuman BCRP antibody (Miltenyi Biotec) at 4 °C for 45 min. After staining, the cells were washed once with 500 μL of cold FACS buffer and resuspended in 200 μL of FACS buffer. The BCRP-FITC level was analyzed by a BD C6 Accuri flow cytometer using the FL1 channel at EX 480 nm and EM 533/30 nm. For each sample, a total of 30,000 events was collected.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160">4.11.  Topotecan Efflux Study</h3><div class="NLM_p last">To measure the topotecan efflux, HEK293/pcDNA3.1 or HEK293/R2 cells were preincubated with 5 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 2 h at 37 °C with 5% CO<sub>2</sub>. After preincubation, the cells were trypsinized and the number of cells was counted using a hemocytometer. The cells were then coincubated with 50 μM of topotecan and 5 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> in supplemented RPMI1640 media for 2 h at 37 °C. After 2 h, the cells were spun down and washed once with cold PBS. Then the cells were further incubated with or without compound <b>Ac22(Az8)</b><sub><b>2</b></sub> (5 μM). At 0, 5, 10, and 15 min, 1 × 10<sup>5</sup> cells in 1 mL volume were harvested for measuring the intracellular topotecan concentration. The % of topotecan reduction was calculated = [(topotecan level at final time point/topotecan level at 0 min) * 100%]. The topotecan level was determined by C6 Accuri flow cytometer at FL1 channel as described previously.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161">4.12.  Vanadate-Sensitive BCRP-ATPase Activity</h3><div class="NLM_p last">5 × 10<sup>7</sup> cells of S1M180 were resuspended in 5 mL of homogenization buffer (0.33 M sucrose, 300 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, 2 mM DTT, 100 mM 6-aminocaproic acid, 1 mM PMSF, and 1× protease inhibitor (cOmplete Protease Inhibitor Cocktail Tablets, Roche) and lysed using a Branson SFX550 sonicator for 10 cycles at 50% amplitude with 30 s on/30 s off. Lysate was centrifuged at 3,500<i>g</i> for 10 min at 4 °C. The membrane fraction of cells was collected by ultracentrifugation of cell lysate at 45,000 rpm using Himac CP70G (Hitachi) for 1.5 h. The membrane fraction pellet was resuspended in 300 μL of ATPase assay buffer (50 mM Tris at pH 7.5, 2 mM EGTA at pH 7.0, 2 mM DTT, 50 mM KCl, 10 mM MgCl<sub>2</sub>, 5 mM sodium azide, and 1 mM ouabain). Protein concentration was determined by Bradford assay. The membrane fraction was incubated with or without 0.3 mM sodium orthovanadate and 2.5 mM ATP for 1 h at 37 °C. Reactions were stopped by adding 200 μL of freshly prepared cold stop buffer (0.2% ammonium molybdate, 1.4% sulfuric acid, 0.9% SDS, and 1% ascorbic acid) and incubated at room temperature for 15 min. An absorbance of 655 nm was measured by a CLARIOstar microplate reader (BMG).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162">4.13.  In Silico Docking Study</h3><div class="NLM_p last">CLC Drug Discovery Workbench (version 2.5, QIAGEN) software was used. Three high-resolution cryo-EM structures of BCRP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ">6FEQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO">6HCO</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>) were downloaded from the Protein Data Bank (<a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a>) and used directly without any changes. Briefly, the 2-D structures of different ligands were generated from SMILES and imported individually into the software for docking study. Employing the function of “Find Binding Pockets”, the software was able to identify the central translocation pathway of BCRP as one of the potential binding pockets in all BCRP models. The binding sites of each cryo-EM structure of BCRP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ">6FEQ</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO">6HCO</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>) were individually validated using the cocrystallized ligands MB136, estrone-3-sulfate, and MZ29, providing reliable RMSD values of 1.2 Å, 0.3 Å, and 0.5 Å, respectively. The identification of ligand binding modes was done iteratively by evaluating 3,000 random ligand conformations and estimating the binding energy of their interactions with the potential binding pockets. The 10 top-ranked binding poses of ligands were returned for visual inspection. The highest scores positioned the ligands into the central cavity of BCRP, which was mainly formed by the transmembrane helices 1b, 1b′, 2, 2′, 5a, and 5a′. Important amino acid residues involved in the putative interactions with ligands are highlighted in black, and potential hydrogen bonding interactions are indicated as dotted blue lines. These docking results are illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref internalNav" href="#notes2" aria-label="S68–S69">S68–S69</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, respectively.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i163"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00963" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00963" class="ext-link">10.1021/acs.jmedchem.9b00963</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC chromatogram of <b>Ac22(Az8)</b><sub><b>2</b></sub>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of all representative compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>; <i>in silico</i> docking studies and <sup>1</sup>H and <sup>13</sup>C NMR assignment of <b>Ac2Az2</b> and <b>Ac22(Az8)</b><sub><b>2</b></sub>  (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES molecular strings formulas (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_001.pdf">jm9b00963_si_001.pdf (9.76 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_002.csv">jm9b00963_si_002.csv (13.08 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00963" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Larry M. C. Chow</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9222-8322" title="Orcid link">http://orcid.org/0000-0002-9222-8322</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c6aaa7b4b4bfe8a5aea9b186b6a9aabfb3e8a3a2b3e8aead"><span class="__cf_email__" data-cfemail="35595447474c1b565d5a4275455a594c401b5051401b5d5e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tak Hang Chan</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, McGill University, Montreal, Quebec H3A 2K6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8702-4499" title="Orcid link">http://orcid.org/0000-0002-8702-4499</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0773666c2a6f66696029646f66694777686b7e7229626372296f6c"><span class="__cf_email__" data-cfemail="90e4f1fbbdf8f1fef7bef3f8f1fed0e0fffce9e5bef5f4e5bef8fb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuezhen Zhu</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Iris L. K. Wong</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kin-Fai Chan</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1475-288X" title="Orcid link">http://orcid.org/0000-0003-1475-288X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiahua Cui</span> - <span class="hlFld-Affiliation affiliation">School
of Environmental Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7164-6851" title="Orcid link">http://orcid.org/0000-0001-7164-6851</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Man Chun Law</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsz Cheung Chong</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuesen Hu</span> - <span class="hlFld-Affiliation affiliation">Department
of Applied Biology and Chemical Technology and State Key Laboratory
of Chemical Biology and Drug Discovery, Hong Kong Polytechnic University, Hong Kong SAR, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Xuezhen Zhu, Iris L. K. Wong, and Kin-Fai Chan contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">Binding <b>Ac22(Az8)</b><sub><b>2</b></sub>, mitoxantrone, and topotecan to BCRP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>). Authors will release the atomic coordinates upon article publication.</p><br /></br><p class="inlineNote">The patent US 9611256 B1 associated with this manuscript has been licensed to Athenex Inc.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i167">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The work described in this paper was supported by the Hong Kong Research Grant Council General Research Fund (B-Q21B), Early Career Scheme (25100014), and Hong Kong Polytechnic University internal grant (GU383) and Area of Strategic Importance grant (1-ZE22). We thank University Research Facilities of Life Science (ULS) of The Hong Kong Polytechnic University for providing the flow cytometry service.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance protein-1</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">DOX</td><td class="NLM_def"><p class="first last">doxorubicin</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration</p></td></tr><tr><td class="NLM_term">RPMI1640</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute 1640</p></td></tr><tr><td class="NLM_term">MTS</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i169">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 62 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortet-Tieulent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eZ9YEMwPFVq4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elferink, R. O.</span></span> <span> </span><span class="NLM_article-title">Mammalian ABC transporters in health and disease</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.71.102301.093055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1146%2Fannurev.biochem.71.102301.093055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=12045106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1Clt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=537-592&author=P.+Borstauthor=R.+O.+Elferink&title=Mammalian+ABC+transporters+in+health+and+disease&doi=10.1146%2Fannurev.biochem.71.102301.093055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian ABC transporters in health and disease</span></div><div class="casAuthors">Borst, P.; Elferink, R. Oude</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">537-592</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette (ABC) transporters are a family of large proteins in membranes and are able to transport a variety of compds. through membranes against steep concn. gradients at the cost of ATP hydrolysis.  The available outline of the human genome contains 48 ABC genes; 16 of these have a known function and 14 are assocd. with a defined human disease.  Major physiol. functions of ABC transporters include the transport of lipids, bile salts, toxic compds., and peptides for antigen presentation or other purposes.  We review the functions of mammalian ABC transporters, emphasizing biochem. mechanisms and genetic defects.  Our overview illustrates the importance of ABC transporters in human physiol., toxicol., pharmacol., and disease.  We focus on three topics: (a) ABC transporters transporting drugs (xenotoxins) and drug conjugates.  (b) Mammalian secretory epithelia using ABC transporters to excrete a large no. of substances, sometimes against a steep concn. gradient.  Several inborn errors in liver metab. are due to mutations in one of the genes for these pumps; these are discussed.  (c) A rapidly increasing no. of ABC transporters are found to play a role in lipid transport.  Defects in each of these transporters are involved in human inborn or acquired diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZi7RJl5EgbVg90H21EOLACvtfcHk0lg9Uc8AarMnzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1Clt74%253D&md5=f29b99f0717f3f343dc4b23548132d47</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.71.102301.093055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.71.102301.093055%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DElferink%26aufirst%3DR.%2BO.%26atitle%3DMammalian%2520ABC%2520transporters%2520in%2520health%2520and%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2002%26volume%3D71%26spage%3D537%26epage%3D592%26doi%3D10.1146%2Fannurev.biochem.71.102301.093055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnholds, J.</span></span> <span> </span><span class="NLM_article-title">A family of drug transporters: the multidrug resistance-associated proteins</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.16.1295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1093%2Fjnci%2F92.16.1295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10944550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlektr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1295-1302&author=P.+Borstauthor=R.+Eversauthor=M.+Koolauthor=J.+Wijnholds&title=A+family+of+drug+transporters%3A+the+multidrug+resistance-associated+proteins&doi=10.1093%2Fjnci%2F92.16.1295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A family of drug transporters: The multidrug resistance-associated proteins</span></div><div class="casAuthors">Borst, Piet; Evers, Raymond; Kool, Marcel; Wijnholds, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1295-1302</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 93 refs.  The human multidrug resistance-assocd. protein (MRP) family currently has seven members.  The ability of several of these membrane proteins to transport a wide range of anti-cancer drugs out of cells and their presence in many tumors make them prime suspects in unexplained cases of drug resistance, although proof that they contribute to clin. drug resistance is still lacking.  Recent studies have begun to clarify the function of the MRP family members.  MRPs are org. anion transporters; i.e., they transport anionic drugs, exemplified by methotrexate, and neutral drugs conjugated to acidic ligands, such as glutathione (GSH), glucuronate, or sulfate.  However, MRP1, MRP2, and MRP3 can also cause resistance to neutral org. drugs that are not known to be conjugated to acidic ligands by transporting these drugs together with free GSH.  MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compds. in complexes with GSH.  MRP4 overexpression is assocd. with high-level resistance to the nucleoside analogs 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.  MRPs may, therefore, also have a role in resistance against nucleoside analogs used in cancer chemotherapy.  Mice without Mrp1, a high-affinity leukotriene C4 transporter, have an altered response to inflammatory stimuli but are otherwise healthy and fertile.  MRP2 is the major transporter responsible for the secretion of bilirubin glucuronides into bile, and humans without MRP2 develop a mild liver disease known as the Dubin-Johnson syndrome.  The physiol. functions of the other MRPs are not known.  Whether long-term inhibition of MRPs in humans can be tolerated (assuming that suitable inhibitors will be found) remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEoI-EICNsS7Vg90H21EOLACvtfcHk0lgM1ImBb6Lhhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlektr8%253D&md5=d7b5b6c8f74b1805e61ebfdbf223ad05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.16.1295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.16.1295%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DWijnholds%26aufirst%3DJ.%26atitle%3DA%2520family%2520of%2520drug%2520transporters%253A%2520the%2520multidrug%2520resistance-associated%2520proteins%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2000%26volume%3D92%26spage%3D1295%26epage%3D1302%26doi%3D10.1093%2Fjnci%2F92.16.1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domenichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falasca, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters as cancer drivers: potential functions in cancer development</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2018.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbagen.2018.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=30268729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2019&pages=52-60&author=A.+Domenichiniauthor=A.+Adamskaauthor=M.+Falasca&title=ABC+transporters+as+cancer+drivers%3A+potential+functions+in+cancer+development&doi=10.1016%2Fj.bbagen.2018.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters as cancer drivers: Potential functions in cancer development</span></div><div class="casAuthors">Domenichini, Alice; Adamska, Aleksandra; Falasca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-60</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  ABC transporters have attracted considerable attention for their function as drug transporters in a broad range of tumors and are therefore considered as major players in cancer chemoresistance.  However, less attention has been focused on their potential role as active players in cancer development and progression.  This review presents the evidence suggesting that ABC transporters might have a more active role in cancer other than the well known involvement in multidrug resistance and discusses the potential strategies to target each ABC transporter for a specific tumor setting.  Emerging evidence suggests that ABC transporters are able to transport bioactive mols. capable of playing key roles in tumor development.  Characterization of the effects of these transporters in specific cancer settings opens the possibility for the development of personalized treatments.  A more targeted approach of ABC transporters should be implemented that considers which specific transporter is playing a major role in a particular tumor setting in order to achieve a more successful outcome for ABC transporters inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg9SQX3ldK77Vg90H21EOLACvtfcHk0lgM1ImBb6Lhhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbfP&md5=f3cd17f9810f869702475322380a514b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2018.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DDomenichini%26aufirst%3DA.%26aulast%3DAdamska%26aufirst%3DA.%26aulast%3DFalasca%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520as%2520cancer%2520drivers%253A%2520potential%2520functions%2520in%2520cancer%2520development%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2019%26volume%3D1863%26spage%3D52%26epage%3D60%26doi%3D10.1016%2Fj.bbagen.2018.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters as mediators of drug resistance and contributors to cancer cell biology</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.drup.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=27180306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC28bpsFKqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1-9&author=J.+I.+Fletcherauthor=R.+T.+Williamsauthor=M.+J.+Hendersonauthor=M.+D.+Norrisauthor=M.+Haber&title=ABC+transporters+as+mediators+of+drug+resistance+and+contributors+to+cancer+cell+biology&doi=10.1016%2Fj.drup.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters as mediators of drug resistance and contributors to cancer cell biology</span></div><div class="casAuthors">Fletcher Jamie I; Williams Rebekka T; Henderson Michelle J; Norris Murray D; Haber Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The extrusion of anticancer drugs by members of the ATP-binding cassette (ABC) transporter family is one of the most widely recognized mechanisms of multidrug resistance, and can be considered a hijacking of their normal roles in the transport of xenobiotics, metabolites and signaling molecules across cell membranes.  While roles in cancer multidrug resistance have been clearly demonstrated for P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP) and Multidrug Resistance Protein 1 (MRP1), direct evidence for a role in multidrug resistance in vivo is lacking for other family members.  A less well understood but emerging theme is the drug efflux-independent contributions of ABC transporters to cancer biology, supported by a growing body of evidence that their loss or inhibition impacts on the malignant potential of cancer cells in vitro and in vivo.  As with multidrug resistance, these contributions likely represent a hijacking of normal ABC transporter functions in the efflux of endogenous metabolites and signaling molecules, however they may expand the clinical relevance of ABC transporters beyond P-gp, BCRP and MRP1.  This review summarizes established and emerging roles for ABC transporters in cancer, with a focus on neuroblastoma and ovarian cancer, and considers approaches to validate and better understand these roles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10lMkvlLDKIqdXsLcGTEUfW6udTcc2eZbLZ0n9ohh6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bpsFKqtg%253D%253D&md5=41325cd19f32cf04ef269f4bc6c114fc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DWilliams%26aufirst%3DR.%2BT.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26aulast%3DHaber%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520as%2520mediators%2520of%2520drug%2520resistance%2520and%2520contributors%2520to%2520cancer%2520cell%2520biology%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2016%26volume%3D26%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.drup.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.drup.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=27449595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2s3js1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=14-29&author=W.+Liauthor=H.+Zhangauthor=Y.+G.+Assarafauthor=K.+Zhaoauthor=X.+Xuauthor=J.+Xieauthor=D.+H.+Yangauthor=Z.+S.+Chen&title=Overcoming+ABC+transporter-mediated+multidrug+resistance%3A+molecular+mechanisms+and+novel+therapeutic+drug+strategies&doi=10.1016%2Fj.drup.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies</span></div><div class="casAuthors">Li Wen; Zhang Han; Assaraf Yehuda G; Zhao Kun; Xu Xiaojun; Xie Jinbing; Yang Dong-Hua; Chen Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance is a key determinant of cancer chemotherapy failure.  One of the major causes of multidrug resistance is the enhanced efflux of drugs by membrane ABC transporters.  Targeting ABC transporters projects a promising approach to eliminating or suppressing drug resistance in cancer treatment.  To reveal the functional mechanisms of ABC transporters in drug resistance, extensive studies have been conducted from identifying drug binding sites to elucidating structural dynamics.  In this review article, we examined the recent crystal structures of ABC proteins to depict the functionally important structural elements, such as domains, conserved motifs, and critical amino acids that are involved in ATP-binding and drug efflux.  We inspected the drug-binding sites on ABC proteins and the molecular mechanisms of various substrate interactions with the drug binding pocket.  While our continuous battle against drug resistance is far from over, new approaches and technologies have emerged to push forward our frontier.  Most recent developments in anti-MDR strategies include P-gp inhibitors, RNA-interference, nano-medicines, and delivering combination strategies.  With the advent of the 'Omics' era - genomics, epigenomics, transcriptomics, proteomics, and metabolomics - these disciplines play an important role in fighting the battle against chemoresistance by further unraveling the molecular mechanisms of drug resistance and shed light on medical therapies that specifically target MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTme07GYSiBx8SzjBFCN0BJfW6udTcc2eZZYN-ZY1l6lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3js1ShsQ%253D%253D&md5=a233ff2b23c4d4108bc2ac785868b873</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DOvercoming%2520ABC%2520transporter-mediated%2520multidrug%2520resistance%253A%2520molecular%2520mechanisms%2520and%2520novel%2520therapeutic%2520drug%2520strategies%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2016%26volume%3D27%26spage%3D14%26epage%3D29%26doi%3D10.1016%2Fj.drup.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1038/nrc706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters&doi=10.1038%2Fnrc706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0liWUTC0s0ESnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58%26doi%3D10.1038%2Fnrc706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span> <span> </span><span class="NLM_article-title">Purification and structural analyses of ABCG2</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.addr.2008.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19124053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=57-65&author=C.+A.+McDevittauthor=R.+Collinsauthor=I.+D.+Kerrauthor=R.+Callaghan&title=Purification+and+structural+analyses+of+ABCG2&doi=10.1016%2Fj.addr.2008.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and structural analyses of ABCG2</span></div><div class="casAuthors">McDevitt, Christopher A.; Collins, Richard; Kerr, Ian D.; Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ABCG2/BRCP protein is best known as a multidrug transporter capable of conferring resistance to cancer cells.  However, the protein is also inherently expressed in numerous barrier tissues and intriguingly within hematopoietic stem cells.  Unlike its partners, ABCB1 and ABCC1, there is considerably less information available on the mol. mechanism of ABCG2/BRCP.  The transporter has a distinct topol. and is presumed to function as a homodimer.  However, a no. of biochem. studies have presented data to suggest that the protein adopts higher order oligomers.  This review focuses on this controversial issue with particular ref. to findings from low resoln. structural data.  In addn., a no. of mol. models of ABCG2/BRCP based on high-resoln. structures of bacterial ABC transporters have recently become available and are critically assessed.  ABCG2/BRCP is a structurally distinct member of the triumvirate of human multidrug transporters and continues to evade description of a unifying mol. mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-26N0eXV32LVg90H21EOLACvtfcHk0liWUTC0s0ESnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7g%253D&md5=8afc7467f79e661e505d5bccbc17cfbf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcDevitt%26aufirst%3DC.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DPurification%2520and%2520structural%2520analyses%2520of%2520ABCG2%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D57%26epage%3D65%26doi%3D10.1016%2Fj.addr.2008.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikadi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.str.2010.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.str.2010.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20399185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=482-493&author=M.+F.+Rosenbergauthor=Z.+Bikadiauthor=J.+Chanauthor=X.+Liuauthor=Z.+Niauthor=X.+Caiauthor=R.+C.+Fordauthor=Q.+Mao&title=The+human+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+shows+conformational+changes+with+mitoxantrone&doi=10.1016%2Fj.str.2010.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Human Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with Mitoxantrone</span></div><div class="casAuthors">Rosenberg, Mark F.; Bikadi, Zsolt; Chan, Janice; Liu, Xiaoping; Ni, Zhanglin; Cai, Xiaokun; Ford, Robert C.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-493</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BCRP/ABCG2 mediates efflux of drugs and xenobiotics.  BCRP was expressed in Pichia pastoris, purified to > 90% homogeneity, and subjected to two-dimensional (2D) crystn.  The 2D crystals showed a p121 symmetry and projection maps were detd. at 5 Å resoln. by cryo-electron microscopy.  Two crystal forms with and without mitoxantrone were obsd. with unit cell dimensions of a = 55.4 Å, b = 81.4 Å, γ = 89.8°, and a = 57.3 Å, b = 88.0 Å, γ = 89.7°, resp.  The projection map without mitoxantrone revealed an asym. structure with ring-shaped d. features probably corresponding to a bundle of transmembrane α helixes, and appeared more open and less sym. than the map with mitroxantrone.  The open and closed inward-facing forms of BCRP were generated by homol. modeling, representing the substrate-free and substrate-bound conformations in the absence of nucleotide, resp.  These models are consistent with the exptl. obsd. conformational change upon substrate binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy41Lg_ARysLVg90H21EOLACvtfcHk0lj_Yqhiaqzvbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKnu7s%253D&md5=259f90447cbb30589018f12c155cf19e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2010.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2010.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BF.%26aulast%3DBikadi%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DFord%26aufirst%3DR.%2BC.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DThe%2520human%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520shows%2520conformational%2520changes%2520with%2520mitoxantrone%26jtitle%3DStructure%26date%3D2010%26volume%3D18%26spage%3D482%26epage%3D493%26doi%3D10.1016%2Fj.str.2010.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span> <span> </span><span class="NLM_article-title">Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbamcr.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26453803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Chtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2016&pages=19-29&author=K.+Wongauthor=S.+J.+Briddonauthor=N.+D.+Hollidayauthor=I.+D.+Kerr&title=Plasma+membrane+dynamics+and+tetrameric+organisation+of+ABCG2+transporters+in+mammalian+cells+revealed+by+single+particle+imaging+techniques&doi=10.1016%2Fj.bbamcr.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques</span></div><div class="casAuthors">Wong, Kelvin; Briddon, Stephen J.; Holliday, Nicholas D.; Kerr, Ian D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-29</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ABCG2 is one of three human ATP binding cassette (ABC) transporters involved in the export from cells of a chem. and structurally diverse range of compds.  This multidrug efflux capability, together with a broad tissue distribution in the body, means that ABCG2 exerts a range of effects on normal physiol. such as kidney urate transport, as well as contributing towards the pharmacokinetic profiles of many exogenous drugs.  The primary sequence of ABCG2 contains only half the no. of domains required for a functioning ABC transporter and so it must oligomerise in order to function, yet its oligomeric state in intact cell membranes remains uncharacterized.  We have analyzed ABCG2 in living cell membranes using a combination of fluorescence correlation spectroscopy, photon counting histogram anal., and stepwise photobleaching to demonstrate a predominantly tetrameric structure for ABCG2 in the presence or absence of transport substrates.  These results provide the essential basis for exploring pharmacol. manipulation of oligomeric state as a strategy to modulate ABCG2 activity in future selective therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBGt4Y70W5LVg90H21EOLACvtfcHk0lj_Yqhiaqzvbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Chtb%252FN&md5=89fe45505b932fa860e4c9151fc610e0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DBriddon%26aufirst%3DS.%2BJ.%26aulast%3DHolliday%26aufirst%3DN.%2BD.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26atitle%3DPlasma%2520membrane%2520dynamics%2520and%2520tetrameric%2520organisation%2520of%2520ABCG2%2520transporters%2520in%2520mammalian%2520cells%2520revealed%2520by%2520single%2520particle%2520imaging%2520techniques%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2016%26volume%3D1863%26spage%3D19%26epage%3D29%26doi%3D10.1016%2Fj.bbamcr.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dezi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fribourg, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cicco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pietro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lévy, D.</span></span> <span> </span><span class="NLM_article-title">The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1798</i></span>,  <span class="NLM_fpage">2094</span>– <span class="NLM_lpage">2101</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2010.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbamem.2010.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20691149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=2094-2101&author=M.+Deziauthor=P.-F.+Fribourgauthor=A.+Di+Ciccoauthor=O.+Arnaudauthor=S.+Marcoauthor=P.+Falsonauthor=A.+Di+Pietroauthor=D.+L%C3%A9vy&title=The+multidrug+resistance+half-transporter+ABCG2+is+purified+as+a+tetramer+upon+selective+extraction+from+membranes&doi=10.1016%2Fj.bbamem.2010.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes</span></div><div class="casAuthors">Dezi, Manuela; Fribourg, Pierre-Frederic; Di Cicco, Aurelie; Arnaud, Ophelie; Marco, Sergio; Falson, Pierre; Di Pietro, Attilio; Levy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2094-2101</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ABCG2 is a human membrane ATP-binding cassette half-transporter that hydrolyzes ATP to efflux a large no. of chemotherapeutic agents.  Several oligomeric states of ABCG2 from homodimers to dodecamers have been reported depending on the overexpression systems and/or the protocols used for purifn.  Here, we compared the oligomeric state of His6-ABCG2 expressed in Sf9 insect cells and in human Flp-In-293/ABCG2 cells after solubilization in mild detergents.  His6-ABCG2 was purified through a new approach involving its specific recognition onto a functionalized lipid layer contg. a Ni-NTA lipid.  This approach allowed the purifn. of His-ABCG2 in presence of all solubilized membrane components that might be involved in the stabilization of native oligomers and without requiring any addnl. washing or concn. passages.  ABCG2 purified onto the NiNTA lipid surfaces were directly analyzed by electron microscopy and by biochem. assays.  Altogether, our data are consistent with a tetrameric organization of ABCG2 when expressed in either heterologous Sf9 insect cells or in human homologous cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83AnAMdQg6bVg90H21EOLACvtfcHk0lj_Yqhiaqzvbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvL&md5=9e1f93b37b94937cb10dd19ec9a8c985</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DDezi%26aufirst%3DM.%26aulast%3DFribourg%26aufirst%3DP.-F.%26aulast%3DDi%2BCicco%26aufirst%3DA.%26aulast%3DArnaud%26aufirst%3DO.%26aulast%3DMarco%26aufirst%3DS.%26aulast%3DFalson%26aufirst%3DP.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26aulast%3DL%25C3%25A9vy%26aufirst%3DD.%26atitle%3DThe%2520multidrug%2520resistance%2520half-transporter%2520ABCG2%2520is%2520purified%2520as%2520a%2520tetramer%2520upon%2520selective%2520extraction%2520from%2520membranes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26spage%3D2094%26epage%3D2101%26doi%3D10.1016%2Fj.bbamem.2010.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span> <span> </span><span class="NLM_article-title">Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1623</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1016/j.str.2006.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.str.2006.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=17098188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SmtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1623-1632&author=C.+A.+McDevittauthor=R.+F.+Collinsauthor=M.+Conwayauthor=S.+Modokauthor=J.+Stormauthor=I.+D.+Kerrauthor=R.+C.+Fordauthor=R.+Callaghan&title=Purification+and+3D+structural+analysis+of+oligomeric+human+multidrug+transporter+ABCG2&doi=10.1016%2Fj.str.2006.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and 3D Structural Analysis of Oligomeric Human Multidrug Transporter ABCG2</span></div><div class="casAuthors">McDevitt, Christopher A.; Collins, Richard F.; Conway, Michael; Modok, Szabolcs; Storm, Janet; Kerr, Ian D.; Ford, Robert C.; Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1623-1632</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ABCG2 is a multidrug efflux pump assocd. with resistance of cancer cells to a plethora of unrelated drugs.  ABCG2 is a "half-transporter," and previous studies have indicated that it forms homodimers and higher oligomeric species.  In this manuscript, electron microscopic structural anal. directly addressed this issue.  An N-terminal hexahistidine-tagged ABCG2R482G isoform was expressed to high levels in insect cells.  An extensive detergent screen was employed to effect extn. of ABCG2R482G from membranes and identified only the fos-choline detergents as efficient.  Sol. protein was purified to >95% homogeneity by a three-step procedure while retaining the ability to bind substrates.  Cryoneg. stain electron microscopy of purified ABCG2R482G provided 3D structural data at a resoln. of ∼18 Å.  Single-particle anal. revealed that the complex forms a tetrameric complex (∼180 Å in diam. × ∼140 Å high) with an aq. central region.  We interpret the tetrameric structure as comprising four homodimeric ABCG2R482G complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwtScpCugTgbVg90H21EOLACvtfcHk0lj_Yqhiaqzvbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SmtrzN&md5=f56278a6fc2b6b53312b604f018d89d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DMcDevitt%26aufirst%3DC.%2BA.%26aulast%3DCollins%26aufirst%3DR.%2BF.%26aulast%3DConway%26aufirst%3DM.%26aulast%3DModok%26aufirst%3DS.%26aulast%3DStorm%26aufirst%3DJ.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26aulast%3DFord%26aufirst%3DR.%2BC.%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DPurification%2520and%25203D%2520structural%2520analysis%2520of%2520oligomeric%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D1623%26epage%3D1632%26doi%3D10.1016%2Fj.str.2006.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-T.</span></span> <span> </span><span class="NLM_article-title">Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">19781</span>– <span class="NLM_lpage">19789</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310785200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1074%2Fjbc.M310785200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15001581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Wit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=19781-19789&author=J.+Xuauthor=Y.+Liuauthor=Y.+Yangauthor=S.+Batesauthor=J.-T.+Zhang&title=Characterization+of+oligomeric+human+half-ABC+transporter+ATP-binding+cassette+G2&doi=10.1074%2Fjbc.M310785200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2</span></div><div class="casAuthors">Xu, Junkang; Liu, Yang; Yang, Youyun; Bates, Susan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">19781-19789</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human ATP-binding cassette G2 (ABCG2, also known as mitoxantrone resistance protein, breast cancer-resistance protein, ABC placenta) is a member of the superfamily of ATP-binding cassette (ABC) transporters that have a wide variety of substrates.  Overexpression of human ABCG2 in model cancer cell lines causes multidrug resistance by actively effluxing anticancer drugs.  Unlike most of the other ABC transporters which usually have two nucleotide-binding domains and two transmembrane domains, ABCG2 consists of only one nucleotide-binding domain followed by one transmembrane domain.  Thus, ABCG2 has been thought to be a half-transporter that may function as a homodimer.  In this study, we characterized the oligomeric feature of human ABCG2 using non-denaturing detergent perfluoro-octanoic acid and Triton X-100 in combination with gel filtration, sucrose d. gradient sedimentation, and gel electrophoresis.  Unexpectedly, we found that human ABCG2 exists mainly as a tetramer, with a possibility of a higher form of oligomerization.  Monomeric and dimeric ABCG2 did not appear to be the major form of the protein.  Further immunopptn. anal. showed that the oligomeric ABCG2 did not contain any other proteins.  Taken together, we conclude that human ABCG2 likely exists and functions as a homotetramer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogS9hRAh_FSbVg90H21EOLACvtfcHk0lgx-mtyQxn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Wit7g%253D&md5=c45adb759c2de874ef4c299eb3d0c99e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310785200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310785200%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBates%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.-T.%26atitle%3DCharacterization%2520of%2520oligomeric%2520human%2520half-ABC%2520transporter%2520ATP-binding%2520cassette%2520G2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D19781%26epage%3D19789%26doi%3D10.1074%2Fjbc.M310785200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caracciolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papineschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canestraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrini, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1502</span>– <span class="NLM_lpage">1509</span>, <span class="refDoi"> DOI: 10.1080/10428190701402895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1080%2F10428190701402895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=17701580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1502-1509&author=S.+Galimbertiauthor=B.+Nagyauthor=E.+Benedettiauthor=S.+Paciniauthor=S.+Brizziauthor=F.+Caraccioloauthor=F.+Papineschiauthor=E.+Ciabattiauthor=F.+Guerriniauthor=R.+Fazziauthor=M.+Canestraroauthor=M.+Petrini&title=Evaluation+of+the+MDR1%2C+ABCG2%2C+Topoisomerases+IIalpha+and+GSTpi+gene+expression+in+patients+affected+by+aggressive+mantle+cell+lymphoma+treated+by+the+R-Hyper-CVAD+regimen&doi=10.1080%2F10428190701402895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GSTπ gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen</span></div><div class="casAuthors">Galimberti, Sara; Nagy, Balint; Benedetti, Edoardo; Pacini, Simone; Brizzi, Stefania; Caracciolo, Francesco; Papineschi, Federico; Ciabatti, Elena; Guerrini, Francesca; Fazzi, Rita; Canestraro, Martina; Petrini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1502-1509</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, topoisomerase IIα, glutathione-s-transferaseπ (GSTπ) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL.  In our study, expression levels of the above mentioned genes plus MDR1 were tested on bone marrow samples from 20 patients treated with rituximab plus hyper-CVAD regimen, in order to evaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen.  All patients expressed ABCG2 and MDR1 genes; 85% of cases expressed GSTπ and topoisomerase IIα.  Only ABCG2 were over-expressed in comparison both with marrow from healthy donors and tonsilar CD5+/CD20+ lymphocytes (adopted as normal counterpart of the neoplastic population).  The overall response rate of the entire series was 87.5%, with 44% of complete responses.  Fifty-seven percent of patients achieved the clearance of minimal residual disease.  Levels of tested genes did not condition either quality of clin. response or PFS (76% at 24 mo).  Nevertheless, an ABCG2 higher expression appeared assocd. with a worse PFS and levels of this gene paralleled the status of minimal residual disease.  A further evaluation of ABCG2 expression in larger series of MCL patients would be suitable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhiVof0Ex8GLVg90H21EOLACvtfcHk0lgx-mtyQxn29Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFOqtbg%253D&md5=c2fdd3af5d30c8e204c742d5b9b46ba6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F10428190701402895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701402895%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DS.%26aulast%3DNagy%26aufirst%3DB.%26aulast%3DBenedetti%26aufirst%3DE.%26aulast%3DPacini%26aufirst%3DS.%26aulast%3DBrizzi%26aufirst%3DS.%26aulast%3DCaracciolo%26aufirst%3DF.%26aulast%3DPapineschi%26aufirst%3DF.%26aulast%3DCiabatti%26aufirst%3DE.%26aulast%3DGuerrini%26aufirst%3DF.%26aulast%3DFazzi%26aufirst%3DR.%26aulast%3DCanestraro%26aufirst%3DM.%26aulast%3DPetrini%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520MDR1%252C%2520ABCG2%252C%2520Topoisomerases%2520IIalpha%2520and%2520GSTpi%2520gene%2520expression%2520in%2520patients%2520affected%2520by%2520aggressive%2520mantle%2520cell%2520lymphoma%2520treated%2520by%2520the%2520R-Hyper-CVAD%2520regimen%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1502%26epage%3D1509%26doi%3D10.1080%2F10428190701402895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span> <span> </span><span class="NLM_article-title">Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2008.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.lungcan.2008.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19036469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzotl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=105-111&author=Y.+H.+Kimauthor=G.+Ishiiauthor=K.+Gotoauthor=S.+Otaauthor=K.+Kubotaauthor=Y.+Murataauthor=M.+Mishimaauthor=N.+Saijoauthor=Y.+Nishiwakiauthor=A.+Ochiai&title=Expression+of+breast+cancer+resistance+protein+is+associated+with+a+poor+clinical+outcome+in+patients+with+small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2008.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer</span></div><div class="casAuthors">Kim Young Hak; Ishii Genichiro; Goto Koichi; Ota Shuji; Kubota Kaoru; Murata Yukinori; Mishima Michiaki; Saijo Nagahiro; Nishiwaki Yutaka; Ochiai Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  ATP-binding cassette (ABC) transporter and DNA excision repair proteins play a pivotal role in the mechanisms of drug resistance.  The aim of this study was to investigate the expression of ABC transporter and DNA excision repair proteins, and to elucidate the clinical significance of their expression in biopsy specimens from patients with small-cell lung cancer (SCLC).  METHODS:  We investigated expression of the ABC transporter proteins, P-glycoprotein (Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast cancer resistance protein (BCRP), and the DNA excision repair proteins, excision repair cross-complementation group 1 (ERCC1) protein and breast cancer susceptibility gene 1 (BRCA1) protein, in tumor biopsy specimens obtained before chemotherapy from 130 SCLC patients who later received platinum-based combination chemotherapy, and investigated the relationship between their expression and both response and survival.  RESULTS:  No significant associations were found between expression of Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and either response or survival.  However, there was a significant association between BCRP expression and both response (p=0.026) and progression-free survival (PFS; p=0.0103).  CONCLUSIONS:  BCRP expression was significantly predictive of both response and progression-free survival (PFS) in SCLC patients receiving chemotherapy.  These findings suggest that BCRP may play a crucial role in drug resistance mechanisms, and that it may serve as an ideal molecular target for the treatment of SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbY9UEAyJVSs-crCu0nI_sfW6udTcc2eZKRrQOugrs6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzotl2hsw%253D%253D&md5=879423621387778616666b1a58bb5f6f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2008.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2008.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DOta%26aufirst%3DS.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DMishima%26aufirst%3DM.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DExpression%2520of%2520breast%2520cancer%2520resistance%2520protein%2520is%2520associated%2520with%2520a%2520poor%2520clinical%2520outcome%2520in%2520patients%2520with%2520small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2009%26volume%3D65%26spage%3D105%26epage%3D111%26doi%3D10.1016%2Fj.lungcan.2008.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovalev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsvetaeva, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudinskaja, T. V.</span></span> <span> </span><span class="NLM_article-title">Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer</span>. <i>Exp Oncol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=24382439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2czhsVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=287-290&author=A.+A.+Kovalevauthor=D.+A.+Tsvetaevaauthor=T.+V.+Grudinskaja&title=Role+of+ABC-cassette+transporters+%28MDR1%2C+MRP1%2C+BCRP%29+in+the+development+of+primary+and+acquired+multiple+drug+resistance+in+patients+with+early+and+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer</span></div><div class="casAuthors">Kovalev A A; Tsvetaeva D A; Grudinskaja T V</div><div class="citationInfo"><span class="NLM_cas:title">Experimental oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-90</span>
        ISSN:<span class="NLM_cas:issn">1812-9269</span>.
    </div><div class="casAbstract">UNLABELLED:  The aim of the research was to study the influence of multiple drug resistance (MDR1), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP) proteins expression on the effectiveness of chemotherapy in breast cancer (BC) patients.  PATIENTS AND METHODS:  The retrospective analysis of the results of treatment of 77 women with invasive BC with different molecular subtypes at the age of 54.1±12.5, who received treatment in Zaporizhzhya Regional Clinical Oncological Dispensary during 2011-2013, has been carried out. 23 (29.8%) patients were in II stage of disease, 32 (41.5%) - in III stage, 22 patients (28.5%) - IV stage.  Neoadjuvant therapy has been given to 34 (44.2%) patients, palliative therapy in connection with presence of hematogenous visceral and bone metastases - to 43 (55.8%) patients.  Transport proteins BCRP, MRP and PGP have been studied in tissues of primary BC tumor, in tissues of visceral metastases, in metastatically altered regional lymph nodes, as well as in circulating in blood tumor cells (CTC).  In every case, 1000 of tumor cells has been calculated.  The intensity of staining (0, 1+, 2+, 3+), percentage of stained cells (threshold has constituted 10%) and homogeneity of tumor cells staining (homogeneous was considered 80% staining of cytoplasm or membrane of studied cells) has been taken in consideration.  RESULTS:  Retrospective analysis has determined the dependence of results of polychemotherapy (PCT) on level and pattern of expression of BCRP, MRP and PGP proteins.  In 1(st) group, in the absence thereof expression of transport proteins in BC cells, the objective response (CR + PR) from the tumor has been observed in 17 out of 18 patients (94.4%).  In 2nd group (only cytoplasmic staining) the objective response has been observed in 36 patients (85.7%).  Ineffectiveness of therapy and tumor progression in this group has been observed in 6 (14.2%) patients.  In 3(rd)group (high membrane BCRP, MRP and PGP expression), in 14 out of 17 patients (82.3%), during the PCT occurred progression of the disease.  Malignant phenotype of this tumor corresponded with the state of primary multiple drug resistance.  In 80.0% of patients of this group, the neoadjuvant therapy turned out to be ineffective.  CONCLUSION:  Clinical trials for determination of role of ABC-transporters in the development of drug resistance of BC patients have not yet ended.  The leading role in development of resistance of BC cells plays not only PGP, but also MRP1 and BCRP.  Marker of resistance is not cytological, but membrane staining of cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS15-eiQP9NhlvAgqb2vdc5fW6udTcc2eb-0VwS8Nrtyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czhsVSitg%253D%253D&md5=d2a5f2e6a8836423edc78e8b7fadb891</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovalev%26aufirst%3DA.%2BA.%26aulast%3DTsvetaeva%26aufirst%3DD.%2BA.%26aulast%3DGrudinskaja%26aufirst%3DT.%2BV.%26atitle%3DRole%2520of%2520ABC-cassette%2520transporters%2520%2528MDR1%252C%2520MRP1%252C%2520BCRP%2529%2520in%2520the%2520development%2520of%2520primary%2520and%2520acquired%2520multiple%2520drug%2520resistance%2520in%2520patients%2520with%2520early%2520and%2520metastatic%2520breast%2520cancer%26jtitle%3DExp%2520Oncol%26date%3D2013%26volume%3D35%26spage%3D287%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span>. <i>Pathol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1827.2011.02772.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1111%2Fj.1440-1827.2011.02772.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=22360504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=167-175&author=S.+H.+Leeauthor=H.+Kimauthor=J.+H.+Hwangauthor=H.+S.+Leeauthor=J.+Y.+Choauthor=Y.+S.+Yoonauthor=H.+S.+Han&title=Breast+cancer+resistance+protein+expression+is+associated+with+early+recurrence+and+decreased+survival+in+resectable+pancreatic+cancer+patients&doi=10.1111%2Fj.1440-1827.2011.02772.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span></div><div class="casAuthors">Lee Sang Hyub; Kim Haeryoung; Hwang Jin-Hyeok; Lee Hye Seung; Cho Jai Young; Yoon Yoo-Seok; Han Ho-Seong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology international</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1-2 years postoperatively.  Adenosine triphosphate (ATP)-binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers.  In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR-associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry.  MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively.  The expression statuses of the MDR-related proteins were positively correlated with each other (P < 0.05).  Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion.  MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047).  High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001).  MDR-related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival.  Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTweVYj99EDj4NpW7w2tapOfW6udTcc2eb-0VwS8Nrtyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D&md5=4c10b59d6b30b8664e12e62edeacc920</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1827.2011.02772.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1827.2011.02772.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DY.%2BS.%26aulast%3DHan%26aufirst%3DH.%2BS.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520expression%2520is%2520associated%2520with%2520early%2520recurrence%2520and%2520decreased%2520survival%2520in%2520resectable%2520pancreatic%2520cancer%2520patients%26jtitle%3DPathol.%2520Int.%26date%3D2012%26volume%3D62%26spage%3D167%26epage%3D175%26doi%3D10.1111%2Fj.1440-1827.2011.02772.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rijavec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegovnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korosec, P.</span></span> <span> </span><span class="NLM_article-title">Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients</span>. <i>Pathol. Oncol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1007/s12253-011-9370-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs12253-011-9370-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=21455636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKltr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=691-696&author=M.+Rijavecauthor=M.+Silarauthor=N.+Trillerauthor=I.+Kernauthor=U.+Cegovnikauthor=M.+Kosnikauthor=P.+Korosec&title=Expressions+of+topoisomerase+IIalpha+and+BCRP+in+metastatic+cells+are+associated+with+overall+survival+in+small+cell+lung+cancer+patients&doi=10.1007%2Fs12253-011-9370-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expressions of Topoisomerase IIα and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Rijavec, Matija; Silar, Mira; Triller, Nadja; Kern, Izidor; Cegovnik, Urska; Kosnik, Mitja; Korosec, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">691-696</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the mRNA expression levels of multidrug resistance-assocd. proteins in chemo-naive metastatic lung cancer cells and to det. the correlation with response to chemotherapy and overall survival.  Metastatic cells were obtained by transbronchial fine needle aspiration biopsy of enlarged mediastinal lymph nodes in 14 patients with small cell lung cancer (SCLC) and 7 patients with non-small cell lung cancer (NSCLC).  After cytol. confirmation of lung cancer type, total RNA was extd. from biopsy samples and reverse transcribed to cDNA, and real-time PCR for the genes of interest [P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance protein (LRP) and topoisomerase IIα (TOPIIα)], was performed.  We obsd. significantly decreased expression of BCRP and significantly increased expression of TOPIIα in metastatic SCLC cells compared to NSCLC.  Furthermore, in SCLC high topoisomerase IIα and low BCRP expression levels pos. correlated with longer overall survival.  Our results showed higher expression levels of BCRP as well as lower levels of topoisomerase IIα in chemo-naive metastatic cells in NSCLC than in SCLC.  These results correlate with previous observations that metastatic SCLC cells at the beginning of chemotherapy are potentially more sensitive to chemotherapeutic agents while in metastatic NSCLC cells resistance is usually inherent.  We also showed that altered levels of topoisomerase IIα and BCRP in SCLC are important factors that contribute to resistance to chemotherapeutics that interfere with the enzyme and/or DNA and are highly assocd. with overall survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqt7ZV62xV77Vg90H21EOLACvtfcHk0ljmc8-2Iw7qvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKltr3L&md5=be380db800bfa685100b915a14be26c6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12253-011-9370-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-011-9370-2%26sid%3Dliteratum%253Aachs%26aulast%3DRijavec%26aufirst%3DM.%26aulast%3DSilar%26aufirst%3DM.%26aulast%3DTriller%26aufirst%3DN.%26aulast%3DKern%26aufirst%3DI.%26aulast%3DCegovnik%26aufirst%3DU.%26aulast%3DKosnik%26aufirst%3DM.%26aulast%3DKorosec%26aufirst%3DP.%26atitle%3DExpressions%2520of%2520topoisomerase%2520IIalpha%2520and%2520BCRP%2520in%2520metastatic%2520cells%2520are%2520associated%2520with%2520overall%2520survival%2520in%2520small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2011%26volume%3D17%26spage%3D691%26epage%3D696%26doi%3D10.1007%2Fs12253-011-9370-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosone, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivak, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bookman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moysich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoia, J. A.</span></span> <span> </span><span class="NLM_article-title">Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a gynecologic oncology group study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.ygyno.2011.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=22112610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1Oqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2012&pages=575-581&author=C.+Tianauthor=C.+B.+Ambrosoneauthor=K.+M.+Darcyauthor=T.+C.+Krivakauthor=D.+K.+Armstrongauthor=M.+A.+Bookmanauthor=W.+Davisauthor=H.+Zhaoauthor=K.+Moysichauthor=H.+Gallionauthor=J.+A.+DeLoia&title=Common+variants+in+ABCB1%2C+ABCC2+and+ABCG2+genes+and+clinical+outcomes+among+women+with+advanced+stage+ovarian+cancer+treated+with+platinum+and+taxane-based+chemotherapy%3A+a+gynecologic+oncology+group+study&doi=10.1016%2Fj.ygyno.2011.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study</span></div><div class="casAuthors">Tian, Chunqiao; Ambrosone, Christine B.; Darcy, Kathleen M.; Krivak, Thomas C.; Armstrong, Deborah K.; Bookman, Michael A.; Davis, Warren; Zhao, Hua; Moysich, Kirsten; Gallion, Holly; DeLoia, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Purpose: Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells.  This study examd. assocns. between functional variants in ABCB1, ABCC2 and ABCG2 genes and clin. outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) following platinum and taxane-based chemotherapy.  Methods: Sequenom iPLEXTMGOLD Assay and MALDI-TOF platform were used to genotype the non-synonymous G2677T/A (rs2032582; encoding Ala893Ser/Thr) and synonymous C3435T (rs1045642; encoding Ile1145Ile) variants in ABCB1, the non-synonymous G1249A variant in ABCC2 (rs2273697; encoding Val417Ile), and the non-synonymous C421A variant in ABCG2 (rs2231142; encoding Q141K, Gln141Lys) in normal DNA from up to 511 women in Gynecol. Oncol. Group (GOG) phase III trials, GOG-172 or GOG-182.  Progression-free survival (PFS) and overall survival (OS) were analyzed in relation to genetic polymorphisms using Kaplan-Meier and Cox proportional hazards model.  Results: The C421A variant (CA + AA vs. CC) in ABCG2 was assocd. with a 6-mo longer median PFS (22.7 vs. 16.8 mo, p = 0.041).  In multivariate anal., patients with variant genotypes were at a reduced risk of disease progression (hazard ratio [HR] = 0.75, 95% confidence interval [CI] = 0.59-0.96, p = 0.022).  The assocn. between C421A and OS was not statistically significant (HR = 0.88, 95% CI = 0.67-1.15, p = 0.356).  None of the other variants measured in either ABCB1 or ABCC2 was assocd. with PFS or OS.  Conclusion: The C421A variant in ABCG2, previously shown to be assocd. with enhanced protein degrdn. and drug sensitivity, was assocd. with longer PFS in advanced stage EOC/PPC patents treated with platinum + taxane-based chemotherapy.  This finding requires further validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5_G7N8B60rVg90H21EOLACvtfcHk0ljsaSwlE9NLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1Oqt70%253D&md5=64af8b990deb0f04a4e43d53b1119bb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DAmbrosone%26aufirst%3DC.%2BB.%26aulast%3DDarcy%26aufirst%3DK.%2BM.%26aulast%3DKrivak%26aufirst%3DT.%2BC.%26aulast%3DArmstrong%26aufirst%3DD.%2BK.%26aulast%3DBookman%26aufirst%3DM.%2BA.%26aulast%3DDavis%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMoysich%26aufirst%3DK.%26aulast%3DGallion%26aufirst%3DH.%26aulast%3DDeLoia%26aufirst%3DJ.%2BA.%26atitle%3DCommon%2520variants%2520in%2520ABCB1%252C%2520ABCC2%2520and%2520ABCG2%2520genes%2520and%2520clinical%2520outcomes%2520among%2520women%2520with%2520advanced%2520stage%2520ovarian%2520cancer%2520treated%2520with%2520platinum%2520and%2520taxane-based%2520chemotherapy%253A%2520a%2520gynecologic%2520oncology%2520group%2520study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2012%26volume%3D124%26spage%3D575%26epage%3D581%26doi%3D10.1016%2Fj.ygyno.2011.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uggla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagsater, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirsjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidefelt, U.</span></span> <span> </span><span class="NLM_article-title">BCRP mRNA expression v. clinical outcome in 40 adult AML patients</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2004.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.leukres.2004.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15607361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyktLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=141-146&author=B.+Ugglaauthor=E.+Stahlauthor=D.+Wagsaterauthor=C.+Paulauthor=M.+G.+Karlssonauthor=A.+Sirsjoauthor=U.+Tidefelt&title=BCRP+mRNA+expression+v.+clinical+outcome+in+40+adult+AML+patients&doi=10.1016%2Fj.leukres.2004.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP mRNA expression v. clinical outcome in 40 adult AML patients</span></div><div class="casAuthors">Uggla, Bertil; Stahl, Elisabet; Wagsaeter, Dick; Paul, Christer; Karlsson, Mats G.; Sirsjoe, Allan; Tidefelt, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Efflux pumps are considered being mechanisms behind drug resistance in acute myeloid leukemia (AML).  A recently described efflux pump, breast cancer resistance protein (BCRP), can be expressed in AML, but its clin. importance is uncertain.  In this study BCRP mRNA expression was detd. in samples from 40 AML patients by real-time RT-PCR.  The expression varied from neg. to 76 times that of control cells.  There was no difference in BCRP mRNA expression between patients responding to induction treatment and non-responders.  However, in the group of responders, the 14 patients with the highest expression had significantly shorter overall survival (mean 38 mo, SEM 15 mo) than the 14 patients with the lowest (74 mo, SEM 16 mo) (P = 0.047).  This suggests a possible role of BCRP in drug resistance in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowpAhXlUFVcLVg90H21EOLACvtfcHk0ljsaSwlE9NLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyktLfM&md5=e87f5c6fd59ad2f82a47671969572670</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2004.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2004.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DUggla%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DWagsater%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DM.%2BG.%26aulast%3DSirsjo%26aufirst%3DA.%26aulast%3DTidefelt%26aufirst%3DU.%26atitle%3DBCRP%2520mRNA%2520expression%2520v.%2520clinical%2520outcome%2520in%252040%2520adult%2520AML%2520patients%26jtitle%3DLeuk.%2520Res.%26date%3D2005%26volume%3D29%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.leukres.2004.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0937-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1158%2F1078-0432.CCR-0937-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15014021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1691-1697&author=K.+Yohauthor=G.+Ishiiauthor=T.+Yokoseauthor=Y.+Minegishiauthor=K.+Tsutaauthor=K.+Gotoauthor=Y.+Nishiwakiauthor=T.+Kodamaauthor=M.+Sugaauthor=A.+Ochiai&title=Breast+cancer+resistance+protein+impacts+clinical+outcome+in+platinum-based+chemotherapy+for+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-0937-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer</span></div><div class="casAuthors">Yoh, Kiyotaka; Ishii, Genichiro; Yokose, Tomoyuki; Minegishi, Yuji; Tsuta, Kohji; Goto, Koichi; Nishiwaki, Yutaka; Kodama, Tetsuro; Suga, Moritaka; Ochiai, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1691-1697</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the relationship between the level of expression of ATP-binding cassette (ABC) transporter proteins, and response to chemotherapy and prognosis in advanced non-small cell lung cancer (NSCLC).  Expression of ABC transporter proteins, including P-glycoprotein, multidrug resistance protein (MRP) 1, MRP2, MRP3, and breast cancer resistance protein (BCRP), was examd. immunohistochem. in 72 formalin-fixed tumor samples from untreated stage IIIB or IV NSCLC patients.  All of the patients received platinum-based chemotherapy.  Response to chemotherapy, progression-free survival (PFS), and overall survival were compared in relation to expression of each of the ABC transporter proteins and clinicopathol. factors.  Expression of P-glycoprotein, MRP1, and MRP3 was not significantly assocd. with response to chemotherapy or survival.  MRP2 expression was assocd. with overall survival (P = 0.002) but not with response to chemotherapy and PFS.  By contrast, the response rate to chemotherapy of patients with BCRP-neg. tumors was 44%, as opposed to 24% in patients with BCRP-pos. tumors.  Response rate was lower in BCRP-pos. tumors, although this difference was not statistically significant (P = 0.08).  BCRP-pos. patients had also shorter PFS (P = 0.0003) and overall survival (P = 0.004) than BCRP-neg. patients.  Multivariate anal. confirmed BCRP status as an independent variable related to PFS (P = 0.001).  Pos. immunostaining for BCRP appears to be a predictor of survival in patients with advanced NSCLC.  These findings indicate that BCRP may serve as a mol. target for reducing drug resistance to chemotherapy in advanced NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQb03yiZsiDbVg90H21EOLACvtfcHk0ljsaSwlE9NLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCltr0%253D&md5=4e7e59ad490d1778ee1b94162848ecbc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0937-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0937-3%26sid%3Dliteratum%253Aachs%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DYokose%26aufirst%3DT.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520impacts%2520clinical%2520outcome%2520in%2520platinum-based%2520chemotherapy%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D1691%26epage%3D1697%26doi%3D10.1158%2F1078-0432.CCR-0937-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. J.</span></span> <span> </span><span class="NLM_article-title">Preliminary study of the effects of beta-elemene on MCF-7/ADM breast cancer stem cells</span>. <i>GMR, Genet. Mol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2347</span>– <span class="NLM_lpage">2355</span>, <span class="refDoi"> DOI: 10.4238/2015.March.27.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.4238%2F2015.March.27.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=25867381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVWrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2347-2355&author=Y.+Dongauthor=L.+Liauthor=L.+Wangauthor=T.+Zhouauthor=J.+W.+Liuauthor=Y.+J.+Gao&title=Preliminary+study+of+the+effects+of+beta-elemene+on+MCF-7%2FADM+breast+cancer+stem+cells&doi=10.4238%2F2015.March.27.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells</span></div><div class="casAuthors">Dong, Y.; Li, L.; Wang, L.; Zhou, T.; Liu, J. W.; Gao, Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">GMR, Genetics and Molecular Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2347-2355</span>CODEN:
                <span class="NLM_cas:coden">GGMRBI</span>;
        ISSN:<span class="NLM_cas:issn">1676-5680</span>.
    
            (<span class="NLM_cas:orgname">FUNPEP</span>)
        </div><div class="casAbstract">We examd. expression differences in breast cancer stem cells (BCSCs) of the doxorubicin-resistant breast cancer cell line MCF-7/ADM and doxorubicin-sensitive cell line MCF-7/S.  The effects of Chinese medicine β-elemene on BCSCs and resistance protein expression were detd.  The serum-free cell culture method was used for cell culture, and morphol. was obsd. to det. the rate of cell sphere formation.  Reverse transcription-polymerase chain reaction was used to detect breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) gene expression.  Flow cytometry was used to det. BCRP- and P-gp-pos. cell rates and CD44 + CD24-/low cell ratios.  Morphol. observation and gene amplification showed that compared with MCF-7/S cells, the serum-free cell sphere-forming rate and P-gp and BCRP gene expression levels were higher in MCF-7/ADM cells.  Flow cytometry results showed that P-gp and BCRP protein expression in MCF-7/ADM cells was 77.78 ± 9.55% and 32.33 ± 5.12%, resp., and the CD44 + CD24-/low cell rate was 64.79 ± 11.78%, which were all significantly higher than those in MCF-7/S cells (3.97 ± 1.51, 14.26 ± 2.51, 18.79 ± 3.28%; P < 0.05). β-elemene significantly decreased the serum-free cell sphere-forming rate in MCF-7/ADM cells and BCRP and P-gp gene/protein expression (P < 0.01).  The proportion of CD44 + CD24-/low cells was reduced.  MCF-7/ADM highly expressed the drug-resistant proteins BCRP and P-gp, which can be used for long-term in vitro culture and as a seed cell for studies of BCSCs. β-elemene can inhibit BCSC and the sphere-forming rate in MCF-7/ADM cells and reduce BCRP expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCs8F4vd877Vg90H21EOLACvtfcHk0lhWK3OoF534ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVWrsbw%253D&md5=5d3b6c43d16ee4effc4e5eff1828d7d9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4238%2F2015.March.27.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4238%252F2015.March.27.20%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BW.%26aulast%3DGao%26aufirst%3DY.%2BJ.%26atitle%3DPreliminary%2520study%2520of%2520the%2520effects%2520of%2520beta-elemene%2520on%2520MCF-7%252FADM%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DGMR%252C%2520Genet.%2520Mol.%2520Res.%26date%3D2015%26volume%3D14%26spage%3D2347%26epage%3D2355%26doi%3D10.4238%2F2015.March.27.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszyk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, K.</span></span> <span> </span><span class="NLM_article-title">Expression and function of ABCG2 and XIAP in glioblastomas</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1007/s11060-017-2422-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs11060-017-2422-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28432589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFarur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=47-57&author=I.+F.+Emeryauthor=A.+Gopalanauthor=S.+Woodauthor=K.+H.+Chowauthor=C.+Battelliauthor=J.+Georgeauthor=H.+Blaszykauthor=J.+Flormanauthor=K.+Yun&title=Expression+and+function+of+ABCG2+and+XIAP+in+glioblastomas&doi=10.1007%2Fs11060-017-2422-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and function of ABCG2 and XIAP in glioblastomas</span></div><div class="casAuthors">Emery, Ivette F.; Gopalan, Archana; Wood, Stephanie; Chow, Kin-hoe; Battelli, Chiara; George, Joshy; Blaszyk, Hagen; Florman, Jeffrey; Yun, Kyuson</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells.  To identify potential new therapeutic targets in GBMs, we examd. the expression and function of proteins that are assocd. with therapy resistance and cancer cell survival.  We measured the expression of eight such proteins in 50 GBM samples by immunohistochem. and analyzed patient survival.  We report that GBM patients with high expression of ABCG2 (also called BCRP) or XIAP at the protein level had worse survival than those with low expression.  The adjusted hazard ratio for ABCG2 was 2.35 and for XIAP was 2.65.  Since glioma stem cells (GSCs) have been shown to be more resistant than bulk tumor cells to anti-cancer therapies and to express high levels of these proteins, we also sought to det. if ABCG2 and XIAP have functional roles in GSCs.  We used small mol. inhibitors to treat patient-derived GBM tumorspheres in vitro and obsd. that inhibitors of ABCG2, Ko143 and fumitremorgin, significantly reduced self-renewal.  These results suggest that ABCG2 and XIAP proteins may be useful indicators of patient survival and that inhibition of ABCG2 may be a promising therapeutic strategy in GBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz7aD1B1fhxLVg90H21EOLACvtfcHk0lhWK3OoF534ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFarur0%253D&md5=677f4b3a08f18f1e1594f49517066e72</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11060-017-2422-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-017-2422-z%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DI.%2BF.%26aulast%3DGopalan%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DK.%2BH.%26aulast%3DBattelli%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DBlaszyk%26aufirst%3DH.%26aulast%3DFlorman%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DK.%26atitle%3DExpression%2520and%2520function%2520of%2520ABCG2%2520and%2520XIAP%2520in%2520glioblastomas%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2017%26volume%3D133%26spage%3D47%26epage%3D57%26doi%3D10.1007%2Fs11060-017-2422-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12889</span>– <span class="NLM_lpage">12896</span>, <span class="refDoi"> DOI: 10.1007/s13277-016-5209-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs13277-016-5209-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWgtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=12889-12896&author=L.+Maauthor=T.+Liuauthor=Y.+Jinauthor=J.+Weiauthor=Y.+Yangauthor=H.+Zhang&title=ABCG2+is+required+for+self-renewal+and+chemoresistance+of+CD133-positive+human+colorectal+cancer+cells&doi=10.1007%2Fs13277-016-5209-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells</span></div><div class="casAuthors">Ma, Lijun; Liu, Ting; Jin, Yiran; Wei, Jun; Yang, Yinxue; Zhang, Hongquan</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">12889-12896</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is increasing evidence supporting the cancer stem cell (CSC) hypothesis, which suggests that a population of tumor cells with stem cell characteristics is responsible for tumor growth, resistance, and recurrence as well as drug resistance.  In colorectal cancer, the CD133 antigen defines distinct cell subpopulations that are rich in tumor-initiating cells; however, the drug resistance properties of these CD133-pos. cells have not been well defined.  The breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2) is present on the plasma membrane of many types of human cancer cells and contributes to multidrug resistance during chemotherapy.  The results of the present study showed that ABCG2 is expressed in CD133-pos. CSCs from human colorectal tumors.  Furthermore, the downregulation of ABCG2 expression inhibited the self-renewal capacity of these cells, and significantly enhanced the efficacy of chemotherapy-induced apoptosis in LS174T colon adenocarcinoma cells and CD133-pos. colorectal carcinoma cells.  Together, these data show that ABCG2 expression correlates with the presence of CD133-pos. cancer cells, and thus is a possible therapeutic target for colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwuitGCyYFsrVg90H21EOLACvtfcHk0lhWK3OoF534ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWgtbjI&md5=896e8ba43a9792ce66a1b1d768aa668d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs13277-016-5209-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-016-5209-5%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DABCG2%2520is%2520required%2520for%2520self-renewal%2520and%2520chemoresistance%2520of%2520CD133-positive%2520human%2520colorectal%2520cancer%2520cells%26jtitle%3DTumor%2520Biol.%26date%3D2016%26volume%3D37%26spage%3D12889%26epage%3D12896%26doi%3D10.1007%2Fs13277-016-5209-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriml, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano-Spica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span> <span> </span><span class="NLM_article-title">A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9850061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1cXotVSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5337-5339&author=R.+Allikmetsauthor=L.+M.+Schrimlauthor=A.+Hutchinsonauthor=V.+Romano-Spicaauthor=M.+Dean&title=A+human+placenta-specific+ATP-binding+cassette+gene+%28ABCP%29+on+chromosome+4q22+that+is+involved+in+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance</span></div><div class="casAuthors">Allikmets, Rando; Schriml, Lynn M.; Hutchinson, Amy; Romano-Spica, Vincenzo; Dean, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5337-5339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">We characterized a new human ATP-binding cassette (ABC) transporter gene that is highly expressed in the placenta.  The gene, ABCP, produces two transcripts that differ at the 5' end and encode the same 655-amino acid protein.  The predicted protein is closely related to the Drosophila white and yeast ADP1 genes and is a member of a subfamily that includes several multidrug resistance transporters.  ABCP, white, and ADP1 all have a single ATP-binding domain at the NH2 terminus and a single COOH-terminal set of transmembrane segments.  ABCP maps to human chromosome 4q22, between the markers D4S2462 and D4S1557, and the murine gene (Abcp) is located on chromosome 6, 28-29 cM from the centromere.  ABCP defines a new syntenic segment between human chromosome 4 and mouse chromosome 6.  The abundant expression of this gene in the placenta suggests that the protein product has an important role in transport of specific mol.(s) into or out of this tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoelWb8FwUhcbVg90H21EOLACvtfcHk0lilJjBqfIO0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVSkt7Y%253D&md5=9077feec7eff1ff318503c48d6ef8599</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSchriml%26aufirst%3DL.%2BM.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DRomano-Spica%26aufirst%3DV.%26aulast%3DDean%26aufirst%3DM.%26atitle%3DA%2520human%2520placenta-specific%2520ATP-binding%2520cassette%2520gene%2520%2528ABCP%2529%2520on%2520chromosome%25204q22%2520that%2520is%2520involved%2520in%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5337%26epage%3D5339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abruzzo, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span> <span> </span><span class="NLM_article-title">A multidrug resistance transporter from human MCF-7 breast cancer cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">15665</span>– <span class="NLM_lpage">15670</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.26.15665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1073%2Fpnas.95.26.15665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15665-15670&author=L.+A.+Doyleauthor=W.+Yangauthor=L.+V.+Abruzzoauthor=T.+Krogmannauthor=Y.+Gaoauthor=A.+K.+Rishiauthor=D.+D.+Ross&title=A+multidrug+resistance+transporter+from+human+MCF-7+breast+cancer+cells&doi=10.1073%2Fpnas.95.26.15665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A multidrug resistance transporter from human MCF-7 breast cancer cells</span></div><div class="casAuthors">Doyle, L. Austin; Yang, Weidong; Abruzzo, Lynne V.; Krogmann, Tammy; Gao, Yongming; Rishi, Arun K.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15665-15670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent redn. in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein.  RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells.  The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP).  Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.  BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowbckt6jTJYLVg90H21EOLACvtfcHk0lilJjBqfIO0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D&md5=ef3e4ddd772833b363ba458401e3331a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.26.15665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.26.15665%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DAbruzzo%26aufirst%3DL.%2BV.%26aulast%3DKrogmann%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26atitle%3DA%2520multidrug%2520resistance%2520transporter%2520from%2520human%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D15665%26epage%3D15670%26doi%3D10.1073%2Fpnas.95.26.15665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9892175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=8-13&author=K.+Miyakeauthor=L.+Mickleyauthor=T.+Litmanauthor=Z.+Zhanauthor=R.+Robeyauthor=B.+Cristensenauthor=M.+Brangiauthor=L.+Greenbergerauthor=M.+Deanauthor=T.+Fojoauthor=S.+E.+Bates&title=Molecular+cloning+of+cDNAs+which+are+highly+overexpressed+in+mitoxantrone-resistant+cells%3A+demonstration+of+homology+to+ABC+transport+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes</span></div><div class="casAuthors">Miyake, Keisuke; Mickley, Lyn; Litman, Thomas; Zhan, Zhirong; Robey, Robert; Cristensen, Barbara; Brangi, Mariafiorella; Greenberger, Lee; Dean, Michael; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-13</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance assocd. protein have raised the possibility of the existence of another major transporter conferring drug resistance.  In the present study, a cDNA library from mitoxantrone-resistant S1-M1-80 human colon carcinoma cells was screened by differential hybridization.  Two cDNAs of different lengths were isolated and designated MXR1 and MXR2.  Sequencing revealed a high degree of homol. for the cDNAs with Expressed Sequence Tag sequences previously identified as belonging to an ATP binding cassette transporter.  Homol. to the Drosophila white gene and its homologues was found for the predicted amino acid sequence.  Using either cDNA as a probe in a Northern anal. demonstrated high levels of expression in the S1-M1-80 cells and in the human breast cancer subline, MCF-7 AdVp3000.  Levels were lower in earlier steps of selection, and in partial revertants.  The gene is amplified 10-12-fold in the MCF-7 AdVp3000 cells, but not in the S1-M1-80 cells.  These studies are consistent with the identification of a new ATP binding cassette transporter, which is overexpressed in mitoxantrone-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tfK3k_pnibVg90H21EOLACvtfcHk0lilJjBqfIO0Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKqsQ%253D%253D&md5=2fd30ec6844cb5c45a17e6e1646214f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DMickley%26aufirst%3DL.%26aulast%3DLitman%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DZ.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DCristensen%26aufirst%3DB.%26aulast%3DBrangi%26aufirst%3DM.%26aulast%3DGreenberger%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMolecular%2520cloning%2520of%2520cDNAs%2520which%2520are%2520highly%2520overexpressed%2520in%2520mitoxantrone-resistant%2520cells%253A%2520demonstration%2520of%2520homology%2520to%2520ABC%2520transport%2520genes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D8%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikadi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.2174/138920010792927325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2174%2F138920010792927325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20812902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=603-617&author=Z.+Niauthor=Z.+Bikadiauthor=M.+F.+Rosenbergauthor=Q.+Mao&title=Structure+and+function+of+the+human+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.2174%2F138920010792927325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Ni, Zhanglin; Bikadi, Zsolt; Rosenberg, Mark F.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-617</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human breast cancer resistance protein (BCRP/ABCG2) is the second member of the G subfamily of the ATP-binding cassette (ABC) transporter superfamily.  BCRP was initially discovered in multidrug resistant breast cancer cell lines where it confers resistance to chemotherapeutic agents such as mitoxantrone, topotecan and methotrexate by extruding these compds. out of the cell.  BCRP is capable of transporting non-chemotherapy drugs and xenobiotiocs as well, including nitrofurantoin, prazosin, glyburide, and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine.  BCRP is frequently detected at high levels in stem cells, likely providing xenobiotic protection.  BCRP is also highly expressed in normal human tissues including the small intestine, liver, brain endothelium, and placenta.  Therefore, BCRP has been increasingly recognized for its important role in the absorption, elimination, and tissue distribution of drugs and xenobiotics.  At present, little is known about the transport mechanism of BCRP, particularly how it recognizes and transports a large no. of structurally and chem. unrelated drugs and xenobiotics.  Here, we review current knowledge of structure and function of this medically important ABC efflux drug transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSq7fLjXpxb7Vg90H21EOLACvtfcHk0lhoVwgF270xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbvM&md5=d90e86dde1fbff8cbd116f932e62b75e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138920010792927325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010792927325%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DBikadi%26aufirst%3DZ.%26aulast%3DRosenberg%26aufirst%3DM.%2BF.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DStructure%2520and%2520function%2520of%2520the%2520human%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26spage%3D603%26epage%3D617%26doi%3D10.2174%2F138920010792927325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadjem, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risbood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poruchynsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S.</span></span> <span> </span><span class="NLM_article-title">Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1978</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fsj.bjc.6601370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=14612912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1971-1978&author=R.+Robeyauthor=Y.+Honjoauthor=K.+Morisakiauthor=T.+Nadjemauthor=S.+Rungeauthor=M.+Risboodauthor=M.+Poruchynskyauthor=S.+Bates&title=Mutations+at+amino-acid+482+in+the+ABCG2+gene+affect+substrate+and+antagonist+specificity&doi=10.1038%2Fsj.bjc.6601370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity</span></div><div class="casAuthors">Robey, R. W.; Honjo, Y.; Morisaki, K.; Nadjem, T. A.; Runge, S.; Risbood, M.; Poruchynsky, M. S.; Bates, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1971-1978</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recent studies have shown that mutations at amino-acid 482 in the ABCG2 gene affect the substrate specificity of the protein.  To delineate the effects of these mutations clearly, human embryonic kidney cells (HEK-293) were stably transfected with wild-type 482R or mutant 482G and 482T ABCG2.  By flow cytometry, mitoxantrone, BODIPY-prazosin, and Hoechst 33342 were found to be substrates of all ABCG2 proteins, while rhodamine 123, daunorubicin, and LysoTracker Green were transported only by mutant ABCG2.  In cytotoxicity assays, all ABCG2 proteins conferred high levels of resistance to mitoxantrone, SN-38, and topotecan, while mutant ABCG2 also exhibited a gain of function for mitoxantrone as they conferred a four-fold greater resistance compared to wild type.  Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin, epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold resistant to these compds.  ABCG2 did not confer appreciable resistance to etoposide, taxol or the histone deacetylase inhibitor depsipeptide.  None of the transfected cell lines demonstrated resistance to flavopiridol despite our previous observation that ABCG2-overexpressing cell lines are cross-resistant to the drug.  Recently reported inhibitors of ABCG2 were evaluated and 50 μM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially.  The studies presented here serve to underscore the importance of amino-acid 482 in defining the substrate specificity of the ABCG2 protein and raise the possibility that amino-acid 482 mutations in human cancers could affect the clin. application of antagonists for ABCG2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon8onO595iKLVg90H21EOLACvtfcHk0lhoVwgF270xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVers7g%253D&md5=3e8bbb529899a2aca87aa93d4a68aabd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601370%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DHonjo%26aufirst%3DY.%26aulast%3DMorisaki%26aufirst%3DK.%26aulast%3DNadjem%26aufirst%3DT.%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DRisbood%26aufirst%3DM.%26aulast%3DPoruchynsky%26aufirst%3DM.%26aulast%3DBates%26aufirst%3DS.%26atitle%3DMutations%2520at%2520amino-acid%2520482%2520in%2520the%2520ABCG2%2520gene%2520affect%2520substrate%2520and%2520antagonist%2520specificity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1971%26epage%3D1978%26doi%3D10.1038%2Fsj.bjc.6601370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resau, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10806112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2000&pages=2011-2021&author=T.+Litmanauthor=M.+Brangiauthor=E.+Hudsonauthor=P.+Fetschauthor=A.+Abatiauthor=D.+D.+Rossauthor=K.+Miyakeauthor=J.+H.+Resauauthor=S.+E.+Bates&title=The+multidrug-resistant+phenotype+associated+with+overexpression+of+the+new+ABC+half-transporter%2C+MXR+%28ABCG2%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)</span></div><div class="casAuthors">Litman, Thomas; Brangi, Mariafiorella; Hudson, Eric; Fetsch, Patricia; Abati, Andrea; Ross, Douglas D.; Miyake, Keisuke; Resau, James H.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2011-2021</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mechanisms of drug resistance other than P-glycoprotein are of increasing interest as the list of newly identified members of the ABC transport family has grown.  We sought to characterize the phenotype of the newly discovered ABC transporter encoded by the mitoxantrone resistance gene, MXR, also known as ABCP1 or BCRP.  The pharmacodynamics of mitoxantrone and 12 other fluorescent drugs were evaluated by confocal microscopy in four multidrug-resistant human colon (S1) and breast (MCF-7) cancer cell lines.  We utilized two sublines, MCF-7 AdVp3000 and S1-M1-80, and detected overexpression of MXR by PCR, immunoblot assay and immunohistochem.  These MXR overexpressing sublines were compared to cell lines with P-glycoprotein- and MRP-mediated resistance.  High levels of cross-resistance were obsd. for mitoxantrone, the anthracyclines, bisantrene and topotecan.  Reduced levels of mitoxantrone, daunorubicin, bisantrene, topotecan, rhodamine 123 and prazosin were obsd. in the two sublines with high MXR expression.  Neither the P-glycoprotein substrates vinblastine, paclitaxel, verapamil and calcein-AM, nor the MRP substrate calcein, were extruded from MCF-7 AdVp3000 and S1-M1-80 cells.  Thus, the multidrug-resistant phenotype due to MXR expression is overlapping with, but distinct from, that due to P-glycoprotein.  Further, cells that overexpress the MXR protein seem to be more resistant to mitoxantrone and topotecan than cells with P-glycoprotein-mediated multidrug resistance.  Our studies suggest that the ABC half-transporter, MXR, is a potent, new mechanism for conferring multiple drug resistance.  Definition of its mechanism of transport and its role in clin. oncol. is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpb_xS4uC0-rVg90H21EOLACvtfcHk0lhoVwgF270xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKntrg%253D&md5=305a9a9c80f0f583c99b3b4c6744f5f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLitman%26aufirst%3DT.%26aulast%3DBrangi%26aufirst%3DM.%26aulast%3DHudson%26aufirst%3DE.%26aulast%3DFetsch%26aufirst%3DP.%26aulast%3DAbati%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DThe%2520multidrug-resistant%2520phenotype%2520associated%2520with%2520overexpression%2520of%2520the%2520new%2520ABC%2520half-transporter%252C%2520MXR%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2000%26volume%3D113%26spage%3D2011%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annable, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span> <span> </span><span class="NLM_article-title">Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5850</span>– <span class="NLM_lpage">5858</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9865745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXivFah" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5850-5858&author=S.+K.+Rabindranauthor=H.+Heauthor=M.+Singhauthor=E.+Brownauthor=K.+I.+Collinsauthor=T.+Annableauthor=L.+M.+Greenberger&title=Reversal+of+a+novel+multidrug+resistance+mechanism+in+human+colon+carcinoma+cells+by+fumitremorgin+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C</span></div><div class="casAuthors">Rabindran, Sridhar K.; He, Haiyin; Singh, Maya; Brown, Eileen; Collins, Karen I.; Annable, Tami; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5850-5858</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">We selected a human colon carcinoma cell line in increasing concns. of mitoxantrone to obtain a resistant subline, S1-M1-3.2, with the following characteristics: profound resistance to mitoxantrone; significant cross-resistance to doxorubicin, bisantrene, and topotecan; and very low levels of resistance to Taxol, vinblastine, colchicine, and camptothecin.  This multidrug resistance (MDR) phenotype, which was not reversed by verapamil or another potent P-glycoprotein (Pgp) inhibitor, CL 329,753, was dependent, in part, upon an energy-dependent drug efflux mechanism.  Pgp and the multidrug resistance protein (MRP) were not elevated in the resistant cells relative to the drug-sensitive parent, suggesting that resistance was mediated by a novel pathway of drug transport.  A cell-based screen with S1-M1-3.2 cells was used to identify agents capable of circumventing this non-Pgp, non-MRP MDR.  One of the active agents identified was a mycotoxin, fumitremorgin C.  This mol. was extremely effective in reversing resistance to mitoxantrone, doxorubicin, and topotecan in multidrug-selected cell lines showing this novel phenotype.  Reversal of resistance was assocd. with an increase in drug accumulation.  The compd. did not reverse drug resistance in cells with elevated expression of Pgp or MRP.  We suggest that fumitremorgin C is a highly selective chemosensitizing agent for the resistance pathway we have identified and can be used as a specific pharmacol. probe to distinguish between the diverse resistance mechanisms that occur in the MDR cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-Y6qf2FmRbVg90H21EOLACvtfcHk0lhoVwgF270xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFah&md5=cacafc261f829003219cdd9f518ac900</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DK.%2BI.%26aulast%3DAnnable%26aufirst%3DT.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DReversal%2520of%2520a%2520novel%2520multidrug%2520resistance%2520mechanism%2520in%2520human%2520colon%2520carcinoma%2520cells%2520by%2520fumitremorgin%2520C%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5850%26epage%3D5858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ABCG2: a perspective</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.addr.2008.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19135109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=3-13&author=R.+W.+Robeyauthor=K.+K.+Toauthor=O.+Polgarauthor=M.+Dohseauthor=P.+Fetschauthor=M.+Deanauthor=S.+E.+Bates&title=ABCG2%3A+a+perspective&doi=10.1016%2Fj.addr.2008.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2: A perspective</span></div><div class="casAuthors">Robey, Robert W.; To, Kenneth K. K.; Polgar, Orsolya; Dohse, Marius; Fetsch, Patricia; Dean, Michael; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the subject of intense study since its discovery a decade ago.  With high normal tissue expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is believed to be important in the protection from xenobiotics, regulating oral bioavailability, forming part of the blood-brain barrier, the blood-testis barrier, and the maternal-fetal barrier.  Notably, ABCG2 is often expressed in stem cell populations, where it likely plays a role in xenobiotic protection.  However, clues to its epigenetic regulation in various cell populations are only beginning to emerge.  While ABCG2 overexpression has been demonstrated in cancer cells after in vitro drug treatment, endogenous ABCG2 expression in certain cancers is likely a reflection of the differentiated phenotype of the cell of origin and likely contributes to intrinsic drug resistance.  Notably, research into the transporter's role in cancer drug resistance and its development as a therapeutic target in cancer has lagged.  Substrates and inhibitors of the transporter have been described, among them chemotherapy drugs, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase inhibitors, carcinogens, and flavonoids.  This broad range of substrates complements the efficiency of ABCG2 as a transporter in lab. studies and suggests that, while there are redundant mechanisms of xenobiotic protection, the protein is important in normal physiol.  Indeed, emerging studies in pharmacol. and toxicol. assessing polymorphic variants in man, in combination with murine knockout models have confirmed its dynamic role.  Work in pharmacol. may eventually lead us to a greater understanding of the physiol. role of ABCG2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXHdrQffcZprVg90H21EOLACvtfcHk0lieDsoxp8_Epg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu70%253D&md5=dc00a9793b185b7a23290a21ed3ea8ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPolgar%26aufirst%3DO.%26aulast%3DDohse%26aufirst%3DM.%26aulast%3DFetsch%26aufirst%3DP.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DABCG2%253A%2520a%2520perspective%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D3%26epage%3D13%26doi%3D10.1016%2Fj.addr.2008.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC multidrug transporters: structure, function and role in chemoresistance</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.2217/14622416.9.1.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2217%2F14622416.9.1.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=18154452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=105-127&author=F.+J.+Sharom&title=ABC+multidrug+transporters%3A+structure%2C+function+and+role+in+chemoresistance&doi=10.2217%2F14622416.9.1.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ABC multidrug transporters: structure, function and role in chemoresistance</span></div><div class="casAuthors">Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-127</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Three ATP-binding cassette (ABC)-superfamily multidrug efflux pumps are known to be responsible for chemoresistance; P-glycoprotein (ABCB1), MRP1 (ABCC1) and ABCG2 (BCRP).  These transporters play an important role in normal physiol. by protecting tissues from toxic xenobiotics and endogenous metabolites.  Hydrophobic amphipathic compds., including many clin. used drugs, interact with the substrate-binding pocket of these proteins via flexible hydrophobic and H-bonding interactions.  These efflux pumps are expressed in many human tumors, where they likely contribute to resistance to chemotherapy treatment.  However, the use of efflux-pump modulators in clin. cancer treatment has proved disappointing.  Single nucleotide polymorphisms in ABC drug-efflux pumps may play a role in responses to drug therapy and disease susceptibility.  The effect of various genotypes and haplotypes on the expression and function of these proteins is not yet clear, and their true impact remains controversial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodtANKweyrPrVg90H21EOLACvtfcHk0lieDsoxp8_Epg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOjsg%253D%253D&md5=7594f33bc3a524c65d3622b00750dbe6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2217%2F14622416.9.1.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14622416.9.1.105%26sid%3Dliteratum%253Aachs%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520multidrug%2520transporters%253A%2520structure%252C%2520function%2520and%2520role%2520in%2520chemoresistance%26jtitle%3DPharmacogenomics%26date%3D2008%26volume%3D9%26spage%3D105%26epage%3D127%26doi%3D10.2217%2F14622416.9.1.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannock, I. F.</span></span> <span> </span><span class="NLM_article-title">Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1007/s10555-012-9402-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs10555-012-9402-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=23093326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=211-227&author=M.+Yuauthor=A.+Ocanaauthor=I.+F.+Tannock&title=Reversal+of+ATP-binding+cassette+drug+transporter+activity+to+modulate+chemoresistance%3A+why+has+it+failed+to+provide+clinical+benefit%3F&doi=10.1007%2Fs10555-012-9402-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?</span></div><div class="casAuthors">Yu, Man; Ocana, Alberto; Tannock, Ian F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">211-227</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Enhanced drug extrusion from cells due to the overexpression of the ATP-binding cassette (ABC) drug transporters inhibits the cytotoxic effects of structurally diverse and mechanistically unrelated anticancer agents and is a major cause of multidrug resistance (MDR) of human malignancies.  Multiple compds. can suppress the activity of these efflux transporters and sensitize resistant tumor cells, but despite promising preclin. and early clin. data, they have yet to find a role in oncol. practice.  Based on the knowledge of the structure, function, and distribution of MDR-related ABC transporters and the results of their preclin. and clin. evaluation, we discuss probable reasons why these inhibitors have not improved the outcome of therapy for cancer patients.  We also outline new MDR-reversing strategies that directly target ABC transporters or circumvent relevant signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBAZK6a3syH7Vg90H21EOLACvtfcHk0lieDsoxp8_Epg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFWit78%253D&md5=76bbcfcf06b4b4274310f9f48a8cf3cd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs10555-012-9402-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-012-9402-8%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DOcana%26aufirst%3DA.%26aulast%3DTannock%26aufirst%3DI.%2BF.%26atitle%3DReversal%2520of%2520ATP-binding%2520cassette%2520drug%2520transporter%2520activity%2520to%2520modulate%2520chemoresistance%253A%2520why%2520has%2520it%2520failed%2520to%2520provide%2520clinical%2520benefit%253F%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2013%26volume%3D32%26spage%3D211%26epage%3D227%26doi%3D10.1007%2Fs10555-012-9402-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span> <span> </span><span class="NLM_article-title">Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10646850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=47-50&author=S.+K.+Rabindranauthor=D.+D.+Rossauthor=L.+A.+Doyleauthor=W.+Yangauthor=L.+M.+Greenberger&title=Fumitremorgin+C+reverses+multidrug+resistance+in+cells+transfected+with+the+breast+cancer+resistance+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein</span></div><div class="casAuthors">Rabindran, Sridhar K.; Ross, Douglas D.; Doyle, L. Austin; Yang, Weidong; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-50</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Fumitremorgin C (FTC) is a potent and specific chemosensitizing agent in cell lines selected for resistance to mitoxantrone that do not overexpress P-glycoprotein or multidrug resistance protein.  The gene encoding a novel transporter, the breast cancer resistance protein (BCRP), was recently overexpressed in a mitoxantrone-selected human colon cell line, S1-M1-3.2, which was used to identify FTC.  Because the drug-selected cell line may contain multiple alterations contributing to the multidrug resistance phenotype, the authors examd. the effect of FTC on MCF-7 cells transfected with the BCRP gene.  The authors report that FTC almost completely reverses resistance mediated by BCRP in vitro and is a pharmacol. probe for the expression and mol. action of this transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv8QZa80NcbVg90H21EOLACvtfcHk0ljX9_7tu--Dow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ahtw%253D%253D&md5=46f893b6e504412c489cba2f4b87cfee</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DFumitremorgin%2520C%2520reverses%2520multidrug%2520resistance%2520in%2520cells%2520transfected%2520with%2520the%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D47%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Loevezijn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Valk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C</span>. <i>Mol. Cancer Ther</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.4161%2Fcbt.1.4.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=12477054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=417-425&author=J.+D.+Allenauthor=A.+Van+Loevezijnauthor=J.+M.+Lakhaiauthor=M.+Van+Der+Valkauthor=O.+Van+Tellingenauthor=G.+Reidauthor=J.+H.+Schellensauthor=G.-J.+Koomenauthor=A.+H.+Schinkel&title=Potent+and+specific+inhibition+of+the+breast+cancer+resistance+protein+multidrug+transporter+in+vitro+and+in+mouse+intestine+by+a+novel+analogue+of+fumitremorgin+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C</span></div><div class="casAuthors">Allen, John D.; Van Loevezijn, Arnold; Lakhai, Jeany M.; Van der Valk, Martin; Van Tellingen, Olaf; Reid, Glen; Schellens, Jan H. M.; Koomen, Gerrit-Jan; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibitors of the breast cancer resistance protein (BCRP/ABCG2) multidrug transporter are of interest as chemosensitizers for clin. drug resistance, for improving the pharmacokinetics of substrate chemotherapeutic drugs, and in functional assays of BCRP activity for tailoring chemotherapy.  The fungal toxin fumitremorgin C (FTC) is a potent and specific inhibitor of BCRP, but its neurotoxic effects preclude use in vivo.  We have therefore evaluated a new tetracyclic analog of FTC, Ko143, as a practical inhibitor of BCRP, comparing it with two other analogs in the same class and with GF120918.  All three FTC analogs are effective inhibitors of both mouse Bcrp1 and human BCRP, proving highly active for increasing the intracellular drug accumulation and reversing Bcrp1/BCRP-mediated multidrug resistance.  Indeed, Ko143 appears to be the most potent BCRP inhibitor known thus far.  In contrast, the compds. have only low activity against P-glycoprotein, the multidrug resistance-assocd. protein (MRP1), or other known drug transporters.  They are nontoxic in vitro at useful concns. and evinced no signs of toxicity in mice at high oral or i.p. doses.  Administered p.o. to inhibit intestinal Bcrp1, Ko143 markedly increased the oral availability of topotecan in mice.  It is thus the first highly potent and specific BCRP inhibitor applicable in vivo.  As such, Ko143 and other FTC analogs of this type represent valuable reagents for anal. of drug resistance mechanisms and may be candidates for development as clin. BCRP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdmIQAa5j5rVg90H21EOLACvtfcHk0ljX9_7tu--Dow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs7g%253D&md5=8a54c6c38d9639ec70faa97a279d0a12</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4161%2Fcbt.1.4.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.1.4.22%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BD.%26aulast%3DVan%2BLoevezijn%26aufirst%3DA.%26aulast%3DLakhai%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BDer%2BValk%26aufirst%3DM.%26aulast%3DVan%2BTellingen%26aufirst%3DO.%26aulast%3DReid%26aufirst%3DG.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DKoomen%26aufirst%3DG.-J.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DPotent%2520and%2520specific%2520inhibition%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520multidrug%2520transporter%2520in%2520vitro%2520and%2520in%2520mouse%2520intestine%2520by%2520a%2520novel%2520analogue%2520of%2520fumitremorgin%2520C%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2002%26volume%3D1%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">The inhibitor Ko143 is not specific for ABCG2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.225482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1124%2Fjpet.115.225482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26148857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=384-393&author=L.+D.+Weidnerauthor=S.+S.+Zoghbiauthor=S.+Luauthor=S.+Shuklaauthor=S.+V.+Ambudkarauthor=V.+W.+Pikeauthor=J.+Mulderauthor=M.+M.+Gottesmanauthor=R.+B.+Innisauthor=M.+D.+Hall&title=The+inhibitor+Ko143+is+not+specific+for+ABCG2&doi=10.1124%2Fjpet.115.225482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitor Ko143 is not specific for ABCG2</span></div><div class="casAuthors">Weidner, Lora D.; Zoghbi, Sami S.; Lu, Shuiyu; Shukla, Suneet; Ambudkar, Suresh V.; Pike, Victor W.; Mulder, Jan; Gottesman, Michael M.; Innis, Robert B.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-393</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Imaging ATP-binding cassette (ABC) transporter activity in vivo with positron emission tomog. requires both a substrate and a transporter inhibitor.  However, for ABCG2, there is no inhibitor proven to be specific to that transporter alone at the blood-brain barrier.  Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], a nontoxic analog of fungal toxin fumitremorgin C, is a potent inhibitor of ABCG2, although its specificity in mouse and human systems is unclear.  This study examd. the selectivity of Ko143 using human embryonic kidney cell lines transfected with ABCG2, ABCB1, or ABCC1 in several in vitro assays.  The stability of Ko143 in rat plasma was measured using high performance liq. chromatog.  Our results show that, in addn. to being a potent inhibitor of ABCG2, at higher concns. (≥1 μM) Ko143 also has an effect on the transport activity of both ABCB1 and ABCC1.  Furthermore, Ko143 was found to be unstable in rat plasma.  These findings indicate that Ko143 lacks specificity for ABCG2 and this should be taken into consideration when using Ko143 for both in vitro and in vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWjvTByDwbLVg90H21EOLACvtfcHk0ljX9_7tu--Dow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrtb7L&md5=4336228ff99f608f6452dca312e78a5a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.225482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.225482%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner%26aufirst%3DL.%2BD.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DThe%2520inhibitor%2520Ko143%2520is%2520not%2520specific%2520for%2520ABCG2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D384%26epage%3D393%26doi%3D10.1124%2Fjpet.115.225482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">HM30181 Derivatives as novel potent and selective inhibitors of the breast cancer resistance protein (BCRP/ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3921</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3910-3921&author=S.+C.+Kohlerauthor=M.+Wiese&title=HM30181+Derivatives+as+novel+potent+and+selective+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Facs.jmedchem.5b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kohler Sebastian C; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3910-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The breast cancer resistance protein (BCRP, ABCG2) belongs to the superfamily of ATP binding-cassette (ABC) proteins.  In addition to other physiological functions, it transports potentially cell-damaging compounds out of the cell using the energy from ATP hydrolysis.  Certain tumors overexpressing BCRP were found to become resistant against various anticancer drugs.  In previous work, we found that tariquidar analogues lacking the tetrahydroisoquinoline moiety selectively inhibit BCRP.  In the present study, we synthesized 21 derivatives of the third-generation P-gp inhibitor HM30181, which is structurally related to tariquidar.  The compounds were tested for their inhibitory activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1) to confirm the selectivity toward BCRP.  The most potent compounds are selective toward BCRP and 2-fold more potent than the reference Ko143.  Qualitative structure-activity relationship (SAR) analysis revealed that the presence of a methoxy group in the ortho or para position of at least one phenyl ring is beneficial for inhibitory activity.  Furthermore, the cytotoxicity and multidrug resistance (MDR)-reversal ability of selected compounds were investigated.  It was shown that they have a low cytotoxicity and the ability to reverse the BCRP-mediated SN-38 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_-1BYW7HmO9-cVm4E2RlLfW6udTcc2eZC2I9N7Ep_lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D&md5=777b13f427105e8909ae751d11e8c7b4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00188%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DHM30181%2520Derivatives%2520as%2520novel%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3910%26epage%3D3921%26doi%3D10.1021%2Facs.jmedchem.5b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">The ″specific″ P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2)</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1021/cn100078a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100078a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=82-89&author=P.+Kannanauthor=S.+Teluauthor=S.+Shuklaauthor=S.+V.+Ambudkarauthor=V.+W.+Pikeauthor=C.+Halldinauthor=M.+M.+Gottesmanauthor=R.+B.+Innisauthor=M.+D.+Hall&title=The+%E2%80%B3specific%E2%80%B3+P-glycoprotein+inhibitor+tariquidar+is+also+a+substrate+and+an+inhibitor+for+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Fcn100078a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kannan, Pavitra; Telu, Sanjay; Shukla, Suneet; Ambudkar, Suresh V.; Pike, Victor W.; Halldin, Christer; Gottesman, Michael M.; Innis, Robert B.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-89</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tariquidar was developed as a specific inhibitor of the efflux transporter ABCB1.  Recent positron emission tomog. brain imaging studies using [11C]tariquidar to measure ABCB1 (P-gp, P-glycoprotein) d. in mice indicate that the inhibitor may not be as specific as previously thought.  We examd. its selectivity as an inhibitor and a substrate for the human transporters P-gp, breast cancer resistance protein (BCRP, ABCG2), and multidrug resistance protein 1 (MRP1, ABCC1).  These results show that at low concns., tariquidar acts selectively as an inhibitor of P-gp and also as a substrate of BCRP.  At much higher concns. (≥100 nM), tariquidar acts as an inhibitor of both P-gp and BCRP.  Thus, the in vivo specificity of tariquidar depends on concn. and the relative d. and capacity of P-gp vs BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDSwrbJSyvLVg90H21EOLACvtfcHk0liEcAei3Yw_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtLvI&md5=e5fb835e5610aee9323a3ba40e7b1498</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcn100078a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100078a%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DP.%26aulast%3DTelu%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DThe%2520%25E2%2580%25B3specific%25E2%2580%25B3%2520P-glycoprotein%2520inhibitor%2520tariquidar%2520is%2520also%2520a%2520substrate%2520and%2520an%2520inhibitor%2520for%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D82%26epage%3D89%26doi%3D10.1021%2Fcn100078a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">2,4,6-substituted quinazolines with extraordinary inhibitory potency toward ABCG2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7952</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7952-7976&author=M.+K.+Krapfauthor=J.+Gallusauthor=V.+Namasivayamauthor=M.+Wiese&title=2%2C4%2C6-substituted+quinazolines+with+extraordinary+inhibitory+potency+toward+ABCG2&doi=10.1021%2Facs.jmedchem.8b01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7952-7976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several members of the ABC transporter superfamily play a decisive role in the development of multidrug resistance (MDR) in cancer.  One of these MDR assocd. efflux transporters is ABCG2.  One way to overcome this MDR is the coadministration of potent inhibitors of ABCG2.  In this study, we identified novel inhibitors contg. a 2,4,6-substituted quinazoline scaffold.  Introduction of a 6-nitro function led to extraordinarily potent compds. that were highly selective for ABCG2 and also able to reverse the MDR toward the chemotherapeutic drugs SN-38 and mitoxantrone.  The binding of substrate Hoechst 33342 and the two potent inhibitors 31 and 41 which differ in their mechanism of inhibition was rationalized using the recently published cryo-EM structures of ABCG2.  For a better understanding of the interaction between the inhibitors and ABCG2, addnl. investigations regarding the ATPase activity, the interaction with Hoechst 33342, and with the conformational sensitive 5D3 antibody were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHoikCuvyt-bVg90H21EOLACvtfcHk0lhTnaIaGROyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO&md5=376bdc61d3a65d7ea6877e7b69ca0d74</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01011%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D2%252C4%252C6-substituted%2520quinazolines%2520with%2520extraordinary%2520inhibitory%2520potency%2520toward%2520ABCG2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7952%26epage%3D7976%26doi%3D10.1021%2Facs.jmedchem.8b01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3389-3408&author=M.+K.+Krapfauthor=J.+Gallusauthor=S.+Vahdatiauthor=M.+Wiese&title=New+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+containing+a+2%2C4-disubstituted+pyridopyrimidine+scaffold&doi=10.1021%2Facs.jmedchem.7b01012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Vahdati, Sahel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3389-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) occurring during cancer chemotherapy is a major obstacle for effectiveness and response to therapy and is often caused by ATP-binding cassette (ABC) efflux transporters.  Belonging to the family of ABC transporters, breast cancer resistance protein is getting more and more in the spotlight of research.  As a strategy to overcome MDR, inhibitors of ABC transporters were synthesized, which could be applied in combination with cytostatic drugs.  For this purpose, 2,4-disubstituted pyridopyrimidine derivs. were synthesized.  The investigations confirmed three key characteristics of good inhibitors: a low intrinsic cytotoxicity and a high potency and selectivity toward ABCG2.  For selected compds. the interaction with ABCG2 was elucidated and their effect on ATPase activity and conformation sensitive 5D3 antibody binding was investigated.  Their ability to reverse MDR in coadministration with the active metabolite of irinotecan and mitoxantron was confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1PrWr1uAkvLVg90H21EOLACvtfcHk0lhTnaIaGROyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D&md5=aa27ba46b274bcb0501e596b92973efa</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01012%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DVahdati%26aufirst%3DS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNew%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520containing%2520a%25202%252C4-disubstituted%2520pyridopyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3389%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.7b01012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-anilino-2-pyridylquinazolines and -pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4474-4495&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=4-anilino-2-pyridylquinazolines+and+-pyrimidines+as+highly+potent+and+nontoxic+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.7b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4474-4495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter.  Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP/ABCG2), there is a persistent need for studies of inhibitors of ABCG2.  In this study, the authors investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2.  For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure.  Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).  Interaction of the compds. with ABCG2 was investigated by a colorimetric ATPase assay.  Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compds. binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVIj0DPElPrVg90H21EOLACvtfcHk0lhTnaIaGROyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D&md5=cd9380f0b33fb110c3cde721345f6fe5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00441%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-anilino-2-pyridylquinazolines%2520and%2520-pyrimidines%2520as%2520highly%2520potent%2520and%2520nontoxic%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4474%26epage%3D4495%26doi%3D10.1021%2Facs.jmedchem.7b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure of the human multidrug transporter ABCG2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/nature22345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fnature22345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28554189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=504-509&author=N.+M.+I.+Taylorauthor=I.+Manolaridisauthor=S.+M.+Jacksonauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Structure+of+the+human+multidrug+transporter+ABCG2&doi=10.1038%2Fnature22345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human multidrug transporter ABCG2</span></div><div class="casAuthors">Taylor, Nicholas M. I.; Manolaridis, Ioannis; Jackson, Scott M.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7659</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ABCG2 is a constitutively expressed ATP-binding cassette (ABC) transporter that protects many tissues against xenobiotic mols.  Its activity affects the pharmacokinetics of commonly used drugs and limits the delivery of therapeutics into tumor cells, thus contributing to multidrug resistance.  Here we present the structure of human ABCG2 detd. by cryo-electron microscopy, providing the first high-resoln. insight into a human multidrug transporter.  We visualize ABCG2 in complex with two antigen-binding fragments of the human-specific, inhibitory antibody 5D3 that recognizes extracellular loops of the transporter.  We observe two cholesterol mols. bound in the multidrug-binding pocket that is located in a central, hydrophobic, inward-facing translocation pathway between the transmembrane domains.  Combined with functional in vitro analyses, our results suggest a multidrug recognition and transport mechanism of ABCG2, rationalize disease-causing single nucleotide polymorphisms (SNP) and the allosteric inhibition by the 5D3 antibody, and provide the structural basis of cholesterol recognition by other G-subfamily ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOlfrPNtVhrVg90H21EOLACvtfcHk0lhigT7-3d_cGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D&md5=a3fd5157f639d2958e5abd996e2a6470</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature22345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22345%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructure%2520of%2520the%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D504%26epage%3D509%26doi%3D10.1038%2Fnature22345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zechner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomaeus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0049-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fs41594-018-0049-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=29610494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=333-340&author=S.+M.+Jacksonauthor=I.+Manolaridisauthor=J.+Kowalauthor=M.+Zechnerauthor=N.+M.+I.+Taylorauthor=M.+Bauseauthor=S.+Bauerauthor=R.+Bartholomaeusauthor=G.+Bernhardtauthor=B.+Koenigauthor=A.+Buschauerauthor=H.+Stahlbergauthor=K.-H.+Altmannauthor=K.+P.+Locher&title=Structural+basis+of+small-molecule+inhibition+of+human+multidrug+transporter+ABCG2&doi=10.1038%2Fs41594-018-0049-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span></div><div class="casAuthors">Jackson, Scott M.; Manolaridis, Ioannis; Kowal, Julia; Zechner, Melanie; Taylor, Nicholas M. I.; Bause, Manuel; Bauer, Stefanie; Bartholomaeus, Ruben; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin; Stahlberg, Henning; Altmann, Karl-Heinz; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is an ATP-binding cassette (ABC) transporter that protects tissues against xenobiotics, affects the pharmacokinetics of drugs and contributes to multidrug resistance.  Although many inhibitors and modulators of ABCG2 have been developed, understanding their structure-activity relationship requires high-resoln. structural insight.  Here, we present cryo-EM structures of human ABCG2 bound to synthetic derivs. of the fumitremorgin C-related inhibitor Ko143 or the multidrug resistance modulator tariquidar.  Both compds. are bound to the central, inward-facing cavity of ABCG2, blocking access for substrates and preventing conformational changes required for ATP hydrolysis.  The high resolns. allowed for de novo building of the entire transporter and also revealed tightly bound phospholipids and cholesterol interacting with the lipid-exposed surface of the transmembrane domains (TMDs).  Extensive chem. modifications of the Ko143 scaffold combined with in vitro functional analyses revealed the details of ABCG2 interactions with this compd. family and provide a basis for the design of novel inhibitors and modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBdcwrlGmAbVg90H21EOLACvtfcHk0lhigT7-3d_cGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M&md5=b892ceb7a3ede9784a09c2cc98042d03</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0049-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0049-1%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DZechner%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBartholomaeus%26aufirst%3DR.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKoenig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520of%2520small-molecule%2520inhibition%2520of%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D333%26epage%3D340%26doi%3D10.1038%2Fs41594-018-0049-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1002/jps.21851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1002%2Fjps.21851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19544374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=598-617&author=A.+I.+Alvarezauthor=R.+Realauthor=M.+P%C3%A9rezauthor=G.+Mendozaauthor=J.+G.+Prietoauthor=G.+Merino&title=Modulation+of+the+activity+of+ABC+transporters+%28P-glycoprotein%2C+MRP2%2C+BCRP%29+by+flavonoids+and+drug+response&doi=10.1002%2Fjps.21851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response</span></div><div class="casAuthors">Alvarez, Ana I.; Real, Rebeca; Perez, Miriam; Mendoza, Gracia; Prieto, Julio G.; Merino, Gracia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">598-617</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The present article aims to review the up-to-date information on the most recent studies of the interaction of flavonoids with ABC transporters, in particular the drug pharmacokinetic consequences of such a relationship.  In addn., the modulation of the expression of the ABC transporters by flavonoids is also illustrated.  Flavonoids are a large group of plant polyphenols present extensively in our daily diets and herbal products.  High intake of isoflavones has been assocd. with a variety of beneficial effects on several common diseases.  These polyphenols interact with ABC drug transporters involved in drug resistance and drug absorption, distribution and excretion.  A no. of studies have demonstrated inhibition of drug transporters by flavonoids.  This flavonoid-ABC-transporter interaction could be beneficial for poorly absorbed drugs but could also result in severe drug intoxication, esp. drugs with a narrow therapeutic window.  On the other hand, flavonoids are themselves substrates of ABC transporters.  These proteins can affect the oral availability and tissue distribution of these compds., modifying their beneficial effects.  The challenge is to find a suitable way to predict harmful drug-flavonoid interactions mediated by these transporters. © 2009 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:598-617, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8IbGZLh3cLVg90H21EOLACvtfcHk0lhigT7-3d_cGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsL3N&md5=7255b59ffbaac44c2bf853f7262e1a9a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fjps.21851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21851%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DA.%2BI.%26aulast%3DReal%26aufirst%3DR.%26aulast%3DP%25C3%25A9rez%26aufirst%3DM.%26aulast%3DMendoza%26aufirst%3DG.%26aulast%3DPrieto%26aufirst%3DJ.%2BG.%26aulast%3DMerino%26aufirst%3DG.%26atitle%3DModulation%2520of%2520the%2520activity%2520of%2520ABC%2520transporters%2520%2528P-glycoprotein%252C%2520MRP2%252C%2520BCRP%2529%2520by%2520flavonoids%2520and%2520drug%2520response%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D598%26epage%3D617%26doi%3D10.1002%2Fjps.21851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure–activity relationship and mechanism of modulation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1999</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1021/jm201121b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201121b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVeksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1999-2014&author=K.-F.+Chanauthor=I.+L.+Wongauthor=J.+W.+Kanauthor=C.+S.+Yanauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Amine+linked+flavonoid+dimers+as+modulators+for+P-glycoprotein-based+multidrug+resistance%3A+structure%E2%80%93activity+relationship+and+mechanism+of+modulation&doi=10.1021%2Fjm201121b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationship and Mechanism of Modulation</span></div><div class="casAuthors">Chan, Kin-Fai; Wong, Iris L. K.; Kan, Jason W. Y.; Yan, Clare S. W.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1999-2014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we report a great improvement in reversal potency of cancer drug resistance when flavonoid dimers possess a functionally substituted aminopolyethylene glycol linker.  The most potent compd., (I), contains a N-benzyl group at the linker.  It has many advantages including (1) high potencies in reversing P-glycoprotein (P-gp) mediated resistance in LCC6MDR cells to various anticancer drugs with EC50 in the nanomolar range, (2) low toxicity and high therapeutic index, and (3) preferential inhibition of P-gp over multidrug resistance protein 1 and breast cancer resistance protein.  I stimulates P-gp-ATPase activity by 2.7-fold and mediates a dose-dependent inhibition of doxorubicin (DOX) transport activity.  Lineweaver-Burk and Dixon plots suggest that I is a competitive inhibitor to DOX in binding to P-gp with a Ki of 0.28-0.34 μM and a Hill coeff. of 1.17.  Moreover, the LCC6MDR cell displays about 2.1-fold lower intracellular accumulation of 18 compared to the wild type, suggesting that 18 is a P-gp substrate as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzkFyzfv4ZzrVg90H21EOLACvtfcHk0lhigT7-3d_cGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVeksbY%253D&md5=dee53ec7b3b8651b85dad6d833df4691</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm201121b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201121b%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DKan%26aufirst%3DJ.%2BW.%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DAmine%2520linked%2520flavonoid%2520dimers%2520as%2520modulators%2520for%2520P-glycoprotein-based%2520multidrug%2520resistance%253A%2520structure%25E2%2580%2593activity%2520relationship%2520and%2520mechanism%2520of%2520modulation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1999%26epage%3D2014%26doi%3D10.1021%2Fjm201121b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly (ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6742</span>– <span class="NLM_lpage">6759</span>, <span class="refDoi"> DOI: 10.1021/jm060593+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060593%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOqsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6742-6759&author=K.-F.+Chanauthor=Y.+Zhaoauthor=B.+A.+Burkettauthor=I.+L.+Wongauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Flavonoid+dimers+as+bivalent+modulators+for+P-glycoprotein-based+multidrug+resistance%3A+synthetic+apigenin+homodimers+linked+with+defined-length+poly+%28ethylene+glycol%29+spacers+increase+drug+retention+and+enhance+chemosensitivity+in+resistant+cancer+cells&doi=10.1021%2Fjm060593%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid Dimers as Bivalent Modulators for P-Glycoprotein-Based Multidrug Resistance: Synthetic Apigenin Homodimers Linked with Defined-Length Poly(ethylene glycol) Spacers Increase Drug Retention and Enhance Chemosensitivity in Resistant Cancer Cells</span></div><div class="casAuthors">Chan, Kin-Fai; Zhao, Yunzhe; Burkett, Brendan A.; Wong, Iris L. K.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6742-6759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Much effort has been spent on searching for better P-glycoprotein- (P-gp-) based multidrug resistance (MDR) modulators.  Our approach was to target the binding sites of P-gp using dimers of dietary flavonoids.  A series of apigenin-based flavonoid dimers, linked by poly(ethylene glycol) chains of various lengths, have been synthesized.  These flavonoid dimers modulate drug chemosensitivity and retention in breast and leukemic MDR cells with the optimal no. of ethylene glycol units equal to 2-4.  Compd. 9d bearing four ethylene glycol units increased drug accumulation in drug-resistant cells and enhanced cytotoxicity of paclitaxel, doxorubicin, daunomycin, vincristine, and vinblastine in drug-resistant breast cancer and leukemia cells in vitro, resulting in redn. of IC50 by 5-50 times.  This compd. also stimulated P-gp's ATPase activity by 3.3-fold.  Its modulating activity was presumably by binding to the substrate binding sites of P-gp and disrupting drug efflux.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAs5cv1zQgVLVg90H21EOLACvtfcHk0lhIMPkaXG7Imw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOqsLfM&md5=236d3561a062922ed3656b61abafd0bb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm060593%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060593%252B%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBurkett%26aufirst%3DB.%2BA.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DFlavonoid%2520dimers%2520as%2520bivalent%2520modulators%2520for%2520P-glycoprotein-based%2520multidrug%2520resistance%253A%2520synthetic%2520apigenin%2520homodimers%2520linked%2520with%2520defined-length%2520poly%2520%2528ethylene%2520glycol%2529%2520spacers%2520increase%2520drug%2520retention%2520and%2520enhance%2520chemosensitivity%2520in%2520resistant%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6742%26epage%3D6759%26doi%3D10.1021%2Fjm060593%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1002%2Fcmdc.200800413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19288491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlCgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=594-614&author=K.+F.+Chanauthor=Y.+Zhaoauthor=T.+W.+Chowauthor=C.+S.+Yanauthor=D.+L.+Maauthor=B.+A.+Burkettauthor=I.+L.+Wongauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Flavonoid+dimers+as+bivalent+modulators+for+p-glycoprotein-based+multidrug+resistance%3A+structure-activity+relationships&doi=10.1002%2Fcmdc.200800413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid Dimers as Bivalent Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationships</span></div><div class="casAuthors">Chan, Kin-Fai; Zhao, Yunzhe; Chow, Toby W. S.; Yan, Clare S. W.; Ma, Dik Lung; Burkett, Brendan A.; Wong, Iris L. K.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">594-614</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sym. and unsym. tetra(ethylene glycol)-linked dimers of flavonoids such as I are prepd. as potential multidrug resistance-reversing agents; their abilities to potential the cytotoxicity of paclitaxel in a multidrug resistant human breast cancer cell line and their lipophilicities are detd., while the abilities of selected compds. to potentiate the toxicities of doxorubicin, vincristine, and vinblastine in a human breast cancer cell line are detd.  Tetra(ethylene glycol)-linked flavanoid dimers with nonpolar, hydrophobic, and less bulky substituents generally show more potent reversing activities than those with other substituents.  Flavonoid dimers with nonpolar and hydrophobic substituents such as Me and Et groups are more potent resistance-reversing agents than dimers with polar and hydrophilic substituents such as hydroxy groups at the C3, C6, and C7 positions of the flavone moieties, but not at C5.  I, contg. Me groups at C6 of the flavone moieties, is optimal, with dimers contg. bulkier substituents at C6 leading to lower multidrug reversing activity.  Comparison of unsym. flavanoid dimers with the corresponding sym. dimers revealed that the two binding sites on P-gp for flavonoid moieties are similar to each other.  The compds. are not cytotoxic towards normal or multidrug resistant cancer cells at 1, 2, or 5 μM concns. (no data).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEk32GHrRA67Vg90H21EOLACvtfcHk0liSfYBzgvecXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlCgtr8%253D&md5=eea708b2cbb50b5f7c703760d1e7a1fc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800413%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChow%26aufirst%3DT.%2BW.%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DBurkett%26aufirst%3DB.%2BA.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DFlavonoid%2520dimers%2520as%2520bivalent%2520modulators%2520for%2520p-glycoprotein-based%2520multidrug%2520resistance%253A%2520structure-activity%2520relationships%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D594%26epage%3D614%26doi%3D10.1002%2Fcmdc.200800413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Novel classes of dimer antitumour drug candidates</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.2174/138161209787315576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2174%2F138161209787315576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19199989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=659-674&author=L.+Chowauthor=T.+H.+Chan&title=Novel+classes+of+dimer+antitumour+drug+candidates&doi=10.2174%2F138161209787315576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel classes of dimer antitumour drug candidates</span></div><div class="casAuthors">Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">659-674</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polyvalency in the biol. world is defined as the simultaneous binding of multiple ligands to one receptor.  Polyvalency can increase the affinity of the polyvalent ligand by 100-1000 fold over the monovalent ligand.  Such phenomenon has been employed to design polyvalent toxin inhibitors.  Bivalency is a similar approach where two ligands are joined together with a linker to form a homo- or hetero-dimer with an increase in affinity by up to several hundred fold over the monovalent ligand.  This review will summarize the recent advancement in designing bivalent inhibitors to be used as antitumor agents.  Some dimers (e.g. artemisinin homo-dimer) simply increase the affinity of the monovalent ligands without detailed knowledge of the target.  Other dimers are designed with well-characterized targets, for example, jesterone dimer (inhibiting Rel/NF-κB) and 3,3'-diindolymethane and their derivs. (inhibiting Akt and NFκB).  Some dimers are designed based on the high definition structure between ligand and target (e.g. benzodiazepine and daunorubicin interacting with DNA).  Heterodimers have also been produced by combining either two different antitumor drugs (e.g. cis-platin/acridine or cis-platin/naphthalimide) or combining one antitumor candidate (artemisinin) with a mol. which can increase the efficacy of the former (transferrin receptor).  Finally we will discuss the design of bivalent inhibitors of the P-glycoprotein (ABCB1; MDR or P-gp) to overcome the problem of antitumor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXhqOSnGxmLVg90H21EOLACvtfcHk0liSfYBzgvecXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns7k%253D&md5=00d01b4aafa8cef596a8bce572c757f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F138161209787315576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315576%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DNovel%2520classes%2520of%2520dimer%2520antitumour%2520drug%2520candidates%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D659%26epage%3D674%26doi%3D10.2174%2F138161209787315576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span> <span> </span><span class="NLM_article-title">Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5311</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/jm900194w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900194w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWntb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5311-5322&author=I.+L.+Wongauthor=K.-F.+Chanauthor=K.+H.+Tsangauthor=C.+Y.+Lamauthor=Y.+Zhaoauthor=T.+H.+Chanauthor=L.+M.+C.+Chow&title=Modulation+of+multidrug+resistance+protein+1+%28MRP1%2FABCC1%29-mediated+multidrug+resistance+by+bivalent+apigenin+homodimers+and+their+derivatives&doi=10.1021%2Fjm900194w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Multidrug Resistance by Bivalent Apigenin Homodimers and Their Derivatives</span></div><div class="casAuthors">Wong, Iris L. K.; Chan, Kin-Fai; Tsang, Ka Hing; Lam, Chi Yin; Zhao, Yunzhe; Chan, Tak Hang; Chow, Larry Ming Cheung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5311-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here it is showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.  Flavonoid dimers bearing five or six ethylene glycol (EG) units with 6-Me or 7-Me substitution on the ring A of flavonoid dimers have the highest modulating activity for DOX against MRP1 with an EC50 ranging from 73 to 133 nM.  At 0.5 μM, the flavonoid dimer I was sufficient to restore DOX accumulation in 2008/MRP1 to parental 2008/P level.  Lineweaver-Burk and Dixon plot suggested that it is likely a competitive inhibitor of DOX transport with a Ki = 0.2 μM.  The data suggest that flavonoid dimers have a high affinity toward binding to DOX recognition site of MRP1.  This results in inhibiting DOX transport, increasing intracellular DOX retention, and finally resensitizing 2008/MRP1 to DOX.  The present study demonstrates that flavonoid dimers can be employed as an effective modulator of MRP1-mediated drug resistance in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2E1QnkQ3jrVg90H21EOLACvtfcHk0liSfYBzgvecXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWntb3E&md5=5acb996cd44f205b7344d2b91e34e9f2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm900194w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900194w%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DTsang%26aufirst%3DK.%2BH.%26aulast%3DLam%26aufirst%3DC.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DT.%2BH.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26atitle%3DModulation%2520of%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252FABCC1%2529-mediated%2520multidrug%2520resistance%2520by%2520bivalent%2520apigenin%2520homodimers%2520and%2520their%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5311%26epage%3D5322%26doi%3D10.1021%2Fjm900194w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span> <span> </span><span class="NLM_article-title">A New class of safe, potent, and specific P-gp modulator: flavonoid dimer FD18 reverses P-gp-mediated multidrug resistance in human breast xenograft in vivo</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3507</span>– <span class="NLM_lpage">3517</span>, <span class="refDoi"> DOI: 10.1021/mp500770e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500770e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3507-3517&author=C.+S.+Yanauthor=I.+L.+Wongauthor=K.+F.+Chanauthor=J.+W.+Kanauthor=T.+C.+Chongauthor=M.+C.+Lawauthor=Y.+Zhaoauthor=S.+W.+Chanauthor=T.+H.+Chanauthor=L.+M.+Chow&title=A+New+class+of+safe%2C+potent%2C+and+specific+P-gp+modulator%3A+flavonoid+dimer+FD18+reverses+P-gp-mediated+multidrug+resistance+in+human+breast+xenograft+in+vivo&doi=10.1021%2Fmp500770e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo</span></div><div class="casAuthors">Yan, Clare S. W.; Wong, Iris L. K.; Chan, Kin-Fai; Kan, Jason W. Y.; Chong, Tsz Cheung; Law, Man Chun; Zhao, Yunzhe; Chan, Shun Wan; Chan, Tak Hang; Chow, Larry M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3507-3517</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Flavonoid dimer FD18 is a new class of dimeric P-gp modulator that can reverse cancer drug resistance.  FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.  FD18 can modulate multidrug resistance toward paclitaxel, vinblastine, vincristine, doxorubicin, daunorubicin, and mitoxantrone in human breast cancer LCC6MDR in vitro.  FD18 (1 μM) can revert chemosensitivity of LCC6MDR back to parental LCC6 level.  FD18 was 11- to 46-fold more potent than verapamil.  FD18 (1 μM) can increase accumulation of doxorubicin by 2.7-fold, daunorubicin (2.1-fold), and rhodamine 123 (5.2-fold) in LCC6MDR.  FD18 inhibited P-gp-mediated doxorubicin efflux and has no effect on influx.  FD18 at 1 μM did not affect the protein expression level of P-gp.  Pharmacokinetics studies indicated that i.p. administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.  Acute toxicity studies with FD18 (90 mg/kg, i.p. for 12 times in 22 days) with paclitaxel (12 mg/kg, i.v. for 12 times in 22 days) revealed no obvious toxicity or death in mice.  In vivo efficacy studies indicated that FD18 (45 mg/kg, i.p. for 12 times in 22 days) together with paclitaxel (12 mg/kg, i.v. for 12 times in 22 days) resulted in a 46% redn. in LCC6MDR xenograft vol. (n = 11; 648 ± 84 mm3) compared to paclitaxel control (n = 8; 1201 ± 118 mm3).  There were no animal deaths or significant drop in body wt. and vital organ wet wt.  FD18 can increase paclitaxel accumulation in LCC6MDR xenograft by 1.8- to 2.2-fold.  The present study suggests that FD18 represents a new class of safe and potent P-gp modulator in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGV4jlyRZZHbVg90H21EOLACvtfcHk0lhAXtS2ZQ6P3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsL7L&md5=ae0ce196912ba2739030b31213c7d7fe</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fmp500770e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500770e%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DKan%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DT.%2BC.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DChan%26aufirst%3DT.%2BH.%26aulast%3DChow%26aufirst%3DL.%2BM.%26atitle%3DA%2520New%2520class%2520of%2520safe%252C%2520potent%252C%2520and%2520specific%2520P-gp%2520modulator%253A%2520flavonoid%2520dimer%2520FD18%2520reverses%2520P-gp-mediated%2520multidrug%2520resistance%2520in%2520human%2520breast%2520xenograft%2520in%2520vivo%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3507%26epage%3D3517%26doi%3D10.1021%2Fmp500770e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel flavonoid dimers to reverse multidrug resistance protein 1 (MRP1, ABCC1) mediated drug resistance in cancers using a high throughput platform with ″click chemistry″</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9931</span>– <span class="NLM_lpage">9951</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9931-9951&author=I.+L.+K.+Wongauthor=X.+Zhuauthor=K.+F.+Chanauthor=M.+C.+Lawauthor=A.+M.+Y.+Loauthor=X.+Huauthor=L.+M.+C.+Chowauthor=T.+H.+Chan&title=Discovery+of+novel+flavonoid+dimers+to+reverse+multidrug+resistance+protein+1+%28MRP1%2C+ABCC1%29+mediated+drug+resistance+in+cancers+using+a+high+throughput+platform+with+%E2%80%B3click+chemistry%E2%80%B3&doi=10.1021%2Facs.jmedchem.8b00834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry"</span></div><div class="casAuthors">Wong, Iris L. K.; Zhu, Xuezhen; Chan, Kin-Fai; Law, Man Chun; Lo, Aya M. Y.; Hu, Xuesen; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9931-9951</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A 300-member flavonoid dimer library of multi-drug resistance-assocd. protein 1 (MRP1, ABCC1) modulators was rapidly assembled using "click chem.".  Subsequent high-throughput screening has led to the discovery of highly potent (EC50 ranging from 53 to 298 nM) and safe (selective indexes ranging from >190 to >1887) MRP1 modulators.  Some dimers have potency about 6.5- to 36-fold and 64- to 358-fold higher than the well-known MRP1 inhibitors, verapamil, and MK571, resp.  They inhibited DOX efflux and restored intracellular DOX concn.  The most potent modulator, Ac3Az11, was predicted to bind to the bipartite substrate-binding site of MRP1 in a competitive manner.  Moreover, it provided sufficient concn. to maintain its plasma level above its in vitro EC50 (53 nM for DOX) for about 90 min.  Overall, we demonstrate that "click chem." coupled with high throughput screening is a rapid, reliable, and efficient tool in the discovery of compds. having potent MRP1-modualting activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr86Kpm9ozErVg90H21EOLACvtfcHk0lhAXtS2ZQ6P3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLzK&md5=59dd8a81cc442fa301a3f8a6c78a8dc8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00834%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DI.%2BL.%2BK.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DA.%2BM.%2BY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DDiscovery%2520of%2520novel%2520flavonoid%2520dimers%2520to%2520reverse%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%2520mediated%2520drug%2520resistance%2520in%2520cancers%2520using%2520a%2520high%2520throughput%2520platform%2520with%2520%25E2%2580%25B3click%2520chemistry%25E2%2580%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9931%26epage%3D9951%26doi%3D10.1021%2Facs.jmedchem.8b00834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">The growing impact of click chemistry on drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02933-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2FS1359-6446%2803%2902933-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=14678739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=1128-1137&author=H.+C.+Kolbauthor=K.+B.+Sharpless&title=The+growing+impact+of+click+chemistry+on+drug+discovery&doi=10.1016%2FS1359-6446%2803%2902933-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The growing impact of click chemistry on drug discovery</span></div><div class="casAuthors">Kolb, Hartmuth C.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1128-1137</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Click chem. is a modular approach that uses only the most practical and reliable chem. transformations.  Its applications are increasingly found in all aspects of drug discovery, ranging from lead finding through combinatorial chem. and target-templated in situ chem., to proteomics and DNA research, using bioconjugation reactions.  The copper-(I)-catalyzed 1,2,3-triazole formation from azides and terminal acetylenes is a particularly powerful linking reaction, due to its high degree of dependability, complete specificity, and the bio-compatibility of the reactants.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen bonding and dipole interactions.  Click chem., a modular approach based on highly reliable chem. transformations, is being applied in all aspects of drug discovery, ranging from lead finding to proteomics and DNA research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqEB1hjIBNhbVg90H21EOLACvtfcHk0lhAXtS2ZQ6P3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D&md5=f0042f3a8f153d1c1192533d90699d19</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902933-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902933-7%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DThe%2520growing%2520impact%2520of%2520click%2520chemistry%2520on%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D1128%26epage%3D1137%26doi%3D10.1016%2FS1359-6446%2803%2902933-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantet, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreyre, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesson, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannetaud, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoux, B.</span></span> <span> </span><span class="NLM_article-title">gem-Difluorination of aminoalkynes via highly reactive dicationic species in superacid HF–SbF5: application to the efficient synthesis of difluorinated cinchona alkaloid derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1021/jo702441p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702441p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Giurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=2875-2878&author=A.-C.+Cantetauthor=H.+Carreyreauthor=J.-P.+Gessonauthor=M.-P.+Jouannetaudauthor=B.+Renoux&title=gem-Difluorination+of+aminoalkynes+via+highly+reactive+dicationic+species+in+superacid+HF%E2%80%93SbF5%3A+application+to+the+efficient+synthesis+of+difluorinated+cinchona+alkaloid+derivatives&doi=10.1021%2Fjo702441p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">gem-Difluorination of Aminoalkynes via Highly Reactive Dicationic Species in Superacid HF-SbF5: Application to the Efficient Synthesis of Difluorinated Cinchona Alkaloid Derivatives</span></div><div class="casAuthors">Cantet, Anne-Celine; Carreyre, Helene; Gesson, Jean-Pierre; Jouannetaud, Marie-Paule; Renoux, Brigitte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2875-2878</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of alkynylated amines, amides, and imides, e.g. PhNHCH2C≡CH, are reacted in the superacid system HF-SbF5 to give regioselectively new β-gem-difluoroamines, e.g. PhNHCH2CF2Me.  The reaction, which is not obsd. in pure HF, is consistent with the formation of a dicationic intermediate (i.e., both vinylic and adjacent protonated N-ammonium cations).  Application to the regioselective and efficient synthesis of difluorinated cinchona alkaloid derivs. is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvnSD03jhxO7Vg90H21EOLACvtfcHk0lhxW8MZB6p5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Giurs%253D&md5=ab7aaa08b45fdd0690bc667b77fcf5e7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjo702441p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702441p%26sid%3Dliteratum%253Aachs%26aulast%3DCantet%26aufirst%3DA.-C.%26aulast%3DCarreyre%26aufirst%3DH.%26aulast%3DGesson%26aufirst%3DJ.-P.%26aulast%3DJouannetaud%26aufirst%3DM.-P.%26aulast%3DRenoux%26aufirst%3DB.%26atitle%3Dgem-Difluorination%2520of%2520aminoalkynes%2520via%2520highly%2520reactive%2520dicationic%2520species%2520in%2520superacid%2520HF%25E2%2580%2593SbF5%253A%2520application%2520to%2520the%2520efficient%2520synthesis%2520of%2520difluorinated%2520cinchona%2520alkaloid%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D2875%26epage%3D2878%26doi%3D10.1021%2Fjo702441p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology of ABCG2 and its role in chemoresistance</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1124/mol.113.088609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1124%2Fmol.113.088609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=24021215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=655-669&author=A.+E.+Stacyauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Molecular+pharmacology+of+ABCG2+and+its+role+in+chemoresistance&doi=10.1124%2Fmol.113.088609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of ABCG2 and its role in chemoresistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-669</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette, subfamily G, isoform 2 protein (ABCG2) is an important member of the ABC transporter superfamily, which has been suggested to be involved in multidrug resistance (MDR) in cancer.  Its diverse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mitoxantrone.  Physiol., ABCG2 is highly expressed in areas such as the blood-brain barrier and gastrointestinal tract, where it is thought to play a role in protection against xenobiotic exposure.  High ABCG2 expression has also been found in a variety of solid tumors and in hematol. malignancies and has been correlated with poorer clin. outcomes.  Furthermore, ABCG2 expression is a characteristic feature of cancer stem cells, which are able to self-renew and differentiate.  These cancer stem cells have been postulated to play an important role in MDR, where their inherent ABCG2 expression may allow them to survive chemotherapy and repopulate the tumor after exposure to chemotherapeutics.  This observation raises the exciting possibility that by inhibiting ABCG2, cancer stem cells and other cancers may be targeted and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the remaining tumor cells.  Inhibitors of ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-type indolyl diketopiperazine, Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], could potentially be used for this purpose.  However, these agents are still awaiting comprehensive clin. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO8F0Ak6Zp7Vg90H21EOLACvtfcHk0lhxW8MZB6p5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP&md5=d619971aca497b3b66e70c3c5bcca0bb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088609%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520pharmacology%2520of%2520ABCG2%2520and%2520its%2520role%2520in%2520chemoresistance%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D655%26epage%3D669%26doi%3D10.1124%2Fmol.113.088609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>563</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0680-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fs41586-018-0680-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=30405239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFejsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=563&publication_year=2018&pages=426-430&author=I.+Manolaridisauthor=S.+M.+Jacksonauthor=N.+M.+I.+Taylorauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Cryo-EM+structures+of+a+human+ABCG2+mutant+trapped+in+ATP-bound+and+substrate-bound+states&doi=10.1038%2Fs41586-018-0680-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states</span></div><div class="casAuthors">Manolaridis, Ioannis; Jackson, Scott M.; Taylor, Nicholas M. I.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">563</span>
        (<span class="NLM_cas:issue">7731</span>),
    <span class="NLM_cas:pages">426-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is a transporter protein of the ATP-binding-cassette (ABC) family that is expressed in the plasma membrane in cells of various tissues and tissue barriers, including the blood-brain, blood-testis, and maternal-fetal barriers.  Powered by ATP, it translocates endogenous substrates, affects the pharmacokinetics of many drugs, and protects against a wide array of xenobiotics, including anti-cancer drugs.  Previous studies revealed the architecture of ABCG2 and the structural basis of its inhibition by small mols. and antibodies.  However, the mechanisms of substrate recognition and ATP-driven transport are unknown.  Here, we present high-resoln. cryo-electron microscopy (cryo-EM) structures of human ABCG2 in a substrate-bound pre-translocation state and an ATP-bound post-translocation state.  For both structures, we used a mutant contg. a Gln residue replacing the catalytic Glu residue (ABCG2EQ), which resulted in reduced ATPase and transport rates and facilitated conformational trapping for structural studies.  In the substrate-bound state, a single mol. of estrone 3-sulfate (E1S) was bound in a central, hydrophobic and cytoplasm-facing cavity about halfway across the membrane.  Only one mol. of E1S could bind in the obsd. binding mode.  In the ATP-bound state, the substrate-binding cavity had collapsed, while an external cavity had opened to the extracellular side of the membrane.  The ATP-induced conformational changes included rigid-body shifts of the transmembrane domains, pivoting of the nucleotide-binding domains (NBDs), and a change in the relative orientation of the NBD subdomains.  Mutagenesis and in vitro characterization of transport and ATPase activities demonstrated the roles of specific residues in substrate recognition, including a Leu residue that formed a 'plug' between the 2 cavities.  These results showed how ABCG2 harnesses the energy of ATP binding to extrude E1S and other substrates, and suggested that the size and binding affinity of compds. are important for distinguishing substrates from inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsiPmRG_U1ILVg90H21EOLACvtfcHk0lhxW8MZB6p5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFejsLfO&md5=a1a1ae9473c667561354e8499327a4c8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0680-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0680-3%26sid%3Dliteratum%253Aachs%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DCryo-EM%2520structures%2520of%2520a%2520human%2520ABCG2%2520mutant%2520trapped%2520in%2520ATP-bound%2520and%2520substrate-bound%2520states%26jtitle%3DNature%26date%3D2018%26volume%3D563%26spage%3D426%26epage%3D430%26doi%3D10.1038%2Fs41586-018-0680-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis of substrate recognition by the multidrug resistance protein MRP1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1085</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.cell.2017.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28238471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlGrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=1075-1085&author=Z.+L.+Johnsonauthor=J.+Chen&title=Structural+basis+of+substrate+recognition+by+the+multidrug+resistance+protein+MRP1&doi=10.1016%2Fj.cell.2017.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1</span></div><div class="casAuthors">Johnson, Zachary Lee; Chen, Jue</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1085.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The multidrug resistance protein MRP1 is an ATP-binding cassette (ABC) transporter that confers resistance to many anticancer drugs and plays a role in the disposition and efficacy of several opiates, antidepressants, statins, and antibiotics.  In addn., MRP1 regulates redox homeostasis, inflammation, and hormone secretion.  Using electron cryomicroscopy, we detd. the mol. structures of bovine MRP1 in two conformations: an apo form at 3.5 Å without any added substrate and a complex form at 3.3 Å with one of its physiol. substrates, leukotriene C4.  These structures show that by forming a single bipartite binding site, MRP1 can recognize a spectrum of substrates with different chem. structures.  We also obsd. large conformational changes induced by leukotriene C4, explaining how substrate binding primes the transporter for ATP hydrolysis.  Structural comparison of MRP1 and P-glycoprotein advances our understanding of the common and unique properties of these two important mols. in multidrug resistance to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo87MmRBg2HsbVg90H21EOLACvtfcHk0lhxW8MZB6p5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlGrurg%253D&md5=1799bd0d0180f8c524ebe97271a08c85</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520of%2520substrate%2520recognition%2520by%2520the%2520multidrug%2520resistance%2520protein%2520MRP1%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D1075%26epage%3D1085%26doi%3D10.1016%2Fj.cell.2017.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">ATP binding enables substrate release from multidrug resistance protein 1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.cell.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=29290467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Ogsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=81-89&author=Z.+L.+Johnsonauthor=J.+Chen&title=ATP+binding+enables+substrate+release+from+multidrug+resistance+protein+1&doi=10.1016%2Fj.cell.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ATP Binding Enables Substrate Release from Multidrug Resistance Protein 1</span></div><div class="casAuthors">Johnson, Zachary Lee; Chen, Jue</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">81-89.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The multidrug resistance protein MRP1 is an ATP-driven pump that confers resistance to chemotherapy.  Previously, we have shown that intracellular substrates are recruited to a bipartite binding site when the transporter rests in an inward-facing conformation.  A key question remains: how are high-affinity substrates transferred across the membrane and released outside the cell.  Using electron cryomicroscopy, we show here that ATP binding opens the transport pathway to the extracellular space and reconfigures the substrate-binding site such that it relinquishes its affinity for substrate.  Thus, substrate is released prior to ATP hydrolysis.  With this result, we now have a complete description of the conformational cycle that enables substrate transfer in a eukaryotic ABC exporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR-gP8vhWQC7Vg90H21EOLACvtfcHk0lhjDDWnplLqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Ogsg%253D%253D&md5=16b3ad685ad58f31c1db6ca3aad4b4ab</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DATP%2520binding%2520enables%2520substrate%2520release%2520from%2520multidrug%2520resistance%2520protein%25201%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.cell.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-cyano-6-phenylpyrimidin derivatives containing an acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated mutidrug resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">6001</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00335</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00335" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5988-6001&author=B.+Wangauthor=L.+Y.+Maauthor=J.+Q.+Wangauthor=Z.+N.+Leiauthor=P.+Guptaauthor=Y.+D.+Zhaoauthor=Z.+H.+Liauthor=Y.+Liuauthor=X.+H.+Zhangauthor=Y.+N.+Liauthor=B.+Zhaoauthor=Z.+S.+Chenauthor=H.+M.+Liu&title=Discovery+of+5-cyano-6-phenylpyrimidin+derivatives+containing+an+acylurea+moiety+as+orally+bioavailable+reversal+agents+against+P-glycoprotein-mediated+mutidrug+resistance&doi=10.1021%2Facs.jmedchem.8b00335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance</span></div><div class="casAuthors">Wang, Bo; Ma, Li-Ying; Wang, Jing-Quan; Lei, Zi-Ning; Gupta, Pranav; Zhao, Yuan-Di; Li, Zhong-Hua; Liu, Ying; Zhang, Xin-Hui; Li, Ya-Nan; Zhao, Bing; Chen, Zhe-Sheng; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5988-6001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylamino)arylpyrimidinecarbonitriles such as I were prepd. as inhibitors of ABCB1 (P-glycoprotein) for the reversal of drug resistance and for potential use in the treatment of cancer.  Of the compds. prepd., I showed the most potent activity in reversing paclitaxel resistance in AD300 (drug-resistant human colon cancer) cells.  I increased the accumulation of paclitaxel in AD300 cells, interrupted ABCB1-mediated rhodamine accumulation and efflux, stimulated ABCB1 ATPase activity, and did not inhibit CYP3A4 (a source of drug interaction-induced toxicity).  Orally administered I significantly enhanced the efficacy of paclitaxel against colon cancer cell xenografts without obvious side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3CJSeoghULVg90H21EOLACvtfcHk0lhjDDWnplLqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrfO&md5=ab39f736e60446f0434ce43434c2b442</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00335%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DL.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%2BD.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DLiu%26aufirst%3DH.%2BM.%26atitle%3DDiscovery%2520of%25205-cyano-6-phenylpyrimidin%2520derivatives%2520containing%2520an%2520acylurea%2520moiety%2520as%2520orally%2520bioavailable%2520reversal%2520agents%2520against%2520P-glycoprotein-mediated%2520mutidrug%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5988%26epage%3D6001%26doi%3D10.1021%2Facs.jmedchem.8b00335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span>; <span class="NLM_string-name">Wong, I. L. K.</span>; <span class="NLM_string-name">Chan, K.-F.</span>; <span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Law, M.
C.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Hu, X.</span>; <span class="NLM_string-name">Chan, T. H.</span>; <span class="NLM_string-name">Chow, L. M. C.</span></span> <span> </span><span class="NLM_article-title">A triazole-bridged flavonoid dimer Ac15(Az8)<sub>2</sub> reverses multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) in human colon xenograft in vivo</span>. (unpublished results).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chong%2C+T.+C.%3B+Wong%2C+I.+L.+K.%3B+Chan%2C+K.-F.%3B+Cui%2C+J.%3B+Law%2C+M.%0AC.%3B+Zhu%2C+X.%3B+Hu%2C+X.%3B+Chan%2C+T.+H.%3B+Chow%2C+L.+M.+C.+A+triazole-bridged+flavonoid+dimer+Ac15%28Az8%292+reverses+multidrug+resistance+mediated+by+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+in+human+colon+xenograft+in+vivo.+%28unpublished+results%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DT.%2BC.%26atitle%3DA%2520triazole-bridged%2520flavonoid%2520dimer%2520Ac15%2528Az8%25292%2520reverses%2520multidrug%2520resistance%2520mediated%2520by%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520in%2520human%2520colon%2520xenograft%2520in%2520vivo" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abellán-Flos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanç, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supuran, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, S. P.</span></span> <span> </span><span class="NLM_article-title">Exploring carbonic anhydrase inhibition with multimeric coumarins displayed on a fullerene scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">7445</span>– <span class="NLM_lpage">7451</span>, <span class="refDoi"> DOI: 10.1039/C5OB01005E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1039%2FC5OB01005E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26058669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsF2ns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=7445-7451&author=M.+Abell%C3%A1n-Flosauthor=M.+Tan%C3%A7author=C.+T.+Supuranauthor=S.+P.+Vincent&title=Exploring+carbonic+anhydrase+inhibition+with+multimeric+coumarins+displayed+on+a+fullerene+scaffold&doi=10.1039%2FC5OB01005E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring carbonic anhydrase inhibition with multimeric coumarins displayed on a fullerene scaffold</span></div><div class="casAuthors">Abellan-Flos, Marta; Tanc, Muhammet; Supuran, Claudiu T.; Vincent, Stephane P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7445-7451</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Carbonic anhydrases (CAs) are ubiquitous Zn metallo-enzymes that catalyze the reversible hydration/dehydration of CO2/HCO3-.  CAs are involved in many key biol. processes, therefore their inhibition has become an attractive research field.  Distinct families of CA inhibitors (CAIs) have been reported, most of them interacting with the Zn(II) at the active site.  Some compds. such as the coumarins are hydrolyzed before binding the entrance of the active site cavity, and thus behave as "suicide" inhibitors.  This study reports the first synthesis of multimeric suicide inhibitors, designed to address the selectivity and the potency of CA multivalent inhibition.  Twelve coumarin units have been grafted to a central fullerene scaffold thanks to a CuAAC reaction and the final dodecamers were assayed against 4 relevant CAs.  The multimers were always stronger inhibitors than the monomeric species but no strong "multivalent effect" was found.  However, our study showed that the multimeric presentation of the coumarin around the C60, indeed affected the selectivity of the relative inhibition among the 4 CAs assayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo6Dq0iC9_0rVg90H21EOLACvtfcHk0lhjDDWnplLqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsF2ns7s%253D&md5=0070b51fbc983cb60b50bf4eda3ffac3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC5OB01005E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01005E%26sid%3Dliteratum%253Aachs%26aulast%3DAbell%25C3%25A1n-Flos%26aufirst%3DM.%26aulast%3DTan%25C3%25A7%26aufirst%3DM.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DVincent%26aufirst%3DS.%2BP.%26atitle%3DExploring%2520carbonic%2520anhydrase%2520inhibition%2520with%2520multimeric%2520coumarins%2520displayed%2520on%2520a%2520fullerene%2520scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D7445%26epage%3D7451%26doi%3D10.1039%2FC5OB01005E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujadhur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintigh, J. T.</span></span> <span> </span><span class="NLM_article-title">Formation of aryl-nitrogen bonds using a soluble copper (I) catalyst</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4791</span>– <span class="NLM_lpage">4793</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)00888-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2FS0040-4039%2801%2900888-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslyjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=4791-4793&author=R.+Gujadhurauthor=D.+Venkataramanauthor=J.+T.+Kintigh&title=Formation+of+aryl-nitrogen+bonds+using+a+soluble+copper+%28I%29+catalyst&doi=10.1016%2FS0040-4039%2801%2900888-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of aryl-nitrogen bonds using a soluble copper(I) catalyst</span></div><div class="casAuthors">Gujadhur, R.; Venkataraman, D.; Kintigh, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4791-4793</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors report a synthetic protocol for the synthesis of functionalized diaryl- and triarylamines under mild conditions, using a sol., air-stable copper(I) complex, Cu(PPh3)3Br, as the catalyst and cesium carbonate as the base.  Using this protocol, the authors were able to synthesize a tri-ortho-ester functionalized triphenylamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJ1A-IU0r_bVg90H21EOLACvtfcHk0lgR6IPGURIHtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslyjtrc%253D&md5=aff77a492ae6c96b786f8416184c5dab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2900888-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252900888-7%26sid%3Dliteratum%253Aachs%26aulast%3DGujadhur%26aufirst%3DR.%26aulast%3DVenkataraman%26aufirst%3DD.%26aulast%3DKintigh%26aufirst%3DJ.%2BT.%26atitle%3DFormation%2520of%2520aryl-nitrogen%2520bonds%2520using%2520a%2520soluble%2520copper%2520%2528I%2529%2520catalyst%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D4791%26epage%3D4793%26doi%3D10.1016%2FS0040-4039%2801%2900888-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Maruti Mali, Vankudoth Jayaram, Gangavaram V. M. Sharma, Subhash Ghosh, Fabienne Berrée, Vincent Dorcet, <span class="NLM_string-name hlFld-ContribAuthor">Bertrand Carboni</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Mediated Synthesis of (E)-1-Azido and (Z)-1,2-Diazido Alkenes from 1-Alkene-1,2-diboronic Esters: An Approach to Mono- and 1,2-Di-(1,2,3-Triazolyl)-Alkenes and Fused Bis-(1,2,3-Triazolo)-Pyrazines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (23)
                                     , 15104-15115. <a href="https://doi.org/10.1021/acs.joc.0c01980" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01980</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01980%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCopper-Mediated%252BSynthesis%252Bof%252B%252528E%252529-1-Azido%252Band%252B%252528Z%252529-1%25252C2-Diazido%252BAlkenes%252Bfrom%252B1-Alkene-1%25252C2-diboronic%252BEsters%25253A%252BAn%252BApproach%252Bto%252BMono-%252Band%252B1%25252C2-Di-%2525281%25252C2%25252C3-Triazolyl%252529-Alkenes%252Band%252BFused%252BBis-%2525281%25252C2%25252C3-Triazolo%252529-Pyrazines%26aulast%3DMali%26aufirst%3DMaruti%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17082020%26date%3D05112020%26volume%3D85%26issue%3D23%26spage%3D15104%26epage%3D15115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Katja Silbermann, Jiyang Li, Vigneshwaran Namasivayam, Fabian Baltes, Gerd Bendas, Sven Marcel Stefan, <span class="NLM_string-name hlFld-ContribAuthor">Michael Wiese</span>. </span><span class="cited-content_cbyCitation_article-title">Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10412-10432. <a href="https://doi.org/10.1021/acs.jmedchem.0c00961" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00961%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSuperior%252BPyrimidine%252BDerivatives%252Bas%252BSelective%252BABCG2%252BInhibitors%252Band%252BBroad-Spectrum%252BABCB1%25252C%252BABCC1%25252C%252Band%252BABCG2%252BAntagonists%26aulast%3DSilbermann%26aufirst%3DKatja%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05062020%26date%3D11092020%26date%3D31072020%26volume%3D63%26issue%3D18%26spage%3D10412%26epage%3D10432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katja  Silbermann</span>, <span class="hlFld-ContribAuthor ">Jiyang  Li</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>, <span class="hlFld-ContribAuthor ">Sven Marcel  Stefan</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>. </span><span class="cited-content_cbyCitation_article-title">Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113045. <a href="https://doi.org/10.1016/j.ejmech.2020.113045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdrug%252Bdesign%252Bof%252B6-substituted%252B4-anilino-2-phenylpyrimidines%252Bfor%252Bexploration%252Bof%252Bnovel%252BABCG2%252Bbinding%252Bsite%26aulast%3DSilbermann%26aufirst%3DKatja%26date%3D2021%26volume%3D212%26spage%3D113045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalie  Guragossian</span>, <span class="hlFld-ContribAuthor ">Billel  Belhani</span>, <span class="hlFld-ContribAuthor ">Alexis  Moreno</span>, <span class="hlFld-ContribAuthor ">Magda Teixeira  Nunes</span>, <span class="hlFld-ContribAuthor ">Lucia  Gonzalez-Lobato</span>, <span class="hlFld-ContribAuthor ">Christelle  Marminon</span>, <span class="hlFld-ContribAuthor ">Laurent  Berthier</span>, <span class="hlFld-ContribAuthor ">Amanda Do  Rocio Andrade Pires</span>, <span class="hlFld-ContribAuthor ">Csilla  Özvegy-Laczka</span>, <span class="hlFld-ContribAuthor ">Balázs  Sarkadi</span>, <span class="hlFld-ContribAuthor ">Raphaël  Terreux</span>, <span class="hlFld-ContribAuthor ">Zouhair  Bouaziz</span>, <span class="hlFld-ContribAuthor ">Malika  Berredjem</span>, <span class="hlFld-ContribAuthor ">Joachim  Jose</span>, <span class="hlFld-ContribAuthor ">Attilio  Di Pietro</span>, <span class="hlFld-ContribAuthor ">Pierre  Falson</span>, <span class="hlFld-ContribAuthor ">Marc  Le Borgne</span>. </span><span class="cited-content_cbyCitation_article-title">Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113017. <a href="https://doi.org/10.1016/j.ejmech.2020.113017" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUncompetitive%252Bnanomolar%252Bdimeric%252Bindenoindole%252Binhibitors%252Bof%252Bthe%252Bhuman%252Bbreast%252Bcancer%252Bresistance%252Bpump%252BABCG2%26aulast%3DGuragossian%26aufirst%3DNathalie%26date%3D2021%26volume%3D211%26spage%3D113017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shrikant G.  Pharande</span>, <span class="hlFld-ContribAuthor ">Manuel A.  Rentería-Gómez</span>, <span class="hlFld-ContribAuthor ">Rocío  Gámez-Montaño</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Polyheterocyclic Dimers Containing Restricted and Constrained Peptidomimetics via IMCR-Based Domino/Double CuAAC Click Strategy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (22)
                                     , 5246. <a href="https://doi.org/10.3390/molecules25225246" title="DOI URL">https://doi.org/10.3390/molecules25225246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25225246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25225246%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Bof%252BPolyheterocyclic%252BDimers%252BContaining%252BRestricted%252Band%252BConstrained%252BPeptidomimetics%252Bvia%252BIMCR-Based%252BDomino%25252FDouble%252BCuAAC%252BClick%252BStrategy%26aulast%3DPharande%26aufirst%3DShrikant%2BG.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D22%26spage%3D5246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bruno  M. F. Gonçalves</span>, <span class="hlFld-ContribAuthor ">David  S. P. Cardoso</span>, <span class="hlFld-ContribAuthor ">Maria-José  U. Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Multidrug Resistance: Flavonoid and Terpenoid Nitrogen-Containing Derivatives as ABC Transporter Modulators. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (15)
                                     , 3364. <a href="https://doi.org/10.3390/molecules25153364" title="DOI URL">https://doi.org/10.3390/molecules25153364</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25153364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25153364%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOvercoming%252BMultidrug%252BResistance%25253A%252BFlavonoid%252Band%252BTerpenoid%252BNitrogen-Containing%252BDerivatives%252Bas%252BABC%252BTransporter%252BModulators%26aulast%3DM.%2BF.%2BGon%25C3%25A7alves%26aufirst%3DBruno%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D15%26spage%3D3364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Hu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Long  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Han</span>, <span class="hlFld-ContribAuthor ">Gengyin  Zhou</span>, <span class="hlFld-ContribAuthor ">Peng  Su</span>. </span><span class="cited-content_cbyCitation_article-title">TRPS1 Confers Multidrug Resistance of Breast Cancer Cells by Regulating BCRP Expression. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.00934" title="DOI URL">https://doi.org/10.3389/fonc.2020.00934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.00934%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DTRPS1%252BConfers%252BMultidrug%252BResistance%252Bof%252BBreast%252BCancer%252BCells%252Bby%252BRegulating%252BBCRP%252BExpression%26aulast%3DHu%26aufirst%3DJing%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron J.  Horsey</span>, <span class="hlFld-ContribAuthor ">Deborah A.  Briggs</span>, <span class="hlFld-ContribAuthor ">Nicholas D.  Holliday</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Briddon</span>, <span class="hlFld-ContribAuthor ">Ian D.  Kerr</span>. </span><span class="cited-content_cbyCitation_article-title">Application of fluorescence correlation spectroscopy to study substrate binding in styrene maleic acid lipid copolymer encapsulated ABCG2. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Biomembranes</span><span> <strong>2020,</strong> <em>1862 </em>
                                    (6)
                                     , 183218. <a href="https://doi.org/10.1016/j.bbamem.2020.183218" title="DOI URL">https://doi.org/10.1016/j.bbamem.2020.183218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbamem.2020.183218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbamem.2020.183218%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Biomembranes%26atitle%3DApplication%252Bof%252Bfluorescence%252Bcorrelation%252Bspectroscopy%252Bto%252Bstudy%252Bsubstrate%252Bbinding%252Bin%252Bstyrene%252Bmaleic%252Bacid%252Blipid%252Bcopolymer%252Bencapsulated%252BABCG2%26aulast%3DHorsey%26aufirst%3DAaron%2BJ.%26date%3D2020%26volume%3D1862%26issue%3D6%26spage%3D183218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinyun  Dong</span>, <span class="hlFld-ContribAuthor ">Zuodong  Qin</span>, <span class="hlFld-ContribAuthor ">Wei-Dong  Zhang</span>, <span class="hlFld-ContribAuthor ">Gang  Cheng</span>, <span class="hlFld-ContribAuthor ">Assaraf G.  Yehuda</span>, <span class="hlFld-ContribAuthor ">Charles R.  Ashby</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiang-Dong  Cheng</span>, <span class="hlFld-ContribAuthor ">Jiang-Jiang  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2020,</strong> <em>49 </em>, 100681. <a href="https://doi.org/10.1016/j.drup.2020.100681" title="DOI URL">https://doi.org/10.1016/j.drup.2020.100681</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2020.100681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2020.100681%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DMedicinal%252Bchemistry%252Bstrategies%252Bto%252Bdiscover%252BP-glycoprotein%252Binhibitors%25253A%252BAn%252Bupdate%26aulast%3DDong%26aufirst%3DJinyun%26date%3D2020%26volume%3D49%26spage%3D100681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of fumitremorgin C, Ko143, tariquidar, and general structures I and II.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Azides <b>Az8</b> and <b>Az9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) (a) H<sub>2</sub>, Pd/C, MeOH, rt; (b) K<sub>2</sub>CO<sub>3</sub>, methyl 3-(bromomethyl)benzoate, acetone, reflux; (ii) (a) methanesulfonyl chloride, NEt<sub>3</sub>, DCM, 0 °C; (b) NaN<sub>3</sub>, ACN.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Azides <b>Az14</b> and <b>Az15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PPh<sub>3</sub>, DIAD, THF; (ii) (a) methanesulfonyl chloride, NEt<sub>3</sub>, DCM, 0 °C; (b) NaN<sub>3</sub>, ACN.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Triazole and <i>Bis</i>-triazole Bridged Flavonoid Dimers<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) cat. Cu(PPh<sub>3</sub>)<sub>3</sub>Br, THF, reflux, 12 h.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of Alkynes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of Azides.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Diacetylenes <b>Ac28 and Ac30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) propargyl bromide, acetone, rt.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Analogues of <b>Ac15(Az8)</b><sub><b>2</b></sub> and <b>Ac15(Az9)</b><sub><b>2</b></sub>.<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) cat. Cu(PPh<sub>3</sub>)<sub>3</sub>Br, THF, reflux, 12 h.</p></p></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on intracellular topotecan accumulation in HEK293/pcDNA3.1 and HEK293/R2 cells. The cells were incubated with 50 μM topotecan for 120 min at 37 °C with or without 1 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub>, and Ko143. 0.1% of DMSO was used as negative control. After incubation, cells were washed and intracellular accumulation of topotecan was measured by flow cytometry at the FL1 channel. (A) Flow cytometric histogram of HEK293/pcDNA3.1 and HEK293/R2 cells after incubating with topotecan in the absence or presence of modulators. (B) Fluorescence level of intracellular topotecan of cells after different treatments. Experiments were performed in duplicate and repeated thrice. The fluorescence units are presented as mean ± standard deviation. Student paired <i>t</i> test was conducted relative to HEK293/R2 cells incubated with 0.1% DMSO. **<i>P</i> < 0.01 and *** <i>P</i> < 0.005.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on surface BCRP protein expression. The HEK293/R2 cells were incubated with 1 or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days, respectively. The surface BCRP protein level was measured by flow cytometer at the FL1 channel. (A) Flow cytometric histogram of BCRP protein expression in HEK293/pcDNA3.1 and HEK293/R2 cells after incubating with 0.3% of DMSO. (B) Surface BCRP protein level of HEK293/R2 cells detected after incubating with 1 or 3 μM of <b>Ac22(Az8)</b><sub><b>2</b></sub> for 4 days. <i>N</i> = 2 independent experiments. The fluorescence units were presented as mean ± standard deviation. 0.3% of DMSO was used as a solvent control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on topotecan efflux in HEK293/pcDNA3.1 and HEK293/R2 cells. Topotecan preloaded cells were incubated with or without compound <b>Ac22(Az8)<sub>2</sub></b> (5 μM) at 37 °C. At 0, 5, 10, and 15 min, cells were harvested and intracellular topotecan concentration was measured by flow cytometer at the FL-1 channel. The values were presented as mean ± standard deviation. Student paired <i>t</i> test was conducted at each time point in HEK293/R2 cells after incubating with or without <b>Ac22(Az8)</b><sub><b>2</b></sub>. *<i>P</i> < 0.05 and ** <i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of <b>Ac22(Az8)</b><sub><b>2</b></sub> on vanadate-sensitive BCRP-ATPase activity. Membrane fraction of S1M180 was collected after sonication and ultracentrifugation. Ouabain (Na+/K+-ATPase inhibitor) and sodium azide were added to the microsome fraction to inhibit non-ABC transporter ATPase activities. Ko143 and <b>Ac22(Az8)</b><sub><b>2</b></sub> were preincubated at 37 °C for 30 min, followed by 1-h incubation of 2.5 mM ATP. After stopping the reaction, the phosphate level was determined using a colorimetry method. These data were shown as mean ± standard error of mean. <i>N</i> = 3–4 independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/medium/jm9b00963_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In silico</i> docking study using the cryo-EM structure of BCRP (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI">6ETI</a>). (A) Ribbon diagram of the overall human BCRP homodimer with labeled TMD, NBD, and “leucine plug”. The red square indicates the location of the binding pocket of estrone-3-sulfate, MZ29, MB136, mitoxantrone, topotecan, and <b>Ac22(Az8)</b><sub><b>2</b></sub>. Top-ranked binding poses of (B) inhibitor <b>Ac22(Az8)</b><sub><b>2</b></sub> (blue sticks), (C) substrate mitoxantrone (deep green sticks), and (D) substrate topotecan (brown sticks). Transmembrane helices 1b, 1b′, 2, 2′, 5a, and 5a′ are labeled in red. Important amino acid residues (gray sticks) are highlighted in black, and hydrogen bonding interactions are indicated as dotted blue lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-18/acs.jmedchem.9b00963/20190920/images/large/jm9b00963_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00963&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i169">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 62 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortet-Tieulent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eYSuD5ply1Xy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elferink, R. O.</span></span> <span> </span><span class="NLM_article-title">Mammalian ABC transporters in health and disease</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.71.102301.093055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1146%2Fannurev.biochem.71.102301.093055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=12045106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1Clt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=537-592&author=P.+Borstauthor=R.+O.+Elferink&title=Mammalian+ABC+transporters+in+health+and+disease&doi=10.1146%2Fannurev.biochem.71.102301.093055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian ABC transporters in health and disease</span></div><div class="casAuthors">Borst, P.; Elferink, R. Oude</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">537-592</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette (ABC) transporters are a family of large proteins in membranes and are able to transport a variety of compds. through membranes against steep concn. gradients at the cost of ATP hydrolysis.  The available outline of the human genome contains 48 ABC genes; 16 of these have a known function and 14 are assocd. with a defined human disease.  Major physiol. functions of ABC transporters include the transport of lipids, bile salts, toxic compds., and peptides for antigen presentation or other purposes.  We review the functions of mammalian ABC transporters, emphasizing biochem. mechanisms and genetic defects.  Our overview illustrates the importance of ABC transporters in human physiol., toxicol., pharmacol., and disease.  We focus on three topics: (a) ABC transporters transporting drugs (xenotoxins) and drug conjugates.  (b) Mammalian secretory epithelia using ABC transporters to excrete a large no. of substances, sometimes against a steep concn. gradient.  Several inborn errors in liver metab. are due to mutations in one of the genes for these pumps; these are discussed.  (c) A rapidly increasing no. of ABC transporters are found to play a role in lipid transport.  Defects in each of these transporters are involved in human inborn or acquired diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBZi7RJl5EgbVg90H21EOLACvtfcHk0li1HqvxpgfGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1Clt74%253D&md5=f29b99f0717f3f343dc4b23548132d47</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.71.102301.093055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.71.102301.093055%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DElferink%26aufirst%3DR.%2BO.%26atitle%3DMammalian%2520ABC%2520transporters%2520in%2520health%2520and%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2002%26volume%3D71%26spage%3D537%26epage%3D592%26doi%3D10.1146%2Fannurev.biochem.71.102301.093055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kool, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijnholds, J.</span></span> <span> </span><span class="NLM_article-title">A family of drug transporters: the multidrug resistance-associated proteins</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1093/jnci/92.16.1295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1093%2Fjnci%2F92.16.1295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10944550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtlektr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=1295-1302&author=P.+Borstauthor=R.+Eversauthor=M.+Koolauthor=J.+Wijnholds&title=A+family+of+drug+transporters%3A+the+multidrug+resistance-associated+proteins&doi=10.1093%2Fjnci%2F92.16.1295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A family of drug transporters: The multidrug resistance-associated proteins</span></div><div class="casAuthors">Borst, Piet; Evers, Raymond; Kool, Marcel; Wijnholds, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1295-1302</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 93 refs.  The human multidrug resistance-assocd. protein (MRP) family currently has seven members.  The ability of several of these membrane proteins to transport a wide range of anti-cancer drugs out of cells and their presence in many tumors make them prime suspects in unexplained cases of drug resistance, although proof that they contribute to clin. drug resistance is still lacking.  Recent studies have begun to clarify the function of the MRP family members.  MRPs are org. anion transporters; i.e., they transport anionic drugs, exemplified by methotrexate, and neutral drugs conjugated to acidic ligands, such as glutathione (GSH), glucuronate, or sulfate.  However, MRP1, MRP2, and MRP3 can also cause resistance to neutral org. drugs that are not known to be conjugated to acidic ligands by transporting these drugs together with free GSH.  MRP1 can even confer resistance to arsenite and MRP2 to cisplatin, again probably by transporting these compds. in complexes with GSH.  MRP4 overexpression is assocd. with high-level resistance to the nucleoside analogs 9-(2-phosphonylmethoxyethyl) adenine and azidothymidine, both of which are used as anti-human immunodeficiency virus drugs.  MRPs may, therefore, also have a role in resistance against nucleoside analogs used in cancer chemotherapy.  Mice without Mrp1, a high-affinity leukotriene C4 transporter, have an altered response to inflammatory stimuli but are otherwise healthy and fertile.  MRP2 is the major transporter responsible for the secretion of bilirubin glucuronides into bile, and humans without MRP2 develop a mild liver disease known as the Dubin-Johnson syndrome.  The physiol. functions of the other MRPs are not known.  Whether long-term inhibition of MRPs in humans can be tolerated (assuming that suitable inhibitors will be found) remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEoI-EICNsS7Vg90H21EOLACvtfcHk0li1HqvxpgfGDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtlektr8%253D&md5=d7b5b6c8f74b1805e61ebfdbf223ad05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.16.1295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.16.1295%26sid%3Dliteratum%253Aachs%26aulast%3DBorst%26aufirst%3DP.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DKool%26aufirst%3DM.%26aulast%3DWijnholds%26aufirst%3DJ.%26atitle%3DA%2520family%2520of%2520drug%2520transporters%253A%2520the%2520multidrug%2520resistance-associated%2520proteins%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2000%26volume%3D92%26spage%3D1295%26epage%3D1302%26doi%3D10.1093%2Fjnci%2F92.16.1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domenichini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falasca, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters as cancer drivers: potential functions in cancer development</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">52</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2018.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbagen.2018.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=30268729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2019&pages=52-60&author=A.+Domenichiniauthor=A.+Adamskaauthor=M.+Falasca&title=ABC+transporters+as+cancer+drivers%3A+potential+functions+in+cancer+development&doi=10.1016%2Fj.bbagen.2018.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters as cancer drivers: Potential functions in cancer development</span></div><div class="casAuthors">Domenichini, Alice; Adamska, Aleksandra; Falasca, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">52-60</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  ABC transporters have attracted considerable attention for their function as drug transporters in a broad range of tumors and are therefore considered as major players in cancer chemoresistance.  However, less attention has been focused on their potential role as active players in cancer development and progression.  This review presents the evidence suggesting that ABC transporters might have a more active role in cancer other than the well known involvement in multidrug resistance and discusses the potential strategies to target each ABC transporter for a specific tumor setting.  Emerging evidence suggests that ABC transporters are able to transport bioactive mols. capable of playing key roles in tumor development.  Characterization of the effects of these transporters in specific cancer settings opens the possibility for the development of personalized treatments.  A more targeted approach of ABC transporters should be implemented that considers which specific transporter is playing a major role in a particular tumor setting in order to achieve a more successful outcome for ABC transporters inhibitors in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg9SQX3ldK77Vg90H21EOLACvtfcHk0liLxG210bJv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbfP&md5=f3cd17f9810f869702475322380a514b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2018.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DDomenichini%26aufirst%3DA.%26aulast%3DAdamska%26aufirst%3DA.%26aulast%3DFalasca%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520as%2520cancer%2520drivers%253A%2520potential%2520functions%2520in%2520cancer%2520development%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2019%26volume%3D1863%26spage%3D52%26epage%3D60%26doi%3D10.1016%2Fj.bbagen.2018.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span> <span> </span><span class="NLM_article-title">ABC transporters as mediators of drug resistance and contributors to cancer cell biology</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.drup.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=27180306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC28bpsFKqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1-9&author=J.+I.+Fletcherauthor=R.+T.+Williamsauthor=M.+J.+Hendersonauthor=M.+D.+Norrisauthor=M.+Haber&title=ABC+transporters+as+mediators+of+drug+resistance+and+contributors+to+cancer+cell+biology&doi=10.1016%2Fj.drup.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters as mediators of drug resistance and contributors to cancer cell biology</span></div><div class="casAuthors">Fletcher Jamie I; Williams Rebekka T; Henderson Michelle J; Norris Murray D; Haber Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The extrusion of anticancer drugs by members of the ATP-binding cassette (ABC) transporter family is one of the most widely recognized mechanisms of multidrug resistance, and can be considered a hijacking of their normal roles in the transport of xenobiotics, metabolites and signaling molecules across cell membranes.  While roles in cancer multidrug resistance have been clearly demonstrated for P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP) and Multidrug Resistance Protein 1 (MRP1), direct evidence for a role in multidrug resistance in vivo is lacking for other family members.  A less well understood but emerging theme is the drug efflux-independent contributions of ABC transporters to cancer biology, supported by a growing body of evidence that their loss or inhibition impacts on the malignant potential of cancer cells in vitro and in vivo.  As with multidrug resistance, these contributions likely represent a hijacking of normal ABC transporter functions in the efflux of endogenous metabolites and signaling molecules, however they may expand the clinical relevance of ABC transporters beyond P-gp, BCRP and MRP1.  This review summarizes established and emerging roles for ABC transporters in cancer, with a focus on neuroblastoma and ovarian cancer, and considers approaches to validate and better understand these roles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS10lMkvlLDKIqdXsLcGTEUfW6udTcc2eZy882fTwOOqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bpsFKqtg%253D%253D&md5=41325cd19f32cf04ef269f4bc6c114fc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DWilliams%26aufirst%3DR.%2BT.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26aulast%3DHaber%26aufirst%3DM.%26atitle%3DABC%2520transporters%2520as%2520mediators%2520of%2520drug%2520resistance%2520and%2520contributors%2520to%2520cancer%2520cell%2520biology%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2016%26volume%3D26%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.drup.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.drup.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=27449595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2s3js1ShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=14-29&author=W.+Liauthor=H.+Zhangauthor=Y.+G.+Assarafauthor=K.+Zhaoauthor=X.+Xuauthor=J.+Xieauthor=D.+H.+Yangauthor=Z.+S.+Chen&title=Overcoming+ABC+transporter-mediated+multidrug+resistance%3A+molecular+mechanisms+and+novel+therapeutic+drug+strategies&doi=10.1016%2Fj.drup.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies</span></div><div class="casAuthors">Li Wen; Zhang Han; Assaraf Yehuda G; Zhao Kun; Xu Xiaojun; Xie Jinbing; Yang Dong-Hua; Chen Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance is a key determinant of cancer chemotherapy failure.  One of the major causes of multidrug resistance is the enhanced efflux of drugs by membrane ABC transporters.  Targeting ABC transporters projects a promising approach to eliminating or suppressing drug resistance in cancer treatment.  To reveal the functional mechanisms of ABC transporters in drug resistance, extensive studies have been conducted from identifying drug binding sites to elucidating structural dynamics.  In this review article, we examined the recent crystal structures of ABC proteins to depict the functionally important structural elements, such as domains, conserved motifs, and critical amino acids that are involved in ATP-binding and drug efflux.  We inspected the drug-binding sites on ABC proteins and the molecular mechanisms of various substrate interactions with the drug binding pocket.  While our continuous battle against drug resistance is far from over, new approaches and technologies have emerged to push forward our frontier.  Most recent developments in anti-MDR strategies include P-gp inhibitors, RNA-interference, nano-medicines, and delivering combination strategies.  With the advent of the 'Omics' era - genomics, epigenomics, transcriptomics, proteomics, and metabolomics - these disciplines play an important role in fighting the battle against chemoresistance by further unraveling the molecular mechanisms of drug resistance and shed light on medical therapies that specifically target MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTme07GYSiBx8SzjBFCN0BJfW6udTcc2eZy882fTwOOqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3js1ShsQ%253D%253D&md5=a233ff2b23c4d4108bc2ac785868b873</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DOvercoming%2520ABC%2520transporter-mediated%2520multidrug%2520resistance%253A%2520molecular%2520mechanisms%2520and%2520novel%2520therapeutic%2520drug%2520strategies%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2016%26volume%3D27%26spage%3D14%26epage%3D29%26doi%3D10.1016%2Fj.drup.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1038/nrc706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters&doi=10.1038%2Fnrc706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0liLxG210bJv_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58%26doi%3D10.1038%2Fnrc706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span> <span> </span><span class="NLM_article-title">Purification and structural analyses of ABCG2</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.addr.2008.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19124053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=57-65&author=C.+A.+McDevittauthor=R.+Collinsauthor=I.+D.+Kerrauthor=R.+Callaghan&title=Purification+and+structural+analyses+of+ABCG2&doi=10.1016%2Fj.addr.2008.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and structural analyses of ABCG2</span></div><div class="casAuthors">McDevitt, Christopher A.; Collins, Richard; Kerr, Ian D.; Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The ABCG2/BRCP protein is best known as a multidrug transporter capable of conferring resistance to cancer cells.  However, the protein is also inherently expressed in numerous barrier tissues and intriguingly within hematopoietic stem cells.  Unlike its partners, ABCB1 and ABCC1, there is considerably less information available on the mol. mechanism of ABCG2/BRCP.  The transporter has a distinct topol. and is presumed to function as a homodimer.  However, a no. of biochem. studies have presented data to suggest that the protein adopts higher order oligomers.  This review focuses on this controversial issue with particular ref. to findings from low resoln. structural data.  In addn., a no. of mol. models of ABCG2/BRCP based on high-resoln. structures of bacterial ABC transporters have recently become available and are critically assessed.  ABCG2/BRCP is a structurally distinct member of the triumvirate of human multidrug transporters and continues to evade description of a unifying mol. mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-26N0eXV32LVg90H21EOLACvtfcHk0lh2L7xysrm4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu7g%253D&md5=8afc7467f79e661e505d5bccbc17cfbf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DMcDevitt%26aufirst%3DC.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DPurification%2520and%2520structural%2520analyses%2520of%2520ABCG2%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D57%26epage%3D65%26doi%3D10.1016%2Fj.addr.2008.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikadi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.str.2010.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.str.2010.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20399185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFKnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=482-493&author=M.+F.+Rosenbergauthor=Z.+Bikadiauthor=J.+Chanauthor=X.+Liuauthor=Z.+Niauthor=X.+Caiauthor=R.+C.+Fordauthor=Q.+Mao&title=The+human+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+shows+conformational+changes+with+mitoxantrone&doi=10.1016%2Fj.str.2010.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Human Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with Mitoxantrone</span></div><div class="casAuthors">Rosenberg, Mark F.; Bikadi, Zsolt; Chan, Janice; Liu, Xiaoping; Ni, Zhanglin; Cai, Xiaokun; Ford, Robert C.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-493</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">BCRP/ABCG2 mediates efflux of drugs and xenobiotics.  BCRP was expressed in Pichia pastoris, purified to > 90% homogeneity, and subjected to two-dimensional (2D) crystn.  The 2D crystals showed a p121 symmetry and projection maps were detd. at 5 Å resoln. by cryo-electron microscopy.  Two crystal forms with and without mitoxantrone were obsd. with unit cell dimensions of a = 55.4 Å, b = 81.4 Å, γ = 89.8°, and a = 57.3 Å, b = 88.0 Å, γ = 89.7°, resp.  The projection map without mitoxantrone revealed an asym. structure with ring-shaped d. features probably corresponding to a bundle of transmembrane α helixes, and appeared more open and less sym. than the map with mitroxantrone.  The open and closed inward-facing forms of BCRP were generated by homol. modeling, representing the substrate-free and substrate-bound conformations in the absence of nucleotide, resp.  These models are consistent with the exptl. obsd. conformational change upon substrate binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy41Lg_ARysLVg90H21EOLACvtfcHk0lh2L7xysrm4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFKnu7s%253D&md5=259f90447cbb30589018f12c155cf19e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2010.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2010.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BF.%26aulast%3DBikadi%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DFord%26aufirst%3DR.%2BC.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DThe%2520human%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520shows%2520conformational%2520changes%2520with%2520mitoxantrone%26jtitle%3DStructure%26date%3D2010%26volume%3D18%26spage%3D482%26epage%3D493%26doi%3D10.1016%2Fj.str.2010.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span> <span> </span><span class="NLM_article-title">Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbamcr.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26453803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Chtb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2016&pages=19-29&author=K.+Wongauthor=S.+J.+Briddonauthor=N.+D.+Hollidayauthor=I.+D.+Kerr&title=Plasma+membrane+dynamics+and+tetrameric+organisation+of+ABCG2+transporters+in+mammalian+cells+revealed+by+single+particle+imaging+techniques&doi=10.1016%2Fj.bbamcr.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques</span></div><div class="casAuthors">Wong, Kelvin; Briddon, Stephen J.; Holliday, Nicholas D.; Kerr, Ian D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-29</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ABCG2 is one of three human ATP binding cassette (ABC) transporters involved in the export from cells of a chem. and structurally diverse range of compds.  This multidrug efflux capability, together with a broad tissue distribution in the body, means that ABCG2 exerts a range of effects on normal physiol. such as kidney urate transport, as well as contributing towards the pharmacokinetic profiles of many exogenous drugs.  The primary sequence of ABCG2 contains only half the no. of domains required for a functioning ABC transporter and so it must oligomerise in order to function, yet its oligomeric state in intact cell membranes remains uncharacterized.  We have analyzed ABCG2 in living cell membranes using a combination of fluorescence correlation spectroscopy, photon counting histogram anal., and stepwise photobleaching to demonstrate a predominantly tetrameric structure for ABCG2 in the presence or absence of transport substrates.  These results provide the essential basis for exploring pharmacol. manipulation of oligomeric state as a strategy to modulate ABCG2 activity in future selective therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBGt4Y70W5LVg90H21EOLACvtfcHk0lh2L7xysrm4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Chtb%252FN&md5=89fe45505b932fa860e4c9151fc610e0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.%26aulast%3DBriddon%26aufirst%3DS.%2BJ.%26aulast%3DHolliday%26aufirst%3DN.%2BD.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26atitle%3DPlasma%2520membrane%2520dynamics%2520and%2520tetrameric%2520organisation%2520of%2520ABCG2%2520transporters%2520in%2520mammalian%2520cells%2520revealed%2520by%2520single%2520particle%2520imaging%2520techniques%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2016%26volume%3D1863%26spage%3D19%26epage%3D29%26doi%3D10.1016%2Fj.bbamcr.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dezi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fribourg, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cicco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnaud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pietro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lévy, D.</span></span> <span> </span><span class="NLM_article-title">The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1798</i></span>,  <span class="NLM_fpage">2094</span>– <span class="NLM_lpage">2101</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2010.07.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.bbamem.2010.07.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20691149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1798&publication_year=2010&pages=2094-2101&author=M.+Deziauthor=P.-F.+Fribourgauthor=A.+Di+Ciccoauthor=O.+Arnaudauthor=S.+Marcoauthor=P.+Falsonauthor=A.+Di+Pietroauthor=D.+L%C3%A9vy&title=The+multidrug+resistance+half-transporter+ABCG2+is+purified+as+a+tetramer+upon+selective+extraction+from+membranes&doi=10.1016%2Fj.bbamem.2010.07.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes</span></div><div class="casAuthors">Dezi, Manuela; Fribourg, Pierre-Frederic; Di Cicco, Aurelie; Arnaud, Ophelie; Marco, Sergio; Falson, Pierre; Di Pietro, Attilio; Levy, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1798</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2094-2101</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ABCG2 is a human membrane ATP-binding cassette half-transporter that hydrolyzes ATP to efflux a large no. of chemotherapeutic agents.  Several oligomeric states of ABCG2 from homodimers to dodecamers have been reported depending on the overexpression systems and/or the protocols used for purifn.  Here, we compared the oligomeric state of His6-ABCG2 expressed in Sf9 insect cells and in human Flp-In-293/ABCG2 cells after solubilization in mild detergents.  His6-ABCG2 was purified through a new approach involving its specific recognition onto a functionalized lipid layer contg. a Ni-NTA lipid.  This approach allowed the purifn. of His-ABCG2 in presence of all solubilized membrane components that might be involved in the stabilization of native oligomers and without requiring any addnl. washing or concn. passages.  ABCG2 purified onto the NiNTA lipid surfaces were directly analyzed by electron microscopy and by biochem. assays.  Altogether, our data are consistent with a tetrameric organization of ABCG2 when expressed in either heterologous Sf9 insect cells or in human homologous cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83AnAMdQg6bVg90H21EOLACvtfcHk0lhJh2cocd1hzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGhurvL&md5=9e1f93b37b94937cb10dd19ec9a8c985</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.07.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.07.034%26sid%3Dliteratum%253Aachs%26aulast%3DDezi%26aufirst%3DM.%26aulast%3DFribourg%26aufirst%3DP.-F.%26aulast%3DDi%2BCicco%26aufirst%3DA.%26aulast%3DArnaud%26aufirst%3DO.%26aulast%3DMarco%26aufirst%3DS.%26aulast%3DFalson%26aufirst%3DP.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26aulast%3DL%25C3%25A9vy%26aufirst%3DD.%26atitle%3DThe%2520multidrug%2520resistance%2520half-transporter%2520ABCG2%2520is%2520purified%2520as%2520a%2520tetramer%2520upon%2520selective%2520extraction%2520from%2520membranes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2010%26volume%3D1798%26spage%3D2094%26epage%3D2101%26doi%3D10.1016%2Fj.bbamem.2010.07.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span> <span> </span><span class="NLM_article-title">Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1623</span>– <span class="NLM_lpage">1632</span>, <span class="refDoi"> DOI: 10.1016/j.str.2006.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.str.2006.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=17098188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1SmtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1623-1632&author=C.+A.+McDevittauthor=R.+F.+Collinsauthor=M.+Conwayauthor=S.+Modokauthor=J.+Stormauthor=I.+D.+Kerrauthor=R.+C.+Fordauthor=R.+Callaghan&title=Purification+and+3D+structural+analysis+of+oligomeric+human+multidrug+transporter+ABCG2&doi=10.1016%2Fj.str.2006.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and 3D Structural Analysis of Oligomeric Human Multidrug Transporter ABCG2</span></div><div class="casAuthors">McDevitt, Christopher A.; Collins, Richard F.; Conway, Michael; Modok, Szabolcs; Storm, Janet; Kerr, Ian D.; Ford, Robert C.; Callaghan, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1623-1632</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ABCG2 is a multidrug efflux pump assocd. with resistance of cancer cells to a plethora of unrelated drugs.  ABCG2 is a "half-transporter," and previous studies have indicated that it forms homodimers and higher oligomeric species.  In this manuscript, electron microscopic structural anal. directly addressed this issue.  An N-terminal hexahistidine-tagged ABCG2R482G isoform was expressed to high levels in insect cells.  An extensive detergent screen was employed to effect extn. of ABCG2R482G from membranes and identified only the fos-choline detergents as efficient.  Sol. protein was purified to >95% homogeneity by a three-step procedure while retaining the ability to bind substrates.  Cryoneg. stain electron microscopy of purified ABCG2R482G provided 3D structural data at a resoln. of ∼18 Å.  Single-particle anal. revealed that the complex forms a tetrameric complex (∼180 Å in diam. × ∼140 Å high) with an aq. central region.  We interpret the tetrameric structure as comprising four homodimeric ABCG2R482G complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwtScpCugTgbVg90H21EOLACvtfcHk0lhJh2cocd1hzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1SmtrzN&md5=f56278a6fc2b6b53312b604f018d89d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DMcDevitt%26aufirst%3DC.%2BA.%26aulast%3DCollins%26aufirst%3DR.%2BF.%26aulast%3DConway%26aufirst%3DM.%26aulast%3DModok%26aufirst%3DS.%26aulast%3DStorm%26aufirst%3DJ.%26aulast%3DKerr%26aufirst%3DI.%2BD.%26aulast%3DFord%26aufirst%3DR.%2BC.%26aulast%3DCallaghan%26aufirst%3DR.%26atitle%3DPurification%2520and%25203D%2520structural%2520analysis%2520of%2520oligomeric%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D1623%26epage%3D1632%26doi%3D10.1016%2Fj.str.2006.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-T.</span></span> <span> </span><span class="NLM_article-title">Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">19781</span>– <span class="NLM_lpage">19789</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310785200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1074%2Fjbc.M310785200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15001581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Wit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=19781-19789&author=J.+Xuauthor=Y.+Liuauthor=Y.+Yangauthor=S.+Batesauthor=J.-T.+Zhang&title=Characterization+of+oligomeric+human+half-ABC+transporter+ATP-binding+cassette+G2&doi=10.1074%2Fjbc.M310785200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2</span></div><div class="casAuthors">Xu, Junkang; Liu, Yang; Yang, Youyun; Bates, Susan; Zhang, Jian-Ting</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">19781-19789</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Human ATP-binding cassette G2 (ABCG2, also known as mitoxantrone resistance protein, breast cancer-resistance protein, ABC placenta) is a member of the superfamily of ATP-binding cassette (ABC) transporters that have a wide variety of substrates.  Overexpression of human ABCG2 in model cancer cell lines causes multidrug resistance by actively effluxing anticancer drugs.  Unlike most of the other ABC transporters which usually have two nucleotide-binding domains and two transmembrane domains, ABCG2 consists of only one nucleotide-binding domain followed by one transmembrane domain.  Thus, ABCG2 has been thought to be a half-transporter that may function as a homodimer.  In this study, we characterized the oligomeric feature of human ABCG2 using non-denaturing detergent perfluoro-octanoic acid and Triton X-100 in combination with gel filtration, sucrose d. gradient sedimentation, and gel electrophoresis.  Unexpectedly, we found that human ABCG2 exists mainly as a tetramer, with a possibility of a higher form of oligomerization.  Monomeric and dimeric ABCG2 did not appear to be the major form of the protein.  Further immunopptn. anal. showed that the oligomeric ABCG2 did not contain any other proteins.  Taken together, we conclude that human ABCG2 likely exists and functions as a homotetramer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogS9hRAh_FSbVg90H21EOLACvtfcHk0lhJh2cocd1hzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Wit7g%253D&md5=c45adb759c2de874ef4c299eb3d0c99e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310785200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310785200%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBates%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.-T.%26atitle%3DCharacterization%2520of%2520oligomeric%2520human%2520half-ABC%2520transporter%2520ATP-binding%2520cassette%2520G2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D19781%26epage%3D19789%26doi%3D10.1074%2Fjbc.M310785200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caracciolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papineschi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazzi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canestraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrini, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1502</span>– <span class="NLM_lpage">1509</span>, <span class="refDoi"> DOI: 10.1080/10428190701402895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1080%2F10428190701402895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=17701580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1502-1509&author=S.+Galimbertiauthor=B.+Nagyauthor=E.+Benedettiauthor=S.+Paciniauthor=S.+Brizziauthor=F.+Caraccioloauthor=F.+Papineschiauthor=E.+Ciabattiauthor=F.+Guerriniauthor=R.+Fazziauthor=M.+Canestraroauthor=M.+Petrini&title=Evaluation+of+the+MDR1%2C+ABCG2%2C+Topoisomerases+IIalpha+and+GSTpi+gene+expression+in+patients+affected+by+aggressive+mantle+cell+lymphoma+treated+by+the+R-Hyper-CVAD+regimen&doi=10.1080%2F10428190701402895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GSTπ gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen</span></div><div class="casAuthors">Galimberti, Sara; Nagy, Balint; Benedetti, Edoardo; Pacini, Simone; Brizzi, Stefania; Caracciolo, Francesco; Papineschi, Federico; Ciabatti, Elena; Guerrini, Francesca; Fazzi, Rita; Canestraro, Martina; Petrini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1502-1509</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, topoisomerase IIα, glutathione-s-transferaseπ (GSTπ) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL.  In our study, expression levels of the above mentioned genes plus MDR1 were tested on bone marrow samples from 20 patients treated with rituximab plus hyper-CVAD regimen, in order to evaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen.  All patients expressed ABCG2 and MDR1 genes; 85% of cases expressed GSTπ and topoisomerase IIα.  Only ABCG2 were over-expressed in comparison both with marrow from healthy donors and tonsilar CD5+/CD20+ lymphocytes (adopted as normal counterpart of the neoplastic population).  The overall response rate of the entire series was 87.5%, with 44% of complete responses.  Fifty-seven percent of patients achieved the clearance of minimal residual disease.  Levels of tested genes did not condition either quality of clin. response or PFS (76% at 24 mo).  Nevertheless, an ABCG2 higher expression appeared assocd. with a worse PFS and levels of this gene paralleled the status of minimal residual disease.  A further evaluation of ABCG2 expression in larger series of MCL patients would be suitable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhiVof0Ex8GLVg90H21EOLACvtfcHk0ljRsdQ_UIYtSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFOqtbg%253D&md5=c2fdd3af5d30c8e204c742d5b9b46ba6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F10428190701402895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701402895%26sid%3Dliteratum%253Aachs%26aulast%3DGalimberti%26aufirst%3DS.%26aulast%3DNagy%26aufirst%3DB.%26aulast%3DBenedetti%26aufirst%3DE.%26aulast%3DPacini%26aufirst%3DS.%26aulast%3DBrizzi%26aufirst%3DS.%26aulast%3DCaracciolo%26aufirst%3DF.%26aulast%3DPapineschi%26aufirst%3DF.%26aulast%3DCiabatti%26aufirst%3DE.%26aulast%3DGuerrini%26aufirst%3DF.%26aulast%3DFazzi%26aufirst%3DR.%26aulast%3DCanestraro%26aufirst%3DM.%26aulast%3DPetrini%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520the%2520MDR1%252C%2520ABCG2%252C%2520Topoisomerases%2520IIalpha%2520and%2520GSTpi%2520gene%2520expression%2520in%2520patients%2520affected%2520by%2520aggressive%2520mantle%2520cell%2520lymphoma%2520treated%2520by%2520the%2520R-Hyper-CVAD%2520regimen%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1502%26epage%3D1509%26doi%3D10.1080%2F10428190701402895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saijo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span> <span> </span><span class="NLM_article-title">Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2008.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.lungcan.2008.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19036469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzotl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=105-111&author=Y.+H.+Kimauthor=G.+Ishiiauthor=K.+Gotoauthor=S.+Otaauthor=K.+Kubotaauthor=Y.+Murataauthor=M.+Mishimaauthor=N.+Saijoauthor=Y.+Nishiwakiauthor=A.+Ochiai&title=Expression+of+breast+cancer+resistance+protein+is+associated+with+a+poor+clinical+outcome+in+patients+with+small-cell+lung+cancer&doi=10.1016%2Fj.lungcan.2008.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer</span></div><div class="casAuthors">Kim Young Hak; Ishii Genichiro; Goto Koichi; Ota Shuji; Kubota Kaoru; Murata Yukinori; Mishima Michiaki; Saijo Nagahiro; Nishiwaki Yutaka; Ochiai Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  ATP-binding cassette (ABC) transporter and DNA excision repair proteins play a pivotal role in the mechanisms of drug resistance.  The aim of this study was to investigate the expression of ABC transporter and DNA excision repair proteins, and to elucidate the clinical significance of their expression in biopsy specimens from patients with small-cell lung cancer (SCLC).  METHODS:  We investigated expression of the ABC transporter proteins, P-glycoprotein (Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast cancer resistance protein (BCRP), and the DNA excision repair proteins, excision repair cross-complementation group 1 (ERCC1) protein and breast cancer susceptibility gene 1 (BRCA1) protein, in tumor biopsy specimens obtained before chemotherapy from 130 SCLC patients who later received platinum-based combination chemotherapy, and investigated the relationship between their expression and both response and survival.  RESULTS:  No significant associations were found between expression of Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and either response or survival.  However, there was a significant association between BCRP expression and both response (p=0.026) and progression-free survival (PFS; p=0.0103).  CONCLUSIONS:  BCRP expression was significantly predictive of both response and progression-free survival (PFS) in SCLC patients receiving chemotherapy.  These findings suggest that BCRP may play a crucial role in drug resistance mechanisms, and that it may serve as an ideal molecular target for the treatment of SCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbY9UEAyJVSs-crCu0nI_sfW6udTcc2eY08YgxKYtU77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzotl2hsw%253D%253D&md5=879423621387778616666b1a58bb5f6f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2008.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2008.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DOta%26aufirst%3DS.%26aulast%3DKubota%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DY.%26aulast%3DMishima%26aufirst%3DM.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DExpression%2520of%2520breast%2520cancer%2520resistance%2520protein%2520is%2520associated%2520with%2520a%2520poor%2520clinical%2520outcome%2520in%2520patients%2520with%2520small-cell%2520lung%2520cancer%26jtitle%3DLung%2520Cancer%26date%3D2009%26volume%3D65%26spage%3D105%26epage%3D111%26doi%3D10.1016%2Fj.lungcan.2008.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovalev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsvetaeva, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudinskaja, T. V.</span></span> <span> </span><span class="NLM_article-title">Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer</span>. <i>Exp Oncol</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=24382439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2czhsVSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=287-290&author=A.+A.+Kovalevauthor=D.+A.+Tsvetaevaauthor=T.+V.+Grudinskaja&title=Role+of+ABC-cassette+transporters+%28MDR1%2C+MRP1%2C+BCRP%29+in+the+development+of+primary+and+acquired+multiple+drug+resistance+in+patients+with+early+and+metastatic+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer</span></div><div class="casAuthors">Kovalev A A; Tsvetaeva D A; Grudinskaja T V</div><div class="citationInfo"><span class="NLM_cas:title">Experimental oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-90</span>
        ISSN:<span class="NLM_cas:issn">1812-9269</span>.
    </div><div class="casAbstract">UNLABELLED:  The aim of the research was to study the influence of multiple drug resistance (MDR1), multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP) proteins expression on the effectiveness of chemotherapy in breast cancer (BC) patients.  PATIENTS AND METHODS:  The retrospective analysis of the results of treatment of 77 women with invasive BC with different molecular subtypes at the age of 54.1±12.5, who received treatment in Zaporizhzhya Regional Clinical Oncological Dispensary during 2011-2013, has been carried out. 23 (29.8%) patients were in II stage of disease, 32 (41.5%) - in III stage, 22 patients (28.5%) - IV stage.  Neoadjuvant therapy has been given to 34 (44.2%) patients, palliative therapy in connection with presence of hematogenous visceral and bone metastases - to 43 (55.8%) patients.  Transport proteins BCRP, MRP and PGP have been studied in tissues of primary BC tumor, in tissues of visceral metastases, in metastatically altered regional lymph nodes, as well as in circulating in blood tumor cells (CTC).  In every case, 1000 of tumor cells has been calculated.  The intensity of staining (0, 1+, 2+, 3+), percentage of stained cells (threshold has constituted 10%) and homogeneity of tumor cells staining (homogeneous was considered 80% staining of cytoplasm or membrane of studied cells) has been taken in consideration.  RESULTS:  Retrospective analysis has determined the dependence of results of polychemotherapy (PCT) on level and pattern of expression of BCRP, MRP and PGP proteins.  In 1(st) group, in the absence thereof expression of transport proteins in BC cells, the objective response (CR + PR) from the tumor has been observed in 17 out of 18 patients (94.4%).  In 2nd group (only cytoplasmic staining) the objective response has been observed in 36 patients (85.7%).  Ineffectiveness of therapy and tumor progression in this group has been observed in 6 (14.2%) patients.  In 3(rd)group (high membrane BCRP, MRP and PGP expression), in 14 out of 17 patients (82.3%), during the PCT occurred progression of the disease.  Malignant phenotype of this tumor corresponded with the state of primary multiple drug resistance.  In 80.0% of patients of this group, the neoadjuvant therapy turned out to be ineffective.  CONCLUSION:  Clinical trials for determination of role of ABC-transporters in the development of drug resistance of BC patients have not yet ended.  The leading role in development of resistance of BC cells plays not only PGP, but also MRP1 and BCRP.  Marker of resistance is not cytological, but membrane staining of cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS15-eiQP9NhlvAgqb2vdc5fW6udTcc2eY08YgxKYtU77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czhsVSitg%253D%253D&md5=d2a5f2e6a8836423edc78e8b7fadb891</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKovalev%26aufirst%3DA.%2BA.%26aulast%3DTsvetaeva%26aufirst%3DD.%2BA.%26aulast%3DGrudinskaja%26aufirst%3DT.%2BV.%26atitle%3DRole%2520of%2520ABC-cassette%2520transporters%2520%2528MDR1%252C%2520MRP1%252C%2520BCRP%2529%2520in%2520the%2520development%2520of%2520primary%2520and%2520acquired%2520multiple%2520drug%2520resistance%2520in%2520patients%2520with%2520early%2520and%2520metastatic%2520breast%2520cancer%26jtitle%3DExp%2520Oncol%26date%3D2013%26volume%3D35%26spage%3D287%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span>. <i>Pathol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1827.2011.02772.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1111%2Fj.1440-1827.2011.02772.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=22360504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=167-175&author=S.+H.+Leeauthor=H.+Kimauthor=J.+H.+Hwangauthor=H.+S.+Leeauthor=J.+Y.+Choauthor=Y.+S.+Yoonauthor=H.+S.+Han&title=Breast+cancer+resistance+protein+expression+is+associated+with+early+recurrence+and+decreased+survival+in+resectable+pancreatic+cancer+patients&doi=10.1111%2Fj.1440-1827.2011.02772.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span></div><div class="casAuthors">Lee Sang Hyub; Kim Haeryoung; Hwang Jin-Hyeok; Lee Hye Seung; Cho Jai Young; Yoon Yoo-Seok; Han Ho-Seong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology international</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1-2 years postoperatively.  Adenosine triphosphate (ATP)-binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers.  In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR-associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry.  MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively.  The expression statuses of the MDR-related proteins were positively correlated with each other (P < 0.05).  Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion.  MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047).  High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001).  MDR-related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival.  Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTweVYj99EDj4NpW7w2tapOfW6udTcc2eb1QBWsAEsT37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D&md5=4c10b59d6b30b8664e12e62edeacc920</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1827.2011.02772.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1827.2011.02772.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DY.%2BS.%26aulast%3DHan%26aufirst%3DH.%2BS.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520expression%2520is%2520associated%2520with%2520early%2520recurrence%2520and%2520decreased%2520survival%2520in%2520resectable%2520pancreatic%2520cancer%2520patients%26jtitle%3DPathol.%2520Int.%26date%3D2012%26volume%3D62%26spage%3D167%26epage%3D175%26doi%3D10.1111%2Fj.1440-1827.2011.02772.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rijavec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegovnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korosec, P.</span></span> <span> </span><span class="NLM_article-title">Expressions of topoisomerase IIalpha and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients</span>. <i>Pathol. Oncol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">696</span>, <span class="refDoi"> DOI: 10.1007/s12253-011-9370-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs12253-011-9370-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=21455636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKltr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=691-696&author=M.+Rijavecauthor=M.+Silarauthor=N.+Trillerauthor=I.+Kernauthor=U.+Cegovnikauthor=M.+Kosnikauthor=P.+Korosec&title=Expressions+of+topoisomerase+IIalpha+and+BCRP+in+metastatic+cells+are+associated+with+overall+survival+in+small+cell+lung+cancer+patients&doi=10.1007%2Fs12253-011-9370-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expressions of Topoisomerase IIα and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Rijavec, Matija; Silar, Mira; Triller, Nadja; Kern, Izidor; Cegovnik, Urska; Kosnik, Mitja; Korosec, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">691-696</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the mRNA expression levels of multidrug resistance-assocd. proteins in chemo-naive metastatic lung cancer cells and to det. the correlation with response to chemotherapy and overall survival.  Metastatic cells were obtained by transbronchial fine needle aspiration biopsy of enlarged mediastinal lymph nodes in 14 patients with small cell lung cancer (SCLC) and 7 patients with non-small cell lung cancer (NSCLC).  After cytol. confirmation of lung cancer type, total RNA was extd. from biopsy samples and reverse transcribed to cDNA, and real-time PCR for the genes of interest [P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance protein (LRP) and topoisomerase IIα (TOPIIα)], was performed.  We obsd. significantly decreased expression of BCRP and significantly increased expression of TOPIIα in metastatic SCLC cells compared to NSCLC.  Furthermore, in SCLC high topoisomerase IIα and low BCRP expression levels pos. correlated with longer overall survival.  Our results showed higher expression levels of BCRP as well as lower levels of topoisomerase IIα in chemo-naive metastatic cells in NSCLC than in SCLC.  These results correlate with previous observations that metastatic SCLC cells at the beginning of chemotherapy are potentially more sensitive to chemotherapeutic agents while in metastatic NSCLC cells resistance is usually inherent.  We also showed that altered levels of topoisomerase IIα and BCRP in SCLC are important factors that contribute to resistance to chemotherapeutics that interfere with the enzyme and/or DNA and are highly assocd. with overall survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqt7ZV62xV77Vg90H21EOLACvtfcHk0liqCoWRyT7L1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKltr3L&md5=be380db800bfa685100b915a14be26c6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs12253-011-9370-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-011-9370-2%26sid%3Dliteratum%253Aachs%26aulast%3DRijavec%26aufirst%3DM.%26aulast%3DSilar%26aufirst%3DM.%26aulast%3DTriller%26aufirst%3DN.%26aulast%3DKern%26aufirst%3DI.%26aulast%3DCegovnik%26aufirst%3DU.%26aulast%3DKosnik%26aufirst%3DM.%26aulast%3DKorosec%26aufirst%3DP.%26atitle%3DExpressions%2520of%2520topoisomerase%2520IIalpha%2520and%2520BCRP%2520in%2520metastatic%2520cells%2520are%2520associated%2520with%2520overall%2520survival%2520in%2520small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2011%26volume%3D17%26spage%3D691%26epage%3D696%26doi%3D10.1007%2Fs12253-011-9370-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosone, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivak, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bookman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moysich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoia, J. A.</span></span> <span> </span><span class="NLM_article-title">Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a gynecologic oncology group study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.ygyno.2011.11.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=22112610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1Oqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2012&pages=575-581&author=C.+Tianauthor=C.+B.+Ambrosoneauthor=K.+M.+Darcyauthor=T.+C.+Krivakauthor=D.+K.+Armstrongauthor=M.+A.+Bookmanauthor=W.+Davisauthor=H.+Zhaoauthor=K.+Moysichauthor=H.+Gallionauthor=J.+A.+DeLoia&title=Common+variants+in+ABCB1%2C+ABCC2+and+ABCG2+genes+and+clinical+outcomes+among+women+with+advanced+stage+ovarian+cancer+treated+with+platinum+and+taxane-based+chemotherapy%3A+a+gynecologic+oncology+group+study&doi=10.1016%2Fj.ygyno.2011.11.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study</span></div><div class="casAuthors">Tian, Chunqiao; Ambrosone, Christine B.; Darcy, Kathleen M.; Krivak, Thomas C.; Armstrong, Deborah K.; Bookman, Michael A.; Davis, Warren; Zhao, Hua; Moysich, Kirsten; Gallion, Holly; DeLoia, Julie A.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Purpose: Efflux transporters of the ATP-binding cassette (ABC) family are major determinants of chemoresistance in tumor cells.  This study examd. assocns. between functional variants in ABCB1, ABCC2 and ABCG2 genes and clin. outcomes in patients with epithelial ovarian/primary peritoneal cancer (EOC/PPC) following platinum and taxane-based chemotherapy.  Methods: Sequenom iPLEXTMGOLD Assay and MALDI-TOF platform were used to genotype the non-synonymous G2677T/A (rs2032582; encoding Ala893Ser/Thr) and synonymous C3435T (rs1045642; encoding Ile1145Ile) variants in ABCB1, the non-synonymous G1249A variant in ABCC2 (rs2273697; encoding Val417Ile), and the non-synonymous C421A variant in ABCG2 (rs2231142; encoding Q141K, Gln141Lys) in normal DNA from up to 511 women in Gynecol. Oncol. Group (GOG) phase III trials, GOG-172 or GOG-182.  Progression-free survival (PFS) and overall survival (OS) were analyzed in relation to genetic polymorphisms using Kaplan-Meier and Cox proportional hazards model.  Results: The C421A variant (CA + AA vs. CC) in ABCG2 was assocd. with a 6-mo longer median PFS (22.7 vs. 16.8 mo, p = 0.041).  In multivariate anal., patients with variant genotypes were at a reduced risk of disease progression (hazard ratio [HR] = 0.75, 95% confidence interval [CI] = 0.59-0.96, p = 0.022).  The assocn. between C421A and OS was not statistically significant (HR = 0.88, 95% CI = 0.67-1.15, p = 0.356).  None of the other variants measured in either ABCB1 or ABCC2 was assocd. with PFS or OS.  Conclusion: The C421A variant in ABCG2, previously shown to be assocd. with enhanced protein degrdn. and drug sensitivity, was assocd. with longer PFS in advanced stage EOC/PPC patents treated with platinum + taxane-based chemotherapy.  This finding requires further validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5_G7N8B60rVg90H21EOLACvtfcHk0liqCoWRyT7L1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1Oqt70%253D&md5=64af8b990deb0f04a4e43d53b1119bb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DAmbrosone%26aufirst%3DC.%2BB.%26aulast%3DDarcy%26aufirst%3DK.%2BM.%26aulast%3DKrivak%26aufirst%3DT.%2BC.%26aulast%3DArmstrong%26aufirst%3DD.%2BK.%26aulast%3DBookman%26aufirst%3DM.%2BA.%26aulast%3DDavis%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMoysich%26aufirst%3DK.%26aulast%3DGallion%26aufirst%3DH.%26aulast%3DDeLoia%26aufirst%3DJ.%2BA.%26atitle%3DCommon%2520variants%2520in%2520ABCB1%252C%2520ABCC2%2520and%2520ABCG2%2520genes%2520and%2520clinical%2520outcomes%2520among%2520women%2520with%2520advanced%2520stage%2520ovarian%2520cancer%2520treated%2520with%2520platinum%2520and%2520taxane-based%2520chemotherapy%253A%2520a%2520gynecologic%2520oncology%2520group%2520study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2012%26volume%3D124%26spage%3D575%26epage%3D581%26doi%3D10.1016%2Fj.ygyno.2011.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uggla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagsater, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirsjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidefelt, U.</span></span> <span> </span><span class="NLM_article-title">BCRP mRNA expression v. clinical outcome in 40 adult AML patients</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2004.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.leukres.2004.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15607361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyktLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2005&pages=141-146&author=B.+Ugglaauthor=E.+Stahlauthor=D.+Wagsaterauthor=C.+Paulauthor=M.+G.+Karlssonauthor=A.+Sirsjoauthor=U.+Tidefelt&title=BCRP+mRNA+expression+v.+clinical+outcome+in+40+adult+AML+patients&doi=10.1016%2Fj.leukres.2004.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP mRNA expression v. clinical outcome in 40 adult AML patients</span></div><div class="casAuthors">Uggla, Bertil; Stahl, Elisabet; Wagsaeter, Dick; Paul, Christer; Karlsson, Mats G.; Sirsjoe, Allan; Tidefelt, Ulf</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-146</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Efflux pumps are considered being mechanisms behind drug resistance in acute myeloid leukemia (AML).  A recently described efflux pump, breast cancer resistance protein (BCRP), can be expressed in AML, but its clin. importance is uncertain.  In this study BCRP mRNA expression was detd. in samples from 40 AML patients by real-time RT-PCR.  The expression varied from neg. to 76 times that of control cells.  There was no difference in BCRP mRNA expression between patients responding to induction treatment and non-responders.  However, in the group of responders, the 14 patients with the highest expression had significantly shorter overall survival (mean 38 mo, SEM 15 mo) than the 14 patients with the lowest (74 mo, SEM 16 mo) (P = 0.047).  This suggests a possible role of BCRP in drug resistance in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowpAhXlUFVcLVg90H21EOLACvtfcHk0lg0X_1X_gD4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyktLfM&md5=e87f5c6fd59ad2f82a47671969572670</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2004.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2004.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DUggla%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DWagsater%26aufirst%3DD.%26aulast%3DPaul%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DM.%2BG.%26aulast%3DSirsjo%26aufirst%3DA.%26aulast%3DTidefelt%26aufirst%3DU.%26atitle%3DBCRP%2520mRNA%2520expression%2520v.%2520clinical%2520outcome%2520in%252040%2520adult%2520AML%2520patients%26jtitle%3DLeuk.%2520Res.%26date%3D2005%26volume%3D29%26spage%3D141%26epage%3D146%26doi%3D10.1016%2Fj.leukres.2004.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minegishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1697</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-0937-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1158%2F1078-0432.CCR-0937-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=15014021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1691-1697&author=K.+Yohauthor=G.+Ishiiauthor=T.+Yokoseauthor=Y.+Minegishiauthor=K.+Tsutaauthor=K.+Gotoauthor=Y.+Nishiwakiauthor=T.+Kodamaauthor=M.+Sugaauthor=A.+Ochiai&title=Breast+cancer+resistance+protein+impacts+clinical+outcome+in+platinum-based+chemotherapy+for+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-0937-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer</span></div><div class="casAuthors">Yoh, Kiyotaka; Ishii, Genichiro; Yokose, Tomoyuki; Minegishi, Yuji; Tsuta, Kohji; Goto, Koichi; Nishiwaki, Yutaka; Kodama, Tetsuro; Suga, Moritaka; Ochiai, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1691-1697</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the relationship between the level of expression of ATP-binding cassette (ABC) transporter proteins, and response to chemotherapy and prognosis in advanced non-small cell lung cancer (NSCLC).  Expression of ABC transporter proteins, including P-glycoprotein, multidrug resistance protein (MRP) 1, MRP2, MRP3, and breast cancer resistance protein (BCRP), was examd. immunohistochem. in 72 formalin-fixed tumor samples from untreated stage IIIB or IV NSCLC patients.  All of the patients received platinum-based chemotherapy.  Response to chemotherapy, progression-free survival (PFS), and overall survival were compared in relation to expression of each of the ABC transporter proteins and clinicopathol. factors.  Expression of P-glycoprotein, MRP1, and MRP3 was not significantly assocd. with response to chemotherapy or survival.  MRP2 expression was assocd. with overall survival (P = 0.002) but not with response to chemotherapy and PFS.  By contrast, the response rate to chemotherapy of patients with BCRP-neg. tumors was 44%, as opposed to 24% in patients with BCRP-pos. tumors.  Response rate was lower in BCRP-pos. tumors, although this difference was not statistically significant (P = 0.08).  BCRP-pos. patients had also shorter PFS (P = 0.0003) and overall survival (P = 0.004) than BCRP-neg. patients.  Multivariate anal. confirmed BCRP status as an independent variable related to PFS (P = 0.001).  Pos. immunostaining for BCRP appears to be a predictor of survival in patients with advanced NSCLC.  These findings indicate that BCRP may serve as a mol. target for reducing drug resistance to chemotherapy in advanced NSCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQb03yiZsiDbVg90H21EOLACvtfcHk0lg0X_1X_gD4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFCltr0%253D&md5=4e7e59ad490d1778ee1b94162848ecbc</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-0937-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-0937-3%26sid%3Dliteratum%253Aachs%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DYokose%26aufirst%3DT.%26aulast%3DMinegishi%26aufirst%3DY.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DSuga%26aufirst%3DM.%26aulast%3DOchiai%26aufirst%3DA.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520impacts%2520clinical%2520outcome%2520in%2520platinum-based%2520chemotherapy%2520for%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D1691%26epage%3D1697%26doi%3D10.1158%2F1078-0432.CCR-0937-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. J.</span></span> <span> </span><span class="NLM_article-title">Preliminary study of the effects of beta-elemene on MCF-7/ADM breast cancer stem cells</span>. <i>GMR, Genet. Mol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2347</span>– <span class="NLM_lpage">2355</span>, <span class="refDoi"> DOI: 10.4238/2015.March.27.20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.4238%2F2015.March.27.20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=25867381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVWrsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=2347-2355&author=Y.+Dongauthor=L.+Liauthor=L.+Wangauthor=T.+Zhouauthor=J.+W.+Liuauthor=Y.+J.+Gao&title=Preliminary+study+of+the+effects+of+beta-elemene+on+MCF-7%2FADM+breast+cancer+stem+cells&doi=10.4238%2F2015.March.27.20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells</span></div><div class="casAuthors">Dong, Y.; Li, L.; Wang, L.; Zhou, T.; Liu, J. W.; Gao, Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">GMR, Genetics and Molecular Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2347-2355</span>CODEN:
                <span class="NLM_cas:coden">GGMRBI</span>;
        ISSN:<span class="NLM_cas:issn">1676-5680</span>.
    
            (<span class="NLM_cas:orgname">FUNPEP</span>)
        </div><div class="casAbstract">We examd. expression differences in breast cancer stem cells (BCSCs) of the doxorubicin-resistant breast cancer cell line MCF-7/ADM and doxorubicin-sensitive cell line MCF-7/S.  The effects of Chinese medicine β-elemene on BCSCs and resistance protein expression were detd.  The serum-free cell culture method was used for cell culture, and morphol. was obsd. to det. the rate of cell sphere formation.  Reverse transcription-polymerase chain reaction was used to detect breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) gene expression.  Flow cytometry was used to det. BCRP- and P-gp-pos. cell rates and CD44 + CD24-/low cell ratios.  Morphol. observation and gene amplification showed that compared with MCF-7/S cells, the serum-free cell sphere-forming rate and P-gp and BCRP gene expression levels were higher in MCF-7/ADM cells.  Flow cytometry results showed that P-gp and BCRP protein expression in MCF-7/ADM cells was 77.78 ± 9.55% and 32.33 ± 5.12%, resp., and the CD44 + CD24-/low cell rate was 64.79 ± 11.78%, which were all significantly higher than those in MCF-7/S cells (3.97 ± 1.51, 14.26 ± 2.51, 18.79 ± 3.28%; P < 0.05). β-elemene significantly decreased the serum-free cell sphere-forming rate in MCF-7/ADM cells and BCRP and P-gp gene/protein expression (P < 0.01).  The proportion of CD44 + CD24-/low cells was reduced.  MCF-7/ADM highly expressed the drug-resistant proteins BCRP and P-gp, which can be used for long-term in vitro culture and as a seed cell for studies of BCSCs. β-elemene can inhibit BCSC and the sphere-forming rate in MCF-7/ADM cells and reduce BCRP expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCs8F4vd877Vg90H21EOLACvtfcHk0lg0X_1X_gD4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVWrsbw%253D&md5=5d3b6c43d16ee4effc4e5eff1828d7d9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4238%2F2015.March.27.20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4238%252F2015.March.27.20%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%2BW.%26aulast%3DGao%26aufirst%3DY.%2BJ.%26atitle%3DPreliminary%2520study%2520of%2520the%2520effects%2520of%2520beta-elemene%2520on%2520MCF-7%252FADM%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DGMR%252C%2520Genet.%2520Mol.%2520Res.%26date%3D2015%26volume%3D14%26spage%3D2347%26epage%3D2355%26doi%3D10.4238%2F2015.March.27.20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emery, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszyk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, K.</span></span> <span> </span><span class="NLM_article-title">Expression and function of ABCG2 and XIAP in glioblastomas</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1007/s11060-017-2422-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs11060-017-2422-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28432589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFarur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2017&pages=47-57&author=I.+F.+Emeryauthor=A.+Gopalanauthor=S.+Woodauthor=K.+H.+Chowauthor=C.+Battelliauthor=J.+Georgeauthor=H.+Blaszykauthor=J.+Flormanauthor=K.+Yun&title=Expression+and+function+of+ABCG2+and+XIAP+in+glioblastomas&doi=10.1007%2Fs11060-017-2422-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and function of ABCG2 and XIAP in glioblastomas</span></div><div class="casAuthors">Emery, Ivette F.; Gopalan, Archana; Wood, Stephanie; Chow, Kin-hoe; Battelli, Chiara; George, Joshy; Blaszyk, Hagen; Florman, Jeffrey; Yun, Kyuson</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-57</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Despite multimodal treatment that includes surgery, radiation and chemotherapy, virtually all glioblastomas (GBM) recur, indicating that these interventions are insufficient to eradicate all malignant cells.  To identify potential new therapeutic targets in GBMs, we examd. the expression and function of proteins that are assocd. with therapy resistance and cancer cell survival.  We measured the expression of eight such proteins in 50 GBM samples by immunohistochem. and analyzed patient survival.  We report that GBM patients with high expression of ABCG2 (also called BCRP) or XIAP at the protein level had worse survival than those with low expression.  The adjusted hazard ratio for ABCG2 was 2.35 and for XIAP was 2.65.  Since glioma stem cells (GSCs) have been shown to be more resistant than bulk tumor cells to anti-cancer therapies and to express high levels of these proteins, we also sought to det. if ABCG2 and XIAP have functional roles in GSCs.  We used small mol. inhibitors to treat patient-derived GBM tumorspheres in vitro and obsd. that inhibitors of ABCG2, Ko143 and fumitremorgin, significantly reduced self-renewal.  These results suggest that ABCG2 and XIAP proteins may be useful indicators of patient survival and that inhibition of ABCG2 may be a promising therapeutic strategy in GBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz7aD1B1fhxLVg90H21EOLACvtfcHk0ljnck94U68a_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFarur0%253D&md5=677f4b3a08f18f1e1594f49517066e72</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs11060-017-2422-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-017-2422-z%26sid%3Dliteratum%253Aachs%26aulast%3DEmery%26aufirst%3DI.%2BF.%26aulast%3DGopalan%26aufirst%3DA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DChow%26aufirst%3DK.%2BH.%26aulast%3DBattelli%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DBlaszyk%26aufirst%3DH.%26aulast%3DFlorman%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DK.%26atitle%3DExpression%2520and%2520function%2520of%2520ABCG2%2520and%2520XIAP%2520in%2520glioblastomas%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2017%26volume%3D133%26spage%3D47%26epage%3D57%26doi%3D10.1007%2Fs11060-017-2422-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12889</span>– <span class="NLM_lpage">12896</span>, <span class="refDoi"> DOI: 10.1007/s13277-016-5209-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs13277-016-5209-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWgtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=12889-12896&author=L.+Maauthor=T.+Liuauthor=Y.+Jinauthor=J.+Weiauthor=Y.+Yangauthor=H.+Zhang&title=ABCG2+is+required+for+self-renewal+and+chemoresistance+of+CD133-positive+human+colorectal+cancer+cells&doi=10.1007%2Fs13277-016-5209-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells</span></div><div class="casAuthors">Ma, Lijun; Liu, Ting; Jin, Yiran; Wei, Jun; Yang, Yinxue; Zhang, Hongquan</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">12889-12896</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is increasing evidence supporting the cancer stem cell (CSC) hypothesis, which suggests that a population of tumor cells with stem cell characteristics is responsible for tumor growth, resistance, and recurrence as well as drug resistance.  In colorectal cancer, the CD133 antigen defines distinct cell subpopulations that are rich in tumor-initiating cells; however, the drug resistance properties of these CD133-pos. cells have not been well defined.  The breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2) is present on the plasma membrane of many types of human cancer cells and contributes to multidrug resistance during chemotherapy.  The results of the present study showed that ABCG2 is expressed in CD133-pos. CSCs from human colorectal tumors.  Furthermore, the downregulation of ABCG2 expression inhibited the self-renewal capacity of these cells, and significantly enhanced the efficacy of chemotherapy-induced apoptosis in LS174T colon adenocarcinoma cells and CD133-pos. colorectal carcinoma cells.  Together, these data show that ABCG2 expression correlates with the presence of CD133-pos. cancer cells, and thus is a possible therapeutic target for colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwuitGCyYFsrVg90H21EOLACvtfcHk0ljnck94U68a_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWgtbjI&md5=896e8ba43a9792ce66a1b1d768aa668d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs13277-016-5209-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-016-5209-5%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DABCG2%2520is%2520required%2520for%2520self-renewal%2520and%2520chemoresistance%2520of%2520CD133-positive%2520human%2520colorectal%2520cancer%2520cells%26jtitle%3DTumor%2520Biol.%26date%3D2016%26volume%3D37%26spage%3D12889%26epage%3D12896%26doi%3D10.1007%2Fs13277-016-5209-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allikmets, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriml, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano-Spica, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span> <span> </span><span class="NLM_article-title">A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5337</span>– <span class="NLM_lpage">5339</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9850061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1cXotVSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5337-5339&author=R.+Allikmetsauthor=L.+M.+Schrimlauthor=A.+Hutchinsonauthor=V.+Romano-Spicaauthor=M.+Dean&title=A+human+placenta-specific+ATP-binding+cassette+gene+%28ABCP%29+on+chromosome+4q22+that+is+involved+in+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance</span></div><div class="casAuthors">Allikmets, Rando; Schriml, Lynn M.; Hutchinson, Amy; Romano-Spica, Vincenzo; Dean, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5337-5339</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">We characterized a new human ATP-binding cassette (ABC) transporter gene that is highly expressed in the placenta.  The gene, ABCP, produces two transcripts that differ at the 5' end and encode the same 655-amino acid protein.  The predicted protein is closely related to the Drosophila white and yeast ADP1 genes and is a member of a subfamily that includes several multidrug resistance transporters.  ABCP, white, and ADP1 all have a single ATP-binding domain at the NH2 terminus and a single COOH-terminal set of transmembrane segments.  ABCP maps to human chromosome 4q22, between the markers D4S2462 and D4S1557, and the murine gene (Abcp) is located on chromosome 6, 28-29 cM from the centromere.  ABCP defines a new syntenic segment between human chromosome 4 and mouse chromosome 6.  The abundant expression of this gene in the placenta suggests that the protein product has an important role in transport of specific mol.(s) into or out of this tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoelWb8FwUhcbVg90H21EOLACvtfcHk0ljnck94U68a_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVSkt7Y%253D&md5=9077feec7eff1ff318503c48d6ef8599</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAllikmets%26aufirst%3DR.%26aulast%3DSchriml%26aufirst%3DL.%2BM.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DRomano-Spica%26aufirst%3DV.%26aulast%3DDean%26aufirst%3DM.%26atitle%3DA%2520human%2520placenta-specific%2520ATP-binding%2520cassette%2520gene%2520%2528ABCP%2529%2520on%2520chromosome%25204q22%2520that%2520is%2520involved%2520in%2520multidrug%2520resistance%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5337%26epage%3D5339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abruzzo, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span> <span> </span><span class="NLM_article-title">A multidrug resistance transporter from human MCF-7 breast cancer cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">15665</span>– <span class="NLM_lpage">15670</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.26.15665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1073%2Fpnas.95.26.15665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9861027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=15665-15670&author=L.+A.+Doyleauthor=W.+Yangauthor=L.+V.+Abruzzoauthor=T.+Krogmannauthor=Y.+Gaoauthor=A.+K.+Rishiauthor=D.+D.+Ross&title=A+multidrug+resistance+transporter+from+human+MCF-7+breast+cancer+cells&doi=10.1073%2Fpnas.95.26.15665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A multidrug resistance transporter from human MCF-7 breast cancer cells</span></div><div class="casAuthors">Doyle, L. Austin; Yang, Weidong; Abruzzo, Lynne V.; Krogmann, Tammy; Gao, Yongming; Rishi, Arun K.; Ross, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">15665-15670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent redn. in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein.  RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells.  The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP).  Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells.  BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowbckt6jTJYLVg90H21EOLACvtfcHk0ljnck94U68a_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhvFeitQ%253D%253D&md5=ef3e4ddd772833b363ba458401e3331a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.26.15665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.26.15665%26sid%3Dliteratum%253Aachs%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DAbruzzo%26aufirst%3DL.%2BV.%26aulast%3DKrogmann%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DRishi%26aufirst%3DA.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26atitle%3DA%2520multidrug%2520resistance%2520transporter%2520from%2520human%2520MCF-7%2520breast%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D15665%26epage%3D15670%26doi%3D10.1073%2Fpnas.95.26.15665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">13</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9892175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=8-13&author=K.+Miyakeauthor=L.+Mickleyauthor=T.+Litmanauthor=Z.+Zhanauthor=R.+Robeyauthor=B.+Cristensenauthor=M.+Brangiauthor=L.+Greenbergerauthor=M.+Deanauthor=T.+Fojoauthor=S.+E.+Bates&title=Molecular+cloning+of+cDNAs+which+are+highly+overexpressed+in+mitoxantrone-resistant+cells%3A+demonstration+of+homology+to+ABC+transport+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes</span></div><div class="casAuthors">Miyake, Keisuke; Mickley, Lyn; Litman, Thomas; Zhan, Zhirong; Robey, Robert; Cristensen, Barbara; Brangi, Mariafiorella; Greenberger, Lee; Dean, Michael; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-13</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance assocd. protein have raised the possibility of the existence of another major transporter conferring drug resistance.  In the present study, a cDNA library from mitoxantrone-resistant S1-M1-80 human colon carcinoma cells was screened by differential hybridization.  Two cDNAs of different lengths were isolated and designated MXR1 and MXR2.  Sequencing revealed a high degree of homol. for the cDNAs with Expressed Sequence Tag sequences previously identified as belonging to an ATP binding cassette transporter.  Homol. to the Drosophila white gene and its homologues was found for the predicted amino acid sequence.  Using either cDNA as a probe in a Northern anal. demonstrated high levels of expression in the S1-M1-80 cells and in the human breast cancer subline, MCF-7 AdVp3000.  Levels were lower in earlier steps of selection, and in partial revertants.  The gene is amplified 10-12-fold in the MCF-7 AdVp3000 cells, but not in the S1-M1-80 cells.  These studies are consistent with the identification of a new ATP binding cassette transporter, which is overexpressed in mitoxantrone-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tfK3k_pnibVg90H21EOLACvtfcHk0lgmNVMGVgPbzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFKqsQ%253D%253D&md5=2fd30ec6844cb5c45a17e6e1646214f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DMickley%26aufirst%3DL.%26aulast%3DLitman%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DZ.%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DCristensen%26aufirst%3DB.%26aulast%3DBrangi%26aufirst%3DM.%26aulast%3DGreenberger%26aufirst%3DL.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMolecular%2520cloning%2520of%2520cDNAs%2520which%2520are%2520highly%2520overexpressed%2520in%2520mitoxantrone-resistant%2520cells%253A%2520demonstration%2520of%2520homology%2520to%2520ABC%2520transport%2520genes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D8%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikadi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span> <span> </span><span class="NLM_article-title">Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.2174/138920010792927325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2174%2F138920010792927325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=20812902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=603-617&author=Z.+Niauthor=Z.+Bikadiauthor=M.+F.+Rosenbergauthor=Q.+Mao&title=Structure+and+function+of+the+human+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.2174%2F138920010792927325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Ni, Zhanglin; Bikadi, Zsolt; Rosenberg, Mark F.; Mao, Qingcheng</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-617</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The human breast cancer resistance protein (BCRP/ABCG2) is the second member of the G subfamily of the ATP-binding cassette (ABC) transporter superfamily.  BCRP was initially discovered in multidrug resistant breast cancer cell lines where it confers resistance to chemotherapeutic agents such as mitoxantrone, topotecan and methotrexate by extruding these compds. out of the cell.  BCRP is capable of transporting non-chemotherapy drugs and xenobiotiocs as well, including nitrofurantoin, prazosin, glyburide, and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine.  BCRP is frequently detected at high levels in stem cells, likely providing xenobiotic protection.  BCRP is also highly expressed in normal human tissues including the small intestine, liver, brain endothelium, and placenta.  Therefore, BCRP has been increasingly recognized for its important role in the absorption, elimination, and tissue distribution of drugs and xenobiotics.  At present, little is known about the transport mechanism of BCRP, particularly how it recognizes and transports a large no. of structurally and chem. unrelated drugs and xenobiotics.  Here, we review current knowledge of structure and function of this medically important ABC efflux drug transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSq7fLjXpxb7Vg90H21EOLACvtfcHk0lgmNVMGVgPbzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbvM&md5=d90e86dde1fbff8cbd116f932e62b75e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F138920010792927325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010792927325%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DBikadi%26aufirst%3DZ.%26aulast%3DRosenberg%26aufirst%3DM.%2BF.%26aulast%3DMao%26aufirst%3DQ.%26atitle%3DStructure%2520and%2520function%2520of%2520the%2520human%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26spage%3D603%26epage%3D617%26doi%3D10.2174%2F138920010792927325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadjem, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risbood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poruchynsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S.</span></span> <span> </span><span class="NLM_article-title">Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1978</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fsj.bjc.6601370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=14612912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVers7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2003&pages=1971-1978&author=R.+Robeyauthor=Y.+Honjoauthor=K.+Morisakiauthor=T.+Nadjemauthor=S.+Rungeauthor=M.+Risboodauthor=M.+Poruchynskyauthor=S.+Bates&title=Mutations+at+amino-acid+482+in+the+ABCG2+gene+affect+substrate+and+antagonist+specificity&doi=10.1038%2Fsj.bjc.6601370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity</span></div><div class="casAuthors">Robey, R. W.; Honjo, Y.; Morisaki, K.; Nadjem, T. A.; Runge, S.; Risbood, M.; Poruchynsky, M. S.; Bates, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1971-1978</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recent studies have shown that mutations at amino-acid 482 in the ABCG2 gene affect the substrate specificity of the protein.  To delineate the effects of these mutations clearly, human embryonic kidney cells (HEK-293) were stably transfected with wild-type 482R or mutant 482G and 482T ABCG2.  By flow cytometry, mitoxantrone, BODIPY-prazosin, and Hoechst 33342 were found to be substrates of all ABCG2 proteins, while rhodamine 123, daunorubicin, and LysoTracker Green were transported only by mutant ABCG2.  In cytotoxicity assays, all ABCG2 proteins conferred high levels of resistance to mitoxantrone, SN-38, and topotecan, while mutant ABCG2 also exhibited a gain of function for mitoxantrone as they conferred a four-fold greater resistance compared to wild type.  Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin, epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold resistant to these compds.  ABCG2 did not confer appreciable resistance to etoposide, taxol or the histone deacetylase inhibitor depsipeptide.  None of the transfected cell lines demonstrated resistance to flavopiridol despite our previous observation that ABCG2-overexpressing cell lines are cross-resistant to the drug.  Recently reported inhibitors of ABCG2 were evaluated and 50 μM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially.  The studies presented here serve to underscore the importance of amino-acid 482 in defining the substrate specificity of the ABCG2 protein and raise the possibility that amino-acid 482 mutations in human cancers could affect the clin. application of antagonists for ABCG2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon8onO595iKLVg90H21EOLACvtfcHk0lgmNVMGVgPbzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVers7g%253D&md5=3e8bbb529899a2aca87aa93d4a68aabd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601370%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%26aulast%3DHonjo%26aufirst%3DY.%26aulast%3DMorisaki%26aufirst%3DK.%26aulast%3DNadjem%26aufirst%3DT.%26aulast%3DRunge%26aufirst%3DS.%26aulast%3DRisbood%26aufirst%3DM.%26aulast%3DPoruchynsky%26aufirst%3DM.%26aulast%3DBates%26aufirst%3DS.%26atitle%3DMutations%2520at%2520amino-acid%2520482%2520in%2520the%2520ABCG2%2520gene%2520affect%2520substrate%2520and%2520antagonist%2520specificity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D89%26spage%3D1971%26epage%3D1978%26doi%3D10.1038%2Fsj.bjc.6601370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resau, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2011</span>– <span class="NLM_lpage">2021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10806112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2000&pages=2011-2021&author=T.+Litmanauthor=M.+Brangiauthor=E.+Hudsonauthor=P.+Fetschauthor=A.+Abatiauthor=D.+D.+Rossauthor=K.+Miyakeauthor=J.+H.+Resauauthor=S.+E.+Bates&title=The+multidrug-resistant+phenotype+associated+with+overexpression+of+the+new+ABC+half-transporter%2C+MXR+%28ABCG2%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)</span></div><div class="casAuthors">Litman, Thomas; Brangi, Mariafiorella; Hudson, Eric; Fetsch, Patricia; Abati, Andrea; Ross, Douglas D.; Miyake, Keisuke; Resau, James H.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2011-2021</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mechanisms of drug resistance other than P-glycoprotein are of increasing interest as the list of newly identified members of the ABC transport family has grown.  We sought to characterize the phenotype of the newly discovered ABC transporter encoded by the mitoxantrone resistance gene, MXR, also known as ABCP1 or BCRP.  The pharmacodynamics of mitoxantrone and 12 other fluorescent drugs were evaluated by confocal microscopy in four multidrug-resistant human colon (S1) and breast (MCF-7) cancer cell lines.  We utilized two sublines, MCF-7 AdVp3000 and S1-M1-80, and detected overexpression of MXR by PCR, immunoblot assay and immunohistochem.  These MXR overexpressing sublines were compared to cell lines with P-glycoprotein- and MRP-mediated resistance.  High levels of cross-resistance were obsd. for mitoxantrone, the anthracyclines, bisantrene and topotecan.  Reduced levels of mitoxantrone, daunorubicin, bisantrene, topotecan, rhodamine 123 and prazosin were obsd. in the two sublines with high MXR expression.  Neither the P-glycoprotein substrates vinblastine, paclitaxel, verapamil and calcein-AM, nor the MRP substrate calcein, were extruded from MCF-7 AdVp3000 and S1-M1-80 cells.  Thus, the multidrug-resistant phenotype due to MXR expression is overlapping with, but distinct from, that due to P-glycoprotein.  Further, cells that overexpress the MXR protein seem to be more resistant to mitoxantrone and topotecan than cells with P-glycoprotein-mediated multidrug resistance.  Our studies suggest that the ABC half-transporter, MXR, is a potent, new mechanism for conferring multiple drug resistance.  Definition of its mechanism of transport and its role in clin. oncol. is required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpb_xS4uC0-rVg90H21EOLACvtfcHk0lj9XmEW_f-qjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKntrg%253D&md5=305a9a9c80f0f583c99b3b4c6744f5f3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLitman%26aufirst%3DT.%26aulast%3DBrangi%26aufirst%3DM.%26aulast%3DHudson%26aufirst%3DE.%26aulast%3DFetsch%26aufirst%3DP.%26aulast%3DAbati%26aufirst%3DA.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DResau%26aufirst%3DJ.%2BH.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DThe%2520multidrug-resistant%2520phenotype%2520associated%2520with%2520overexpression%2520of%2520the%2520new%2520ABC%2520half-transporter%252C%2520MXR%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2000%26volume%3D113%26spage%3D2011%26epage%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annable, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span> <span> </span><span class="NLM_article-title">Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5850</span>– <span class="NLM_lpage">5858</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=9865745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADyaK1MXivFah" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=5850-5858&author=S.+K.+Rabindranauthor=H.+Heauthor=M.+Singhauthor=E.+Brownauthor=K.+I.+Collinsauthor=T.+Annableauthor=L.+M.+Greenberger&title=Reversal+of+a+novel+multidrug+resistance+mechanism+in+human+colon+carcinoma+cells+by+fumitremorgin+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C</span></div><div class="casAuthors">Rabindran, Sridhar K.; He, Haiyin; Singh, Maya; Brown, Eileen; Collins, Karen I.; Annable, Tami; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5850-5858</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">We selected a human colon carcinoma cell line in increasing concns. of mitoxantrone to obtain a resistant subline, S1-M1-3.2, with the following characteristics: profound resistance to mitoxantrone; significant cross-resistance to doxorubicin, bisantrene, and topotecan; and very low levels of resistance to Taxol, vinblastine, colchicine, and camptothecin.  This multidrug resistance (MDR) phenotype, which was not reversed by verapamil or another potent P-glycoprotein (Pgp) inhibitor, CL 329,753, was dependent, in part, upon an energy-dependent drug efflux mechanism.  Pgp and the multidrug resistance protein (MRP) were not elevated in the resistant cells relative to the drug-sensitive parent, suggesting that resistance was mediated by a novel pathway of drug transport.  A cell-based screen with S1-M1-3.2 cells was used to identify agents capable of circumventing this non-Pgp, non-MRP MDR.  One of the active agents identified was a mycotoxin, fumitremorgin C.  This mol. was extremely effective in reversing resistance to mitoxantrone, doxorubicin, and topotecan in multidrug-selected cell lines showing this novel phenotype.  Reversal of resistance was assocd. with an increase in drug accumulation.  The compd. did not reverse drug resistance in cells with elevated expression of Pgp or MRP.  We suggest that fumitremorgin C is a highly selective chemosensitizing agent for the resistance pathway we have identified and can be used as a specific pharmacol. probe to distinguish between the diverse resistance mechanisms that occur in the MDR cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-Y6qf2FmRbVg90H21EOLACvtfcHk0lj9XmEW_f-qjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXivFah&md5=cacafc261f829003219cdd9f518ac900</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DK.%2BI.%26aulast%3DAnnable%26aufirst%3DT.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DReversal%2520of%2520a%2520novel%2520multidrug%2520resistance%2520mechanism%2520in%2520human%2520colon%2520carcinoma%2520cells%2520by%2520fumitremorgin%2520C%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D5850%26epage%3D5858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fetsch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ABCG2: a perspective</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.addr.2008.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19135109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1alu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=3-13&author=R.+W.+Robeyauthor=K.+K.+Toauthor=O.+Polgarauthor=M.+Dohseauthor=P.+Fetschauthor=M.+Deanauthor=S.+E.+Bates&title=ABCG2%3A+a+perspective&doi=10.1016%2Fj.addr.2008.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2: A perspective</span></div><div class="casAuthors">Robey, Robert W.; To, Kenneth K. K.; Polgar, Orsolya; Dohse, Marius; Fetsch, Patricia; Dean, Michael; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the subject of intense study since its discovery a decade ago.  With high normal tissue expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is believed to be important in the protection from xenobiotics, regulating oral bioavailability, forming part of the blood-brain barrier, the blood-testis barrier, and the maternal-fetal barrier.  Notably, ABCG2 is often expressed in stem cell populations, where it likely plays a role in xenobiotic protection.  However, clues to its epigenetic regulation in various cell populations are only beginning to emerge.  While ABCG2 overexpression has been demonstrated in cancer cells after in vitro drug treatment, endogenous ABCG2 expression in certain cancers is likely a reflection of the differentiated phenotype of the cell of origin and likely contributes to intrinsic drug resistance.  Notably, research into the transporter's role in cancer drug resistance and its development as a therapeutic target in cancer has lagged.  Substrates and inhibitors of the transporter have been described, among them chemotherapy drugs, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase inhibitors, carcinogens, and flavonoids.  This broad range of substrates complements the efficiency of ABCG2 as a transporter in lab. studies and suggests that, while there are redundant mechanisms of xenobiotic protection, the protein is important in normal physiol.  Indeed, emerging studies in pharmacol. and toxicol. assessing polymorphic variants in man, in combination with murine knockout models have confirmed its dynamic role.  Work in pharmacol. may eventually lead us to a greater understanding of the physiol. role of ABCG2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXHdrQffcZprVg90H21EOLACvtfcHk0lj9XmEW_f-qjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1alu70%253D&md5=dc00a9793b185b7a23290a21ed3ea8ba</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPolgar%26aufirst%3DO.%26aulast%3DDohse%26aufirst%3DM.%26aulast%3DFetsch%26aufirst%3DP.%26aulast%3DDean%26aufirst%3DM.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DABCG2%253A%2520a%2520perspective%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2009%26volume%3D61%26spage%3D3%26epage%3D13%26doi%3D10.1016%2Fj.addr.2008.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharom, F. J.</span></span> <span> </span><span class="NLM_article-title">ABC multidrug transporters: structure, function and role in chemoresistance</span>. <i>Pharmacogenomics</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.2217/14622416.9.1.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2217%2F14622416.9.1.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=18154452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=105-127&author=F.+J.+Sharom&title=ABC+multidrug+transporters%3A+structure%2C+function+and+role+in+chemoresistance&doi=10.2217%2F14622416.9.1.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ABC multidrug transporters: structure, function and role in chemoresistance</span></div><div class="casAuthors">Sharom, Frances J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-127</span>CODEN:
                <span class="NLM_cas:coden">PARMFL</span>;
        ISSN:<span class="NLM_cas:issn">1462-2416</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Three ATP-binding cassette (ABC)-superfamily multidrug efflux pumps are known to be responsible for chemoresistance; P-glycoprotein (ABCB1), MRP1 (ABCC1) and ABCG2 (BCRP).  These transporters play an important role in normal physiol. by protecting tissues from toxic xenobiotics and endogenous metabolites.  Hydrophobic amphipathic compds., including many clin. used drugs, interact with the substrate-binding pocket of these proteins via flexible hydrophobic and H-bonding interactions.  These efflux pumps are expressed in many human tumors, where they likely contribute to resistance to chemotherapy treatment.  However, the use of efflux-pump modulators in clin. cancer treatment has proved disappointing.  Single nucleotide polymorphisms in ABC drug-efflux pumps may play a role in responses to drug therapy and disease susceptibility.  The effect of various genotypes and haplotypes on the expression and function of these proteins is not yet clear, and their true impact remains controversial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodtANKweyrPrVg90H21EOLACvtfcHk0lgUssB8I83Flg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFOjsg%253D%253D&md5=7594f33bc3a524c65d3622b00750dbe6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2217%2F14622416.9.1.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F14622416.9.1.105%26sid%3Dliteratum%253Aachs%26aulast%3DSharom%26aufirst%3DF.%2BJ.%26atitle%3DABC%2520multidrug%2520transporters%253A%2520structure%252C%2520function%2520and%2520role%2520in%2520chemoresistance%26jtitle%3DPharmacogenomics%26date%3D2008%26volume%3D9%26spage%3D105%26epage%3D127%26doi%3D10.2217%2F14622416.9.1.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tannock, I. F.</span></span> <span> </span><span class="NLM_article-title">Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1007/s10555-012-9402-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1007%2Fs10555-012-9402-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=23093326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=211-227&author=M.+Yuauthor=A.+Ocanaauthor=I.+F.+Tannock&title=Reversal+of+ATP-binding+cassette+drug+transporter+activity+to+modulate+chemoresistance%3A+why+has+it+failed+to+provide+clinical+benefit%3F&doi=10.1007%2Fs10555-012-9402-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?</span></div><div class="casAuthors">Yu, Man; Ocana, Alberto; Tannock, Ian F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">211-227</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Enhanced drug extrusion from cells due to the overexpression of the ATP-binding cassette (ABC) drug transporters inhibits the cytotoxic effects of structurally diverse and mechanistically unrelated anticancer agents and is a major cause of multidrug resistance (MDR) of human malignancies.  Multiple compds. can suppress the activity of these efflux transporters and sensitize resistant tumor cells, but despite promising preclin. and early clin. data, they have yet to find a role in oncol. practice.  Based on the knowledge of the structure, function, and distribution of MDR-related ABC transporters and the results of their preclin. and clin. evaluation, we discuss probable reasons why these inhibitors have not improved the outcome of therapy for cancer patients.  We also outline new MDR-reversing strategies that directly target ABC transporters or circumvent relevant signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBAZK6a3syH7Vg90H21EOLACvtfcHk0lgUssB8I83Flg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFWit78%253D&md5=76bbcfcf06b4b4274310f9f48a8cf3cd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs10555-012-9402-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-012-9402-8%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DOcana%26aufirst%3DA.%26aulast%3DTannock%26aufirst%3DI.%2BF.%26atitle%3DReversal%2520of%2520ATP-binding%2520cassette%2520drug%2520transporter%2520activity%2520to%2520modulate%2520chemoresistance%253A%2520why%2520has%2520it%2520failed%2520to%2520provide%2520clinical%2520benefit%253F%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2013%26volume%3D32%26spage%3D211%26epage%3D227%26doi%3D10.1007%2Fs10555-012-9402-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span> <span> </span><span class="NLM_article-title">Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10646850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ahtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=47-50&author=S.+K.+Rabindranauthor=D.+D.+Rossauthor=L.+A.+Doyleauthor=W.+Yangauthor=L.+M.+Greenberger&title=Fumitremorgin+C+reverses+multidrug+resistance+in+cells+transfected+with+the+breast+cancer+resistance+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein</span></div><div class="casAuthors">Rabindran, Sridhar K.; Ross, Douglas D.; Doyle, L. Austin; Yang, Weidong; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-50</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Fumitremorgin C (FTC) is a potent and specific chemosensitizing agent in cell lines selected for resistance to mitoxantrone that do not overexpress P-glycoprotein or multidrug resistance protein.  The gene encoding a novel transporter, the breast cancer resistance protein (BCRP), was recently overexpressed in a mitoxantrone-selected human colon cell line, S1-M1-3.2, which was used to identify FTC.  Because the drug-selected cell line may contain multiple alterations contributing to the multidrug resistance phenotype, the authors examd. the effect of FTC on MCF-7 cells transfected with the BCRP gene.  The authors report that FTC almost completely reverses resistance mediated by BCRP in vitro and is a pharmacol. probe for the expression and mol. action of this transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv8QZa80NcbVg90H21EOLACvtfcHk0lgUssB8I83Flg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ahtw%253D%253D&md5=46f893b6e504412c489cba2f4b87cfee</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DFumitremorgin%2520C%2520reverses%2520multidrug%2520resistance%2520in%2520cells%2520transfected%2520with%2520the%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D47%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Loevezijn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Valk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tellingen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C</span>. <i>Mol. Cancer Ther</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.4161%2Fcbt.1.4.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=12477054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=417-425&author=J.+D.+Allenauthor=A.+Van+Loevezijnauthor=J.+M.+Lakhaiauthor=M.+Van+Der+Valkauthor=O.+Van+Tellingenauthor=G.+Reidauthor=J.+H.+Schellensauthor=G.-J.+Koomenauthor=A.+H.+Schinkel&title=Potent+and+specific+inhibition+of+the+breast+cancer+resistance+protein+multidrug+transporter+in+vitro+and+in+mouse+intestine+by+a+novel+analogue+of+fumitremorgin+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C</span></div><div class="casAuthors">Allen, John D.; Van Loevezijn, Arnold; Lakhai, Jeany M.; Van der Valk, Martin; Van Tellingen, Olaf; Reid, Glen; Schellens, Jan H. M.; Koomen, Gerrit-Jan; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417-425</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Inhibitors of the breast cancer resistance protein (BCRP/ABCG2) multidrug transporter are of interest as chemosensitizers for clin. drug resistance, for improving the pharmacokinetics of substrate chemotherapeutic drugs, and in functional assays of BCRP activity for tailoring chemotherapy.  The fungal toxin fumitremorgin C (FTC) is a potent and specific inhibitor of BCRP, but its neurotoxic effects preclude use in vivo.  We have therefore evaluated a new tetracyclic analog of FTC, Ko143, as a practical inhibitor of BCRP, comparing it with two other analogs in the same class and with GF120918.  All three FTC analogs are effective inhibitors of both mouse Bcrp1 and human BCRP, proving highly active for increasing the intracellular drug accumulation and reversing Bcrp1/BCRP-mediated multidrug resistance.  Indeed, Ko143 appears to be the most potent BCRP inhibitor known thus far.  In contrast, the compds. have only low activity against P-glycoprotein, the multidrug resistance-assocd. protein (MRP1), or other known drug transporters.  They are nontoxic in vitro at useful concns. and evinced no signs of toxicity in mice at high oral or i.p. doses.  Administered p.o. to inhibit intestinal Bcrp1, Ko143 markedly increased the oral availability of topotecan in mice.  It is thus the first highly potent and specific BCRP inhibitor applicable in vivo.  As such, Ko143 and other FTC analogs of this type represent valuable reagents for anal. of drug resistance mechanisms and may be candidates for development as clin. BCRP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdmIQAa5j5rVg90H21EOLACvtfcHk0lgUssB8I83Flg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs7g%253D&md5=8a54c6c38d9639ec70faa97a279d0a12</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4161%2Fcbt.1.4.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.1.4.22%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BD.%26aulast%3DVan%2BLoevezijn%26aufirst%3DA.%26aulast%3DLakhai%26aufirst%3DJ.%2BM.%26aulast%3DVan%2BDer%2BValk%26aufirst%3DM.%26aulast%3DVan%2BTellingen%26aufirst%3DO.%26aulast%3DReid%26aufirst%3DG.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DKoomen%26aufirst%3DG.-J.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DPotent%2520and%2520specific%2520inhibition%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520multidrug%2520transporter%2520in%2520vitro%2520and%2520in%2520mouse%2520intestine%2520by%2520a%2520novel%2520analogue%2520of%2520fumitremorgin%2520C%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2002%26volume%3D1%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidner, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoghbi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">The inhibitor Ko143 is not specific for ABCG2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.225482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1124%2Fjpet.115.225482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26148857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlGrtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=384-393&author=L.+D.+Weidnerauthor=S.+S.+Zoghbiauthor=S.+Luauthor=S.+Shuklaauthor=S.+V.+Ambudkarauthor=V.+W.+Pikeauthor=J.+Mulderauthor=M.+M.+Gottesmanauthor=R.+B.+Innisauthor=M.+D.+Hall&title=The+inhibitor+Ko143+is+not+specific+for+ABCG2&doi=10.1124%2Fjpet.115.225482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibitor Ko143 is not specific for ABCG2</span></div><div class="casAuthors">Weidner, Lora D.; Zoghbi, Sami S.; Lu, Shuiyu; Shukla, Suneet; Ambudkar, Suresh V.; Pike, Victor W.; Mulder, Jan; Gottesman, Michael M.; Innis, Robert B.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-393</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Imaging ATP-binding cassette (ABC) transporter activity in vivo with positron emission tomog. requires both a substrate and a transporter inhibitor.  However, for ABCG2, there is no inhibitor proven to be specific to that transporter alone at the blood-brain barrier.  Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], a nontoxic analog of fungal toxin fumitremorgin C, is a potent inhibitor of ABCG2, although its specificity in mouse and human systems is unclear.  This study examd. the selectivity of Ko143 using human embryonic kidney cell lines transfected with ABCG2, ABCB1, or ABCC1 in several in vitro assays.  The stability of Ko143 in rat plasma was measured using high performance liq. chromatog.  Our results show that, in addn. to being a potent inhibitor of ABCG2, at higher concns. (≥1 μM) Ko143 also has an effect on the transport activity of both ABCB1 and ABCC1.  Furthermore, Ko143 was found to be unstable in rat plasma.  These findings indicate that Ko143 lacks specificity for ABCG2 and this should be taken into consideration when using Ko143 for both in vitro and in vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWjvTByDwbLVg90H21EOLACvtfcHk0lhzZ2XLSWDc7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlGrtb7L&md5=4336228ff99f608f6452dca312e78a5a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.225482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.225482%26sid%3Dliteratum%253Aachs%26aulast%3DWeidner%26aufirst%3DL.%2BD.%26aulast%3DZoghbi%26aufirst%3DS.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DThe%2520inhibitor%2520Ko143%2520is%2520not%2520specific%2520for%2520ABCG2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D384%26epage%3D393%26doi%3D10.1124%2Fjpet.115.225482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">HM30181 Derivatives as novel potent and selective inhibitors of the breast cancer resistance protein (BCRP/ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3921</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3910-3921&author=S.+C.+Kohlerauthor=M.+Wiese&title=HM30181+Derivatives+as+novel+potent+and+selective+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Facs.jmedchem.5b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kohler Sebastian C; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3910-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The breast cancer resistance protein (BCRP, ABCG2) belongs to the superfamily of ATP binding-cassette (ABC) proteins.  In addition to other physiological functions, it transports potentially cell-damaging compounds out of the cell using the energy from ATP hydrolysis.  Certain tumors overexpressing BCRP were found to become resistant against various anticancer drugs.  In previous work, we found that tariquidar analogues lacking the tetrahydroisoquinoline moiety selectively inhibit BCRP.  In the present study, we synthesized 21 derivatives of the third-generation P-gp inhibitor HM30181, which is structurally related to tariquidar.  The compounds were tested for their inhibitory activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1) to confirm the selectivity toward BCRP.  The most potent compounds are selective toward BCRP and 2-fold more potent than the reference Ko143.  Qualitative structure-activity relationship (SAR) analysis revealed that the presence of a methoxy group in the ortho or para position of at least one phenyl ring is beneficial for inhibitory activity.  Furthermore, the cytotoxicity and multidrug resistance (MDR)-reversal ability of selected compounds were investigated.  It was shown that they have a low cytotoxicity and the ability to reverse the BCRP-mediated SN-38 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_-1BYW7HmO9-cVm4E2RlLfW6udTcc2eZjNQ6f8Y5ls7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D&md5=777b13f427105e8909ae751d11e8c7b4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00188%26sid%3Dliteratum%253Aachs%26aulast%3DKohler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DHM30181%2520Derivatives%2520as%2520novel%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3910%26epage%3D3921%26doi%3D10.1021%2Facs.jmedchem.5b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innis, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">The ″specific″ P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2)</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1021/cn100078a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100078a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=82-89&author=P.+Kannanauthor=S.+Teluauthor=S.+Shuklaauthor=S.+V.+Ambudkarauthor=V.+W.+Pikeauthor=C.+Halldinauthor=M.+M.+Gottesmanauthor=R.+B.+Innisauthor=M.+D.+Hall&title=The+%E2%80%B3specific%E2%80%B3+P-glycoprotein+inhibitor+tariquidar+is+also+a+substrate+and+an+inhibitor+for+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Fcn100078a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The "Specific" P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kannan, Pavitra; Telu, Sanjay; Shukla, Suneet; Ambudkar, Suresh V.; Pike, Victor W.; Halldin, Christer; Gottesman, Michael M.; Innis, Robert B.; Hall, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-89</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tariquidar was developed as a specific inhibitor of the efflux transporter ABCB1.  Recent positron emission tomog. brain imaging studies using [11C]tariquidar to measure ABCB1 (P-gp, P-glycoprotein) d. in mice indicate that the inhibitor may not be as specific as previously thought.  We examd. its selectivity as an inhibitor and a substrate for the human transporters P-gp, breast cancer resistance protein (BCRP, ABCG2), and multidrug resistance protein 1 (MRP1, ABCC1).  These results show that at low concns., tariquidar acts selectively as an inhibitor of P-gp and also as a substrate of BCRP.  At much higher concns. (≥100 nM), tariquidar acts as an inhibitor of both P-gp and BCRP.  Thus, the in vivo specificity of tariquidar depends on concn. and the relative d. and capacity of P-gp vs BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDSwrbJSyvLVg90H21EOLACvtfcHk0lhzZ2XLSWDc7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtLvI&md5=e5fb835e5610aee9323a3ba40e7b1498</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcn100078a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100078a%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DP.%26aulast%3DTelu%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DInnis%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DThe%2520%25E2%2580%25B3specific%25E2%2580%25B3%2520P-glycoprotein%2520inhibitor%2520tariquidar%2520is%2520also%2520a%2520substrate%2520and%2520an%2520inhibitor%2520for%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D82%26epage%3D89%26doi%3D10.1021%2Fcn100078a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">2,4,6-substituted quinazolines with extraordinary inhibitory potency toward ABCG2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7952</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7952-7976&author=M.+K.+Krapfauthor=J.+Gallusauthor=V.+Namasivayamauthor=M.+Wiese&title=2%2C4%2C6-substituted+quinazolines+with+extraordinary+inhibitory+potency+toward+ABCG2&doi=10.1021%2Facs.jmedchem.8b01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7952-7976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several members of the ABC transporter superfamily play a decisive role in the development of multidrug resistance (MDR) in cancer.  One of these MDR assocd. efflux transporters is ABCG2.  One way to overcome this MDR is the coadministration of potent inhibitors of ABCG2.  In this study, we identified novel inhibitors contg. a 2,4,6-substituted quinazoline scaffold.  Introduction of a 6-nitro function led to extraordinarily potent compds. that were highly selective for ABCG2 and also able to reverse the MDR toward the chemotherapeutic drugs SN-38 and mitoxantrone.  The binding of substrate Hoechst 33342 and the two potent inhibitors 31 and 41 which differ in their mechanism of inhibition was rationalized using the recently published cryo-EM structures of ABCG2.  For a better understanding of the interaction between the inhibitors and ABCG2, addnl. investigations regarding the ATPase activity, the interaction with Hoechst 33342, and with the conformational sensitive 5D3 antibody were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHoikCuvyt-bVg90H21EOLACvtfcHk0lidROXsk72yJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO&md5=376bdc61d3a65d7ea6877e7b69ca0d74</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01011%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D2%252C4%252C6-substituted%2520quinazolines%2520with%2520extraordinary%2520inhibitory%2520potency%2520toward%2520ABCG2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7952%26epage%3D7976%26doi%3D10.1021%2Facs.jmedchem.8b01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3389-3408&author=M.+K.+Krapfauthor=J.+Gallusauthor=S.+Vahdatiauthor=M.+Wiese&title=New+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+containing+a+2%2C4-disubstituted+pyridopyrimidine+scaffold&doi=10.1021%2Facs.jmedchem.7b01012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Vahdati, Sahel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3389-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) occurring during cancer chemotherapy is a major obstacle for effectiveness and response to therapy and is often caused by ATP-binding cassette (ABC) efflux transporters.  Belonging to the family of ABC transporters, breast cancer resistance protein is getting more and more in the spotlight of research.  As a strategy to overcome MDR, inhibitors of ABC transporters were synthesized, which could be applied in combination with cytostatic drugs.  For this purpose, 2,4-disubstituted pyridopyrimidine derivs. were synthesized.  The investigations confirmed three key characteristics of good inhibitors: a low intrinsic cytotoxicity and a high potency and selectivity toward ABCG2.  For selected compds. the interaction with ABCG2 was elucidated and their effect on ATPase activity and conformation sensitive 5D3 antibody binding was investigated.  Their ability to reverse MDR in coadministration with the active metabolite of irinotecan and mitoxantron was confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1PrWr1uAkvLVg90H21EOLACvtfcHk0lidROXsk72yJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D&md5=aa27ba46b274bcb0501e596b92973efa</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01012%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DVahdati%26aufirst%3DS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNew%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520containing%2520a%25202%252C4-disubstituted%2520pyridopyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3389%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.7b01012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-anilino-2-pyridylquinazolines and -pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4474-4495&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=4-anilino-2-pyridylquinazolines+and+-pyrimidines+as+highly+potent+and+nontoxic+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.7b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4474-4495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter.  Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP/ABCG2), there is a persistent need for studies of inhibitors of ABCG2.  In this study, the authors investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2.  For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure.  Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).  Interaction of the compds. with ABCG2 was investigated by a colorimetric ATPase assay.  Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compds. binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVIj0DPElPrVg90H21EOLACvtfcHk0lidROXsk72yJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D&md5=cd9380f0b33fb110c3cde721345f6fe5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00441%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-anilino-2-pyridylquinazolines%2520and%2520-pyrimidines%2520as%2520highly%2520potent%2520and%2520nontoxic%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4474%26epage%3D4495%26doi%3D10.1021%2Facs.jmedchem.7b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure of the human multidrug transporter ABCG2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/nature22345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fnature22345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28554189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=504-509&author=N.+M.+I.+Taylorauthor=I.+Manolaridisauthor=S.+M.+Jacksonauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Structure+of+the+human+multidrug+transporter+ABCG2&doi=10.1038%2Fnature22345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human multidrug transporter ABCG2</span></div><div class="casAuthors">Taylor, Nicholas M. I.; Manolaridis, Ioannis; Jackson, Scott M.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7659</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ABCG2 is a constitutively expressed ATP-binding cassette (ABC) transporter that protects many tissues against xenobiotic mols.  Its activity affects the pharmacokinetics of commonly used drugs and limits the delivery of therapeutics into tumor cells, thus contributing to multidrug resistance.  Here we present the structure of human ABCG2 detd. by cryo-electron microscopy, providing the first high-resoln. insight into a human multidrug transporter.  We visualize ABCG2 in complex with two antigen-binding fragments of the human-specific, inhibitory antibody 5D3 that recognizes extracellular loops of the transporter.  We observe two cholesterol mols. bound in the multidrug-binding pocket that is located in a central, hydrophobic, inward-facing translocation pathway between the transmembrane domains.  Combined with functional in vitro analyses, our results suggest a multidrug recognition and transport mechanism of ABCG2, rationalize disease-causing single nucleotide polymorphisms (SNP) and the allosteric inhibition by the 5D3 antibody, and provide the structural basis of cholesterol recognition by other G-subfamily ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOlfrPNtVhrVg90H21EOLACvtfcHk0lgqSHrpeBRlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D&md5=a3fd5157f639d2958e5abd996e2a6470</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnature22345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22345%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructure%2520of%2520the%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D504%26epage%3D509%26doi%3D10.1038%2Fnature22345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zechner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomaeus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0049-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fs41594-018-0049-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=29610494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=333-340&author=S.+M.+Jacksonauthor=I.+Manolaridisauthor=J.+Kowalauthor=M.+Zechnerauthor=N.+M.+I.+Taylorauthor=M.+Bauseauthor=S.+Bauerauthor=R.+Bartholomaeusauthor=G.+Bernhardtauthor=B.+Koenigauthor=A.+Buschauerauthor=H.+Stahlbergauthor=K.-H.+Altmannauthor=K.+P.+Locher&title=Structural+basis+of+small-molecule+inhibition+of+human+multidrug+transporter+ABCG2&doi=10.1038%2Fs41594-018-0049-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span></div><div class="casAuthors">Jackson, Scott M.; Manolaridis, Ioannis; Kowal, Julia; Zechner, Melanie; Taylor, Nicholas M. I.; Bause, Manuel; Bauer, Stefanie; Bartholomaeus, Ruben; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin; Stahlberg, Henning; Altmann, Karl-Heinz; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is an ATP-binding cassette (ABC) transporter that protects tissues against xenobiotics, affects the pharmacokinetics of drugs and contributes to multidrug resistance.  Although many inhibitors and modulators of ABCG2 have been developed, understanding their structure-activity relationship requires high-resoln. structural insight.  Here, we present cryo-EM structures of human ABCG2 bound to synthetic derivs. of the fumitremorgin C-related inhibitor Ko143 or the multidrug resistance modulator tariquidar.  Both compds. are bound to the central, inward-facing cavity of ABCG2, blocking access for substrates and preventing conformational changes required for ATP hydrolysis.  The high resolns. allowed for de novo building of the entire transporter and also revealed tightly bound phospholipids and cholesterol interacting with the lipid-exposed surface of the transmembrane domains (TMDs).  Extensive chem. modifications of the Ko143 scaffold combined with in vitro functional analyses revealed the details of ABCG2 interactions with this compd. family and provide a basis for the design of novel inhibitors and modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBdcwrlGmAbVg90H21EOLACvtfcHk0lgqSHrpeBRlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M&md5=b892ceb7a3ede9784a09c2cc98042d03</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0049-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0049-1%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DZechner%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBartholomaeus%26aufirst%3DR.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKoenig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520of%2520small-molecule%2520inhibition%2520of%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D333%26epage%3D340%26doi%3D10.1038%2Fs41594-018-0049-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Real, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieto, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, G.</span></span> <span> </span><span class="NLM_article-title">Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1002/jps.21851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1002%2Fjps.21851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19544374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=598-617&author=A.+I.+Alvarezauthor=R.+Realauthor=M.+P%C3%A9rezauthor=G.+Mendozaauthor=J.+G.+Prietoauthor=G.+Merino&title=Modulation+of+the+activity+of+ABC+transporters+%28P-glycoprotein%2C+MRP2%2C+BCRP%29+by+flavonoids+and+drug+response&doi=10.1002%2Fjps.21851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response</span></div><div class="casAuthors">Alvarez, Ana I.; Real, Rebeca; Perez, Miriam; Mendoza, Gracia; Prieto, Julio G.; Merino, Gracia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">598-617</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The present article aims to review the up-to-date information on the most recent studies of the interaction of flavonoids with ABC transporters, in particular the drug pharmacokinetic consequences of such a relationship.  In addn., the modulation of the expression of the ABC transporters by flavonoids is also illustrated.  Flavonoids are a large group of plant polyphenols present extensively in our daily diets and herbal products.  High intake of isoflavones has been assocd. with a variety of beneficial effects on several common diseases.  These polyphenols interact with ABC drug transporters involved in drug resistance and drug absorption, distribution and excretion.  A no. of studies have demonstrated inhibition of drug transporters by flavonoids.  This flavonoid-ABC-transporter interaction could be beneficial for poorly absorbed drugs but could also result in severe drug intoxication, esp. drugs with a narrow therapeutic window.  On the other hand, flavonoids are themselves substrates of ABC transporters.  These proteins can affect the oral availability and tissue distribution of these compds., modifying their beneficial effects.  The challenge is to find a suitable way to predict harmful drug-flavonoid interactions mediated by these transporters. © 2009 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci 99:598-617, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH8IbGZLh3cLVg90H21EOLACvtfcHk0lgqSHrpeBRlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsL3N&md5=7255b59ffbaac44c2bf853f7262e1a9a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fjps.21851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21851%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez%26aufirst%3DA.%2BI.%26aulast%3DReal%26aufirst%3DR.%26aulast%3DP%25C3%25A9rez%26aufirst%3DM.%26aulast%3DMendoza%26aufirst%3DG.%26aulast%3DPrieto%26aufirst%3DJ.%2BG.%26aulast%3DMerino%26aufirst%3DG.%26atitle%3DModulation%2520of%2520the%2520activity%2520of%2520ABC%2520transporters%2520%2528P-glycoprotein%252C%2520MRP2%252C%2520BCRP%2529%2520by%2520flavonoids%2520and%2520drug%2520response%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D598%26epage%3D617%26doi%3D10.1002%2Fjps.21851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure–activity relationship and mechanism of modulation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1999</span>– <span class="NLM_lpage">2014</span>, <span class="refDoi"> DOI: 10.1021/jm201121b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201121b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC38XitVeksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1999-2014&author=K.-F.+Chanauthor=I.+L.+Wongauthor=J.+W.+Kanauthor=C.+S.+Yanauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Amine+linked+flavonoid+dimers+as+modulators+for+P-glycoprotein-based+multidrug+resistance%3A+structure%E2%80%93activity+relationship+and+mechanism+of+modulation&doi=10.1021%2Fjm201121b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationship and Mechanism of Modulation</span></div><div class="casAuthors">Chan, Kin-Fai; Wong, Iris L. K.; Kan, Jason W. Y.; Yan, Clare S. W.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1999-2014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here we report a great improvement in reversal potency of cancer drug resistance when flavonoid dimers possess a functionally substituted aminopolyethylene glycol linker.  The most potent compd., (I), contains a N-benzyl group at the linker.  It has many advantages including (1) high potencies in reversing P-glycoprotein (P-gp) mediated resistance in LCC6MDR cells to various anticancer drugs with EC50 in the nanomolar range, (2) low toxicity and high therapeutic index, and (3) preferential inhibition of P-gp over multidrug resistance protein 1 and breast cancer resistance protein.  I stimulates P-gp-ATPase activity by 2.7-fold and mediates a dose-dependent inhibition of doxorubicin (DOX) transport activity.  Lineweaver-Burk and Dixon plots suggest that I is a competitive inhibitor to DOX in binding to P-gp with a Ki of 0.28-0.34 μM and a Hill coeff. of 1.17.  Moreover, the LCC6MDR cell displays about 2.1-fold lower intracellular accumulation of 18 compared to the wild type, suggesting that 18 is a P-gp substrate as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzkFyzfv4ZzrVg90H21EOLACvtfcHk0lgX58xqaTiVNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitVeksbY%253D&md5=dee53ec7b3b8651b85dad6d833df4691</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm201121b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201121b%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DKan%26aufirst%3DJ.%2BW.%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DAmine%2520linked%2520flavonoid%2520dimers%2520as%2520modulators%2520for%2520P-glycoprotein-based%2520multidrug%2520resistance%253A%2520structure%25E2%2580%2593activity%2520relationship%2520and%2520mechanism%2520of%2520modulation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1999%26epage%3D2014%26doi%3D10.1021%2Fjm201121b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly (ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6742</span>– <span class="NLM_lpage">6759</span>, <span class="refDoi"> DOI: 10.1021/jm060593+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060593%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOqsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6742-6759&author=K.-F.+Chanauthor=Y.+Zhaoauthor=B.+A.+Burkettauthor=I.+L.+Wongauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Flavonoid+dimers+as+bivalent+modulators+for+P-glycoprotein-based+multidrug+resistance%3A+synthetic+apigenin+homodimers+linked+with+defined-length+poly+%28ethylene+glycol%29+spacers+increase+drug+retention+and+enhance+chemosensitivity+in+resistant+cancer+cells&doi=10.1021%2Fjm060593%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid Dimers as Bivalent Modulators for P-Glycoprotein-Based Multidrug Resistance: Synthetic Apigenin Homodimers Linked with Defined-Length Poly(ethylene glycol) Spacers Increase Drug Retention and Enhance Chemosensitivity in Resistant Cancer Cells</span></div><div class="casAuthors">Chan, Kin-Fai; Zhao, Yunzhe; Burkett, Brendan A.; Wong, Iris L. K.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6742-6759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Much effort has been spent on searching for better P-glycoprotein- (P-gp-) based multidrug resistance (MDR) modulators.  Our approach was to target the binding sites of P-gp using dimers of dietary flavonoids.  A series of apigenin-based flavonoid dimers, linked by poly(ethylene glycol) chains of various lengths, have been synthesized.  These flavonoid dimers modulate drug chemosensitivity and retention in breast and leukemic MDR cells with the optimal no. of ethylene glycol units equal to 2-4.  Compd. 9d bearing four ethylene glycol units increased drug accumulation in drug-resistant cells and enhanced cytotoxicity of paclitaxel, doxorubicin, daunomycin, vincristine, and vinblastine in drug-resistant breast cancer and leukemia cells in vitro, resulting in redn. of IC50 by 5-50 times.  This compd. also stimulated P-gp's ATPase activity by 3.3-fold.  Its modulating activity was presumably by binding to the substrate binding sites of P-gp and disrupting drug efflux.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAs5cv1zQgVLVg90H21EOLACvtfcHk0lgX58xqaTiVNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOqsLfM&md5=236d3561a062922ed3656b61abafd0bb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm060593%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060593%252B%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBurkett%26aufirst%3DB.%2BA.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DFlavonoid%2520dimers%2520as%2520bivalent%2520modulators%2520for%2520P-glycoprotein-based%2520multidrug%2520resistance%253A%2520synthetic%2520apigenin%2520homodimers%2520linked%2520with%2520defined-length%2520poly%2520%2528ethylene%2520glycol%2529%2520spacers%2520increase%2520drug%2520retention%2520and%2520enhance%2520chemosensitivity%2520in%2520resistant%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6742%26epage%3D6759%26doi%3D10.1021%2Fjm060593%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1002%2Fcmdc.200800413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19288491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlCgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=594-614&author=K.+F.+Chanauthor=Y.+Zhaoauthor=T.+W.+Chowauthor=C.+S.+Yanauthor=D.+L.+Maauthor=B.+A.+Burkettauthor=I.+L.+Wongauthor=L.+M.+Chowauthor=T.+H.+Chan&title=Flavonoid+dimers+as+bivalent+modulators+for+p-glycoprotein-based+multidrug+resistance%3A+structure-activity+relationships&doi=10.1002%2Fcmdc.200800413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Flavonoid Dimers as Bivalent Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationships</span></div><div class="casAuthors">Chan, Kin-Fai; Zhao, Yunzhe; Chow, Toby W. S.; Yan, Clare S. W.; Ma, Dik Lung; Burkett, Brendan A.; Wong, Iris L. K.; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">594-614</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sym. and unsym. tetra(ethylene glycol)-linked dimers of flavonoids such as I are prepd. as potential multidrug resistance-reversing agents; their abilities to potential the cytotoxicity of paclitaxel in a multidrug resistant human breast cancer cell line and their lipophilicities are detd., while the abilities of selected compds. to potentiate the toxicities of doxorubicin, vincristine, and vinblastine in a human breast cancer cell line are detd.  Tetra(ethylene glycol)-linked flavanoid dimers with nonpolar, hydrophobic, and less bulky substituents generally show more potent reversing activities than those with other substituents.  Flavonoid dimers with nonpolar and hydrophobic substituents such as Me and Et groups are more potent resistance-reversing agents than dimers with polar and hydrophilic substituents such as hydroxy groups at the C3, C6, and C7 positions of the flavone moieties, but not at C5.  I, contg. Me groups at C6 of the flavone moieties, is optimal, with dimers contg. bulkier substituents at C6 leading to lower multidrug reversing activity.  Comparison of unsym. flavanoid dimers with the corresponding sym. dimers revealed that the two binding sites on P-gp for flavonoid moieties are similar to each other.  The compds. are not cytotoxic towards normal or multidrug resistant cancer cells at 1, 2, or 5 μM concns. (no data).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEk32GHrRA67Vg90H21EOLACvtfcHk0lgX58xqaTiVNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlCgtr8%253D&md5=eea708b2cbb50b5f7c703760d1e7a1fc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800413%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChow%26aufirst%3DT.%2BW.%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DBurkett%26aufirst%3DB.%2BA.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DFlavonoid%2520dimers%2520as%2520bivalent%2520modulators%2520for%2520p-glycoprotein-based%2520multidrug%2520resistance%253A%2520structure-activity%2520relationships%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D594%26epage%3D614%26doi%3D10.1002%2Fcmdc.200800413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Novel classes of dimer antitumour drug candidates</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.2174/138161209787315576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.2174%2F138161209787315576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=19199989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=659-674&author=L.+Chowauthor=T.+H.+Chan&title=Novel+classes+of+dimer+antitumour+drug+candidates&doi=10.2174%2F138161209787315576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Novel classes of dimer antitumour drug candidates</span></div><div class="casAuthors">Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">659-674</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polyvalency in the biol. world is defined as the simultaneous binding of multiple ligands to one receptor.  Polyvalency can increase the affinity of the polyvalent ligand by 100-1000 fold over the monovalent ligand.  Such phenomenon has been employed to design polyvalent toxin inhibitors.  Bivalency is a similar approach where two ligands are joined together with a linker to form a homo- or hetero-dimer with an increase in affinity by up to several hundred fold over the monovalent ligand.  This review will summarize the recent advancement in designing bivalent inhibitors to be used as antitumor agents.  Some dimers (e.g. artemisinin homo-dimer) simply increase the affinity of the monovalent ligands without detailed knowledge of the target.  Other dimers are designed with well-characterized targets, for example, jesterone dimer (inhibiting Rel/NF-κB) and 3,3'-diindolymethane and their derivs. (inhibiting Akt and NFκB).  Some dimers are designed based on the high definition structure between ligand and target (e.g. benzodiazepine and daunorubicin interacting with DNA).  Heterodimers have also been produced by combining either two different antitumor drugs (e.g. cis-platin/acridine or cis-platin/naphthalimide) or combining one antitumor candidate (artemisinin) with a mol. which can increase the efficacy of the former (transferrin receptor).  Finally we will discuss the design of bivalent inhibitors of the P-glycoprotein (ABCB1; MDR or P-gp) to overcome the problem of antitumor resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXhqOSnGxmLVg90H21EOLACvtfcHk0lizZbDXF7TUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns7k%253D&md5=00d01b4aafa8cef596a8bce572c757f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F138161209787315576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315576%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DNovel%2520classes%2520of%2520dimer%2520antitumour%2520drug%2520candidates%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D659%26epage%3D674%26doi%3D10.2174%2F138161209787315576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span> <span> </span><span class="NLM_article-title">Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5311</span>– <span class="NLM_lpage">5322</span>, <span class="refDoi"> DOI: 10.1021/jm900194w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900194w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWntb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5311-5322&author=I.+L.+Wongauthor=K.-F.+Chanauthor=K.+H.+Tsangauthor=C.+Y.+Lamauthor=Y.+Zhaoauthor=T.+H.+Chanauthor=L.+M.+C.+Chow&title=Modulation+of+multidrug+resistance+protein+1+%28MRP1%2FABCC1%29-mediated+multidrug+resistance+by+bivalent+apigenin+homodimers+and+their+derivatives&doi=10.1021%2Fjm900194w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1)-Mediated Multidrug Resistance by Bivalent Apigenin Homodimers and Their Derivatives</span></div><div class="casAuthors">Wong, Iris L. K.; Chan, Kin-Fai; Tsang, Ka Hing; Lam, Chi Yin; Zhao, Yunzhe; Chan, Tak Hang; Chow, Larry Ming Cheung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5311-5322</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here it is showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells.  Flavonoid dimers bearing five or six ethylene glycol (EG) units with 6-Me or 7-Me substitution on the ring A of flavonoid dimers have the highest modulating activity for DOX against MRP1 with an EC50 ranging from 73 to 133 nM.  At 0.5 μM, the flavonoid dimer I was sufficient to restore DOX accumulation in 2008/MRP1 to parental 2008/P level.  Lineweaver-Burk and Dixon plot suggested that it is likely a competitive inhibitor of DOX transport with a Ki = 0.2 μM.  The data suggest that flavonoid dimers have a high affinity toward binding to DOX recognition site of MRP1.  This results in inhibiting DOX transport, increasing intracellular DOX retention, and finally resensitizing 2008/MRP1 to DOX.  The present study demonstrates that flavonoid dimers can be employed as an effective modulator of MRP1-mediated drug resistance in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM2E1QnkQ3jrVg90H21EOLACvtfcHk0lizZbDXF7TUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWntb3E&md5=5acb996cd44f205b7344d2b91e34e9f2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm900194w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900194w%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChan%26aufirst%3DK.-F.%26aulast%3DTsang%26aufirst%3DK.%2BH.%26aulast%3DLam%26aufirst%3DC.%2BY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DT.%2BH.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26atitle%3DModulation%2520of%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252FABCC1%2529-mediated%2520multidrug%2520resistance%2520by%2520bivalent%2520apigenin%2520homodimers%2520and%2520their%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5311%26epage%3D5322%26doi%3D10.1021%2Fjm900194w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span> <span> </span><span class="NLM_article-title">A New class of safe, potent, and specific P-gp modulator: flavonoid dimer FD18 reverses P-gp-mediated multidrug resistance in human breast xenograft in vivo</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3507</span>– <span class="NLM_lpage">3517</span>, <span class="refDoi"> DOI: 10.1021/mp500770e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500770e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3507-3517&author=C.+S.+Yanauthor=I.+L.+Wongauthor=K.+F.+Chanauthor=J.+W.+Kanauthor=T.+C.+Chongauthor=M.+C.+Lawauthor=Y.+Zhaoauthor=S.+W.+Chanauthor=T.+H.+Chanauthor=L.+M.+Chow&title=A+New+class+of+safe%2C+potent%2C+and+specific+P-gp+modulator%3A+flavonoid+dimer+FD18+reverses+P-gp-mediated+multidrug+resistance+in+human+breast+xenograft+in+vivo&doi=10.1021%2Fmp500770e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo</span></div><div class="casAuthors">Yan, Clare S. W.; Wong, Iris L. K.; Chan, Kin-Fai; Kan, Jason W. Y.; Chong, Tsz Cheung; Law, Man Chun; Zhao, Yunzhe; Chan, Shun Wan; Chan, Tak Hang; Chow, Larry M. C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3507-3517</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Flavonoid dimer FD18 is a new class of dimeric P-gp modulator that can reverse cancer drug resistance.  FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.  FD18 can modulate multidrug resistance toward paclitaxel, vinblastine, vincristine, doxorubicin, daunorubicin, and mitoxantrone in human breast cancer LCC6MDR in vitro.  FD18 (1 μM) can revert chemosensitivity of LCC6MDR back to parental LCC6 level.  FD18 was 11- to 46-fold more potent than verapamil.  FD18 (1 μM) can increase accumulation of doxorubicin by 2.7-fold, daunorubicin (2.1-fold), and rhodamine 123 (5.2-fold) in LCC6MDR.  FD18 inhibited P-gp-mediated doxorubicin efflux and has no effect on influx.  FD18 at 1 μM did not affect the protein expression level of P-gp.  Pharmacokinetics studies indicated that i.p. administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.  Acute toxicity studies with FD18 (90 mg/kg, i.p. for 12 times in 22 days) with paclitaxel (12 mg/kg, i.v. for 12 times in 22 days) revealed no obvious toxicity or death in mice.  In vivo efficacy studies indicated that FD18 (45 mg/kg, i.p. for 12 times in 22 days) together with paclitaxel (12 mg/kg, i.v. for 12 times in 22 days) resulted in a 46% redn. in LCC6MDR xenograft vol. (n = 11; 648 ± 84 mm3) compared to paclitaxel control (n = 8; 1201 ± 118 mm3).  There were no animal deaths or significant drop in body wt. and vital organ wet wt.  FD18 can increase paclitaxel accumulation in LCC6MDR xenograft by 1.8- to 2.2-fold.  The present study suggests that FD18 represents a new class of safe and potent P-gp modulator in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGV4jlyRZZHbVg90H21EOLACvtfcHk0lizZbDXF7TUug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKnsL7L&md5=ae0ce196912ba2739030b31213c7d7fe</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fmp500770e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500770e%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DC.%2BS.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DKan%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DT.%2BC.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DChan%26aufirst%3DT.%2BH.%26aulast%3DChow%26aufirst%3DL.%2BM.%26atitle%3DA%2520New%2520class%2520of%2520safe%252C%2520potent%252C%2520and%2520specific%2520P-gp%2520modulator%253A%2520flavonoid%2520dimer%2520FD18%2520reverses%2520P-gp-mediated%2520multidrug%2520resistance%2520in%2520human%2520breast%2520xenograft%2520in%2520vivo%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3507%26epage%3D3517%26doi%3D10.1021%2Fmp500770e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, A. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel flavonoid dimers to reverse multidrug resistance protein 1 (MRP1, ABCC1) mediated drug resistance in cancers using a high throughput platform with ″click chemistry″</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9931</span>– <span class="NLM_lpage">9951</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9931-9951&author=I.+L.+K.+Wongauthor=X.+Zhuauthor=K.+F.+Chanauthor=M.+C.+Lawauthor=A.+M.+Y.+Loauthor=X.+Huauthor=L.+M.+C.+Chowauthor=T.+H.+Chan&title=Discovery+of+novel+flavonoid+dimers+to+reverse+multidrug+resistance+protein+1+%28MRP1%2C+ABCC1%29+mediated+drug+resistance+in+cancers+using+a+high+throughput+platform+with+%E2%80%B3click+chemistry%E2%80%B3&doi=10.1021%2Facs.jmedchem.8b00834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry"</span></div><div class="casAuthors">Wong, Iris L. K.; Zhu, Xuezhen; Chan, Kin-Fai; Law, Man Chun; Lo, Aya M. Y.; Hu, Xuesen; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9931-9951</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A 300-member flavonoid dimer library of multi-drug resistance-assocd. protein 1 (MRP1, ABCC1) modulators was rapidly assembled using "click chem.".  Subsequent high-throughput screening has led to the discovery of highly potent (EC50 ranging from 53 to 298 nM) and safe (selective indexes ranging from >190 to >1887) MRP1 modulators.  Some dimers have potency about 6.5- to 36-fold and 64- to 358-fold higher than the well-known MRP1 inhibitors, verapamil, and MK571, resp.  They inhibited DOX efflux and restored intracellular DOX concn.  The most potent modulator, Ac3Az11, was predicted to bind to the bipartite substrate-binding site of MRP1 in a competitive manner.  Moreover, it provided sufficient concn. to maintain its plasma level above its in vitro EC50 (53 nM for DOX) for about 90 min.  Overall, we demonstrate that "click chem." coupled with high throughput screening is a rapid, reliable, and efficient tool in the discovery of compds. having potent MRP1-modualting activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr86Kpm9ozErVg90H21EOLACvtfcHk0li5arvvOvLBnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLzK&md5=59dd8a81cc442fa301a3f8a6c78a8dc8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00834%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DI.%2BL.%2BK.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DA.%2BM.%2BY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DDiscovery%2520of%2520novel%2520flavonoid%2520dimers%2520to%2520reverse%2520multidrug%2520resistance%2520protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%2520mediated%2520drug%2520resistance%2520in%2520cancers%2520using%2520a%2520high%2520throughput%2520platform%2520with%2520%25E2%2580%25B3click%2520chemistry%25E2%2580%25B3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9931%26epage%3D9951%26doi%3D10.1021%2Facs.jmedchem.8b00834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">The growing impact of click chemistry on drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02933-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2FS1359-6446%2803%2902933-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=14678739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=1128-1137&author=H.+C.+Kolbauthor=K.+B.+Sharpless&title=The+growing+impact+of+click+chemistry+on+drug+discovery&doi=10.1016%2FS1359-6446%2803%2902933-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The growing impact of click chemistry on drug discovery</span></div><div class="casAuthors">Kolb, Hartmuth C.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1128-1137</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Click chem. is a modular approach that uses only the most practical and reliable chem. transformations.  Its applications are increasingly found in all aspects of drug discovery, ranging from lead finding through combinatorial chem. and target-templated in situ chem., to proteomics and DNA research, using bioconjugation reactions.  The copper-(I)-catalyzed 1,2,3-triazole formation from azides and terminal acetylenes is a particularly powerful linking reaction, due to its high degree of dependability, complete specificity, and the bio-compatibility of the reactants.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen bonding and dipole interactions.  Click chem., a modular approach based on highly reliable chem. transformations, is being applied in all aspects of drug discovery, ranging from lead finding to proteomics and DNA research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqEB1hjIBNhbVg90H21EOLACvtfcHk0li5arvvOvLBnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D&md5=f0042f3a8f153d1c1192533d90699d19</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902933-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902933-7%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DThe%2520growing%2520impact%2520of%2520click%2520chemistry%2520on%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D1128%26epage%3D1137%26doi%3D10.1016%2FS1359-6446%2803%2902933-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantet, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreyre, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesson, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannetaud, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoux, B.</span></span> <span> </span><span class="NLM_article-title">gem-Difluorination of aminoalkynes via highly reactive dicationic species in superacid HF–SbF5: application to the efficient synthesis of difluorinated cinchona alkaloid derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2875</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1021/jo702441p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702441p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1Giurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=2875-2878&author=A.-C.+Cantetauthor=H.+Carreyreauthor=J.-P.+Gessonauthor=M.-P.+Jouannetaudauthor=B.+Renoux&title=gem-Difluorination+of+aminoalkynes+via+highly+reactive+dicationic+species+in+superacid+HF%E2%80%93SbF5%3A+application+to+the+efficient+synthesis+of+difluorinated+cinchona+alkaloid+derivatives&doi=10.1021%2Fjo702441p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">gem-Difluorination of Aminoalkynes via Highly Reactive Dicationic Species in Superacid HF-SbF5: Application to the Efficient Synthesis of Difluorinated Cinchona Alkaloid Derivatives</span></div><div class="casAuthors">Cantet, Anne-Celine; Carreyre, Helene; Gesson, Jean-Pierre; Jouannetaud, Marie-Paule; Renoux, Brigitte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2875-2878</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of alkynylated amines, amides, and imides, e.g. PhNHCH2C≡CH, are reacted in the superacid system HF-SbF5 to give regioselectively new β-gem-difluoroamines, e.g. PhNHCH2CF2Me.  The reaction, which is not obsd. in pure HF, is consistent with the formation of a dicationic intermediate (i.e., both vinylic and adjacent protonated N-ammonium cations).  Application to the regioselective and efficient synthesis of difluorinated cinchona alkaloid derivs. is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvnSD03jhxO7Vg90H21EOLACvtfcHk0li5arvvOvLBnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1Giurs%253D&md5=ab7aaa08b45fdd0690bc667b77fcf5e7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjo702441p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702441p%26sid%3Dliteratum%253Aachs%26aulast%3DCantet%26aufirst%3DA.-C.%26aulast%3DCarreyre%26aufirst%3DH.%26aulast%3DGesson%26aufirst%3DJ.-P.%26aulast%3DJouannetaud%26aufirst%3DM.-P.%26aulast%3DRenoux%26aufirst%3DB.%26atitle%3Dgem-Difluorination%2520of%2520aminoalkynes%2520via%2520highly%2520reactive%2520dicationic%2520species%2520in%2520superacid%2520HF%25E2%2580%2593SbF5%253A%2520application%2520to%2520the%2520efficient%2520synthesis%2520of%2520difluorinated%2520cinchona%2520alkaloid%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D2875%26epage%3D2878%26doi%3D10.1021%2Fjo702441p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology of ABCG2 and its role in chemoresistance</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1124/mol.113.088609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1124%2Fmol.113.088609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=24021215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=655-669&author=A.+E.+Stacyauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Molecular+pharmacology+of+ABCG2+and+its+role+in+chemoresistance&doi=10.1124%2Fmol.113.088609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of ABCG2 and its role in chemoresistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-669</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The ATP-binding cassette, subfamily G, isoform 2 protein (ABCG2) is an important member of the ABC transporter superfamily, which has been suggested to be involved in multidrug resistance (MDR) in cancer.  Its diverse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mitoxantrone.  Physiol., ABCG2 is highly expressed in areas such as the blood-brain barrier and gastrointestinal tract, where it is thought to play a role in protection against xenobiotic exposure.  High ABCG2 expression has also been found in a variety of solid tumors and in hematol. malignancies and has been correlated with poorer clin. outcomes.  Furthermore, ABCG2 expression is a characteristic feature of cancer stem cells, which are able to self-renew and differentiate.  These cancer stem cells have been postulated to play an important role in MDR, where their inherent ABCG2 expression may allow them to survive chemotherapy and repopulate the tumor after exposure to chemotherapeutics.  This observation raises the exciting possibility that by inhibiting ABCG2, cancer stem cells and other cancers may be targeted and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the remaining tumor cells.  Inhibitors of ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-type indolyl diketopiperazine, Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], could potentially be used for this purpose.  However, these agents are still awaiting comprehensive clin. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO8F0Ak6Zp7Vg90H21EOLACvtfcHk0li5arvvOvLBnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLjP&md5=d619971aca497b3b66e70c3c5bcca0bb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.088609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.088609%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520pharmacology%2520of%2520ABCG2%2520and%2520its%2520role%2520in%2520chemoresistance%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D655%26epage%3D669%26doi%3D10.1124%2Fmol.113.088609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>563</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0680-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1038%2Fs41586-018-0680-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=30405239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFejsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=563&publication_year=2018&pages=426-430&author=I.+Manolaridisauthor=S.+M.+Jacksonauthor=N.+M.+I.+Taylorauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Cryo-EM+structures+of+a+human+ABCG2+mutant+trapped+in+ATP-bound+and+substrate-bound+states&doi=10.1038%2Fs41586-018-0680-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states</span></div><div class="casAuthors">Manolaridis, Ioannis; Jackson, Scott M.; Taylor, Nicholas M. I.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">563</span>
        (<span class="NLM_cas:issue">7731</span>),
    <span class="NLM_cas:pages">426-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is a transporter protein of the ATP-binding-cassette (ABC) family that is expressed in the plasma membrane in cells of various tissues and tissue barriers, including the blood-brain, blood-testis, and maternal-fetal barriers.  Powered by ATP, it translocates endogenous substrates, affects the pharmacokinetics of many drugs, and protects against a wide array of xenobiotics, including anti-cancer drugs.  Previous studies revealed the architecture of ABCG2 and the structural basis of its inhibition by small mols. and antibodies.  However, the mechanisms of substrate recognition and ATP-driven transport are unknown.  Here, we present high-resoln. cryo-electron microscopy (cryo-EM) structures of human ABCG2 in a substrate-bound pre-translocation state and an ATP-bound post-translocation state.  For both structures, we used a mutant contg. a Gln residue replacing the catalytic Glu residue (ABCG2EQ), which resulted in reduced ATPase and transport rates and facilitated conformational trapping for structural studies.  In the substrate-bound state, a single mol. of estrone 3-sulfate (E1S) was bound in a central, hydrophobic and cytoplasm-facing cavity about halfway across the membrane.  Only one mol. of E1S could bind in the obsd. binding mode.  In the ATP-bound state, the substrate-binding cavity had collapsed, while an external cavity had opened to the extracellular side of the membrane.  The ATP-induced conformational changes included rigid-body shifts of the transmembrane domains, pivoting of the nucleotide-binding domains (NBDs), and a change in the relative orientation of the NBD subdomains.  Mutagenesis and in vitro characterization of transport and ATPase activities demonstrated the roles of specific residues in substrate recognition, including a Leu residue that formed a 'plug' between the 2 cavities.  These results showed how ABCG2 harnesses the energy of ATP binding to extrude E1S and other substrates, and suggested that the size and binding affinity of compds. are important for distinguishing substrates from inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsiPmRG_U1ILVg90H21EOLACvtfcHk0liJRhEnpas-vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFejsLfO&md5=a1a1ae9473c667561354e8499327a4c8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0680-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0680-3%26sid%3Dliteratum%253Aachs%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DCryo-EM%2520structures%2520of%2520a%2520human%2520ABCG2%2520mutant%2520trapped%2520in%2520ATP-bound%2520and%2520substrate-bound%2520states%26jtitle%3DNature%26date%3D2018%26volume%3D563%26spage%3D426%26epage%3D430%26doi%3D10.1038%2Fs41586-018-0680-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Structural basis of substrate recognition by the multidrug resistance protein MRP1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1085</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.cell.2017.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=28238471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtlGrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=1075-1085&author=Z.+L.+Johnsonauthor=J.+Chen&title=Structural+basis+of+substrate+recognition+by+the+multidrug+resistance+protein+MRP1&doi=10.1016%2Fj.cell.2017.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1</span></div><div class="casAuthors">Johnson, Zachary Lee; Chen, Jue</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1085.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The multidrug resistance protein MRP1 is an ATP-binding cassette (ABC) transporter that confers resistance to many anticancer drugs and plays a role in the disposition and efficacy of several opiates, antidepressants, statins, and antibiotics.  In addn., MRP1 regulates redox homeostasis, inflammation, and hormone secretion.  Using electron cryomicroscopy, we detd. the mol. structures of bovine MRP1 in two conformations: an apo form at 3.5 Å without any added substrate and a complex form at 3.3 Å with one of its physiol. substrates, leukotriene C4.  These structures show that by forming a single bipartite binding site, MRP1 can recognize a spectrum of substrates with different chem. structures.  We also obsd. large conformational changes induced by leukotriene C4, explaining how substrate binding primes the transporter for ATP hydrolysis.  Structural comparison of MRP1 and P-glycoprotein advances our understanding of the common and unique properties of these two important mols. in multidrug resistance to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo87MmRBg2HsbVg90H21EOLACvtfcHk0liJRhEnpas-vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtlGrurg%253D&md5=1799bd0d0180f8c524ebe97271a08c85</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DStructural%2520basis%2520of%2520substrate%2520recognition%2520by%2520the%2520multidrug%2520resistance%2520protein%2520MRP1%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D1075%26epage%3D1085%26doi%3D10.1016%2Fj.cell.2017.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">ATP binding enables substrate release from multidrug resistance protein 1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2Fj.cell.2017.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=29290467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Ogsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=81-89&author=Z.+L.+Johnsonauthor=J.+Chen&title=ATP+binding+enables+substrate+release+from+multidrug+resistance+protein+1&doi=10.1016%2Fj.cell.2017.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">ATP Binding Enables Substrate Release from Multidrug Resistance Protein 1</span></div><div class="casAuthors">Johnson, Zachary Lee; Chen, Jue</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">81-89.e10</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The multidrug resistance protein MRP1 is an ATP-driven pump that confers resistance to chemotherapy.  Previously, we have shown that intracellular substrates are recruited to a bipartite binding site when the transporter rests in an inward-facing conformation.  A key question remains: how are high-affinity substrates transferred across the membrane and released outside the cell.  Using electron cryomicroscopy, we show here that ATP binding opens the transport pathway to the extracellular space and reconfigures the substrate-binding site such that it relinquishes its affinity for substrate.  Thus, substrate is released prior to ATP hydrolysis.  With this result, we now have a complete description of the conformational cycle that enables substrate transfer in a eukaryotic ABC exporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR-gP8vhWQC7Vg90H21EOLACvtfcHk0liJRhEnpas-vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Ogsg%253D%253D&md5=16b3ad685ad58f31c1db6ca3aad4b4ab</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DZ.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DATP%2520binding%2520enables%2520substrate%2520release%2520from%2520multidrug%2520resistance%2520protein%25201%26jtitle%3DCell%26date%3D2018%26volume%3D172%26spage%3D81%26epage%3D89%26doi%3D10.1016%2Fj.cell.2017.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-cyano-6-phenylpyrimidin derivatives containing an acylurea moiety as orally bioavailable reversal agents against P-glycoprotein-mediated mutidrug resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">6001</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00335</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00335" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5988-6001&author=B.+Wangauthor=L.+Y.+Maauthor=J.+Q.+Wangauthor=Z.+N.+Leiauthor=P.+Guptaauthor=Y.+D.+Zhaoauthor=Z.+H.+Liauthor=Y.+Liuauthor=X.+H.+Zhangauthor=Y.+N.+Liauthor=B.+Zhaoauthor=Z.+S.+Chenauthor=H.+M.+Liu&title=Discovery+of+5-cyano-6-phenylpyrimidin+derivatives+containing+an+acylurea+moiety+as+orally+bioavailable+reversal+agents+against+P-glycoprotein-mediated+mutidrug+resistance&doi=10.1021%2Facs.jmedchem.8b00335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance</span></div><div class="casAuthors">Wang, Bo; Ma, Li-Ying; Wang, Jing-Quan; Lei, Zi-Ning; Gupta, Pranav; Zhao, Yuan-Di; Li, Zhong-Hua; Liu, Ying; Zhang, Xin-Hui; Li, Ya-Nan; Zhao, Bing; Chen, Zhe-Sheng; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5988-6001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylamino)arylpyrimidinecarbonitriles such as I were prepd. as inhibitors of ABCB1 (P-glycoprotein) for the reversal of drug resistance and for potential use in the treatment of cancer.  Of the compds. prepd., I showed the most potent activity in reversing paclitaxel resistance in AD300 (drug-resistant human colon cancer) cells.  I increased the accumulation of paclitaxel in AD300 cells, interrupted ABCB1-mediated rhodamine accumulation and efflux, stimulated ABCB1 ATPase activity, and did not inhibit CYP3A4 (a source of drug interaction-induced toxicity).  Orally administered I significantly enhanced the efficacy of paclitaxel against colon cancer cell xenografts without obvious side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3CJSeoghULVg90H21EOLACvtfcHk0ljxLeC4X1gpBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KnsrfO&md5=ab39f736e60446f0434ce43434c2b442</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00335%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DL.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%2BD.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DLi%26aufirst%3DY.%2BN.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DLiu%26aufirst%3DH.%2BM.%26atitle%3DDiscovery%2520of%25205-cyano-6-phenylpyrimidin%2520derivatives%2520containing%2520an%2520acylurea%2520moiety%2520as%2520orally%2520bioavailable%2520reversal%2520agents%2520against%2520P-glycoprotein-mediated%2520mutidrug%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5988%26epage%3D6001%26doi%3D10.1021%2Facs.jmedchem.8b00335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span>; <span class="NLM_string-name">Wong, I. L. K.</span>; <span class="NLM_string-name">Chan, K.-F.</span>; <span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Law, M.
C.</span>; <span class="NLM_string-name">Zhu, X.</span>; <span class="NLM_string-name">Hu, X.</span>; <span class="NLM_string-name">Chan, T. H.</span>; <span class="NLM_string-name">Chow, L. M. C.</span></span> <span> </span><span class="NLM_article-title">A triazole-bridged flavonoid dimer Ac15(Az8)<sub>2</sub> reverses multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) in human colon xenograft in vivo</span>. (unpublished results).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chong%2C+T.+C.%3B+Wong%2C+I.+L.+K.%3B+Chan%2C+K.-F.%3B+Cui%2C+J.%3B+Law%2C+M.%0AC.%3B+Zhu%2C+X.%3B+Hu%2C+X.%3B+Chan%2C+T.+H.%3B+Chow%2C+L.+M.+C.+A+triazole-bridged+flavonoid+dimer+Ac15%28Az8%292+reverses+multidrug+resistance+mediated+by+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+in+human+colon+xenograft+in+vivo.+%28unpublished+results%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DT.%2BC.%26atitle%3DA%2520triazole-bridged%2520flavonoid%2520dimer%2520Ac15%2528Az8%25292%2520reverses%2520multidrug%2520resistance%2520mediated%2520by%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520in%2520human%2520colon%2520xenograft%2520in%2520vivo" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abellán-Flos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanç, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supuran, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, S. P.</span></span> <span> </span><span class="NLM_article-title">Exploring carbonic anhydrase inhibition with multimeric coumarins displayed on a fullerene scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">7445</span>– <span class="NLM_lpage">7451</span>, <span class="refDoi"> DOI: 10.1039/C5OB01005E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1039%2FC5OB01005E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=26058669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsF2ns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=7445-7451&author=M.+Abell%C3%A1n-Flosauthor=M.+Tan%C3%A7author=C.+T.+Supuranauthor=S.+P.+Vincent&title=Exploring+carbonic+anhydrase+inhibition+with+multimeric+coumarins+displayed+on+a+fullerene+scaffold&doi=10.1039%2FC5OB01005E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring carbonic anhydrase inhibition with multimeric coumarins displayed on a fullerene scaffold</span></div><div class="casAuthors">Abellan-Flos, Marta; Tanc, Muhammet; Supuran, Claudiu T.; Vincent, Stephane P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7445-7451</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Carbonic anhydrases (CAs) are ubiquitous Zn metallo-enzymes that catalyze the reversible hydration/dehydration of CO2/HCO3-.  CAs are involved in many key biol. processes, therefore their inhibition has become an attractive research field.  Distinct families of CA inhibitors (CAIs) have been reported, most of them interacting with the Zn(II) at the active site.  Some compds. such as the coumarins are hydrolyzed before binding the entrance of the active site cavity, and thus behave as "suicide" inhibitors.  This study reports the first synthesis of multimeric suicide inhibitors, designed to address the selectivity and the potency of CA multivalent inhibition.  Twelve coumarin units have been grafted to a central fullerene scaffold thanks to a CuAAC reaction and the final dodecamers were assayed against 4 relevant CAs.  The multimers were always stronger inhibitors than the monomeric species but no strong "multivalent effect" was found.  However, our study showed that the multimeric presentation of the coumarin around the C60, indeed affected the selectivity of the relative inhibition among the 4 CAs assayed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo6Dq0iC9_0rVg90H21EOLACvtfcHk0ljxLeC4X1gpBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsF2ns7s%253D&md5=0070b51fbc983cb60b50bf4eda3ffac3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC5OB01005E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5OB01005E%26sid%3Dliteratum%253Aachs%26aulast%3DAbell%25C3%25A1n-Flos%26aufirst%3DM.%26aulast%3DTan%25C3%25A7%26aufirst%3DM.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26aulast%3DVincent%26aufirst%3DS.%2BP.%26atitle%3DExploring%2520carbonic%2520anhydrase%2520inhibition%2520with%2520multimeric%2520coumarins%2520displayed%2520on%2520a%2520fullerene%2520scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2015%26volume%3D13%26spage%3D7445%26epage%3D7451%26doi%3D10.1039%2FC5OB01005E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujadhur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintigh, J. T.</span></span> <span> </span><span class="NLM_article-title">Formation of aryl-nitrogen bonds using a soluble copper (I) catalyst</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">4791</span>– <span class="NLM_lpage">4793</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)00888-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=10.1016%2FS0040-4039%2801%2900888-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslyjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2001&pages=4791-4793&author=R.+Gujadhurauthor=D.+Venkataramanauthor=J.+T.+Kintigh&title=Formation+of+aryl-nitrogen+bonds+using+a+soluble+copper+%28I%29+catalyst&doi=10.1016%2FS0040-4039%2801%2900888-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of aryl-nitrogen bonds using a soluble copper(I) catalyst</span></div><div class="casAuthors">Gujadhur, R.; Venkataraman, D.; Kintigh, J. T.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4791-4793</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors report a synthetic protocol for the synthesis of functionalized diaryl- and triarylamines under mild conditions, using a sol., air-stable copper(I) complex, Cu(PPh3)3Br, as the catalyst and cesium carbonate as the base.  Using this protocol, the authors were able to synthesize a tri-ortho-ester functionalized triphenylamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJ1A-IU0r_bVg90H21EOLACvtfcHk0ljxLeC4X1gpBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslyjtrc%253D&md5=aff77a492ae6c96b786f8416184c5dab</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2900888-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252900888-7%26sid%3Dliteratum%253Aachs%26aulast%3DGujadhur%26aufirst%3DR.%26aulast%3DVenkataraman%26aufirst%3DD.%26aulast%3DKintigh%26aufirst%3DJ.%2BT.%26atitle%3DFormation%2520of%2520aryl-nitrogen%2520bonds%2520using%2520a%2520soluble%2520copper%2520%2528I%2529%2520catalyst%26jtitle%3DTetrahedron%2520Lett.%26date%3D2001%26volume%3D42%26spage%3D4791%26epage%3D4793%26doi%3D10.1016%2FS0040-4039%2801%2900888-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6HCO','PDB','6HCO'); return false;">PDB: 6HCO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ETI','PDB','6ETI'); return false;">PDB: 6ETI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FEQ','PDB','6FEQ'); return false;">PDB: 6FEQ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i163"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00963">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51811"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00963">10.1021/acs.jmedchem.9b00963</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC chromatogram of <b>Ac22(Az8)</b><sub><b>2</b></sub>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of all representative compounds listed in <a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" href="#tbl3">Table <a class="ref showTableEvent internalNav" href="#tbl3">3</a></a>; <i>in silico</i> docking studies and <sup>1</sup>H and <sup>13</sup>C NMR assignment of <b>Ac2Az2</b> and <b>Ac22(Az8)</b><sub><b>2</b></sub>  (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES molecular strings formulas (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_001.pdf">jm9b00963_si_001.pdf (9.76 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00963/suppl_file/jm9b00963_si_002.csv">jm9b00963_si_002.csv (13.08 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00963%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00963" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a519cdc1f3c4c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
